CAS,Active Ingredient,Representative Proprietary Name,PFE ID,DC_Strc_ID,Canonical_Smiles,Dosage Form,Dosage Form_IR,Dosage Form_Delayed Release,Dosage Form_Extended Release,Dosage Form_Amorphous Dispersion,Route,Dose typical daily PO (mg/day),Marketing Status,"Discontinued year (Onakpoya 2016, WITHDRAWN)",Safety potential contributing factor to discontinuation (Pfizer),Withdrawn by FDA,Discontinued (Potential Reason),Discontinued (Source),Originator Name,Originator Industry Sector,Sponsor Name,Sponsor Industry Sector,Approval Date,Approval Year,Approval Date Source,Combination Only,Prodrug,F,Fa,Oral BA Class,Oral BA Class Comment,fu,Vdss (L/kg),Oral t1/2 (h),Covalent MOA,Ranking (2006),Ranking (2016),MAT 1Q2019 (USD),Orphan Drug,Therapeutic Class(s),Target_Enzyme,Target_Kinase,Target_Kinase Type,Target_ion channel,Target_GPCR,Target_transporter,Target_transcription factor,DILIrank Concern,DILIrank Concern (PFE augmented),DILIst Source,DILIst Classification,LiverTox Likelihood Score,LiverTox Likelihood Cluster,LiverTox Likelihood Text,SkinTox Rank,SA_2011,SA_NAME_2011,SA_ANILINE,SA_MICHAEL ACCEPTOR,SA_THIOPHENE,PDB,MW,HBDONORCNT,HBACCPTCNT,NHOHCNT,NOCNT,RO5,ROTBNDCNT,PSA,FSP3,cSFLOGD,cPFLOGD,CLOGP,CLOGP_ErrorMsg,CLOGP_MoKa,CLOGD_MoKa,CLOGP_ACD-Consensus,CLOGD_ACD,ACID1PKA_ACD14,BASIC1PKA_ACD14,ACID1PKA_MOKA,BASIC1PKA_MOKA,IONIZATION_ACD,ECCS Class,B_Count,F_Count,Si_Count,P_Count,Cl_Count,Br_Count,I_Count,Num_AromaticRings,aromaticfusion_Count,Biphenyl_Count,H2_Isotopic,SECONDARY_ALKYL_ARYL_AMINE,TERTIARY_TRIALKYL_AMINE,Z3_HALO_HETEROARYL,PHENYL_HALIDE,Z4_Chloro_HET_ARYL,CB_Sulfonyl_Fluoride,ESTER,ALPHABROMO_KETONE,IMIDE,O_HALO_HETEROARYL,NITROSO,PRIMARY_HYDRAZINE,CB_Cyclooctyne,ANHYDRIDE,UREA,CB_Norbornene,BORONIC_ACID,ARYL_PRIMARY_AMINE,ALKYNE,IMINO,SULFAMOYL_HALIDE,Z3_FLUORO_HET_ARYL,CB_alphaHalocarbonyl,Z3_IODO_HET_ARYL,ME_RING,BRIDGED_RING,O_FLUORIDE_HET_ARYL,PHENYL_IODIDE,PHENOL,SPIRAL_RING,Z4_BROMO_HET_ARYL,TERTIARY_DIALKYL_ARYL_AMINE,LACTAM_OR_CYCLIC_IMIDE,z6_member_arhethalide,THIOPHENE,AZIDE,z5_member_arhethalide,O_BROMIDE_HET_ARYL,O_IODO_HET_ARYL,EPOXIDE,HEMIACETAL,HYDRAZONE,THIOCARBAMATE,SULFONE,ISOCYANATE,FREE_AMINOACID,ESTER_AMINOACID,ALKYL_PRIMARY_AMINE,CB_acrylamide,CB_Tetrazine,CB_Aryl_Azide,CB_Cyclopropene,Tertiary_ALKYL_HALIDE,Alkyl_DiHalide_TriHalide,IMIDAZOLE,Z4_FLUORO_HET_ARYL,SECONDARY_AMINE,BOC_AMINOACID,Z2_SecondaryAmine_Het_Aryl,z5_member_hethalide,Z3_CHLORO_HET_ARYL,CB_Sulfamoyl_Fluorides,TERMINAL_ALKYNE,C14_ISOTOPIC,THIOESTER,ANILINE,Z3_PrimaryAmine_Het_Aryl,AMIDE,ACETOPHENONE,SUCCINYL,CB_Alkyl_Azide,Z4_PrimaryAmine_Het_Aryl,CB_Benzophenone,TERTIARY_AMINE,HYDROXYLAMINE,CB_Alkyne,SULFONAMIDE,CB_LigandDirectedTosyl,CB_Vinyl_sulfones,z7_member_hethalide,z9_member_arhethalide,Z4_HALO_HETEROARYL,HETERARYL_5_MEMBERED,KETONE,PHENYL,Sulfur,FUSED_RING,ISOTHIOCYANATE,GRIGARD_REAGENT,THIOAMIDE,TRICYCLIC_AND_MORE,PRIMARY_ALCOHOL,OXALYL,PYRIDINE,CYCLIC_ALKENES,SULFONIC_ESTER,SULFONIC_ACID,z7_member_arhethalide,CYCLIC_ALKYNES,PRIMARY_AMINE,HEMIKETAL,MOLANDERATE,CARBAMATE,NITRO,FURAN,z6_member_hethalide,THIOETHER,ALKYL_Floride,PYRIMIDINE,FMOC_AMINOACID,HETEROARYL,CB_Biotin,CB_Diazirine,HYDRAZIDE,SULFONYL_HALIDE,PHENYL_BROMIDE,MALONYL,KETAL,LACTONE,TERTIARY_ALCOHOL,AROMATIC_ALDEHYDE,Z4_IODO_HET_ARYL,Quarternary_Amine,Z3_SecondaryAmine_Het_Aryl,TRIAZINE,ALDEHYDE,NITRILE,ALIPHATIC_ALDEHYDE,BOC_AMINES,HYDROXAMIC_ACID,ALIPHATIC_HETERO_RING,AZO,ALKENE,PHOSPHONIC_ACID,TERTIARY_DIALKYL_PHENYL_AMINE,HYDRAZINE,z8_member_arhethalide,ET_RING,THIOL,ETHER_ALKYL_PHENYL,AZOLE,CYANAMIDE,BORONIC_ESTER,ACETAL,ACID_CHLORIDE,OXAZOLIDONE,Carbonate,CB_Isothiocyanate,PHOSPHONIC_ESTER,SECONDARY_DIPHENYL_AMINE,IMINE_ACYCLIC,HETERARYL_6_MEMBERED,Amino_Alcohol,Z3_BROMO_HET_ARYL,CB_Fluorosulfate,SECONDARY_ALCOHOL,Z2_PrimaryAmine_Het_Aryl,TERMINAL_ALKENE,CARBOXYLIC_ACID,Primary_ALKYL_HALIDE,Secondary_ALKYL_HALIDE,C13_ISOTOPIC,Z4_SecondaryAmine_Het_Aryl,PHENYL_CHLORIDE,AMIDOXIMES,Phosphorus,CB_Transcyclooctene,HALIDE,ENOL_ETHER,ETHER_DIALKYL,O_CHLORIDE_HET_ARYL,ENAMINE,Macrocycle,QED,QED_Unweighted,QED_MW,QED_ALOGP,QED_HBA,QED_HBD,QED_PSA,QED_ROTB,QED_AROM,Complexity_Cm,cRRCK,cHHEP,cHLM
136470-78-5,ABACAVIR SULFATE,ZIAGEN,PF-00558077,34,c1nc2c(nc(nc2n1[C@@H]3C[C@@H](C=C3)CO)N)NC4CC4,TABLET,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,VIIV HLTHCARE,pharma,36146,1998,Drugs@FDA,NO,NO,0.83,,High,Reported bioavailability,0.5,0.86,1.5,,136,48,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,286.3323,4,4,3,7,0,4,101.88,0.5,1.28,1.224,0.806,All fragments measured,0.99,0.99,1.32,1.318,,4.86,13,5.4,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,NO,0.74432,0.70095,0.97016,0.71043,0.52457,0.37866,0.66783,0.96969,0.93773,327,6,4.08,10.8
1231929-97-7,ABEMACICLIB,VERZENIO,PF-06737210,5259,CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,Eli Lilly,major pharma,ELI LILLY AND CO,major pharma,43006,2017,Drugs@FDA,NO,NO,0.45,,High,Reported bioavailability,0.037,0.69,18.3,,,,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,"E* (unproved but suspected, rare cause of clinically apparent liver injury)",Less,0,,NO,NO,NO,5L2S,506.5934,1,6,1,8,1,7,75,0.407407407,2.83,3.094,4.915,All fragments measured,4.8,3.7,3,2.818,,7.69,,8.4,Basic,Class 4,0,2,0,0,0,0,0,4,1,1,0,0,2,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.29444,0.33047,0.16038,0.48802,0.33223,0.98659,0.91154,0.53315,0.03452,509.4,9.91,19.9,116
154229-18-2,ABIRATERONE ACETATE,ZYTIGA,PF-06755026,4176,CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4c5cccnc5)C)C,TABLET,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,BTG,pharma,JANSSEN PHARMS,major pharma,40661,2011,Drugs@FDA,NO,YES,,0.23,Moderate,Fa estimated from reported excretion data,0.01,281,12,Suicide,,44,,NO,Oncology,YES,NO,,NO,NO,NO,NO,,Less,FEARS Addition ,1,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,1,Pyridine,NO,NO,NO,,391.5457,0,2,0,3,1,3,39.19,0.615384615,4.34,5.35,6.111,All fragments measured,5.9,5.9,5.87,5.874,,5.31,,3.6,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72993,0.78332,0.62122,0.64657,0.9848,0.59178,0.94128,0.99269,0.82734,374,5.31,64.1,49.2
1420477-60-6,ACALABRUTINIB,CALQUENCE,PF-07072383,5260,CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5,CAPSULE,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Acerta Pharma,pharma,ASTRAZENECA AB,major pharma,43039,2017,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.025,1.4,1,Parent CRG,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Less,,,D,Less,D (possible rare cause of clinically apparent liver injury and suspected cause of reactivation of hepatitis B),Less,1,Alkynes,NO,NO,NO,,465.5065,3,5,2,9,0,5,118.51,0.192307692,2.02,1.804,1.581,A priori fragment value used,2.3,2.3,1.08,0.994,8.87,6.12,11,6.3,Neutral,Class 2,0,0,0,0,0,0,0,4,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.38764,0.39866,0.26579,0.99908,0.52457,0.79222,0.49558,0.84757,0.03452,512.3,2.58,10.6,50.6
77337-76-9,ACAMPROSATE CALCIUM,CAMPRAL,PF-01492448,38,CC(=O)NCCCS(=O)(=O)O,"TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,1998,Prescription,,NO,NO,,,Merck KGaA,pharma,FOREST LABS,pharma,38197,2004,Drugs@FDA,NO,NO,0.11,,Moderate,Reported bioavailability,1,1,20,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,181.2101,2,3,2,5,0,4,83.47,0.8,-1.48,-1.48,-2.465,All fragments measured,-1.7,-5.2,-2.57,-6.066,1.7,,0.25,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50531,0.55234,0.34173,0.18556,0.88651,0.79222,0.76867,0.96969,0.47245,154.5,0.8,1.66,6.65
37517-30-9,ACEBUTOLOL HYDROCHLORIDE,SECTRAL,PF-00344843,40,CCCC(=O)Nc1ccc(c(c1)C(=O)C)OCC(CNC(C)C)O,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,PROMIUS PHARMA,pharma,31044,1984,Drugs@FDA,NO,NO,0.4,0.9,High,Reported bioavailability,0.74,1.7,3.5,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,336.4259,3,5,3,6,0,10,87.66,0.555555556,-0.0297,-0.0297,1.71,All fragments measured,1.6,-0.33,1.68,-0.406,,9.4,14,9.2,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.54322,0.61394,0.9341,0.90378,0.72615,0.37866,0.80807,0.21184,0.82734,303.3,5.54,5.92,8.18
103-90-2,ACETAMINOPHEN,TYLENOL,PF-00344524,52,CC(=O)Nc1ccc(cc1)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,4000,Over-the-counter,,NO,NO,,,,,J AND J CONSUMER INC,major pharma,34493,1994,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.75,1,2.5,,,,,NO,Musculoskeletal/Pain,YES,NO,,YES,YES,NO,NO,Most,Most,DILIRank,1,A[HD],Most,"A[HD] (well established cause of liver injury, but severe cases occur only with high doses)",Moderate,2,Aniline; Hydroxy_Aniline,YES,NO,NO,,151.1626,2,2,2,3,0,1,49.33,0.125,0.762,0.3067,0.494,All fragments measured,0.76,0.76,0.4,0.402,9.86,1.72,9.7,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56274,0.66607,0.21689,0.6927,0.93048,0.79222,0.99636,0.63709,0.82734,124.3,18.5,22.2,10.2
59-66-5,ACETAZOLAMIDE,DIAMOX,PF-00344598,56,CC(=O)Nc1nnc(s1)S(=O)(=O)N,"CAPSULE, EXTENDED RELEASE; TABLET",YES,NO,YES,NO,ORAL,1000,Prescription,,NO,NO,,,,,TEVA,major pharma,19567,1953,Drugs@FDA,NO,NO,,,NA,NA,0.2,0.2,4,,,,1654306,NO,"Metabolic Disease, Neurological",YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,D,Less,D (possible but rare cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,1AZM,222.2454,3,6,2,7,0,2,115.04,0.25,-0.645,-0.645,-0.981,All fragments measured,-1.5,-1.7,-0.31,-0.925,7.25,,6.8,2.3,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57951,0.50807,0.59179,0.15931,0.72615,0.79222,0.22376,0.87038,0.82734,257.1,2.62,1.86,6.65
968-81-0,ACETOHEXAMIDE,DYMELOR,PF-00344845,57,CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC2CCCCC2,TABLET,YES,NO,NO,NO,ORAL,1500,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,23734,1964,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.1,,1.3,,,,,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,,,LiverTox Additions,1,,,,,0,,NO,NO,NO,,324.3953,2,4,2,6,0,4,92.34,0.466666667,-0.146,-0.146,2.254,All fragments measured,2,-0.72,2.32,0.437,4.35,,4.7,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.89967,0.86469,0.97497,0.96785,0.88651,0.79222,0.67982,0.96969,0.82734,280,6.99,5.69,9.29
546-88-3,ACETOHYDROXAMIC ACID,LITHOSTAT,PF-00344676,58,CC(=O)NO,TABLET,YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,,,MISSION PHARMA,pharma,30467,1983,Drugs@FDA,NO,NO,,0.36,High,Fa estimated from reported excretion data,,0.6,10,,,,,NO,Genitourinary,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,1FWE,75.0666,2,1,2,3,0,0,49.33,0.5,-1.06,-1.06,-1.594,All fragments measured,-1.4,-1.4,-1.22,-1.231,9.26,,9.4,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.30994,0.42454,0.07249,0.25014,0.93048,0.79222,0.99636,0.39503,0.47245,70.27,8.28,3.84,6.65
2751-68-0,ACETOPHENAZINE MALEATE,TINDAL,PF-00344849,59,CC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCN(CC4)CCO,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,,NO,NO,,,,,SCHERING,major pharma,22376,1961,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,None,,,,,,Less,0,,NO,NO,NO,,411.5603,1,5,1,5,0,7,47.02,0.434782609,2.37,2.322,2.709,All fragments measured,3.3,2.7,3.32,2.974,,7.39,14,8.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,2,1,4,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72792,0.73829,0.50396,0.98627,0.52457,0.98659,0.92963,0.53315,0.93773,367.6,9.06,31.4,50.4
616-91-1,ACETYLCYSTEINE,MUCOMYST,PF-00345335,66,CC(=O)N[C@@H](CS)C(=O)O,"SOLUTION; TABLET, EFFERVESCENT",YES,NO,NO,NO,ORAL,29400,Prescription,,NO,NO,,,,,APOTHECON,pharma,23268,1963,Drugs@FDA,NO,NO,0.09,,Low,Reported bioavailability,0.33,0.47,5.6,,,,4552466,YES,Respiratory,YES,NO,,NO,NO,YES,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Thiol_Disulfide,NO,NO,NO,,163.1949,2,4,2,4,0,3,66.4,0.6,-1.54,-1.54,-0.624,All fragments measured,-0.53,-3.8,0,-3.698,3.25,,3.2,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44254,0.50146,0.26085,0.30661,0.88651,0.37866,0.63329,0.99269,0.47245,155,0.315,1.66,13.5
1111-39-3,ACETYLDIGITOXIN,ACYLANID,RS-248667,67,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)OC(=O)C)O,TABLET,YES,NO,NO,NO,ORAL,0.2,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,27508,1975,Drugs@FDA,NO,YES,0.7,,High,Reported bioavailability,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,,,,,,,1,Michael_acceptor,NO,YES,NO,,806.9757,4,12,4,14,2,9,188.9,0.906976744,2.94,5.084,3.461,All fragments measured,1.9,1.9,3.1,3.1,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,NO,0.18324,0.13871,0.02825,0.96294,0.02183,0.14694,0.0817,0.29329,0.47245,1086,2.66,10.3,22.9
55079-83-9,ACITRETIN,SORIATANE,PF-00346410,78,Cc1cc(c(c(c1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,CAPSULE,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,STIEFEL LABS INC,pharma,35366,1996,Drugs@FDA,NO,NO,0.59,,High,Reported bioavailability,0.001,9,49,,,,,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,,326.4293,1,3,1,3,1,6,46.53,0.285714286,2.53,2.53,6.065,All fragments measured,6.3,3.5,5.36,2.709,4.72,,4.2,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70089,0.73679,0.96929,0.22232,0.9848,0.98659,0.98835,0.6885,0.82734,210.9,7.99,29.7,28.4
87848-99-5,ACRIVASTINE,SEMPREX-D,PF-01049535,82,Cc1ccc(cc1)/C(=C/CN2CCCC2)/c3cccc(n3)/C=C/C(=O)O,CAPSULE,YES,NO,NO,NO,ORAL,24,Prescription,,NO,NO,,,,,AUXILIUM PHARMS LLC,pharma,34418,1994,Drugs@FDA,YES,NO,,0.84,High,Fa estimated from reported excretion data,0.5,0.46,1.5,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,LiverTox Additions,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,,348.4382,1,4,1,4,0,6,53.43,0.272727273,0.138,0.138,1.461,All fragments measured,3.7,1.4,3.51,0.992,1.99,8.88,3.9,9,Zwitter,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86692,0.89052,0.87828,0.89555,0.88651,0.98659,0.99996,0.6885,0.93773,265.3,8.74,4.71,14.8
59277-89-3,ACYCLOVIR,ZOVIRAX,PF-00344525,85,c1nc2c(=O)[nH]c(nc2n1COCCO)N,CAPSULE; TABLET,YES,NO,NO,NO,ORAL,4800,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,31072,1985,Drugs@FDA,NO,YES,0.23,,Moderate,Reported bioavailability,0.85,0.8,2.9,,,,9979983,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,FEARS Addition ,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,2KI5,225.2046,4,5,3,8,0,4,119.05,0.375,-0.697,-0.4,-2.422,All fragments measured,-1.7,-1.8,-1.45,-1.46,9.32,2.55,8.8,1.6,Neutral,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.51329,0.49828,0.6124,0.14642,0.52457,0.37866,0.53374,0.96969,0.82734,263.6,0.491,3.43,11
142340-99-6,ADEFOVIR DIPIVOXIL,HEPSERA,PF-00579961,88,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c1ncnc2N)OCOC(=O)C(C)(C)C,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,37519,2002,Drugs@FDA,NO,YES (Presystemic),0.59,,High,Reported bioavailability,0.96,5,7.5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,LiverTox Additions,0,E,None,"E (unlikely cause of clinically apparent, idiosyncratic liver injury)",None,0,,NO,NO,NO,,501.4705,2,7,1,13,2,13,166.98,0.65,2,2.445,1.398,All fragments measured,0.75,0.75,2.2,2.2,,4.16,,4.4,Neutral,Class 2,0,0,0,1,0,0,0,2,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,NO,0.28823,0.20935,0.17065,0.91195,0.02915,0.98659,0.11274,0.03725,0.93773,467,4.65,158,39.6
850140-72-6,AFATINIB DIMALEATE,GILOTRIF,PF-05305726,4318,CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,BOEHRINGER INGELHEIM,major pharma,41467,2013,Drugs@FDA,NO,NO,0.92,,High,Reported bioavailability,0.05,,37,Parent CRG,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,D,Less,D (possible cause of clinically apparent liver injury),,2,Aniline; Michael_acceptor,YES,YES,NO,4G5J,485.9384,2,6,2,8,0,8,88.61,0.291666667,3,3.36,4.49,All fragments measured,4.1,2.5,3.44,2.877,11.79,8.01,12,8.7,Basic,Class 4,0,1,0,0,1,0,0,3,1,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,0,1,0,0,NO,0.42276,0.45346,0.20645,0.8843,0.33223,0.79222,0.79932,0.39983,0.25672,494.1,1.37,18.9,38.6
54965-21-8,ALBENDAZOLE,ALBENZA,PF-00344680,103,CCCSc1ccc2c(c1)[nH]c(n2)NC(=O)OC,"TABLET; TABLET, CHEWABLE",YES,NO,NO,YES,ORAL,800,Prescription,,NO,NO,,,,,IMPAX LABS INC,pharma,35227,1996,Drugs@FDA,NO,NO,0.05,,Low,Reported bioavailability,0.3,,8,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,1,2_AminoImidazole_2_AminoThiazole,NO,NO,NO,,265.3314,2,3,2,5,0,5,67.01,0.333333333,3.17,3.42,3.461,All fragments measured,3.1,3,3.11,3.101,7.49,4.27,9.8,4.1,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87694,0.86864,0.87889,0.99525,0.88651,0.79222,0.76422,0.84757,0.93773,255.6,17.1,46.7,20.6
18559-94-9,ALBUTEROL SULFATE,PROVENTIL,PF-00344925,105,CC(C)(C)NCC(c1ccc(c(c1)CO)O)O,"SYRUP; TABLET; TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,16,Prescription,,NO,NO,,,,,SCHERING,major pharma,30078,1982,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.9,2.3,9.3,,,130,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,239.3107,4,4,4,4,0,4,72.72,0.538461538,-1.04,-1.04,0.061,All fragments measured,0.63,-1.6,0.61,-1.526,9.99,9.62,10,9.5,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.55834,0.64347,0.71157,0.75809,0.88651,0.14694,0.92703,0.84757,0.82734,187.3,0.493,3.22,7.19
1256580-46-7,ALECTINIB HYDROCHLORIDE,ALECENSA,PF-06452816,4937,CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Chugai Pharmaceutical,pharma,HOFFMANN-LA ROCHE,major pharma,42349,2015,Drugs@FDA,NO,NO,0.37,,High,Reported bioavailability,0.01,57.4,33,,,,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,D,Less,D (possible cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,5XV7,482.6166,1,3,1,6,1,3,72.36,0.466666667,4.39,4.682,5.533,All fragments measured,5.2,4.1,5.16,4.922,,7.54,10,7.5,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,2,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.48605,0.54318,0.21509,0.38226,0.72615,0.98659,0.92937,0.99269,0.25672,408.9,1.83,23.5,38.5
66376-36-1,ALENDRONATE SODIUM,FOSAMAX,PF-00346292,112,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,SOLUTION; TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,MERCK,major pharma,34971,1995,Drugs@FDA,NO,NO,0.007,,Low,Reported bioavailability,0.22,36.8,1.9,,23,,4729605,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,249.096,7,4,6,8,1,5,161.31,1,-1.76,-1.76,-5.642,A priori fragment value used,-3,-8.1,-4.41,-8.787,1.66,10.31,1.2,11,Zwitter,Class 3A,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,NO,0.26492,0.21974,0.77867,0.17839,0.19128,0.02306,0.10082,0.84757,0.47245,188.4,0.867,2.32,8.69
81403-80-7,ALFUZOSIN HYDROCHLORIDE,UROXATRAL,PF-00346413,115,CN(CCCNC(=O)C1CCCO1)c2nc3cc(c(cc3c(n2)N)OC)OC,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,10,Prescription,,NO,NO,,,Sanofi,major pharma,CONCORDIA PHARMS INC,pharma,37784,2003,Drugs@FDA,NO,NO,0.49,,High,Reported bioavailability,0.1,2.3,10,,,,943,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,389.4488,3,6,2,9,0,8,111.83,0.526315789,1.47,1.371,2.548,All fragments measured,2.3,2,1.02,-0.084,,8.4,13,7.3,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.65616,0.56172,0.63408,0.86844,0.19128,0.79222,0.56404,0.39983,0.93773,414.2,8.73,10.3,17.2
173334-57-1,ALISKIREN HEMIFUMARATE,TEKTURNA,PF-06264015,119,CC(C)[C@@H](Cc1ccc(c(c1)OCCCOC)OC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N,CAPSULE; TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Novartis ,major pharma,NODEN PHARMA,pharma,39146,2007,Drugs@FDA,NO,NO,0.025,0.25,Low,Reported bioavailability,0.5,1.9,40,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),,0,,NO,NO,NO,2V0Z,551.7583,6,7,4,9,2,19,146.13,0.733333333,1.34,0.8589,3.514,All fragments measured,3.3,1.3,2.93,0.266,12.54,9.78,12,9.7,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.13148,0.18928,0.09548,0.97892,0.33223,0.14694,0.25894,0.0089,0.82734,474,1.16,3.48,56.2
315-30-0,ALLOPURINOL,ZYLOPRIM,PF-00344681,124,c1c2c([nH]n1)nc[nH]c2=O,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,CASPER PHARMA LLC,pharma,24338,1966,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.97,1.6,1.5,,,,513485,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,136.1115,2,3,2,5,0,0,74.43,0,-0.252,-0.252,-0.835,All fragments measured,-0.83,-0.84,-0.66,-0.664,9.2,1.14,9.4,2.6,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47038,0.57877,0.17205,0.53195,0.88651,0.79222,0.91371,0.39503,0.93773,166,7.24,1.8,6.65
154323-57-6,ALMOTRIPTAN MALATE,AXERT,PF-01221537,128,CN(C)CCc1c[nH]c2c1cc(cc2)CS(=O)(=O)N3CCCC3,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Almirall,pharma,JANSSEN PHARMS,major pharma,37018,2001,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.65,2.6,3,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,3_Methyl_Indole,NO,NO,NO,,335.4643,1,1,1,5,0,6,56.41,0.529411765,0.547,-0.07412,1.793,Benzyl approx. based on a priori value,1.9,0.19,2.2,0.166,,9.48,11,8.7,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.89116,0.91867,0.93797,0.96636,0.9848,0.98659,0.97125,0.6885,0.93773,298.6,14.1,14.4,13.6
850649-61-5,ALOGLIPTIN BENZOATE,NESINA,PF-05015628,4340,Cn1c(=O)cc(n(c1=O)Cc2ccccc2C#N)N3CCC[C@H](C3)N,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Takeda,major pharma,TAKEDA PHARMS USA,major pharma,41299,2013,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.8,6,21,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,"E* (unproven but suspected cause of acute, idiosyncratic liver injury)",,0,,NO,NO,NO,3G0B,339.3916,2,5,1,7,0,3,97.05,0.388888889,-0.639,-0.6491,0.989,Benzyl approx. based on a priori value,1.5,1.3,0.97,-1.35,,9.89,,9,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91239,0.85763,0.92154,0.83813,0.72615,0.98659,0.75096,0.99269,0.82734,364,2.81,3.66,7.39
122852-42-0,ALOSETRON HYDROCHLORIDE,LOTRONEX,PF-01332021,129,Cc1c(nc[nH]1)CN2CCc3c(c4ccccc4n3C)C2=O,TABLET,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,SEBELA IRELAND LTD,pharma,36565,2000,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.18,1.1,1.5,,,,,NO,Gastrointestinal,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,294.351,1,2,1,5,0,2,53.92,0.294117647,2.05,1.956,1.737,Approximated fragment value used,1.4,1.4,1.88,1.734,,7,15,6.4,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76255,0.78559,0.98943,0.91007,0.93048,0.98659,0.99981,0.87038,0.25672,318,17.9,6.06,13.5
1217486-61-7,ALPELISIB,PIQRAY,PF-06676207,,O=C(N1[C@H](C(N)=O)CCC1)NC2=NC(C)=C(C3=CC(C(C)(C)C(F)(F)F)=NC=C3)S2,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,43609,2019,Drugs@FDA,NO,NO,,0.59,High,Fa estimated from reported excretion data,0.11,1.6,8,,,,,NO,Oncology,NO,YES,,NO,NO,NO,NO,,,,,,,,,1,Aminothiazole,NO,NO,NO,4JPS,441.4716896,3,4,2,7,0,5,101.21,0.474,2.44,2.794,2.129,Benzyl approx. based on a priori value,3.2,2.6,1.49,1.449,10.56,2.36,5.7,5.1,Neutral,Class 1B,0,3,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.70849,0.69431,0.35653,0.99998,0.88651,0.79222,0.39083,0.84757,0.93773,439.9,13.7,9.71,24.8
28981-97-7,ALPRAZOLAM,XANAX,PF-00345338,136,Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4)Cl,"TABLET; TABLET, EXTENDED RELEASE; TABLET, ORALLY DISINTEGRATING",YES,NO,YES,NO,ORAL,6,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,29875,1981,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.2,,12,,,,234234188,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,308.7649,0,2,0,4,0,1,43.07,0.117647059,1.78,1.819,2.555,Benzyl approx. based on a priori value,2,2,2.63,2.627,,2.28,,9.1,Neutral,Class 2,0,0,0,0,1,0,0,3,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.64812,0.70747,0.99943,0.95879,0.9848,0.59178,0.97123,0.63709,0.25672,283.7,30.5,12.4,10.4
645-05-6,ALTRETAMINE,HEXALEN,PF-00345017,141,CN(C)c1nc(nc(n1)N(C)C)N(C)C,CAPSULE,YES,NO,NO,NO,ORAL,260,Prescription,,NO,NO,,,,,EISAI INC,pharma,33233,1990,Drugs@FDA,NO,NO,,0.92,High,Fa estimated from reported excretion data,0.06,,4.7,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unlikely but suspected rare cause of liver injury),Less,0,,NO,NO,NO,,210.2794,0,3,0,6,0,3,48.39,0.666666667,2.4,2.323,1.665,All fragments measured,2,2,2.57,2.471,,6.81,,5.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73546,0.74192,0.51092,0.95543,0.52457,0.59178,0.99421,0.99269,0.82734,142.3,14.5,39.8,48.1
156053-89-3,ALVIMOPAN,ENTEREG,PF-04119294,143,C[C@H]1CN(CC[C@@]1(C)c2cccc(c2)O)C[C@H](Cc3ccccc3)C(=O)NCC(=O)O,CAPSULE,YES,NO,NO,NO,ORAL,24,Prescription,,NO,NO,,,Eli Lilly ,major pharma,CUBIST PHARMS,pharma,39588,2008,Drugs@FDA,NO,NO,0.06,,Low,Reported bioavailability,0.2,0.4,10,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,424.5326,3,5,3,6,0,8,89.87,0.44,0.516,0.516,2.164,All fragments measured,3.1,0.28,3.18,0.547,3.39,7.97,3.2,9.3,Zwitter,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50847,0.58108,0.43538,0.6328,0.72615,0.37866,0.78754,0.39983,0.93773,365.4,2.23,9.9,7.71
768-94-5,AMANTADINE HYDROCHLORIDE,SYMMETREL,PF-00344601,144,C1C2CC3CC1CC(C2)(C3)N,"CAPSULE, EXTENDED RELEASE; SYRUP; TABLET; TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,200,Prescription,,NO,NO,,,,,ENDO PHARMS,pharma,24882,1968,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.33,6.6,16,,,,,YES,"Anti-infective, Neurological",NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,151.2487,2,1,1,1,0,0,26.02,1,-0.486,-0.486,1.995,All fragments measured,2.5,-0.54,2.54,-0.369,,10.76,,10,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.48855,0.48297,0.21717,0.88297,0.23327,0.98659,0.74426,0.39503,0.47245,106.7,21.5,5.08,7.42
7648-98-8,AMBENONIUM CHLORIDE,MYTELASE,PF-00346332,146,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc2ccccc2Cl,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,20576,1956,Drugs@FDA,NO,NO,,,Low,Based on textual comment,,,,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,537.5647,2,4,2,6,1,15,58.2,0.5,0.807,0.807,0.18,Calculated fragment value,-4.3,-4.3,-4.15,-4.142,11.09,,13,,Neutral,Class 4,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.28055,0.43142,0.11161,0.9737,0.93048,0.79222,0.99393,0.03725,0.93773,433.4,0.77,14.7,30.8
177036-94-1,AMBRISENTAN,LETAIRIS,PF-06438825,4337,Cc1cc(nc(n1)O[C@H](C(=O)O)C(c2ccccc2)(c3ccccc3)OC)C,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Abbott,major pharma,GILEAD SCIENCES INC,major pharma,39248,2007,Drugs@FDA,NO,NO,,,NA,NA,0.01,,9,,,156,,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,378.4211,1,6,1,6,0,7,81.54,0.227272727,0.275,0.275,3.751,All fragments measured,3.6,0.15,5.21,1.495,,2.76,0.84,3,Acidic,Class 3A,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.62965,0.63177,0.70249,0.93713,0.52457,0.98659,0.86142,0.53315,0.25672,327.4,5.73,7.48,10.5
54-96-6,AMIFAMPRIDINE PHOSPHATE,FIRDAPSE,PF-01448103,4336,c1cncc(c1N)N,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Jazz Pharmaceuticals ,pharma,CATALYST PHARMS,pharma,43432,2018,Drugs@FDA,NO,NO,,0.93,High,Fa estimated from reported excretion data,0.75,,1.8,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,,,,,E,None,"E (unlikely cause of clinically apparent liver injury, but experience with its use is limited)",,1,Pyridine,NO,NO,NO,,109.1292,4,1,2,3,0,0,64.93,0,-0.553,-0.553,0.391,All fragments measured,-0.52,-2.4,-0.18,-1.512,,9.17,,8.7,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.37628,0.49365,0.11481,0.25143,0.9848,0.79222,0.97062,0.39503,0.82734,108.8,10.7,2.9,11.6
2609-46-3,AMILORIDE HYDROCHLORIDE,MIDAMOR,PF-00248544,158,c1(c(nc(c(n1)Cl)N)N)C(=O)NC(=N)N,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,PADDOCK LLC,pharma,29864,1981,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.75,5,9,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of liver injury),Less,1,Reactive_HeteroCycle,NO,NO,NO,,229.627,8,5,5,8,1,2,156.79,0,-0.146,-0.9,0.108,A priori fragment value used,-0.56,-1.9,-0.03,-0.15,7.81,,,9.1,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,NO,0.36717,0.35417,0.64344,0.26604,0.52457,0.05547,0.19488,0.87038,0.82734,245.9,5.53,6.35,7.05
60-32-2,AMINOCAPROIC ACID,AMICAR,PF-00345020,163,C(CCC(=O)O)CCN,SYRUP; TABLET,YES,NO,NO,NO,ORAL,5000,Prescription,,NO,NO,,,,,CLOVER PHARMS,pharma,23531,1964,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,1,0.3,3,,,,4009486,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,1HPK,131.1729,3,3,2,3,0,5,63.32,0.833333333,-0.989,-0.989,-2.235,All fragments measured,0.16,-2.1,-0.95,-3.444,4.68,10.63,4.2,11,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.36426,0.45069,0.15953,0.07752,0.9848,0.79222,0.9776,0.84757,0.47245,76.98,2.89,4.98,6.65
125-84-8,AMINOGLUTETHIMIDE,CYTADREN,PF-00344926,164,CCC1(CCC(=O)NC1=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,2000,Discontinued,1966,YES,NO,Agranulocytosis,WITHDRAWN,,,NOVARTIS,major pharma,21916,1960,Drugs@FDA,NO,NO,,0.54,High,Fa estimated from reported excretion data,0.75,,12.5,,,,,NO,Oncology,YES,NO,,NO,NO,NO,NO,,None,Gerren Additions,0,,,,Less,1,Aniline,YES,NO,NO,,232.2783,3,2,2,4,0,2,72.19,0.384615385,0.725,0.725,0.766,Estimated fragment value used,0.7,0.69,1.27,1.269,11.6,4.41,9.7,5.1,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79534,0.83839,0.66213,0.84116,0.9848,0.79222,0.93047,0.87038,0.82734,209,35.6,7.82,6.96
106-60-5,AMINOLEVULINIC ACID HYDROCHLORIDE,GLEOLAN,PF-00345484,166,C(CC(=O)O)C(=O)CN,FOR SOLUTION,YES,NO,NO,NO,ORAL,1400,Prescription,,NO,NO,,,Medac,pharma,NXDC,pharma,42892,2017,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.88,,0.9,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,131.1299,3,4,2,4,0,4,80.39,0.6,-1.54,-1.54,-3.415,All fragments measured,-2,-2.8,-1.13,-3.744,4.13,7.37,3.8,9.6,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.32693,0.39363,0.15943,0.03278,0.88651,0.79222,0.87079,0.96969,0.47245,96.15,1.59,5.03,6.65
58-55-9,AMINOPHYLLINE,AMINOPHYLLIN,PF-00345485,2620,Cn1c2c(c(=O)n(c1=O)C)nc[nH]2,TABLET,YES,NO,NO,NO,ORAL,760,Discontinued,,NO,NO,,,,,GD SEARLE,major pharma,14720,1940,Drugs@FDA,NO,NO,,,NA,NA,0.6,0.45,8.7,,,,4750644,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,180.164,1,3,1,6,0,0,72.68,0.285714286,-0.0815,0.375,-0.034,Valid estimate for difficult structure,-0.22,-0.22,0,-0.032,8.6,1.48,8.8,1.6,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5326,0.62789,0.33652,0.37977,0.9848,0.98659,0.94806,0.39503,0.82734,232.5,18.9,3.18,6.65
58-15-1,AMINOPYRINE,N/A,PF-01048302,171,Cc1c(c(=O)n(n1C)c2ccccc2)N(C)C,N/A,N/A,N/A,N/A,NO,ORAL,1200,Discontinued,1965,YES,YES,Agranulocytosis,FederalRegister,,,BAYER HEALTHCARE,major pharma,23377,1964,DrugCentral,NO,NO,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,231.2936,0,1,0,4,0,2,30.17,0.307692308,1,1,1.043,All fragments measured,0.35,0.35,1.1,1.094,,4.5,,5,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73427,0.77033,0.65519,0.77071,0.9848,0.59178,0.75963,0.87038,0.82734,215.9,24,9.42,12.9
65-49-6,AMINOSALICYLIC ACID,PARASAL,PF-00344682,2050,c1cc(c(cc1N)O)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,12000,Prescription,,NO,NO,,,,,PANRAY,pharma,17867,1948,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.4,,1.4,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,,,,,,Less,1,Aniline,YES,NO,NO,,153.1354,4,3,3,4,0,1,83.55,0,-0.652,-0.652,1.056,All fragments measured,0.67,-2.6,1.46,-1.681,3.58,2.21,3.7,2.3,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47665,0.57482,0.22357,0.62066,0.88651,0.37866,0.84452,0.63709,0.82734,127.7,8.08,2.13,8.17
1951-25-3,AMIODARONE HYDROCHLORIDE,CORDARONE,PF-00344526,176,CCCCc1c(c2ccccc2o1)C(=O)c3cc(c(c(c3)I)OCCN(CC)CC)I,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,WYETH,major pharma,31405,1985,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.04,60,624,,,,,YES,Cardiovascular,NO,NO,,YES,YES,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Moderate,2,Benzofuran; Organic_Iodide,NO,NO,NO,,645.3116,0,3,0,4,2,11,42.68,0.4,4.76,6.1,8.945,Very high LogP unrealistic in nature,7.5,6.2,7.36,5.417,,9.37,,8.7,Basic,Class 4,0,0,0,0,0,0,2,3,1,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.14412,0.23372,0.04354,0.03988,0.9848,0.59178,0.96876,0.15134,0.25672,345.7,0.754,74.9,62.1
50-48-6,AMITRIPTYLINE HYDROCHLORIDE,ELAVIL,PF-00296683,180,CN(C)CCC=C1c2ccccc2CCc3c1cccc3,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,ASTRAZENECA AB,major pharma,22378,1961,Drugs@FDA,NO,NO,0.48,,High,Reported bioavailability,0.07,8.7,15,,,,434,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,NO,YES,YES,NO,Less,Less,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,277.4033,0,1,0,1,0,3,3.24,0.3,2.71,2.744,4.851,All fragments measured,4.6,3,4.72,2.958,,9.18,,9.1,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76188,0.56465,0.93798,0.57127,0.23327,0.59178,0.26577,0.99269,0.93773,174.2,13,13.8,28.6
88150-42-9,AMLODIPINE BESYLATE,NORVASC,PF-00579887,183,CCOC(=O)C1=C(NC(=C(C1c2ccccc2Cl)C(=O)OC)C)COCCN,"TABLET; TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,PFIZER,major pharma,33816,1992,Drugs@FDA,NO,NO,0.64,,High,Reported bioavailability,0.07,17,30,,9,132,711574523,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable but rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,408.8759,3,5,2,7,0,10,99.88,0.4,1.04,1.464,3.434,Estimated fragment value used,2,0.47,3.42,1.907,,8.97,,9.1,Basic,Class 4,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,2,NO,0.54511,0.54772,0.51896,0.89726,0.33223,0.79222,0.68846,0.21184,0.82734,343.1,5.86,6.39,14.3
86-42-0,AMODIAQUINE HYDROCHLORIDE,CAMOQUIN HYDROCHLORIDE,PF-00344846,186,CCN(CC)Cc1cc(ccc1O)Nc2ccnc3c2ccc(c3)Cl,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,,NO,NO,,,,,PARKE DAVIS,major pharma,22175,1960,Drugs@FDA,NO,NO,0.23,,Moderate,Reported bioavailability,0.01,,,,,,974827,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,Gerren Additions,1,A,Most,A (well established cause of clinically apparent liver injury),,2,Aniline; Hydroxy_Aniline,YES,NO,NO,,355.8612,2,3,2,4,1,6,48.39,0.25,2.45,2.45,5.465,All fragments measured,5.4,2.5,4.42,2.239,9.43,6.33,5.9,12,Zwitter,Class 3A,0,0,0,0,1,0,0,3,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,NO,0.62132,0.66849,0.83823,0.57667,0.88651,0.79222,0.99421,0.6885,0.25672,303.9,2.8,20.8,37
14028-44-5,AMOXAPINE,ASENDIN,PF-00344604,191,c1ccc2c(c1)N=C(c3cc(ccc3O2)Cl)N4CCNCC4,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,LEDERLE,major pharma,29486,1980,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.1,65.7,8,,,,4978876,NO,Neurological,NO,NO,,NO,YES,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,313.7814,1,2,1,4,0,1,36.86,0.235294118,1.31,1.477,3.406,Approximated fragment value used,3.6,2.4,2.85,1.766,,8.62,,8.7,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.88985,0.89962,0.99544,0.99949,0.88651,0.98659,0.91729,0.63709,0.93773,288,8.33,7.85,14.9
26787-78-0,AMOXICILLIN,AMOXIL,PF-00344605,192,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](c3ccc(cc3)O)N)C(=O)O)C,"TABLET; TABLET, CHEWABLE; TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1750,Prescription,,NO,NO,,,,,NEOPHARMA,pharma,29515,1980,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.8,0.25,1,Parent CRG,197,190,12986559,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely but rare cause of clinically apparent liver injury),Moderate,1,Beta_Lactams,NO,NO,NO,,365.4042,5,7,4,8,0,4,132.96,0.4375,-0.489,-0.489,-1.872,Benzyl approx. based on a priori value,0.42,-1.6,0.48,-2.716,2.44,7.14,2.8,7.5,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.37627,0.31904,0.78254,0.05863,0.33223,0.14694,0.18724,0.96969,0.82734,457.8,0.407,3.64,7.14
300-62-9,AMPHETAMINE,DYANAVEL XR,PF-00345699,195,CC(Cc1ccccc1)N,"SUSPENSION, EXTENDED RELEASE; TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,10,Prescription,,NO,NO,,,,,TRIS PHARMA INC,pharma,20341,1955,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.8,6.1,,,33,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,Less,Less,DILIRank,1,A[HD],Most,"A[HD] (well established cause of liver injury, but severe cases occur only with high doses)",Moderate,0,,NO,NO,NO,4XP9,135.2062,2,1,1,1,0,2,26.02,0.333333333,-0.571,-0.571,1.742,All fragments measured,1.8,-0.58,1.82,-0.616,,9.94,,9.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60436,0.5676,0.16968,0.90687,0.23327,0.98659,0.74426,0.87038,0.82734,95.93,49.4,5.67,9.39
69-53-4,AMPICILLIN,PENBRITIN,PF-00345185,198,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)N)C(=O)O)C,"CAPSULE; TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,WYETH,major pharma,23277,1963,PharmaPendium,NO,NO,0.5,,High,Reported bioavailability,0.8,0.3,1.5,Parent CRG,,,693615,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable but rare cause of clinically apparentliver injury),Moderate,1,Beta_Lactams,NO,NO,NO,,349.4048,4,6,3,7,0,4,112.73,0.4375,-0.865,-0.865,-1.204,Benzyl approx. based on a priori value,0.86,-1.1,0.94,-2.38,2.44,6.81,2.8,7.6,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.49017,0.43807,0.87327,0.0699,0.52457,0.37866,0.31825,0.96969,0.82734,440.2,0.86,2.87,7.04
161814-49-9,AMPRENAVIR,AGENERASE,PF-00579963,200,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)c3ccc(cc3)N,CAPSULE; SOLUTION,YES,NO,NO,NO,ORAL,1400,Discontinued,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,36265,1999,Drugs@FDA,NO,NO,,0.89,High,Fa estimated from reported excretion data,0.1,6.1,7,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,1HPV,505.6269,4,3,3,9,1,12,131.19,0.48,2.45,3.023,3.293,All fragments measured,2.9,2.9,3.22,3.224,11.54,1.76,12,1.6,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.31775,0.34837,0.16226,0.98997,0.33223,0.37866,0.30627,0.10729,0.93773,507.7,10.4,22.2,154
68475-42-3,ANAGRELIDE HYDROCHLORIDE,AGRYLIN,PF-06224848,209,c1cc(c(c2c1NC3=NC(=O)CN3C2)Cl)Cl,CAPSULE,YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,,,SHIRE,major pharma,35503,1997,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,,12,1.5,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E*,Ambiguous,"E* (unlikely, but suspected rare cause of clinically apparent liver injury)",Less,0,,NO,NO,NO,,256.0881,1,2,1,4,0,0,44.7,0.2,2.07,2.514,1.802,Calculated fragment value,2.6,2.6,2.28,2.319,,2.08,,4.2,Neutral,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.74981,0.81761,0.82408,0.95211,0.9848,0.98659,0.98035,0.39503,0.82734,253.1,13.3,5.24,56.4
120511-73-1,ANASTROZOLE,ARIMIDEX,PF-00346590,210,CC(C)(C#N)c1cc(cc(c1)C(C)(C)C#N)Cn2cncn2,TABLET,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,,,ANI PHARMS,pharma,35060,1995,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.6,,50,,87,,787269,NO,Oncology,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,1,Imidazole_Triazole,NO,NO,NO,,293.3663,0,1,0,5,0,4,78.29,0.411764706,1.13,1.178,1.475,All fragments measured,0.89,0.89,2.68,2.675,,3.22,,3.9,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87603,0.88265,0.98758,0.99831,0.88651,0.59178,0.88739,0.96969,0.93773,224.9,24.6,5.71,9.2
144-14-9,ANILERIDINE HYDROCHLORIDE,LERITINE,PF-00345340,220,CCOC(=O)C1(CCN(CC1)CCc2ccc(cc2)N)c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,Abuse potential,,,,MERCK,major pharma,20690,1956,PharmaPendium,NO,NO,,,NA,NA,0.05,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,Gerren Additions,0,,,,,1,Aniline,YES,NO,NO,,352.4699,2,2,1,4,0,7,55.56,0.409090909,2.37,2.719,3.097,All fragments measured,4,2.9,3.18,2.216,,8.41,,8.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82221,0.86213,0.85696,0.94609,0.88651,0.98659,0.9985,0.53315,0.93773,238.7,10.9,34.8,27.3
117-37-3,ANISINDIONE,MIRADON,PF-00345542,222,COc1ccc(cc1)C2C(=O)c3ccccc3C2=O,TABLET,YES,NO,NO,NO,ORAL,250,Discontinued,,NO,NO,,,,,SCHERING,major pharma,20915,1957,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.01,,96,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,1_3_Diketones,NO,NO,NO,,252.2647,0,3,0,3,0,2,43.37,0.125,1.28,1.28,2.729,Benzyl approx. based on a priori value,3.1,0.7,2.97,2.946,8.64,,3.8,,Neutral,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81952,0.86762,0.79959,0.99999,0.9848,0.59178,0.97306,0.87038,0.93773,193.2,16.6,40.6,59
80-50-2,ANISOTROPINE METHYLBROMIDE,VALPIN 50,PF-00345488,223,CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C,TABLET,YES,NO,NO,NO,ORAL,150,Discontinued,,NO,NO,,,,,ENDO PHARMS,pharma,22973,1962,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,282.4415,0,2,0,3,0,7,26.3,0.941176471,0.794,0.794,-0.816,Approximated fragment value used,-0.19,-0.19,-0.14,-0.144,,,,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.67936,0.71705,0.95747,0.97865,0.93048,0.59178,0.74989,0.53315,0.47245,267.7,0.444,24.8,13.2
956104-40-8,APALUTAMIDE,ERLEADA,PF-05040013,5278,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C23CCC3)c4cc(c(nc4)C#N)C(F)(F)F,TABLET,YES,NO,NO,YES,ORAL,240,Prescription,,NO,NO,,,Aragon pharmaceuticals,pharma,JANSSEN PHARMS,major pharma,43145,2018,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.04,3.9,72,,,,,NO,Oncology,NO,NO,,NO,NO,NO,YES,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,2,Aniline; Thiourea,YES,NO,NO,,477.4347,1,4,1,7,0,3,89.33,0.285714286,2.12,3.7,2.138,Calculated fragment value,2.5,2.5,1.38,1.829,,,13,-4.4,Neutral,Class 2,0,4,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.65632,0.65081,0.22933,0.70942,0.72615,0.98659,0.46663,0.96969,0.93773,473.6,18.9,2.21,11.1
503612-47-3,APIXABAN,ELIQUIS,PF-04652577,4298,COc1ccc(cc1)n2c3c(c(n2)C(=O)N)CCN(C3=O)c4ccc(cc4)N5CCCCC5=O,TABLET,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,BRISTOL MYERS SQUIBB,major pharma,41271,2012,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.13,0.3,6.8,,,21,606192506,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,Less,,,D,Less,D (possible rare cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,2P16,459.4971,2,5,1,9,0,5,110.76,0.28,2.22,2.342,1.892,Valid estimate for difficult structure,2.5,2.5,0.87,0.867,,,13,-0.57,Neutral,Class 2,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57504,0.59258,0.28623,0.9998,0.72615,0.98659,0.57518,0.84757,0.25672,467.8,8.05,11.7,25.8
608141-41-9,APREMILAST,OTEZLA,PF-06648994,4829,CCOc1cc(ccc1OC)[C@@H](CS(=O)(=O)C)N2C(=O)c3cccc(c3C2=O)NC(=O)C,TABLET,YES,NO,NO,YES,ORAL,60,Prescription,,NO,NO,,,Celgene,major pharma,CELGENE,major pharma,41719,2014,Drugs@FDA,NO,NO,0.73,,High,Reported bioavailability,0.32,1.2,7.5,,,123,,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,,None,,,E,None,"E (unlikely cause of clinically apparent liver injury, but experience with its use is limited)",Less,1,Aniline,YES,NO,NO,,460.5002,1,5,1,9,0,8,119.08,0.318181818,1.19,1.95,1.461,Benzyl approx. based on a priori value,0.77,0.77,1.71,1.714,,,15,,Neutral,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57697,0.53525,0.28272,0.88552,0.33223,0.98659,0.40907,0.39983,0.93773,485.8,3.44,4.23,11.4
170729-80-3,APREPITANT,EMEND,PF-01554086,230,C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)Cc3[nH]c(=O)[nH]n3)c4ccc(cc4)F,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,125,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,37706,2003,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,0.05,1,9,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,534.4267,2,3,2,7,1,6,83.24,0.391304348,3.96,3.96,4.596,Benzyl approx. based on a priori value,4.1,4.1,3.85,3.611,8.06,4.38,5,3.8,Acidic,Class 3B,0,7,0,0,0,0,0,3,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,0,2,0,0,NO,0.44195,0.54539,0.11564,0.6322,0.72615,0.79222,0.9102,0.39983,0.93773,502.5,1.5,36.2,54.3
129722-12-9,ARIPIPRAZOLE,ABILIFY,PF-00619124,242,c1cc(c(c(c1)Cl)Cl)N2CCN(CC2)CCCCOc3ccc4c(c3)NC(=O)CC4,"SOLUTION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,Otsuka Pharmaceutical ,pharma,OTSUKA,pharma,37575,2002,Drugs@FDA,NO,NO,0.87,,High,Reported bioavailability,0.01,4.9,75,,24,144,,YES,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,448.3854,1,3,1,5,1,7,44.81,0.434782609,3.72,5.033,5.312,All fragments measured,5.2,4.4,5.21,4.993,11.48,7.67,14,7.7,Basic,Class 4,0,0,0,0,2,0,0,2,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.59571,0.67833,0.32793,0.4698,0.88651,0.98659,0.9809,0.53315,0.93773,384.3,3.29,14.8,15.4
112111-43-0,ARMODAFINIL,NUVIGIL,VC-001215204,4501,c1ccc(cc1)C(c2ccccc2)[S@](=O)CC(=O)N,TABLET,YES,NO,NO,NO,ORAL,250,Prescription,,NO,NO,,,Teva,major pharma,CEPHALON,pharma,39248,2007,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.4,0.6,15,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,273.3501,2,2,1,3,0,5,60.16,0.133333333,1.5,1.593,0.937,Benzyl approx. based on a priori value,1.2,1.2,1.37,1.367,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91918,0.9167,0.91997,0.92209,0.93048,0.98659,0.87892,0.84757,0.93773,244.4,20,8.74,8.81
71963-77-4,ARTEMETHER,COARTEM,PF-00579958,245,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,Sanofi,major pharma,NOVARTIS,major pharma,39910,2009,Drugs@FDA,YES,NO,,,NA,NA,0.046,6,1,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,,LiverTox Additions,0,,,,Less,0,,NO,NO,NO,,298.3746,0,3,0,5,0,1,46.15,1,2.27,2.638,3.055,Estimated fragment value used,3.4,3.4,3.08,3.084,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,NO,0.71124,0.7403,0.99544,0.95904,0.72615,0.59178,0.98688,0.63709,0.47245,405.8,33.6,20.3,38.2
50-78-2,ASPIRIN,ASPIRIN,PF-00345190,74,CC(=O)Oc1ccccc1C(=O)O,"CAPSULE; CAPSULE, EXTENDED RELEASE; TABLET; TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,3900,Over-the-counter,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,23918,1965,Drugs@FDA,NO,NO,0.68,,High,Reported bioavailability,0.51,0.15,0.5,Parent CRG,,,26589712,NO,"Cardiovascular, Musculoskeletal/Pain",YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A[HD],Most,"A[HD] (well established cause of liver injury, but severe cases occur only with high doses)",Moderate,0,,NO,NO,NO,,180.1574,1,2,1,4,0,3,63.6,0.111111111,-1.19,-1.19,1.023,All fragments measured,1.6,-1.7,1.39,-1.689,3.48,,3.5,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73438,0.79202,0.33648,0.8284,0.88651,0.98659,0.97641,0.99269,0.82734,148.5,17.6,10.5,7.48
68844-77-9,ASTEMIZOLE,HISMANAL,PF-00344530,249,COc1ccc(cc1)CCN2CCC(CC2)Nc3nc4ccccc4n3Cc5ccc(cc5)F,TABLET,YES,NO,NO,NO,ORAL,10,Discontinued,1999,YES,YES,Heart arrhythmia,FederalRegister,,,JANSSEN PHARMS,major pharma,32508,1988,DrugCentral,YES,NO,,0.7,High,Fa estimated from reported excretion data,0.033,3.6,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,Gerren Additions,0,,,,,1,2_AminoImidazole_2_AminoThiazole,NO,NO,NO,,458.5703,1,3,1,5,1,8,42.32,0.321428571,3.9,5,5.837,All fragments measured,5.8,5.2,5.64,4.207,,8.68,,8.4,Basic,Class 4,0,1,0,0,0,0,0,4,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.28277,0.35629,0.28952,0.21572,0.88651,0.98659,0.96637,0.39983,0.03452,378.3,0.311,38.3,110
198904-31-3,ATAZANAVIR SULFATE,REYATAZ,PF-01369715,254,CC(C)(C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)[C@H](CN(Cc2ccc(cc2)c3ccccn3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,"CAPSULE, POWDER",YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Novartis,major pharma,BRISTOL MYERS SQUIBB,major pharma,37792,2003,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.14,,8,,94,141,18337012,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,"D (possible, rare cause of clinically apparent liver injury)",Moderate,0,,NO,NO,NO,2AQU,704.8555,5,6,5,13,3,16,171.22,0.447368421,4.34,5,5.922,Benzyl approx. based on a priori value,4.5,4.2,4.61,4.633,11.11,5.32,9.9,4.8,Neutral,Class 2,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.06866,0.09105,0.03357,0.60795,0.10671,0.05547,0.13129,0.01273,0.25672,681.6,1.66,13.8,153
29122-68-7,ATENOLOL,TENORMIN,PF-00344852,255,CC(C)NCC(COc1ccc(cc1)CC(=O)N)O,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,ALVOGEN MALTA,pharma,29817,1981,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.94,0.95,6,,,,385813,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (Possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,266.3361,4,4,3,5,0,8,84.58,0.5,-1.08,-1.894,-0.109,All fragments measured,0.35,-1.5,0.24,-1.855,,9.43,13,9.2,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59266,0.6623,0.8844,0.68117,0.88651,0.37866,0.83561,0.39983,0.82734,224.7,3.65,2.81,8.98
83015-26-3,ATOMOXETINE HYDROCHLORIDE,STRATTERA,PF-00514723,256,Cc1ccccc1O[C@H](CCNC)c2ccccc2,CAPSULE,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Eli Lilly,major pharma,ELI LILLY AND CO,major pharma,37586,2002,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,0.02,0.85,4.5,,63,145,1050896,NO,Neurological,NO,NO,,NO,NO,YES,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,255.3547,1,2,1,2,0,6,21.26,0.294117647,1.25,1.2,3.937,Benzyl approx. based on a priori value,3.6,1.3,3.66,0.982,,10.15,,9.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85452,0.84045,0.81945,0.94997,0.93048,0.98659,0.64201,0.6885,0.93773,199.6,8.26,10.2,19.3
134523-00-5,ATORVASTATIN CALCIUM,LIPITOR,PF-00079943,257,CC(C)c1c(c(c(n1CC[C@H](C[C@H](CC(=O)O)O)O)c2ccc(cc2)F)c3ccccc3)C(=O)Nc4ccccc4,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,PFIZER,major pharma,35416,1996,Drugs@FDA,NO,NO,0.14,,Moderate,Reported bioavailability,0.02,5.4,14,,1,60,2082792333,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Less,2,Aniline; Pyrrole,YES,NO,NO,1HWK,558.6398,4,5,4,7,1,12,111.79,0.272727273,2.65,1.238,4.457,All fragments measured,5.9,3.2,4.36,1.251,4.29,,4.4,,Acidic,Class 3B,0,1,0,0,0,0,0,4,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.11155,0.1751,0.08877,0.25478,0.72615,0.14694,0.56446,0.10729,0.03452,472.6,1.08,14.2,14.3
95233-18-4,ATOVAQUONE,MEPRON,PF-06264004,258,c1cc2c(cc1)C(=O)C(=C(C2=O)[C@H]3CC[C@@H](CC3)c4ccc(cc4)Cl)O,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,33933,1992,Drugs@FDA,NO,NO,0.47,,High,Reported bioavailability,0.001,0.6,63,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4PD4,366.8375,1,3,1,3,1,2,54.37,0.272727273,3.51,4.657,6.351,All fragments measured,5.5,2.8,4.85,2.497,5.01,,5.2,,Acidic,Class 3A,0,0,0,0,1,0,0,3,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7638,0.7982,0.77389,0.33653,0.9848,0.98659,0.99957,0.87038,0.93773,267.2,2.89,26.5,12.8
51-55-8,ATROPINE SULFATE,LOMOTIL,PF-06700564,260,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(CO)c3ccccc3,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,22174,1960,Drugs@FDA,YES,NO,,,High,Based on textual comment,0.66,3.5,,,,,6399322,NO,"Cardiovascular, Gastrointestinal",NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,289.3694,1,3,1,4,0,5,49.77,0.588235294,-0.3,-0.3,1.299,All fragments measured,2.2,0.71,1.86,-0.467,,9.81,14,9.3,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91452,0.91833,0.97858,0.92033,0.88651,0.98659,0.99719,0.84757,0.82734,305,4.95,14.3,7.25
330784-47-9,AVANAFIL,STENDRA,VC-001215203,4305,COc1ccc(cc1Cl)CNc2c(cnc(n2)N3CCC[C@H]3CO)C(=O)NCc4ncccn4,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Mitsubishi Tanabe Pharma,pharma,METUCHEN PHARMS,pharma,41026,2012,Drugs@FDA,NO,NO,,0.83,High,Fa estimated from reported excretion data,0.01,,5,,,,,NO,Genitourinary,YES,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproved but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,483.9506,3,7,3,10,0,9,125.39,0.347826087,2.74,2.409,2.357,Approximated fragment value used,1.2,1.2,3.19,3.039,11.84,5.89,7,6.4,Neutral,Class 1B,0,0,0,0,1,0,0,3,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,NO,0.33554,0.30883,0.21158,0.97193,0.10671,0.37866,0.42832,0.29329,0.25672,492,12.4,33.2,68.4
677007-74-8,AVATROMBOPAG MALEATE,DOPTELET,PF-03730648,,c1c(cnc(c1Cl)N2CCC(CC2)C(=O)O)C(=O)Nc3nc(c(s3)N4CCN(CC4)C5CCCCC5)c6cc(cs6)Cl,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,AkaRx,pharma,AKARX INC,pharma,43241,2018,Drugs@FDA,NO,NO,0.83,,High,Reported bioavailability,0.04,2.6,19,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Thiophene,NO,NO,YES,,649.6547,2,7,2,9,1,7,101.9,0.517241379,4.25,4.25,4.129,All fragments measured,7.1,4.8,5.63,2.985,4.42,7.51,4.9,6.8,Zwitter,Class 3B,0,0,0,0,2,0,0,3,0,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,2,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.30834,0.28601,0.04247,0.95227,0.19128,0.79222,0.18663,0.53315,0.25672,590.4,0.117,20.4,23.3
319460-85-0,AXITINIB,INLYTA,PF-01367866,4225,CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,40935,2012,Drugs@FDA,NO,NO,0.58,,High,Reported bioavailability,0.01,2.3,4.3,,,,274559244,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,FEARS Addition ,1,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,4AGC,386.4695,2,4,2,5,0,5,70.67,0.045454545,3.97,3.225,3.327,All fragments measured,4,4,3.65,3.657,12.2,4.3,11,3.8,Neutral,Class 2,0,0,0,0,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.45469,0.48985,0.65246,0.6931,0.88651,0.79222,0.72814,0.84757,0.03452,363.7,4.31,33.3,56
2169-64-4,AZARIBINE,TRIAZURE,PF-00346105,27,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n2c(=O)[nH]c(=O)cn2)OC(=O)C)OC(=O)C,N/A,N/A,N/A,N/A,NO,ORAL,,Discontinued,1976,YES,YES,thromboembolism,FederalRegister,,,PARKE DAVIS,major pharma,27395,1975,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,371.2995,1,7,1,12,1,8,155.88,0.571428571,-0.669,-0.669,0.19,A priori fragment value used,-0.81,-1.8,-0.16,-0.348,7.65,,6.4,0,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.47453,0.31841,0.74662,0.16425,0.06191,0.98659,0.23449,0.39983,0.47245,515.5,2.25,7.6,8.38
3964-81-6,AZATADINE MALEATE,OPTIMINE,PF-00344855,268,CN1CCC(=C2c3ccccc3CCc4c2nccc4)CC1,TABLET,YES,NO,NO,NO,ORAL,2,Discontinued,,NO,NO,,,,,SCHERING,major pharma,28213,1977,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,1,,9,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,Gerren Additions,1,,,,,0,,NO,NO,NO,,290.4021,0,2,0,2,0,0,16.13,0.35,2.12,2.187,3.559,All fragments measured,3.9,2.7,4.14,2.631,,8.74,,9.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69278,0.7068,0.98113,0.83918,0.93048,0.59178,0.52472,0.39503,0.93773,220.6,11.1,15.9,14.8
446-86-6,AZATHIOPRINE,IMURAN,PF-00344689,269,Cn1cnc(c1Sc2c-3ncnc3nc[nH]2)N(=O)=O,TABLET,YES,NO,NO,NO,ORAL,175,Prescription,,NO,NO,,,,,SEBELA IRELAND LTD,pharma,24917,1968,Drugs@FDA,NO,NO,0.474,,High,Reported bioavailability,0.7,0.8,5,,,,,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),None,2,Nitroorganics; Reactive_HeteroCycle,NO,NO,NO,,277.2626,1,7,1,9,0,3,118.1,0.111111111,1.13,1.11,0.107,All fragments measured,0.37,-0.51,-0.19,-0.529,,7.47,8.1,2.7,Basic,Class 3A,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72688,0.55987,0.93739,0.79227,0.33223,0.98659,0.27797,0.99269,0.25672,355.8,4.08,5.08,12.6
863031-21-4,AZILSARTAN KAMEDOXOMIL,EDARBI,VC-001215202,4322,CCOc1nc2cccc(c2n1Cc3ccc(cc3)c4ccccc4c5[nH]c(=O)on5)C(=O)OCc6c(oc(=O)o6)C,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Takeda,major pharma,ARBOR PHARMS LLC,pharma,40599,2011,Drugs@FDA,NO,YES (Presystemic),0.6,,High,Reported bioavailability,0.01,0.2,11,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,,,,E*,Ambiguous,E* (Unproved but suspected rare cause of clinically apparent liver injury),,0,,NO,NO,NO,,568.5336,1,6,1,12,2,10,155.59,0.166666667,2.5,2.5,4.243,Calculated fragment value,6.7,6.7,4.57,2.739,4.91,4.07,2.9,2.1,Acidic,Class 3B,0,0,0,0,0,0,0,4,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.18675,0.16879,0.08024,0.35545,0.06191,0.98659,0.30627,0.21184,0.03452,587,0.619,18.5,38.2
83905-01-5,AZITHROMYCIN,ZITHROMAX,PF-00345344,276,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,"CAPSULE, FOR SUSPENSION, FOR SUSPENSION, EXTENDED RELEASE, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,PFIZER,major pharma,33543,1991,Drugs@FDA,NO,NO,0.38,,High,Reported bioavailability,0.88,31.1,68,,,,275190175,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4V7Y,748.9845,5,13,5,14,2,7,180.08,0.973684211,0.624,0.6962,2.638,All fragments measured,2.2,0.02,3.29,1.36,,8.59,13,8.8,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,YES,0.17447,0.13727,0.03027,0.96397,0.02183,0.05547,0.10315,0.53315,0.47245,1027,0.448,2.2,36.1
50972-17-3,BACAMPICILLIN HYDROCHLORIDE,SPECTROBID,PF-00345191,280,CCOC(=O)OC(C)OC(=O)[C@H]1C(S[C@H]2N1C(=O)[C@H]2NC(=O)[C@@H](c3ccccc3)N)(C)C,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1600,Discontinued,,NO,NO,,,,,PFIZER,major pharma,29577,1980,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.8,0.4,1.1,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,1,Beta_Lactams,NO,NO,NO,,465.52,3,6,2,10,0,10,137.26,0.523809524,1.4,1.588,2.064,Benzyl approx. based on a priori value,1.1,0.87,1.44,1.366,12.16,6.81,14,7.1,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.4453,0.34373,0.26574,0.86472,0.10671,0.79222,0.16653,0.21184,0.82734,568.3,2.74,80,36.2
1134-47-0,BACLOFEN,LIORESAL,PF-00344602,282,c1cc(ccc1C(CC(=O)O)CN)Cl,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,28451,1977,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,,0.8,5,,,,,YES,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,"D (Possible, rare cause of clinically apparent liver injury)",Less,0,,NO,NO,NO,4MS4,213.6608,3,3,2,3,0,4,63.32,0.3,-0.508,-0.508,-0.62,All fragments measured,1.4,-0.89,1.56,-0.943,4.04,10.33,3.9,9.6,Zwitter,Class 3A,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.62323,0.67841,0.53328,0.20269,0.9848,0.79222,0.9776,0.96969,0.82734,138.8,1.99,5.27,7.34
1985606-14-1,BALOXAVIR MARBOXIL,XOFLUZA,VC-001215240,,COC(=O)OCOc1c(=O)ccn2c1C(=O)N3CCOC[C@H]3N2[C@@H]4c5ccccc5SCc6c4ccc(c6F)F,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Shionogi,pharma,GENENTECH,major pharma,43397,2018,Drugs@FDA,NO,NO,,0.15,Moderate,Fa estimated from reported excretion data,0.06,16.9,79,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,1,Michael_acceptor,NO,YES,NO,,571.5492,0,5,0,10,1,6,99.54,0.296296296,2.38,3.256,2.362,Benzyl approx. based on a priori value,1.4,1.4,2.39,2.441,,,,5.4,Neutral,Class 2,0,2,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,8,0,0,0,4,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,NO,0.43581,0.36272,0.07787,0.99691,0.06191,0.59178,0.44975,0.6885,0.93773,629.3,7.32,47.8,107
1187594-09-7,BARICITINIB,OLUMIANT,PF-06647511,5202,CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,Incyte,pharma,ELI LILLY AND CO,major pharma,43251,2018,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.5,1,12,,,,,NO,Autoimmune Disease,NO,YES,I,NO,NO,NO,NO,,None,,,E*,Ambiguous,E* (unlikely to be a cause of idiosyncratic clinically apparent liver injury but has had limited general availability and was associated with ALT elevations in prelicensure clinical trials),None,0,,NO,NO,NO,4W9X,371.4169,1,3,1,9,0,5,120.56,0.375,1.5,1.244,0.372,A priori fragment value used,-0.05,-0.05,0.14,0.798,11.66,3.71,8.8,4.2,Neutral,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.6464,0.56961,0.7459,0.58571,0.52457,0.98659,0.39544,0.84757,0.25672,411.8,10,2.74,7.23
198481-32-2,BAZEDOXIFENE ACETATE,DUAVEE,PF-05208749,4334,Cc1c2cc(ccc2n(c1c3ccc(cc3)O)Cc4ccc(cc4)OCCN5CCCCCC5)O,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Ligand Pharmaceuticals,pharma,WYETH,major pharma,41550,2013,Drugs@FDA,YES,NO,0.06,,Low,Reported bioavailability,0.01,14.7,28,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,E*,Ambiguous,"E* (unlikely cause of clinically apparent liver injury, but suspected to be capable of causing the liver injury reported with other SERMs and estrogens)",,0,,NO,NO,NO,4XI3,470.6026,2,4,2,5,1,7,57.86,0.333333333,3.2,3.25,7.148,Very high LogP unrealistic in nature,6.6,5.1,5.84,4.366,10.12,8.85,9.6,8.4,Basic,Class 4,0,0,0,0,0,0,0,4,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.21499,0.27838,0.24956,0.04037,0.88651,0.79222,0.99468,0.53315,0.03452,372.6,4.49,33.3,47.5
843663-66-1,BEDAQUILINE FUMARATE,SIRTURO,PF-06971646,4741,CN(C)CC[C@@](c1cccc2c1cccc2)([C@H](c3ccccc3)c4cc5cc(ccc5nc4OC)Br)O,TABLET,YES,NO,NO,YES,ORAL,85.71,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,JANSSEN PHARMS,major pharma,41271,2012,Drugs@FDA,NO,NO,,,NA,NA,0.001,2.3,3960,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,,555.5047,1,5,1,4,2,8,45.59,0.21875,4.48,4.62,7.251,Very high LogP unrealistic in nature,7.7,6.4,6.86,5.275,,9.31,13,8.3,Basic,Class 4,0,0,0,0,0,1,0,5,2,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,4,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.148,0.21245,0.09174,0.05057,0.88651,0.98659,0.98453,0.39983,0.01222,435,1.97,16.2,52
86541-75-5,BENAZEPRIL HYDROCHLORIDE,LOTENSIN,PF-00579889,299,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CCc3ccccc3N(C2=O)CC(=O)O,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,33414,1991,Drugs@FDA,NO,YES,0.37,,High,Reported bioavailability,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,424.4895,2,5,2,7,0,10,95.94,0.375,0.568,0.1375,1.824,All fragments measured,3.6,0.15,2.84,-0.708,3.73,5.27,2.9,4.8,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.51552,0.5609,0.4356,0.66678,0.52457,0.79222,0.72844,0.21184,0.93773,402.7,1.9,30.6,12.7
73-48-3,BENDROFLUMETHIAZIDE,NATURETIN-2.5,PF-00344853,305,c1ccc(cc1)CC2Nc3cc(c(cc3S(=O)(=O)N2)S(=O)(=O)N)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,15,Discontinued,,NO,NO,,,,,APOTHECON,pharma,21891,1959,Drugs@FDA,NO,NO,,,NA,NA,,1.48,3,,,,1625046,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,E,None,E (unlikely causes of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,421.4146,4,4,3,7,0,3,118.36,0.2,2.08,2.404,1.727,All fragments measured,1.8,1.8,1.49,1.485,9.29,,8.8,0.74,Neutral,Class 4,0,3,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.65042,0.62253,0.45124,0.93961,0.72615,0.37866,0.34179,0.96969,0.93773,411.1,0.819,7.69,14
51234-28-7,BENOXAPROFEN,ORAFLEX,PF-06286719,311,CC(c1ccc2c(c1)nc(o2)c3ccc(cc3)Cl)C(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,1200,Discontinued,1982,YES,YES,Fatal cholestatic jaundice,FederalRegister,,,ELI LILLY AND CO,major pharma,29952,1982,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,0,,NO,NO,NO,,301.7244,1,3,1,4,0,3,63.33,0.125,1.45,1.45,3.824,All fragments measured,4.2,1.2,3.91,1.283,4.36,,3.7,0.49,Acidic,Class 1A,0,0,0,0,1,0,0,3,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.77749,0.79667,0.99855,0.84272,0.9848,0.98659,0.97752,0.99269,0.25672,265.6,16.5,4.88,8.9
1379679-42-1,BENZHYDROCODONE HYDROCHLORIDE,APADAZ,VC-001215245,,CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=CC[C@H]3[C@H]1C5)OC(=O)c6ccccc6)OC,TABLET,YES,NO,NO,NO,ORAL,80.04,Prescription,,NO,NO,,,KemPharm,pharma,KEMPHARM,pharma,43154,2018,Drugs@FDA,YES,YES,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,403.4703,0,4,0,5,0,4,48,0.4,1.81,2.106,3.995,Benzyl approx. based on a priori value,3,2.2,3.72,3.07,,7.95,,8.7,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,6,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.759,0.79283,0.54992,0.92264,0.72615,0.59178,0.99317,0.96969,0.93773,433,17.9,22.2,50
22994-85-0,BENZNIDAZOLE,BENZNIDAZOLE,PF-00346227,322,c1ccc(cc1)CNC(=O)Cn2ccnc2N(=O)=O,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Roche,major pharma,CHEMO RESEARCH SL,pharma,42976,2017,Drugs@FDA,NO,NO,0.92,,High,Reported bioavailability,0.56,0.3,12,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Moderate,1,Nitroorganics,NO,NO,NO,,260.2487,1,4,1,7,0,5,92.74,0.166666667,2.55,2.077,0.9,All fragments measured,0.5,0.5,1.09,1.093,,,13,-0.5,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87563,0.85984,0.8496,0.77408,0.88651,0.98659,0.76005,0.84757,0.93773,263.7,23.9,14.4,11.6
156-08-1,BENZPHETAMINE HYDROCHLORIDE,DIDREX,PF-00346544,329,C[C@@H](Cc1ccccc1)N(C)Cc2ccccc2,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,22215,1960,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,239.3553,0,1,0,1,0,5,3.24,0.294117647,2.06,2.712,4.382,All fragments measured,3.8,2.5,4.25,2.767,,8.88,,8.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73035,0.55762,0.71188,0.80759,0.23327,0.59178,0.26577,0.84757,0.93773,171,22.2,18.1,41.1
91-33-8,BENZTHIAZIDE,EXNA,PF-00344768,332,c1ccc(cc1)CSCC2=NS(=O)(=O)c3cc(c(cc3N2)Cl)S(=O)(=O)N,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,AH ROBINS INC,pharma,22203,1960,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,431.9374,3,6,2,7,0,5,118.69,0.133333333,1.89,1.89,2.113,Approximated fragment value used,1.5,1.5,2.04,1.913,9.57,,7,5.2,Neutral,Class 3B,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.70324,0.5796,0.39938,0.95222,0.52457,0.79222,0.17494,0.84757,0.93773,411.5,1.69,16.2,21.1
86-13-5,BENZTROPINE MESYLATE,COGENTIN,PF-00344608,333,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c3ccccc3)c4ccccc4,TABLET,YES,NO,NO,NO,ORAL,6,Prescription,,NO,NO,,,,,MERCK,major pharma,19788,1954,Drugs@FDA,NO,NO,0.29,,Moderate,Reported bioavailability,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,307.4293,0,2,0,2,0,4,12.47,0.428571429,2.36,2.4,3.52,All fragments measured,4.7,2.9,4.71,2.319,,9.88,,9.5,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.85223,0.79355,0.99985,0.89426,0.93048,0.59178,0.44264,0.96969,0.93773,289.7,20.5,15.2,17.4
64706-54-3,BEPRIDIL HYDROCHLORIDE,BEPADIN,PF-00344532,342,CC(C)COCC(CN(Cc1ccccc1)c2ccccc2)N3CCCC3,TABLET,YES,NO,NO,NO,ORAL,300,Discontinued,2004,YES,NO,QTc prolongation,MicroMedex,,,MEDPOINTE PHARM HLC,pharma,33235,1990,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.05,8,42,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,,,Gerren Additions,1,,,,,1,Aniline,YES,NO,NO,,366.5396,0,2,0,3,1,10,15.71,0.5,3.83,4.45,6.2,Benzyl approx. based on a priori value,5.4,4.6,5.14,3.402,,9.21,,7.7,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.50296,0.55652,0.77569,0.35741,0.9848,0.59178,0.51513,0.21184,0.93773,280.1,2.98,39.6,261
7235-40-7,BETA CAROTENE,SOLATENE,PF-00345493,345,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(CCCC2(C)C)C)\C)\C)/C)/C,CAPSULE,YES,NO,NO,NO,ORAL,300,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,27588,1975,PharmaPendium,NO,NO,,,NA,NA,,,,,,,698322,NO,Metabolic Disease,NO,NO,,NO,NO,NO,NO,,,,,,,,None,0,,NO,NO,NO,,536.8726,0,0,0,0,2,10,0,0.45,4.27,6.6,15.232,Very high LogP unrealistic in nature,9,9,13.64,13.663,,,,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.1788,0.13885,0.11248,0.02416,0.02838,0.59178,0.21777,0.21184,0.47245,276.4,0.0813,47.7,24.6
590-46-5,BETAINE,CYSTADANE,PF-00345108,347,C[N+](C)(C)CC(=O)O,FOR SOLUTION,YES,NO,NO,NO,ORAL,10500,Prescription,,NO,NO,,,,,ORPHAN EUROPE,pharma,35363,1996,Drugs@FDA,NO,NO,,,NA,NA,,,14,,,,,YES,Gastrointestinal,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,118.1543,1,3,1,3,0,2,37.3,0.8,-2.13,-2.13,-4.173,Approximated fragment value used,-4.1,-3.5,-3.72,-3.113,1.8,,1.9,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.39676,0.48084,0.13109,0.13024,0.93048,0.98659,0.92207,0.87038,0.47245,77.63,1.98,1.66,14.3
378-44-9,BETAMETHASONE,CELESTONE,PF-00345196,348,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,7.2,Discontinued,,NO,NO,,,,,SCHERING,major pharma,22388,1961,Drugs@FDA,NO,NO,,,NA,NA,0.36,1.2,,,,,,NO,"Anti-infective, Autoimmune Disease, Cardiovascular, Metabolic Disease, Respiratory",NO,NO,,NO,NO,NO,YES,,Less,,,,,,Less,0,,NO,NO,NO,1M2Z,392.4611,3,5,3,5,0,2,94.83,0.727272727,2.02,2.058,1.785,All fragments measured,1.7,1.7,1.92,1.916,12.13,,11,,Neutral,Class 2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.61663,0.64664,0.61563,0.91839,0.72615,0.37866,0.73951,0.87038,0.47245,458.5,10.8,9.17,10.1
63659-18-7,BETAXOLOL HYDROCHLORIDE,KERLONE,PF-00345343,356,CC(C)NCC(COc1ccc(cc1)CCOCC2CC2)O,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,32808,1989,Drugs@FDA,NO,NO,0.89,,High,Reported bioavailability,0.45,9,16,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,307.4278,2,4,2,4,0,11,50.72,0.666666667,0.686,0.5839,2.319,All fragments measured,2.6,0.71,2.87,0.764,,9.43,16,9.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.60993,0.70604,0.99985,0.99615,0.88651,0.79222,0.9986,0.15134,0.82734,234.3,17.8,7.09,8.59
674-38-4,BETHANECHOL CHLORIDE,URECHOLINE,PF-00344691,358,CC(C[N+](C)(C)C)OC(=O)N,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,ODYSSEY PHARMS,pharma,17818,1948,Drugs@FDA,NO,NO,,,Low,Based on textual comment,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,161.2221,2,3,1,4,0,4,52.32,0.857142857,-1.48,-1.48,-4.01,Approximated fragment value used,-3.9,-3.9,-3.9,-3.897,12.81,,14,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5066,0.58043,0.25311,0.20852,0.93048,0.98659,0.99986,0.96969,0.47245,148.5,1.44,1.66,6.65
55-73-2,BETHANIDINE SULFATE,TENATHAN,PF-00346418,359,CNC(=NCc1ccccc1)NC,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,ROBINS AH,pharma,29735,1981,Drugs@FDA,NO,NO,,0.61,High,Fa estimated from reported excretion data,0.92,2.7,9,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,177.2462,2,2,2,3,0,4,36.42,0.3,-0.171,-0.171,0.966,Benzyl approx. based on a priori value,1.6,-1.8,1.5,-0.48,,,,8.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69165,0.76396,0.32232,0.82524,0.9848,0.79222,0.91223,0.96969,0.82734,118.5,16.3,8.88,8.56
330942-05-7,BETRIXABAN,BEVYXXA,VC-001215206,5241,CN(C)C(=N)c1ccc(cc1)C(=O)Nc2ccc(cc2C(=O)Nc3ccc(cn3)Cl)OC,CAPSULE,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Takeda,major pharma,PORTOLA PHARMS INC,pharma,42909,2017,Drugs@FDA,NO,NO,0.34,,High,Reported bioavailability,0.4,,23,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),None,1,Aniline,YES,NO,NO,,451.9055,3,6,3,8,0,7,107.41,0.130434783,2.09,2.275,3.609,Calculated fragment value,4.1,0.57,3.16,1.147,8.41,,11,10,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.43621,0.4943,0.31416,0.9994,0.72615,0.37866,0.61018,0.53315,0.25672,409.6,2.27,12.8,15.2
153559-49-0,BEXAROTENE,TARGRETIN,PF-01482451,361,Cc1cc2c(cc1C(=C)c3ccc(cc3)C(=O)O)C(CCC2(C)C)(C)C,CAPSULE,YES,NO,NO,NO,ORAL,750,Prescription,,NO,NO,,,,,VALEANT,pharma,36523,1999,Drugs@FDA,NO,NO,,,NA,NA,0.01,,7,,,,,YES,Oncology,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,D,Less,D (possible but uncommon cause of clinically apparent liver injury),Less,0,,NO,NO,NO,3H0A,348.4779,1,2,1,2,1,3,37.3,0.375,3.22,3.22,8.194,Very high LogP unrealistic in nature,5.8,2.9,7.84,4.916,4.08,,4.7,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65485,0.67019,0.87808,0.08777,0.93048,0.98659,0.92207,0.99269,0.93773,204.4,3.56,18.5,22
90357-06-5,BICALUTAMIDE,CASODEX,PF-00345546,367,CC(CS(=O)(=O)c1ccc(cc1)F)(C(=O)Nc2ccc(c(c2)C(F)(F)F)C#N)O,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,ANI PHARMS,pharma,34976,1995,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.04,,139,,147,,6369177,NO,Oncology,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,1Z95,430.3734,2,5,2,6,0,5,107.26,0.222222222,2.74,3.323,2.707,All fragments measured,2.4,2.4,2.53,2.532,11.49,,8.5,,Neutral,Class 2,0,4,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.69882,0.69611,0.40679,0.99907,0.72615,0.79222,0.52471,0.6885,0.93773,393,14.9,2.53,7.99
1611493-60-7,BICTEGRAVIR SODIUM,BIKTARVY,VC-001215248,5274,c1c(cc(c(c1F)CNC(=O)c2cn3c(c(c2=O)O)C(=O)N4[C@H]5CC[C@H](C5)O[C@@H]4C3)F)F,TABLET,YES,NO,NO,NO,ORAL,52.5,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,43138,2018,Drugs@FDA,YES,NO,,0.35,High,Fa estimated from reported excretion data,0.01,,17.3,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected potential cause of liver injury),,1,Michael_acceptor,NO,YES,NO,,449.3799,2,5,2,8,0,3,100.87,0.380952381,1.43,1.667,-0.012,Approximated fragment value used,1.1,1,-0.6,-3.117,4.5,,9.9,,Acidic,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,5,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,NO,0.66381,0.65526,0.32399,0.6743,0.52457,0.79222,0.69563,0.99269,0.82734,567.3,6.87,3.07,9.35
606143-89-9,BINIMETINIB,MEKTOVI,PF-06811462,,Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO,TABLET,YES,NO,NO,YES,ORAL,90,Prescription,,NO,NO,,,Array BioPharma,pharma,ARRAY BIOPHARMA INC,pharma,43278,2018,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.03,1.3,3.5,,,,,YES,Oncology,NO,YES,III,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,4U7Z,441.2268,3,4,3,7,0,6,88.41,0.176470588,2.36,2.709,3.31,A priori fragment value used,2.5,2.5,3.51,3.72,,2.9,8.6,4.6,Neutral,Class 2,0,2,0,0,0,1,0,3,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.47744,0.54302,0.35758,0.99989,0.72615,0.37866,0.80117,0.6885,0.25672,410,14.5,21.6,14.1
514-65-8,BIPERIDEN HYDROCHLORIDE,AKINETON,PF-05281093,374,c1ccc(cc1)C(CCN2CCCCC2)(C3CC4CC3C=C4)O,TABLET,YES,NO,NO,NO,ORAL,16,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,21801,1959,Drugs@FDA,NO,NO,0.33,,High,Reported bioavailability,0.1,24,21.4,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,311.4611,1,2,1,2,0,5,23.47,0.619047619,1.75,1.686,4.942,All fragments measured,4.4,2.4,4.19,2.346,,9.26,15,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91527,0.88242,0.99776,0.93896,0.93048,0.98659,0.69082,0.84757,0.82734,272.9,15,19.4,32.2
66722-44-9,BISOPROLOL FUMARATE,ZEBETA,PF-00579886,380,CC(C)NCC(COc1ccc(cc1)COCCOC(C)C)O,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,TEVA,major pharma,33816,1992,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.7,2.93,10.7,,,,27132,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,325.443,2,5,2,5,0,12,59.95,0.666666667,0.617,0.617,1.831,All fragments measured,2.2,0.36,2.21,0.121,,9.42,16,9.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.55693,0.64632,0.97211,0.95925,0.72615,0.79222,0.98938,0.10729,0.82734,253.9,21.1,3.16,8.37
394730-60-0,BOCEPREVIR,VICTRELIS,PF-04586491,4172,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,CAPSULE,YES,NO,NO,NO,ORAL,2400,Discontinued,,NO,NO,,,Merck,major pharma,MERCK,major pharma,40676,2011,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.25,11,3.4,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Ambiguous,FEARS Addition ,1,E*,Ambiguous,E* (unproven but suspected cause of liver injury),Moderate,0,,NO,NO,NO,2OC8,519.6767,5,5,4,10,1,9,150.7,0.814814815,1.83,2.594,3.344,Calculated fragment value,2.4,2.4,2.4,2.472,12.82,,11,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.2601,0.31451,0.13718,0.90509,0.72615,0.14694,0.22956,0.21184,0.47245,536,1.27,4.91,98.2
147536-97-8,BOSENTAN,TRACLEER,PF-01238578,392,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc2c(c(nc(n2)c3ncccn3)OCCO)Oc4ccccc4OC,"TABLET, TABLET, FOR SUSPENSION",YES,NO,NO,NO,ORAL,250,Prescription,,NO,NO,,,Roche,major pharma,ACTELION PHARMS LTD,pharma,37215,2001,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.02,0.3,5,,,127,838401,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,5XPR,551.6141,2,9,2,11,2,10,145.65,0.259259259,2.03,1.136,4.167,All fragments measured,3.9,1.9,3.53,1.53,4.01,,4.6,3,Acidic,Class 1B,0,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.19682,0.17232,0.09562,0.87659,0.06191,0.79222,0.20997,0.15134,0.03452,534.6,2.2,24,19.6
380843-75-4,BOSUTINIB MONOHYDRATE,BOSULIF,PF-05208763,4359,CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC,TABLET,YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,41156,2012,Drugs@FDA,NO,NO,0.34,,High,Reported bioavailability,0.04,87,22.5,,,,315441542,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,D,Less,D (possible uncommon cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,4OTW,530.4462,1,7,1,8,2,9,82.88,0.384615385,3.13,3.15,5.087,All fragments measured,4.7,3.5,4.54,3.994,,7.63,,8.6,Basic,Class 4,0,0,0,0,2,0,0,3,1,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,2,0,0,0,0,NO,0.33544,0.35857,0.12102,0.52122,0.19128,0.98659,0.85022,0.29329,0.25672,487.3,0.908,23.2,64.3
913611-97-9,BREXPIPRAZOLE,REXULTI,PF-06916990,5014,c1cc(c2ccsc2c1)N3CCN(CC3)CCCCOc4ccc5ccc(=O)[nH]c5c4,TABLET,YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,Otsuka Pharmaceutical ,pharma,OTSUKA PHARM CO LTD,pharma,42195,2015,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.01,1.56,91,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,3,Aniline; BenzoThiophene; Michael_acceptor,YES,YES,NO,,433.5658,1,3,1,5,0,7,48.57,0.32,3.64,4.4,4.652,All fragments measured,5,4.2,4.52,3.897,11.22,7.8,7.4,8,Basic,Class 4,0,0,0,0,0,0,0,4,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,1,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53244,0.60532,0.39178,0.68648,0.88651,0.98659,0.92486,0.53315,0.25672,399.3,1.81,16.7,45.6
1197953-54-0,BRIGATINIB,ALUNBRIG,PF-06256390,5233,CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl,TABLET,YES,NO,NO,NO,ORAL,180,Prescription,,NO,NO,,,Ariad,pharma,ARIAD,pharma,42853,2017,Drugs@FDA,NO,NO,,0.59,High,Fa estimated from reported excretion data,0.09,2.2,25,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproved but suspected cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,5J7H,584.0924,2,7,2,9,1,8,85.86,0.448275862,2.16,2.866,2.024,Vinyl approx. based on a priori value,5.8,4.1,2.79,1.658,,8.14,,8.7,Basic,Class 4,0,0,0,1,1,0,0,3,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,NO,0.29055,0.29391,0.06909,0.43222,0.10671,0.79222,0.73114,0.39983,0.25672,544.5,0.196,5.7,14.9
357336-20-0,BRIVARACETAM,BRIVIACT,PF-03335885,5068,CCC[C@@H]1CC(=O)N(C1)[C@@H](CC)C(=O)N,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,UCB,pharma,UCB INC,pharma,42418,2016,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.645,0.5,9,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,212.2887,2,2,1,4,0,5,63.4,0.818181818,0.757,0.757,1.009,All fragments measured,0.82,0.82,0.61,0.608,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7054,0.75672,0.52415,0.75462,0.93048,0.98659,0.97723,0.84757,0.47245,219,21.2,4.4,6.98
91714-93-1,BROMFENAC SODIUM,DURACT,PF-05166418,401,c1cc(c(c(c1)C(=O)c2ccc(cc2)Br)N)CC(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,,Discontinued,1998,YES,YES,Fatal hepatic failure,FederalRegister,,,WYETH,major pharma,35431,1997,NIH NCATS,NO,NO,0.67,,High,Reported bioavailability,0.11,0.11,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,None,1,Aniline,YES,NO,NO,,334.1647,3,4,2,4,0,4,80.39,0.066666667,-0.00479,0.4637,3.284,All fragments measured,3.3,0.25,3.07,0.2,4.07,,4.1,3.2,Acidic,Class 1A,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.92044,0.91185,0.94306,0.99945,0.88651,0.79222,0.87079,0.96969,0.93773,206,6.8,8.76,17.6
25614-03-3,BROMOCRIPTINE MESYLATE,PARLODEL,PF-00929746,403,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5Cc6c7c(cccc7[nH]c6Br)C5=C4)C)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,28669,1978,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.04,0.9,6,,,,,NO,"Genitourinary, Metabolic Disease, Neurological",NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,654.5945,3,7,3,10,2,5,118.21,0.59375,2.46,2.46,6.585,All fragments measured,4.8,4.8,3.52,3.502,9.6,5.53,8.2,6,Neutral,Class 3B,0,0,0,0,0,1,0,2,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,10,0,0,0,10,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.35892,0.42298,0.04134,0.74433,0.52457,0.37866,0.4986,0.84757,0.93773,805.1,5.37,24.6,282
118-23-0,BROMODIPHENHYDRAMINE HYDROCHLORIDE,AMBODRYL,PF-00345166,404,CN(C)CCOC(c1ccccc1)c2ccc(cc2)Br,CAPSULE,YES,NO,NO,NO,ORAL,150,Discontinued,,NO,NO,,,,,PARKE DAVIS,major pharma,19842,1954,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.04,,2.5,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,334.2508,0,3,0,2,0,6,12.47,0.294117647,2.65,3.12,4.315,All fragments measured,4.4,3.1,4.57,3.245,,8.71,,8.4,Basic,Class 2,0,0,0,0,0,1,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.77063,0.74066,0.94273,0.82426,0.93048,0.59178,0.44264,0.6885,0.93773,203.5,12.4,9.78,16.9
86-22-6,BROMPHENIRAMINE MALEATE,DIMETANE,PF-00344690,408,CN(C)CCC(c1ccc(cc1)Br)c2ccccn2,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,24,Prescription,,NO,NO,,,,,WYETH,major pharma,21055,1957,Drugs@FDA,NO,NO,,,NA,NA,,11.7,25,,,,16,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,319.2395,0,3,0,2,0,5,16.13,0.3125,1.56,1.7,3.298,All fragments measured,3.5,1.8,3.33,1.4,,9.33,,9,Basic,Class 2,0,0,0,0,0,1,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.83085,0.79869,0.98689,0.9148,0.93048,0.59178,0.52472,0.84757,0.93773,196.9,20.6,5.72,10.8
82-95-1,BUCLIZINE HYDROCHLORIDE,BUCLADIN-S,PF-00579926,416,CC(C)(C)c1ccc(cc1)CN2CCN(CC2)C(c3ccccc3)c4ccc(cc4)Cl,TABLET,YES,NO,NO,NO,ORAL,150,Discontinued,,NO,NO,,,,,STUART PHARMS,pharma,20918,1957,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,943991,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,433.028,0,2,0,2,1,5,6.48,0.357142857,4.46,6.64,8.059,Very high LogP unrealistic in nature,7,6.9,5.99,5.88,,6.84,,7.2,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.32426,0.34088,0.39428,0.04335,0.93048,0.59178,0.32149,0.6885,0.25672,291.5,0.161,35.2,46.7
51333-22-3,BUDESONIDE,ENTOCORT EC,PF-02299109,419,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,"CAPSULE; CAPSULE, EXTENDED RELEASE; TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,9,Prescription,,NO,NO,,,AstraZeneca,major pharma,ASTRAZENECA AB,major pharma,37166,2001,Drugs@FDA,NO,NO,0.1,1,Low,Reported bioavailability,0.13,3.9,2.8,,73,,39,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,5NFP,430.5339,2,6,2,6,0,4,93.06,0.76,2.61,3.27,2.905,All fragments measured,3,3,3.02,3.019,12.87,,11,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,8,0,0,0,8,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.67266,0.6642,0.40602,0.97468,0.52457,0.79222,0.75693,0.96969,0.47245,510.5,16.8,86.7,193
28395-03-1,BUMETANIDE,BUMEX,PF-00344857,427,CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,VALIDUS PHARMS,pharma,30375,1983,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.04,0.26,1,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,364.4161,4,4,3,7,0,8,118.72,0.235294118,0.583,-0.2595,3.372,All fragments measured,3.4,0.87,3,0.032,3.18,4.48,4.3,1.3,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.61136,0.58767,0.78847,0.99983,0.52457,0.37866,0.41231,0.39983,0.93773,317.6,1.23,3.28,9.23
34911-55-2,BUPROPION HYDROCHLORIDE,WELLBUTRIN,PF-00344539,435,CC(C(=O)c1cccc(c1)Cl)NC(C)(C)C,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,300,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,31411,1985,Drugs@FDA,NO,NO,,0.87,High,Fa estimated from reported excretion data,0.16,20,20,,16,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,239.7411,1,2,1,2,0,3,29.1,0.461538462,1.86,2.075,3.211,All fragments measured,3.2,2.2,3.08,2.884,,7.16,,8,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.88553,0.88336,0.71458,0.99291,0.93048,0.98659,0.80321,0.96969,0.82734,181.8,32,18.1,18.5
36505-84-7,BUSPIRONE HYDROCHLORIDE,BUSPAR,PF-00344610,437,c1cnc(nc1)N2CCN(CC2)CCCCN3C(=O)CC4(CCCC4)CC3=O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,31684,1986,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.14,5.3,2.5,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,385.5031,0,5,0,7,0,6,69.64,0.714285714,1.28,2.05,2.185,Valid estimate for difficult structure,2,1.5,2.95,2.681,,7.72,,7.4,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71783,0.72526,0.65845,0.95821,0.52457,0.59178,0.9461,0.6885,0.82734,340.7,23.5,22,119
55-98-1,BUSULFAN,MYLERAN,PF-00345490,438,CS(=O)(=O)OCCCCOS(=O)(=O)C,TABLET,YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,,,ASPEN GLOBAL,pharma,19901,1954,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,1,0.55,2.8,,,,21307,YES,Oncology,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,"A (well known cause of clinically apparent liver injury, generally as a result of direct toxicity from high doses given for myeloablation in preparation for hematopoietic cell transplantation and rarely due to idiosyncratic liver injury)",Less,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,246.3018,0,0,0,6,0,7,86.74,1,-0.693,-0.693,-0.592,All fragments measured,-0.72,-0.72,-0.42,-0.416,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.55149,0.5482,0.75984,0.38464,0.52457,0.59178,0.65101,0.53315,0.47245,208.8,11.5,3.74,8.68
125-40-6,BUTABARBITAL SODIUM,BUTISOL SODIUM,PF-00346548,439,CCC(C)C1(C(=O)NC(=O)NC1=O)CC,TABLET,YES,NO,NO,NO,ORAL,120,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,14401,1939,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely causes of clinically apparent liver injury),,0,,NO,NO,NO,,212.2456,2,3,2,5,0,3,75.27,0.7,1.05,1.073,1.583,All fragments measured,1.6,1.5,1.43,1.321,7.93,,7.9,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7138,0.76445,0.52387,0.87497,0.9848,0.79222,0.90963,0.99269,0.47245,195.6,7.57,1.95,6.65
77-26-9,BUTALBITAL,FIORINAL,PF-00346545,441,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,ALLERGAN,major pharma,27884,1976,Drugs@FDA,YES,NO,,0.88,High,Fa estimated from reported excretion data,,,61,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,LiverTox Additions,0,,,,Moderate,0,,NO,NO,NO,,224.2563,2,3,2,5,0,4,75.27,0.545454545,1.09,1.121,1.628,All fragments measured,1.6,1.5,1.66,1.51,7.78,,7.7,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73502,0.77941,0.60578,0.88714,0.9848,0.79222,0.90963,0.96969,0.47245,189.4,10,2.89,6.88
81409-90-7,CABERGOLINE,DOSTINEX,PF-02769433,460,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4c3c(c[nH]4)C[C@H]2N(C1)CC=C,TABLET,YES,NO,NO,NO,ORAL,0.2857,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,35422,1996,Drugs@FDA,NO,NO,,,NA,NA,0.58,,63,,,,78898353,NO,"Genitourinary, Neurological",NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,None,1,3_Methyl_Indole,NO,NO,NO,,451.6043,2,4,2,7,0,10,71.68,0.538461538,1.8,1.784,4.171,A priori fragment value used,4.4,3.5,3.36,1.479,,9.41,9.6,8.2,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59492,0.69362,0.31532,0.99631,0.88651,0.79222,0.93378,0.39983,0.93773,455.5,1.41,6.56,31.5
849217-68-1,CABOZANTINIB S-MALATE,COMETRIQ,PF-06700174,4715,COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,Exelixis,pharma,EXELIXIS,pharma,41242,2012,Drugs@FDA,NO,NO,,0.27,Moderate,Fa estimated from reported excretion data,,4.5,55,,,,,YES,Oncology,NO,YES,II,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (Unproven but suspected rare cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,,501.5057,2,5,2,8,1,8,98.78,0.178571429,4.44,5.3,4.943,All fragments measured,4.2,4.2,4.06,3.794,,5.72,12,4.7,Neutral,Class 4,0,1,0,0,0,0,0,4,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.28718,0.33906,0.17058,0.75227,0.52457,0.79222,0.69972,0.39983,0.03452,474.4,3.52,10.2,15.3
58-08-2,CAFFEINE CITRATE,CAFCIT,PF-00344607,463,Cn1cnc2c1c(=O)n(c(=O)n2C)C,SOLUTION,YES,NO,NO,NO,ORAL,130,Prescription,,NO,NO,,,,,WEST-WARD PHARMS INT,pharma,36424,1999,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.64,0.63,4.5,,,,,NO,"Cardiovascular, Neurological",YES,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,3RFM,194.1906,0,3,0,6,0,0,61.82,0.375,-0.102,0.1419,-0.04,Valid estimate for difficult structure,0.078,0.078,0.28,0.283,,,,1.5,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.51367,0.61775,0.41165,0.44077,0.9848,0.59178,0.99338,0.39503,0.82734,246.6,26.2,2.79,7.43
19356-17-3,CALCIFEDIOL,CALDEROL,PF-06426745,464,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,"CAPSULE; CAPSULE, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,0.06,Prescription,,NO,NO,,,,,ORGANON USA INC,pharma,29438,1980,Drugs@FDA,NO,NO,,,NA,NA,0.02,8.8,384,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,None,,,,,,None,0,,NO,NO,NO,,400.6371,2,2,2,2,1,6,40.46,0.777777778,4.54,6.08,7.269,Very high LogP unrealistic in nature,7.6,7.6,7,7.004,,,15,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.46962,0.52753,0.56652,0.08787,0.93048,0.79222,0.95241,0.6885,0.47245,301.2,6.3,61.7,96.3
32222-06-3,CALCITRIOL,ROCALTROL,PF-06220973,466,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,VALIDUS PHARMS,pharma,28719,1978,Drugs@FDA,NO,NO,,,NA,NA,,,5,,,,83773,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,1IE9,416.6365,3,3,3,3,1,6,60.69,0.777777778,4.25,6.21,6.038,All fragments measured,6,6,5.63,5.63,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.49034,0.58106,0.47632,0.39211,0.9848,0.37866,0.98712,0.6885,0.47245,343.4,12.2,73.5,145
842133-18-0,CANAGLIFLOZIN,INVOKANA,PF-04993378,4758,Cc1ccc(cc1Cc2ccc(s2)c3ccc(cc3)F)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Mitsubishi Tanabe Pharma,pharma,JANSSEN PHARMS,major pharma,41362,2013,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.01,1.2,,,,88,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,1,Thiophene,NO,NO,YES,,444.5157,4,5,4,5,0,5,90.15,0.333333333,3.11,4.6,4.552,All fragments measured,3.3,3.3,3.75,3.755,,,12,,Neutral,Class 4,0,1,0,0,0,0,0,3,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.40176,0.45164,0.34368,0.96695,0.72615,0.14694,0.49679,0.84757,0.25672,462.6,4.53,9.98,16
145040-37-5,CANDESARTAN CILEXETIL,ATACAND,PF-00272939,475,CCOc1nc2cccc(c2n1Cc3ccc(cc3)c4ccccc4c5[nH]nnn5)C(=O)OC(C)OC(=O)OC6CCCCC6,TABLET,YES,NO,NO,NO,ORAL,32,Prescription,,NO,NO,,,,,ANI PHARMS,pharma,35950,1998,Drugs@FDA,NO,NO,0.15,,Moderate,Reported bioavailability,0.01,0.13,9,,181,,1218988,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (Probable cause of rare instances of clinically apparent liver injury),Less,0,,NO,NO,NO,,610.6597,1,7,1,12,3,13,143.34,0.333333333,3.28,3.28,7.084,Very high LogP unrealistic in nature,6.7,3.3,6,4.667,4.16,3.94,4.2,3.1,Acidic,Class 3B,0,0,0,0,0,0,0,5,1,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.0858,0.08912,0.05511,0.05148,0.06191,0.98659,0.2784,0.07566,0.01222,554.5,0.455,30.7,72.5
13956-29-1,CANNABIDIOL,EPIDIOLEX,VC-000722562,,CCCCCc1cc(c(c(c1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O,SOLUTION,YES,NO,NO,NO,ORAL,700,Prescription,,NO,NO,,,GW Pharmaceuticals,pharma,GW RES LTD,pharma,43276,2018,Drugs@FDA,NO,NO,,,NA,NA,0.06,299,56,,,,,YES,"Musculoskeletal/Pain, Neurological",NO,NO,,YES,YES,NO,NO,,Less,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Moderate,1,1_4_Diketones,NO,NO,NO,,314.4617,2,2,2,2,1,6,40.46,0.523809524,4.95,5.57,6.641,All fragments measured,7.4,7.4,6.43,6.429,9.64,,9.2,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56163,0.59872,0.99461,0.06933,0.93048,0.79222,0.95241,0.6885,0.82734,207.9,3.18,47.6,95.5
154361-50-9,CAPECITABINE,XELODA,PF-00346576,480,CCCCCOC(=O)Nc1c(cn(c(=O)n1)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O)F,TABLET,YES,NO,NO,NO,ORAL,4300,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,35915,1998,Drugs@FDA,NO,YES,,0.96,High,Fa estimated from reported excretion data,0.4,,0.75,,152,,14071,NO,Oncology,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (Unproven but suspected cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,359.3501,3,6,3,9,0,7,122.91,0.666666667,1.51,1.699,0.841,All fragments measured,1.1,1.1,0.67,-1.024,5.41,1.75,12,0.75,Neutral,Class 2,0,1,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.55638,0.50946,0.81832,0.72494,0.33223,0.37866,0.47383,0.53315,0.47245,473.3,5.56,7.58,8.29
62571-86-2,CAPTOPRIL,CAPOTEN,PF-00344533,484,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,PAR PHARM,pharma,29682,1981,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.7,0.7,1.9,,,,4627,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely but rare cause of clinically apparent liver injury),Moderate,1,Thiol_Disulfide,NO,NO,NO,4C2P,217.2853,1,4,1,4,0,4,57.61,0.777777778,-0.891,-0.891,0.89,Approximated fragment value used,0.97,-2.1,0.62,-2.831,3.59,,3.8,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69174,0.70948,0.55771,0.68058,0.88651,0.79222,0.72373,0.99269,0.47245,210.7,1.15,2.09,6.65
298-46-4,CARBAMAZEPINE,TEGRETOL,PF-00344611,489,c1ccc2c(c1)C=Cc3ccccc3N2C(=O)N,"CAPSULE, EXTENDED RELEASE, SUSPENSION, TABLET, TABLET, CHEWABLE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1200,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,24908,1968,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.25,1.4,15,,,,,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,YES,NO,YES,NO,Most,Most,DILIRank,1,A,Most,A (Well established cause of clinically apparent liver injury),Most,0,,NO,NO,NO,,236.2686,2,1,1,3,0,1,46.33,0,2.66,2.006,2.38,All fragments measured,2.9,2.9,2.28,2.282,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72342,0.66587,0.69024,0.99874,0.23327,0.98659,0.98759,0.39503,0.93773,207.1,19.8,9.36,16.2
35531-88-5,CARBENICILLIN INDANYL SODIUM,GEOCILLIN,PF-05014977,508,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(c3ccccc3)C(=O)Oc4ccc5c(c4)CCC5)C(=O)O)C,TABLET,YES,NO,NO,NO,ORAL,3056,Discontinued,,NO,NO,,,,,PFIZER,major pharma,26598,1972,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,0.5,0.2,1,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Beta_Lactams,NO,NO,NO,,494.5594,2,5,2,8,0,7,113.01,0.384615385,1.33,1.33,4.179,Benzyl approx. based on a priori value,3.8,-0.62,3.79,0.071,2.44,,2.8,,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53789,0.49539,0.18568,0.9482,0.33223,0.79222,0.31605,0.53315,0.93773,547.1,2.16,8.65,13.6
23142-01-0,CARBETAPENTANE CITRATE,CERTUSS,PF-00345597,494,CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2,TABLET,YES,NO,NO,NO,ORAL,,Discontinued,,NO,NO,,,,,CAPELLON,pharma,30681,1983,DrugBank,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,333.465,0,3,0,4,0,11,38.77,0.65,2.04,1.663,4.703,All fragments measured,4,2.1,3.71,1.398,,9.69,,9.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.55794,0.65632,0.94572,0.90104,0.88651,0.59178,0.9372,0.15134,0.82734,227.7,10.7,101,25.7
28860-95-9,CARBIDOPA,LODOSYN,PF-00345111,496,C[C@](Cc1ccc(c(c1)O)O)(C(=O)O)NN,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,ATON,pharma,28240,1977,Drugs@FDA,NO,NO,0.58,,High,Reported bioavailability,,3.6,1.8,Parent CRG,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,2,Hydrazines; Quinones,NO,NO,NO,1JS3,226.2292,6,5,5,6,1,4,115.81,0.3,-1.02,-1.02,-0.445,All fragments measured,0.38,-2.4,-0.03,-2.583,3.4,7.76,2.4,6.7,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.42991,0.46122,0.61957,0.58698,0.52457,0.05547,0.52297,0.96969,0.82734,215.8,0.675,3.63,6.65
486-16-8,CARBINOXAMINE MALEATE,KARBINAL ER,PF-00344770,499,CN(C)CCOC(c1ccc(cc1)Cl)c2ccccn2,"SUSPENSION, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,24,Prescription,,NO,NO,,,Tris Pharma,pharma,TRIS PHARMA INC,pharma,41361,2013,Drugs@FDA,NO,NO,,,High,Based on textual comment,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,290.7879,0,3,0,3,0,6,25.36,0.3125,1.53,1.57,2.668,All fragments measured,3,1.6,2.65,1.499,,8.65,,8.5,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.8086,0.82789,0.98204,0.98715,0.9848,0.59178,0.73079,0.6885,0.93773,238.8,22.4,6.87,8.44
1188-38-1,CARGLUMIC ACID,CARBAGLU,VC-001218519,3068,C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N,TABLET,YES,NO,NO,NO,ORAL,7000,Prescription,,NO,NO,,,Recordati,pharma,ORPHAN EUROPE,pharma,40255,2010,Drugs@FDA,NO,NO,,0.4,High,Fa estimated from reported excretion data,,38,5.6,,,,,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,None,,,E,None,"E (unlikely cause of clinically apparent liver injury, but experience with its use is limited)",Less,0,,NO,NO,NO,,190.154,5,5,4,7,0,5,129.72,0.5,-1.7,-1.7,-1.935,All fragments measured,-1.3,-6.9,-1.67,-6.407,3.71,,3.6,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.35067,0.38199,0.38888,0.18391,0.72615,0.14694,0.38841,0.84757,0.47245,188.8,0.575,1.66,6.65
839712-12-8,CARIPRAZINE HYDROCHLORIDE,VRAYLAR,PF-06843727,5037,CN(C(=O)N[C@H]1CC[C@@H](CC1)CCN2CCN(CC2)c3c(c(ccc3)Cl)Cl)C,CAPSULE,YES,NO,NO,NO,ORAL,6,Prescription,,NO,NO,,,Gredeon Richter,pharma,ALLERGAN,major pharma,42264,2015,Drugs@FDA,NO,NO,,,NA,NA,,,48,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,,427.411,1,2,1,5,0,6,38.82,0.666666667,3.3,3.57,4.98,Estimated fragment value used,4.6,3.3,4.87,4.59,,7.83,13,8.5,Basic,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.72192,0.78256,0.42111,0.668,0.9848,0.98659,0.93778,0.84757,0.82734,349.1,3.57,29.3,36.7
78-44-4,CARISOPRODOL,SOMA,PF-00344614,509,CCCC(C)(COC(=O)N)COC(=O)NC(C)C,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,350,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,21649,1959,Drugs@FDA,NO,NO,,,NA,NA,0.4,1.1,8,,,,,NO,Musculoskeletal/Pain,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,260.33,3,3,2,6,0,9,90.65,0.833333333,1.78,2.201,2.341,All fragments measured,2.4,2.4,1.93,1.935,12.49,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.61597,0.67358,0.85009,0.97476,0.88651,0.79222,0.78016,0.29329,0.47245,223.3,25.7,12.9,9.37
2622-30-2,CARPHENAZINE MALEATE,PROKETAZINE,PF-01690925,516,CCC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCN(CC4)CCO,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,2013,YES,NO,Fatal risk,NA,,,WYETH,major pharma,23091,1963,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,425.5868,1,5,1,5,0,8,47.02,0.458333333,2.85,2.758,3.238,All fragments measured,3.8,3.2,3.59,3.247,,7.39,14,8.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,2,1,4,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64924,0.68243,0.43011,0.88839,0.52457,0.98659,0.92963,0.39983,0.93773,373.6,4.46,34.9,76.4
53716-49-7,CARPROFEN,RIMADYL,PF-03732988,518,CC(c1ccc2c3cc(ccc3[nH]c2c1)Cl)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,32142,1987,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.01,0.3,12,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,Less,,,,,,None,0,,NO,NO,NO,,273.7143,2,2,2,3,0,2,53.09,0.133333333,1.64,1.64,3.978,All fragments measured,4,1.1,4.28,1.807,4.84,,4.2,,Acidic,Class 1A,0,0,0,0,1,0,0,3,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7074,0.74386,0.92167,0.83014,0.93048,0.79222,0.99999,0.87038,0.25672,229.8,22.1,32.7,29.5
51781-06-7,CARTEOLOL HYDROCHLORIDE,CARTROL,PF-00344613,520,CC(C)(C)NCC(COc1cccc2c1CCC(=O)N2)O,TABLET,YES,NO,NO,NO,ORAL,10,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,32505,1988,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.7,,6,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,None,,,,,,Less,0,,NO,NO,NO,,292.3734,3,4,3,5,0,5,70.59,0.5625,-0.453,-0.453,1.289,All fragments measured,1.3,-0.68,1.84,-0.239,11.45,9.52,14,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70809,0.76185,0.98556,0.84051,0.88651,0.37866,0.94046,0.6885,0.82734,271.8,7.9,5.9,9.96
72956-09-3,CARVEDILOL,COREG,PF-00345548,522,COc1ccccc1OCCNCC(COc2cccc3c2c4ccccc4[nH]3)O,"TABLET, CAPSULE, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,50,Prescription,,NO,NO,,,,,SMITHKLINE BEECHAM,major pharma,34956,1995,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.02,1.3,7,,30,,1318513,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (Possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4AMJ,406.4742,3,5,3,6,0,10,75.74,0.25,2.98,3.118,4.041,All fragments measured,3.6,2.9,4.06,3.041,,8.24,9.3,7.8,Basic,Class 4,0,0,0,0,0,0,0,4,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.28537,0.36322,0.53259,0.85917,0.72615,0.37866,0.90628,0.21184,0.03452,392.7,2.26,61.1,110
53994-73-3,CEFACLOR,CECLOR,PF-00579880,525,c1ccc(cc1)[C@H](C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)Cl)C(=O)O)N,"CAPSULE, FOR SUSPENSION, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1000,Prescription,,NO,NO,,,,,ELI LILLY AND CO,major pharma,28949,1979,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.75,,0.3,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,3,Alkyl_halide_Sulfate_ester; Beta_Lactams; Michael_acceptor,NO,YES,NO,,367.8074,4,6,3,7,0,4,112.73,0.266666667,-0.258,-0.258,-1.636,Benzyl approx. based on a priori value,-0.31,-1.9,-0.48,-3.623,1.95,6.84,2.1,7.6,Zwitter,Class 3A,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,NO,0.47437,0.42844,0.768,0.06803,0.52457,0.37866,0.31825,0.96969,0.82734,434.8,0.195,2.8,7.41
50370-12-2,CEFADROXIL,DURICEF,PF-00344771,526,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](c3ccc(cc3)O)N)SC1)C(=O)O,"CAPSULE, FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,WARNER CHILCOTT,pharma,28538,1978,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.39,0.23,1.5,Parent CRG,,,445062,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,2,Beta_Lactams; Michael_acceptor,NO,YES,NO,,363.3883,5,7,4,8,0,4,132.96,0.3125,-0.466,0.4331,-2.507,Benzyl approx. based on a priori value,-0.7,-2.4,-0.91,-4.057,3.12,7.17,2.8,7.5,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.37926,0.32108,0.7946,0.06037,0.33223,0.14694,0.18724,0.96969,0.82734,436.8,0.36,2.36,7.37
91832-40-5,CEFDINIR,OMNICEF,VC-001215210,533,C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N/O)/c3csc(n3)N)SC1)C(=O)O,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,ABBVIE,major pharma,35768,1997,Drugs@FDA,NO,NO,0.21,,Moderate,Reported bioavailability,0.67,0.35,1.7,Parent CRG,49,,4117799,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,3,Aminothiazole; Beta_Lactams; Michael_acceptor,NO,YES,NO,,395.4135,5,8,4,10,0,5,158.21,0.214285714,-1.48,-1.48,-0.482,A priori fragment value used,0.11,-2.9,-0.48,-4.213,2.8,2.03,2.4,3,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,NO,0.44527,0.27869,0.59771,0.419,0.10671,0.14694,0.04742,0.84757,0.82734,501,0.603,2.79,8.66
117467-28-4,CEFDITOREN PIVOXIL,SPECTRACEF,PF-06700543,534,Cc1c(scn1)/C=C/C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N/OC)/c4csc(n4)N)SC2)C(=O)OCOC(=O)C(C)(C)C,TABLET,YES,NO,NO,NO,ORAL,800,Discontinued,,NO,NO,,,Meji Seika Pharma ,pharma,VANSEN PHARMA,pharma,37132,2001,Drugs@FDA,NO,NO,0.14,,Moderate,Reported bioavailability,0.12,9.3,1.6,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,3,Aminothiazole; Beta_Lactams; Michael_acceptor,NO,YES,NO,,620.7208,3,7,2,13,2,11,175.4,0.4,3.6,4.21,2.711,Benzyl approx. based on a priori value,3.3,3.3,2.46,2.367,8.08,3.3,13,3.3,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,3,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.25905,0.16019,0.05111,0.9476,0.02915,0.79222,0.02405,0.10729,0.93773,707.7,6,33.4,124
79350-37-1,CEFIXIME,SUPRAX,PF-00346420,537,C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N/OCC(=O)O)/c3csc(n3)N)SC1)C(=O)O,"CAPSULE, FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,LEDERLE,major pharma,32626,1989,Drugs@FDA,NO,NO,0.47,0.5,High,Reported bioavailability,0.35,0.6,3,Parent CRG,,,1378986,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,3,Aminothiazole; Beta_Lactams; Michael_acceptor,NO,YES,NO,,453.4496,5,8,4,12,1,8,184.51,0.25,-2.18,-2.18,0.252,Approximated fragment value used,-0.38,-6.7,0.2,-4.589,2.8,1.42,2.1,3.3,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.2999,0.17552,0.30829,0.28868,0.03975,0.14694,0.02984,0.39983,0.82734,565.7,0.51,2.16,9.51
87239-81-4,CEFPODOXIME PROXETIL,VANTIN,PF-00579960,555,CC(C)OC(=O)OC(C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N/OC)/c3csc(n3)N)COC,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,33823,1992,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.75,0.8,2.5,Parent CRG,,,249047,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,3,Aminothiazole; Beta_Lactams; Michael_acceptor,NO,YES,NO,,557.5972,3,7,2,14,2,13,180.97,0.523809524,1.91,2.306,0.801,Approximated fragment value used,0.82,0.82,1.44,1.363,8.13,1.7,12,3.3,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,NO,0.25457,0.15695,0.08974,0.69476,0.02416,0.79222,0.03139,0.07566,0.82734,673.9,5.93,29.4,41
92665-29-7,CEFPROZIL,CEFZIL,PF-00344859,556,C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](c3ccc(cc3)O)N)SC1)C(=O)O,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,,,CORDEN PHARMA,pharma,33595,1991,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.6,0.23,1.5,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,2,Beta_Lactams; Michael_acceptor,NO,YES,NO,,389.4256,5,7,4,8,0,5,132.96,0.277777778,-0.228,-0.228,-1.873,Benzyl approx. based on a priori value,-0.39,-2.1,-0.63,-3.781,2.92,7.17,2.7,7.5,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.3703,0.32104,0.63422,0.08647,0.33223,0.14694,0.18724,0.84757,0.82734,451.2,0.29,3.33,7.44
97519-39-6,CEFTIBUTEN DIHYDRATE,CEDAX,PF-06264006,562,c1c(nc(s1)N)/C(=C\CC(=O)O)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,400,Discontinued,,NO,NO,,,,,SI PHARMS,pharma,35053,1995,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.23,0.21,2,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",,3,Aminothiazole; Beta_Lactams; Michael_acceptor,NO,YES,NO,,410.4249,5,8,4,10,0,6,162.92,0.266666667,-2.53,-2.53,-1.21,Approximated fragment value used,-1.8,-8.1,-1.04,-5.791,2.99,3.74,2.8,3.6,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.39229,0.25045,0.51027,0.31522,0.10671,0.14694,0.04302,0.6885,0.82734,494.9,0.383,1.66,7.58
64544-07-6,CEFUROXIME AXETIL,CEFTIN,VC-001215420,566,CC(OC(=O)C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N/OC)/c3ccco3)COC(=O)N,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,32139,1987,Drugs@FDA,NO,YES,0.37,,High,Reported bioavailability,,,1.5,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,3,Beta_Lactams; Furan; Michael_acceptor,NO,YES,NO,,510.4745,3,7,2,14,2,12,189.06,0.4,1.51,1.699,0.654,Approximated fragment value used,0.57,0.57,0.75,0.703,8.31,,12,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.29041,0.18706,0.15306,0.4172,0.03975,0.79222,0.0449,0.10729,0.82734,645.1,2.44,9.54,21.6
169590-42-5,CELECOXIB,CELEBREX,PF-00345549,568,Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,36160,1998,Drugs@FDA,NO,NO,,0.84,High,Fa estimated from reported excretion data,0.03,5.7,11,,27,176,776128147,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,5JW1,381.3722,2,3,1,5,0,3,77.98,0.117647059,3.51,4.4,4.372,All fragments measured,3.4,3.4,3.24,3.302,9.68,,9.5,-1.1,Neutral,Class 2,0,3,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.69143,0.71713,0.68412,0.71903,0.9848,0.98659,0.81985,0.96969,0.25672,315.5,10.7,7.35,19.5
913088-80-9,CENOBAMATE,XCOPRI,VC-001274377,,NC(O[C@H](C1=CC=CC=C1Cl)CN2N=CN=N2)=O,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,SK Biopharmaceuticals,pharma,SK LIFE SCIENCE INC,pharma,43790,2019,Drugs@FDA,NO,NO,,0.88,High,Fa estimated from reported excretion data,0.4,0.7,55,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,267.6716,2,5,1,7,0,5,95.92,0.2,1.1,1.111,1.251,Valid estimate for difficult structure,0.98,0.98,1.43,1.433,12.76,,14,,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.9068,0.85865,0.89157,0.93033,0.72615,0.98659,0.72864,0.84757,0.93773,264.3,10.9,4.26,7.41
15686-71-2,CEPHALEXIN,KEFLEX,PF-00344976,571,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)N)SC1)C(=O)O,"CAPSULE, FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,PRAGMA,pharma,25937,1971,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.85,0.3,1,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",Moderate,2,Beta_Lactams; Michael_acceptor,NO,YES,NO,,347.3889,4,6,3,7,0,4,112.73,0.3125,-0.0435,-0.0435,-1.84,Benzyl approx. based on a priori value,-0.27,-1.9,-0.35,-3.625,3.12,6.84,2.8,7.6,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.49391,0.44083,0.88365,0.07219,0.52457,0.37866,0.31825,0.96969,0.82734,419.2,0.749,3.21,7.11
22202-75-1,CEPHALOGLYCIN,KAFOCIN,PF-02904255,572,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](c3ccccc3)N)SC1)C(=O)O,CAPSULE,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,25731,1970,Drugs@FDA,NO,NO,,,NA,NA,,,,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,2,Beta_Lactams; Michael_acceptor,NO,YES,NO,,405.425,4,7,3,9,0,7,139.03,0.333333333,-0.552,-0.552,-2.881,Benzyl approx. based on a priori value,-0.69,-2.3,-0.25,-3.54,2.67,6.84,2.4,7.6,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.34964,0.27619,0.53861,0.04492,0.19128,0.37866,0.15859,0.53315,0.82734,476.7,0.262,2.52,7.73
38821-53-3,CEPHRADINE,VELOSEF,PF-00345348,576,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,4000,Discontinued,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,27260,1974,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.92,0.21,0.67,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,B,Most,"B (cephalosporins as a class are very likely but rare causes of clinically apparent liver injury, the association having been made largely with the most frequently used agents, such as cefazolin, cephalexin and ceftriaxone)",,2,Beta_Lactams; Michael_acceptor,NO,YES,NO,,349.4048,4,6,3,7,0,4,112.73,0.4375,-0.0899,-0.0899,-1.727,Approximated fragment value used,0.48,-2.2,-0.44,-3.44,3.12,7.37,2.8,7.6,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.44879,0.40526,0.87327,0.07098,0.52457,0.37866,0.31825,0.96969,0.47245,424.5,0.718,3.09,7.05
1032900-25-6,CERITINIB,ZYKADIA,PF-06727614,4866,Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl,CAPSULE,YES,NO,NO,NO,ORAL,450,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,41758,2014,Drugs@FDA,NO,NO,,0.25,Moderate,Fa estimated from reported excretion data,0.03,60.4,41,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Less,,,D,Less,D (possible cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,4MKC,558.1351,3,6,3,8,2,9,105.24,0.428571429,3.06,2.515,6.713,All fragments measured,6.5,4.1,5.54,2.629,,10.16,,10,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,2,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,NO,0.19111,0.21521,0.08924,0.08052,0.19128,0.37866,0.54559,0.29329,0.25672,476.5,0.113,46.4,42
145599-86-6,CERIVASTATIN SODIUM,BAYCOL,PF-00346556,577,CC(C)c1c(c(c(c(n1)C(C)C)/C=C/[C@H](C[C@H](CC(=O)O)O)O)c2ccc(cc2)F)COC,TABLET,YES,NO,NO,NO,ORAL,0.8,Discontinued,2001,YES,YES,Fatal rhabdomyolysis,FederalRegister,,,BAYER HEALTHCARE,major pharma,35607,1997,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.01,0.33,2.2,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,None,Suzuki Additions,1,,,,Moderate,0,,NO,NO,NO,,459.5503,3,6,3,6,0,11,99.88,0.461538462,1.07,1.783,3.564,All fragments measured,4.3,1.1,3.69,0.652,4.24,5.61,4.2,5.5,Acidic,Class 1B,0,1,0,0,0,0,0,2,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.38522,0.46135,0.28605,0.80129,0.52457,0.37866,0.68846,0.15134,0.93773,369.7,3.98,15,15.9
83881-51-0,CETIRIZINE HYDROCHLORIDE,ZYRTEC ALLERGY,PF-00345629,581,c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCC(=O)O,"CAPSULE, SYRUP, TABLET, TABLET, CHEWABLE, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,10,Over-the-counter,,NO,NO,,,,,J AND J CONSUMER INC,major pharma,35041,1995,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.07,0.58,8.3,,29,,465522,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,388.8878,1,5,1,5,0,8,53.01,0.380952381,0.959,1.259,2.08,All fragments measured,3.4,0.37,2.52,-0.552,3.27,6.71,3.2,8.1,Zwitter,Class 3A,0,0,0,0,1,0,0,2,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.67402,0.72503,0.63753,0.61503,0.72615,0.98659,0.99999,0.39983,0.93773,307.5,4.94,2.02,7.96
107233-08-9,CEVIMELINE HYDROCHLORIDE,EVOXAC,PF-04440270,584,C[C@@H]1O[C@]2(CN3CCC2CC3)CS1,CAPSULE,YES,NO,NO,NO,ORAL,90,Prescription,,NO,NO,,,Daiichi Sankyo,pharma,DAIICHI SANKYO,pharma,36536,2000,Drugs@FDA,NO,NO,,0.84,High,Fa estimated from reported excretion data,0.8,6,5,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,199.3131,0,3,0,2,0,0,12.47,1,1.25,1.188,1.141,Approximated fragment value used,1.9,1.6,1.63,-0.296,,9.51,,6.7,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.52023,0.61912,0.44185,0.78251,0.9848,0.59178,0.92721,0.39503,0.47245,242,29.8,5.42,18.2
474-25-9,CHENODIOL,CHENIX,PF-00345498,4361,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,TABLET,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,LEADIANT BIOSCI INC,pharma,30525,1983,Drugs@FDA,NO,NO,0.81,,High,Reported bioavailability,,,,,,,,YES,Gastrointestinal,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,E*,Ambiguous,E* (Suspected but unproven cause of clinically apparent liver injury),None,0,,NO,NO,NO,,392.572,3,4,3,4,0,4,77.76,0.958333333,1.61,1.61,4.514,All fragments measured,4.4,1.9,3.76,1.166,4.76,,5,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62922,0.68727,0.61495,0.85917,0.88651,0.37866,0.89136,0.96969,0.47245,391.8,4.56,21.4,7.18
791-35-5,CHLOPHEDIANOL HYDROCHLORIDE,ULO,PF-00345496,585,CN(C)CCC(c1ccccc1)(c2ccccc2Cl)O,SYRUP,YES,NO,NO,NO,ORAL,100,Discontinued,,NO,NO,,,,,3M,pharma,22282,1961,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,289.7998,1,2,1,2,0,5,23.47,0.294117647,1.48,1.511,3.63,All fragments measured,3.4,1.8,3.68,2.031,,9.43,15,8.4,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.93226,0.89785,0.97966,0.95256,0.93048,0.98659,0.69082,0.84757,0.93773,221.4,11.2,7.94,22.4
305-03-3,CHLORAMBUCIL,LEUKERAN,PF-00344697,588,c1cc(ccc1CCCC(=O)O)N(CCCl)CCCl,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,ASPEN GLOBAL,pharma,20897,1957,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.01,0.26,1.5,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,2,Alkyl_halide_Sulfate_ester; Aniline,YES,NO,NO,,304.2122,1,2,1,3,0,9,40.54,0.5,1.15,1.15,3.631,All fragments measured,3.8,1.2,3.11,0.557,4.82,4.62,4.6,3.6,Acidic,Class 1A,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.72511,0.79438,0.99973,0.88863,0.9848,0.98659,0.95307,0.29329,0.82734,181.9,7.41,22.7,8.83
56-75-7,CHLORAMPHENICOL,CHLOROMYCETIN,PF-00344536,589,c1cc(ccc1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)N(=O)=O,N/A,N/A,N/A,N/A,NO,ORAL,3000,Discontinued,2007,YES,YES,"Bone marrow depression (anemia, thrombocytopenia, and granulocytopenia temporally associated with treatment)",FederalRegister,,,PFIZER,major pharma,17899,1949,NIH NCATS,NO,NO,0.9,,High,Reported bioavailability,0.34,0.6,2.5,,,,885465,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,B,Most,"B (highly likely cause of clinically apparent liver injury, now rarely seen)",Less,2,Alkyl_halide_Sulfate_ester; Nitroorganics,NO,NO,NO,,323.1294,3,5,3,7,0,6,115.38,0.363636364,1.07,1.101,1.283,All fragments measured,0.54,0.54,1.02,0.855,11.03,,9.5,,Neutral,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,2,0,0,0,0,NO,0.68834,0.67375,0.97823,0.77997,0.72615,0.37866,0.52738,0.6885,0.82734,294.3,8.35,5.25,8.09
58-25-3,CHLORDIAZEPOXIDE HYDROCHLORIDE,LIBRIUM,RS-091738,594,CNC1=Nc2ccc(cc2C(=N(=O)C1)c3ccccc3)Cl,CAPSULE,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,VALEANT,pharma,21970,1960,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.06,0.25,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,"D (Possible, rare cause of clniically apparent liver injury)",None,0,,NO,NO,NO,,299.7549,1,2,1,4,0,2,53.14,0.125,3.13,2.64,2.465,A priori fragment value used,1.4,1.4,2.36,2.356,,2.38,,5,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.95381,0.96449,0.99693,0.98208,0.9848,0.98659,0.99999,0.87038,0.93773,264.4,10.6,11.9,12.6
302-22-7,CHLORMADINONE ACETATE,C-QUENS,PF-00579972,600,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,TABLET,YES,NO,NO,NO,ORAL,2,Discontinued,1972,YES,YES,Mammary tumors in dogs,FederalRegister,,,ELI LILLY AND CO,major pharma,23743,1965,Wikipedia,NO,NO,,,NA,NA,,,,,,,614352,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,FEARS Addition ,1,,,,,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,404.927,0,3,0,4,0,3,60.44,0.695652174,2.93,3.374,3.976,Valid estimate for difficult structure,3.3,3.3,3.72,3.723,,,,,Neutral,Class 2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.68796,0.74513,0.54148,0.96896,0.88651,0.59178,0.9879,0.99269,0.47245,400.3,17.6,47.1,92.1
80-77-3,CHLORMEZANONE,TRANCOPAL,PF-00344617,603,CN1C(S(=O)(=O)CCC1=O)c2ccc(cc2)Cl,TABLET,YES,NO,NO,NO,ORAL,1600,Discontinued,1996,YES,NO,"Toxic epidermal necrolysis, Stevens-Johnson syndrome",WITHDRAWN,,,SANOFI AVENTIS US,major pharma,22056,1960,Drugs@FDA,NO,NO,,0.4,High,Fa estimated from reported excretion data,0.52,,21,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,0,,NO,NO,NO,,273.7359,0,3,0,4,0,1,54.45,0.363636364,0.818,0.818,1.575,Benzyl approx. based on a priori value,0.71,0.71,0.52,0.522,,,,,Neutral,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.761,0.81942,0.92177,0.89435,0.9848,0.59178,0.97951,0.63709,0.82734,272.3,18.1,2.74,6.88
54-05-7,CHLOROQUINE PHOSPHATE,ARALEN,PF-00345351,607,CCN(CC)CCCC(C)Nc1ccnc2c1ccc(c2)Cl,TABLET,YES,NO,NO,NO,ORAL,71.43,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,18202,1949,Drugs@FDA,NO,NO,0.89,,High,Reported bioavailability,0.4,2.9,720,,,,,NO,"Anti-infective, Autoimmune Disease",NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,319.8721,1,2,1,3,1,8,28.16,0.5,1.68,0.6553,5.06,All fragments measured,5.3,2,4.56,1.574,,10.47,,9.9,Basic,Class 4,0,0,0,0,1,0,0,2,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,NO,0.76609,0.80122,0.98562,0.75114,0.9848,0.98659,0.78595,0.39983,0.93773,274.2,5.79,1.99,7.85
58-94-6,CHLOROTHIAZIDE,DIURIL,PF-00344616,609,c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,OAK PHARMS AKORN,pharma,21432,1958,Drugs@FDA,NO,NO,,0.15,Moderate,Fa estimated from reported excretion data,0.6,,1,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,295.7232,3,5,2,7,0,1,118.69,0,-0.127,-0.127,-1,All fragments measured,-0.55,-0.58,-0.02,-0.206,9.62,,6.6,4.5,Neutral,Class 3A,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.71071,0.63705,0.99176,0.4175,0.72615,0.79222,0.33914,0.63709,0.82734,323.3,1.03,2.98,8.81
569-57-3,CHLOROTRIANISENE,TACE,PF-00344773,610,COc1ccc(cc1)C(=C(c2ccc(cc2)OC)Cl)c3ccc(cc3)OC,CAPSULE,YES,NO,NO,NO,ORAL,25,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,21383,1958,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,380.864,0,3,0,3,1,6,27.69,0.130434783,4.53,5.45,5.832,Valid estimate for difficult structure,5.8,5.8,6.15,6.154,,,,,Neutral,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.4863,0.53793,0.68728,0.23692,0.9848,0.59178,0.77707,0.6885,0.25672,250.7,1.15,22.9,35.1
886-74-8,CHLORPHENESIN CARBAMATE,MAOLATE,PF-00346098,614,c1cc(ccc1OCC(COC(=O)N)O)Cl,TABLET,YES,NO,NO,NO,ORAL,2400,Discontinued,,NO,NO,,,,,PAMLAB LLC,pharma,23907,1965,Drugs@FDA,NO,NO,,,NA,NA,,1.27,3.5,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,245.6596,3,4,2,5,0,6,81.78,0.3,1.19,1.27,1.26,All fragments measured,1.3,1.3,1.31,1.313,12.99,,13,,Neutral,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.78369,0.81261,0.75547,0.9008,0.88651,0.79222,0.85944,0.6885,0.82734,215,28.1,9.92,6.65
132-22-9,CHLORPHENIRAMINE MALEATE,CHLOR-TRIMETON,PF-00344535,616,CN(C)CCC(c1ccc(cc1)Cl)c2ccccn2,"SYRUP, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,24,Over-the-counter,,NO,NO,,,,,SCHERING,major pharma,18092,1949,Drugs@FDA,NO,NO,0.41,0.94,High,Reported bioavailability,0.28,3.2,20,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),None,0,,NO,NO,NO,,274.7885,0,2,0,2,0,5,16.13,0.3125,1.38,1.403,3.148,All fragments measured,3.3,1.6,3.09,1.164,,9.33,,9,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.82149,0.79348,0.92659,0.93074,0.93048,0.59178,0.52472,0.84757,0.93773,196.9,28.7,10.9,11.7
461-78-9,CHLORPHENTERMINE HYDROCHLORIDE,PRE-SATE,PF-01003138,618,CC(C)(Cc1ccc(cc1)Cl)N,TABLET,YES,NO,NO,NO,ORAL,65,Discontinued,1969,YES,NO,"Pulminary hypertension, cardiac fibrosis",WITHDRAWN,,,PARKE DAVIS,major pharma,22647,1962,Wikipedia,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,183.6779,2,1,1,1,0,2,26.02,0.4,0.425,0.425,2.854,All fragments measured,2.6,0.19,2.59,0.301,,9.76,,9.9,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7219,0.63881,0.35427,0.99346,0.23327,0.98659,0.74426,0.87038,0.82734,96.94,34,6.42,12.9
50-53-3,CHLORPROMAZINE HYDROCHLORIDE,THORAZINE,PF-00345029,621,CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)Cl,"CAPSULE, EXTENDED RELEASE, CONCENTRATE, SYRUP, TABLET",YES,NO,YES,NO,ORAL,2000,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,21081,1957,Drugs@FDA,NO,NO,0.32,,High,Reported bioavailability,0.06,,6,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),None,0,,NO,NO,NO,,318.8642,0,2,0,2,1,4,6.48,0.294117647,3.01,3.162,5.3,All fragments measured,5.2,3.4,5.36,3.419,,9.41,,9,Basic,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.80737,0.82507,0.98761,0.58609,0.9848,0.59178,0.84849,0.96969,0.93773,267.2,3.2,26.3,66.3
94-20-2,CHLORPROPAMIDE,DIABINESE,PF-00345025,622,CCCNC(=O)NS(=O)(=O)c1ccc(cc1)Cl,TABLET,YES,NO,NO,NO,ORAL,750,Prescription,,NO,NO,,,,,PFIZER,major pharma,21486,1958,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.03,0.19,48,,,,609128,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Less,Less,DILIRank,1,B,Most,"B (likely cause of liver injury as a class, most cases linked to chlorpropamide which was also the most commonly used in the past)",,0,,NO,NO,NO,,276.7398,2,3,2,5,0,4,75.27,0.3,0.182,-0.101,2.35,All fragments measured,2.1,-0.33,2.17,0.196,4.76,,4.9,,Acidic,Class 1A,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.89602,0.89912,0.93517,0.962,0.9848,0.79222,0.84366,0.96969,0.82734,239.1,11.2,2.82,12.8
113-59-7,CHLORPROTHIXENE,TARACTAN,PF-00344974,623,CN(C)CC/C=C/1\c2ccccc2Sc3c1cc(cc3)Cl,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,24642,1967,Drugs@FDA,NO,NO,0.17,,Moderate,Reported bioavailability,,10,8,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,315.8602,0,2,0,1,1,3,3.24,0.222222222,3.67,3.6,5.482,All fragments measured,5.5,3.9,5.48,3.835,,9.05,,9.1,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.76852,0.77484,0.99269,0.41555,0.93048,0.59178,0.79301,0.99269,0.93773,226.9,6.27,21.8,33.1
77-36-1,CHLORTHALIDONE,HYGROTON,PF-00344864,625,c1ccc2c(c1)C(=O)NC2(c3ccc(c(c3)S(=O)(=O)N)Cl)O,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,22013,1960,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.25,3.9,50,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,338.7661,4,4,3,6,0,2,109.49,0.071428571,1.28,0.9433,0.448,Approximated fragment value used,0.85,0.84,0.41,0.322,9.57,,8.1,,Neutral,Class 3A,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.74322,0.7291,0.92427,0.86153,0.88651,0.37866,0.50203,0.87038,0.93773,378.5,4.33,2.93,6.65
95-25-0,CHLORZOXAZONE,PARAFON FORTE DSC,PF-00344777,626,c1cc2c(cc1Cl)[nH]c(=O)o2,TABLET,YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,21412,1958,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.82,0.2,1.1,,,,3149026,NO,Musculoskeletal/Pain,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (Highly likely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,169.5652,1,1,1,3,0,0,46,0,0.966,0.966,1.871,All fragments measured,1.7,1.7,2.37,2.334,8.46,,8.2,,Acidic,Class 1A,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.60797,0.7143,0.28732,0.98355,0.93048,0.98659,0.98731,0.39503,0.93773,170.3,48.2,8.7,16.1
67-97-0,CHOLECALCIFEROL,FOSAMAX PLUS D,PF-04987349,2840,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,TABLET,YES,NO,NO,NO,ORAL,0.25,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,38449,2005,Drugs@FDA,YES,NO,,,High,Based on textual comment,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,384.6377,1,1,1,1,1,6,20.23,0.777777778,5.01,5.97,9.476,Very high LogP unrealistic in nature,8.9,8.9,8.65,8.668,,,15,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.41862,0.36958,0.66382,0.03062,0.23327,0.98659,0.61872,0.6885,0.47245,279.2,0.944,58,31.5
81-25-4,CHOLIC ACID,CHOLBAM,PF-02400182,3096,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Asklepion Pharmaceuticals,pharma,RTRX,pharma,42080,2015,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,YES,Gastrointestinal,NO,NO,,NO,NO,NO,YES,,Less,,,D[HD],Less,D [HD] (possible cause of liver injury but only when given in high doses),None,0,,NO,NO,NO,,408.5714,4,5,4,5,0,4,97.99,0.958333333,0.917,0.583,2.427,All fragments measured,3.4,0.94,2.11,-0.359,4.76,,5,,Acidic,Class 3B,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50697,0.56332,0.52067,0.99929,0.72615,0.14694,0.70777,0.96969,0.47245,434,1.24,4.74,7.4
42017-89-0,CHOLINE FENOFIBRATE,TRILIPIX,PF-00802333,4505,CC(C)(C(=O)O)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl,"CAPSULE, DELAYED RELEASE",NO,YES,NO,NO,ORAL,135,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,39797,2008,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.01,0.9,20,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,YES,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,318.7516,1,4,1,4,0,5,63.6,0.176470588,0.7,0.62,4.065,All fragments measured,3.9,0.7,4.08,0.43,3.09,,3.7,,Acidic,Class 1A,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.91752,0.91745,0.98783,0.81603,0.88651,0.98659,0.97641,0.84757,0.93773,220.8,13.9,6.74,49.9
73963-72-1,CILOSTAZOL,PLETAL,PF-00346586,644,c1cc2c(cc1OCCCCc3nnnn3C4CCCCC4)CCC(=O)N2,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,OTSUKA,pharma,36175,1999,Drugs@FDA,NO,NO,0.87,,High,Reported bioavailability,0.02,,12,,,,3930537,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,369.4607,1,5,1,7,0,7,81.93,0.6,2.99,3.706,3.528,Valid estimate for difficult structure,3.3,3.3,3.01,3.008,11.37,2.19,14,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80012,0.81053,0.75791,0.98648,0.72615,0.98659,0.85819,0.53315,0.93773,314.3,7.93,32.7,37.8
51481-61-9,CIMETIDINE,TAGAMET,PF-00344534,645,Cc1c(nc[nH]1)CSCC/N=C(\NC)/NC#N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1600,Over-the-counter,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,28353,1977,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.78,1,2,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,252.3392,3,4,3,6,0,7,88.89,0.5,0.263,-0.153,0.19,Calculated fragment value,-0.23,-0.28,0.69,0.396,,7.07,14,6.4,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57332,0.56297,0.80008,0.47382,0.52457,0.37866,0.53961,0.53315,0.82734,237.6,0.959,3.01,9.68
226256-56-0,CINACALCET HYDROCHLORIDE,SENSIPAR,PF-06700534,647,C[C@H](c1cccc2c1cccc2)NCCCc3cccc(c3)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,360,Prescription,,NO,NO,,,NPS Pharmaceuticals,pharma,AMGEN,major pharma,38054,2004,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.05,14.3,30,,155,72,,YES,Metabolic Disease,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,357.412,1,1,1,1,1,6,12.03,0.272727273,4.01,5.01,6.352,All fragments measured,6.6,4.6,5.8,4.025,,9.19,,8.9,Basic,Class 4,0,3,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.48027,0.40335,0.82946,0.1535,0.23327,0.98659,0.43308,0.53315,0.25672,254,1.37,29.1,82.7
28657-80-9,CINOXACIN,CINOBAC,PF-00344863,657,CCn1c2cc3c(cc2c(=O)c(n1)C(=O)O)OCO3,CAPSULE,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,29385,1980,Drugs@FDA,NO,NO,,0.57,High,Fa estimated from reported excretion data,0.27,,1.5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,None,,,,,,Moderate,1,BenzoDioxolane,NO,NO,NO,,262.2182,1,4,1,7,0,2,90.65,0.25,-0.848,-0.848,1.735,All fragments measured,1.8,-0.69,0.87,-2.874,,4.33,5,3.5,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87205,0.75967,0.86121,0.89675,0.33223,0.98659,0.80099,0.87038,0.82734,283.6,4.26,3.64,15.4
85721-33-1,CIPROFLOXACIN HYDROCHLORIDE,CIPRO,PF-00344537,659,c1c2c(cc(c1F)N3CCNCC3)n(cc(c2=O)C(=O)O)C4CC4,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1500,Prescription,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,32072,1987,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.7,2.4,5,,179,,6501545,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,2XCT,331.3415,2,4,2,6,0,3,74.57,0.411764706,-1.04,-0.5293,-0.725,All fragments measured,1.8,-0.63,-0.3,-2.515,6.16,8.68,6.1,8.6,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.68429,0.65298,0.95345,0.16798,0.52457,0.79222,0.92598,0.99269,0.82734,317.9,0.825,2.69,7.59
81098-60-4,CISAPRIDE MONOHYDRATE,PROPULSID,PF-06553797,660,COc1cc(c(cc1C(=O)N[C@@H]2CCN(C[C@@H]2OC)CCCOc3ccc(cc3)F)Cl)N,"SUSPENSION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,80,Discontinued,2000,YES,YES,QTc prolongation ,FederalRegister,,,JANSSEN PHARMS,major pharma,34179,1993,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.02,2.4,8,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,None,LiverTox Additions,0,E,None,E (unlikely causes of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,465.9455,3,5,2,7,0,9,86.05,0.434782609,3.41,3.22,3.811,All fragments measured,3.5,2.9,3.02,2.651,,7.47,11,7.7,Basic,Class 2,0,1,0,0,1,0,0,2,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,1,0,0,NO,0.5288,0.58989,0.26435,0.99994,0.52457,0.79222,0.82263,0.29329,0.93773,451.9,21.4,13.3,126
59729-33-8,CITALOPRAM HYDROBROMIDE,CELEXA,PF-00346592,663,CN(C)CCCC1(c2ccc(cc2CO1)C#N)c3ccc(cc3)F,"SOLUTION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,ALLERGAN,major pharma,35993,1998,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.2,12,35,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,0,,NO,NO,NO,5I71,324.3919,0,3,0,3,0,5,36.26,0.35,1.25,1.272,3.132,All fragments measured,4.1,2.5,3.39,1.269,,9.57,,9,Basic,Class 2,0,1,0,0,0,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.8403,0.87116,0.97498,0.92621,0.9848,0.59178,0.91035,0.84757,0.93773,277.6,16.1,2.12,11.9
4291-63-8,CLADRIBINE,MAVENCLAD,PF-01466725,667,OC[C@@H]1[C@H](C[C@H](N2C=NC3=C(N=C(Cl)N=C32)N)O1)O,TABLET,YES,NO,NO,NO,ORAL,70,Prescription,,NO,NO,,,Scripps Research Institute,pharma,EMD SERONO INC,pharma,43553,2019,Drugs@FDA,NO,YES,0.4,,High,Reported bioavailability,0.8,6.9,24,,,,,YES,Neurological,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Reactive_HeteroCycle,NO,NO,NO,,285.68688,4,6,3,8,0,2,119.31,0.5,0.432,0.1871,-0.905,All fragments measured,-0.56,-0.56,0.01,-0.005,,1.25,12,4,Neutral,Class 4,0,0,0,0,1,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,2,0,NO,0.65377,0.56796,0.9682,0.39332,0.33223,0.37866,0.48756,0.87038,0.93773,396.2,0.638,2.48,8.16
81103-11-9,CLARITHROMYCIN,BIAXIN,PF-00344544,668,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,"FOR SUSPENSION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1000,Prescription,,NO,NO,,,,,ABBVIE,major pharma,33542,1991,Drugs@FDA,NO,NO,0.55,,High,Reported bioavailability,0.5,3.5,3,,162,,1737098,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,747.9534,4,13,4,14,2,8,182.91,0.947368421,1.45,1.458,2.374,All fragments measured,2.3,0.98,3.12,2.377,,8.16,12,8.8,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,YES,0.20023,0.15006,0.03032,0.97484,0.02183,0.14694,0.09564,0.39983,0.47245,1010,6.49,6.83,35.2
58001-44-8,CLAVULANATE POTASSIUM,AUGMENTIN '250',PF-00345259,669,C1[C@@H]2N(C1=O)[C@H](/C(=C\CO)/O2)C(=O)O,"FOR SUSPENSION, TABLET, TABLET, CHEWABLE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1000,Prescription,,NO,NO,,,,,NEOPHARMA,pharma,30900,1984,Drugs@FDA,YES,NO,0.7,,High,Reported bioavailability,0.75,0.22,,Parent CRG,197,190,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,Moderate,1,Beta_Lactams,NO,NO,NO,,199.1608,2,5,2,6,0,2,87.07,0.5,-1.57,-1.57,-1.065,All fragments measured,-1.2,-4.6,-1.31,-4.726,3.68,,3,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,NO,0.51563,0.54729,0.44093,0.17334,0.72615,0.79222,0.81345,0.87038,0.47245,279.2,1.22,1.66,10.7
15686-51-8,CLEMASTINE FUMARATE,TAVIST,PF-00344977,671,C[C@@](c1ccccc1)(c2ccc(cc2)Cl)OCC[C@H]3CCCN3C,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,8.04,Over-the-counter,,NO,NO,,,,,NOVARTIS,major pharma,28181,1977,Drugs@FDA,NO,NO,0.39,,High,Reported bioavailability,,11.4,21,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,343.8902,0,2,0,2,1,6,12.47,0.428571429,2.68,3.243,5.447,All fragments measured,5.7,3.5,5.86,3.216,,10.23,,9.4,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.71776,0.69562,0.9009,0.55596,0.93048,0.59178,0.44264,0.6885,0.93773,291.4,8.38,16.9,62.1
7020-55-5,CLIDINIUM BROMIDE,QUARZAN,PF-00344865,676,C[N+]12CCC(CC1)C(C2)OC(=O)C(c3ccccc3)(c4ccccc4)O,CAPSULE,YES,NO,NO,NO,ORAL,20,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,24351,1966,Drugs@FDA,NO,NO,,0.36,High,Fa estimated from reported excretion data,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,None,0,,NO,NO,NO,,352.4467,1,3,1,4,0,5,46.53,0.409090909,0.0982,0.0982,-0.048,Approximated fragment value used,0.59,0.59,-0.44,-0.433,11.13,,14,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.90917,0.93159,0.85709,0.93088,0.9848,0.98659,0.98835,0.84757,0.93773,283.3,1.67,9.1,8.53
18323-44-9,CLINDAMYCIN HYDROCHLORIDE,CLEOCIN HYDROCHLORIDE,PF-00344619,678,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CAPSULE,YES,NO,NO,NO,ORAL,1800,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,25621,1970,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.06,0.79,2.4,,,,217470751,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,424.983,4,7,4,7,0,7,102.26,0.944444444,1.59,1.1,2.569,All fragments measured,1.3,0.96,2.12,1.076,12.87,8.74,12,7.7,Basic,Class 4,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,3,0,0,0,0,0,0,1,0,1,0,0,NO,0.40559,0.40619,0.43313,0.83943,0.33223,0.14694,0.40806,0.53315,0.47245,558.9,1.68,10.5,44.2
22316-47-8,CLOBAZAM,ONFI,PF-00346490,682,CN1c2ccc(cc2N(C(=O)CC1=O)c3ccccc3)Cl,"FILM, SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,Sanofi,major pharma,LUNDBECK PHARMS LLC,pharma,40837,2011,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.1,1.4,39,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,,None,FEARS Addition ,1,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,300.7396,0,2,0,4,0,1,40.62,0.125,2.02,2.448,2.438,All fragments measured,2.5,2.1,2.29,2.258,8.59,,8.5,,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.8029,0.84707,0.99782,0.9996,0.93048,0.59178,0.95372,0.63709,0.93773,290.6,31.4,14.4,15.3
2030-63-9,CLOFAZIMINE,LAMPRENE,PF-01014318,692,CC(C)/N=c/1\cc-2n(c3ccccc3nc2cc1Nc4ccc(cc4)Cl)c5ccc(cc5)Cl,CAPSULE,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,31761,1986,Drugs@FDA,NO,NO,0.45,,High,Reported bioavailability,,,600,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,None,FEARS Addition ,1,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,473.3964,1,1,1,4,1,4,42.21,0.111111111,4.57,5.76,7.699,Very high LogP unrealistic in nature,7,5.7,7.44,5.781,,9.16,,8.8,Basic,Class 4,0,0,0,0,2,0,0,4,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,2,0,0,0,0,NO,0.35472,0.41536,0.24108,0.04284,0.88651,0.98659,0.94845,0.96969,0.25672,405.9,0.103,21.5,41.7
637-07-0,CLOFIBRATE,ATROMID-S,PF-00345116,694,CCOC(=O)C(C)(C)Oc1ccc(cc1)Cl,CAPSULE,YES,NO,NO,NO,ORAL,3000,Discontinued,2002,YES,NO,"Increased incidence of serious effects, including cholelithiasis, cholecystitis, thromboembolic disorders, and certain cardiac arrhythmias",Martindale,,,WYETH,major pharma,24511,1967,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.03,5.2,18,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),,0,,NO,NO,NO,,242.6987,0,2,0,3,0,5,35.53,0.416666667,3.16,3.24,3.679,All fragments measured,3.5,3.5,3.52,3.523,,,,,Neutral,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.77986,0.82722,0.73513,0.97874,0.9848,0.59178,0.90148,0.84757,0.82734,168.1,18.4,82.8,73.6
911-45-5,CLOMIPHENE CITRATE,CLOMID,PF-01421294,700,CCN(CC)CCOc1ccc(cc1)/C(=C(/c2ccccc2)\Cl)/c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,24504,1967,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,,,60,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury as a part of the ovarian hyperstimulation syndrome),Less,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,405.9596,0,2,0,2,1,9,12.47,0.230769231,4.26,4.79,7.151,Very high LogP unrealistic in nature,6.5,4.9,7.09,4.955,,9.6,,8.6,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.31876,0.36027,0.53554,0.08015,0.93048,0.59178,0.44264,0.29329,0.25672,256.8,2.37,12.8,54.6
303-49-1,CLOMIPRAMINE HYDROCHLORIDE,ANAFRANIL,PF-00344569,701,CN(C)CCCN1c2ccccc2CCc3c1cc(cc3)Cl,CAPSULE,YES,NO,NO,NO,ORAL,250,Prescription,,NO,NO,,,,,SPECGX LLC,pharma,32871,1989,Drugs@FDA,NO,NO,0.2,,Moderate,Reported bioavailability,0.03,12,32,,,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,Most,Most,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,314.8523,0,1,0,2,1,4,6.48,0.368421053,2.81,2.6,5.921,All fragments measured,5.1,3.2,5.29,3.305,,9.46,,9,Basic,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7593,0.68585,0.9941,0.44608,0.93048,0.59178,0.32149,0.96969,0.93773,240.9,7,18,53.1
1622-61-3,CLONAZEPAM,KLONOPIN,PF-00345352,703,c1ccc(c(c1)C2=NCC(=O)Nc3c2cc(cc3)N(=O)=O)Cl,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,27549,1975,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.095,3.2,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible but rare cause of clinically apparent liver injury),Less,1,Nitroorganics,NO,NO,NO,,315.7112,1,3,1,6,0,2,87.28,0.066666667,2.87,3.029,2.384,All fragments measured,2.7,2.7,2.53,2.53,11.21,1.55,10,1.7,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.9499,0.92402,0.99291,0.99985,0.88651,0.98659,0.81154,0.87038,0.93773,311.1,40.6,3.56,7.24
4205-90-7,CLONIDINE HYDROCHLORIDE,CATAPRES,PF-00344866,704,c1cc(c(c(c1)Cl)NC2=NCCN2)Cl,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,0.4,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,27275,1974,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.8,2.1,12.5,,,,,YES,"Cardiovascular, Musculoskeletal/Pain, Neurological",NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,230.0939,2,1,2,3,0,2,36.42,0.222222222,0.399,0.709,1.727,Estimated fragment value used,2,0.85,1.8,1.035,,8.1,,8.6,Basic,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.75705,0.81515,0.64673,0.98577,0.9848,0.79222,0.91223,0.63709,0.82734,175.4,10.4,4.76,13.4
113665-84-2,CLOPIDOGREL BISULFATE,PLAVIX,PF-00321567,708,COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2,TABLET,YES,NO,NO,NO,ORAL,75,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35751,1997,Drugs@FDA,NO,YES,0.5,,High,Reported bioavailability,0.02,,6,Prodrug,7,70,3989882,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely but rare cause of clinically apparent liver injury),Moderate,1,Thiophene,NO,NO,YES,,321.8217,0,2,0,3,0,4,29.54,0.3125,3.29,4.06,4.208,Benzyl approx. based on a priori value,3.3,3.3,4.21,4.223,,4.56,,5.3,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.86786,0.89988,0.98137,0.92359,0.9848,0.59178,0.99487,0.96969,0.93773,288.1,18.8,160,185
57109-90-7,CLORAZEPATE DIPOTASSIUM,TRANXENE,PF-00345354,711,c1ccc(cc1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)C(=O)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,RECORDATI RARE,pharma,26473,1972,Drugs@FDA,NO,NO,0.91,,High,Reported bioavailability,0.02,1.3,2.3,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible but rare cause of clinically apparent liver injury),None,0,,NO,NO,NO,,314.7231,2,3,2,5,0,2,78.76,0.0625,-0.103,-0.103,2.51,All fragments measured,2.4,-0.96,2.53,-1.171,,3.43,3.6,2.3,Acidic,Class 3A,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.9099,0.90666,0.99428,0.99997,0.88651,0.79222,0.88369,0.87038,0.93773,302.8,1.74,6.33,7.99
61-72-3,CLOXACILLIN SODIUM,TEGOPEN,PF-00345263,720,Cc1c(c(no1)c2ccccc2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,FOR SOLUTION,YES,NO,NO,NO,ORAL,2000,Discontinued,,NO,NO,,,,,APOTHECON,pharma,27289,1974,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.05,0.1,0.75,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,,1,Beta_Lactams,NO,NO,NO,,435.8813,2,6,2,8,0,4,112.74,0.368421053,-0.508,-0.508,2.516,Approximated fragment value used,2.8,-0.55,2.52,-1.205,2.44,,2.8,-4.6,Acidic,Class 3B,0,0,0,0,1,0,0,2,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.72901,0.64213,0.38117,0.98229,0.52457,0.79222,0.31817,0.96969,0.93773,529.6,0.816,4.74,7.42
5786-21-0,CLOZAPINE,CLOZARIL,PF-00248926,722,CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cccc4)Cl,"SUSPENSION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,900,Prescription,,NO,NO,,,,,HERITAGE LIFE,pharma,32777,1989,Drugs@FDA,NO,NO,0.55,,High,Reported bioavailability,0.03,6,12,,,,11439409,NO,Neurological,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,B,Most,B (very likely cause of clinically apparent liver injury),Moderate,1,Dibenzazepine,NO,NO,NO,,326.8233,1,2,1,4,0,1,30.87,0.277777778,2.96,3.207,3.714,Approximated fragment value used,4.5,4.3,3.11,2.704,,7.33,,7.7,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.87853,0.88009,0.96813,0.96962,0.88651,0.98659,0.83379,0.63709,0.93773,300,5.69,8.88,21.9
1004316-88-4,COBICISTAT,TYBOST,PF-06785712,4299,CC(C)c1nc(cs1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc4cncs4)Cc5ccccc5,TABLET,YES,NO,NO,YES,ORAL,150,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,41906,2014,Drugs@FDA,NO,NO,,0.14,Moderate,Fa estimated from reported excretion data,0.02,,3,,,54,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Ambiguous,LiverTox Additions,0,,,,Moderate,1,Thiazole,NO,NO,NO,,776.0227,3,5,3,12,2,21,138.02,0.475,3.96,4.42,3.979,Benzyl approx. based on a priori value,5.3,5.3,4.79,4.327,11.86,7.16,15,6.7,Basic,Class 4,0,0,0,0,0,0,0,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.06033,0.07855,0.0291,0.57442,0.19128,0.37866,0.07082,0.00623,0.03452,762.8,2.99,16.4,249
934660-93-2,COBIMETINIB FUMARATE,COTELLIC,PF-06749129,5046,c1cc(c(cc1I)F)Nc2c(ccc(c2F)F)C(=O)N3CC(C3)([C@@H]4CCCCN4)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,Exelixis,pharma,GENENTECH,major pharma,42318,2015,Drugs@FDA,NO,NO,0.46,,High,Reported bioavailability,0.05,11.5,44,,,,,YES,Oncology,NO,YES,III,NO,NO,NO,NO,,,,,D,Less,D (possible cause of clinically apparent liver injury),,2,Aniline; Organic_Iodide,YES,NO,NO,4AN2,531.31,3,3,3,5,2,5,64.6,0.380952381,2.66,3.374,5.264,All fragments measured,3.7,2.1,5.29,2.37,,10.2,12,8.7,Basic,Class 4,0,3,0,0,0,0,1,2,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,1,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.49562,0.61443,0.11982,0.92985,0.88651,0.37866,0.97211,0.96969,0.93773,425.9,10,19.2,33
76-57-3,CODEINE SULFATE,CODEINE SULFATE,PF-00345355,725,CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,360,Prescription,,NO,NO,,,,,WEST-WARD PHARMS INT,pharma,40010,2009,Drugs@FDA,NO,NO,0.5,0.9,High,Reported bioavailability,0.93,4,3,,,,2340317,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,299.3642,1,4,1,4,0,1,41.93,0.555555556,0.337,0.337,0.977,All fragments measured,1.3,0.21,1.21,0.282,,8.23,13,8.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86012,0.87784,0.99654,0.90736,0.88651,0.98659,0.96367,0.63709,0.82734,372.5,23.8,3.06,13.6
64-86-8,COLCHICINE,COLCRYS,PF-00344618,726,CC(=O)N[C@H]1CCc2cc(c(c(c2-c3c1cc(=O)c(cc3)OC)OC)OC)OC,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,1.2,Prescription,,NO,NO,,,URL Pharma,pharma,TAKEDA PHARMS USA,major pharma,40023,2009,Drugs@FDA,NO,NO,0.45,,High,Reported bioavailability,0.61,6.5,28.9,,,,295,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,5EYP,399.437,1,6,1,7,0,5,83.09,0.363636364,1.08,1.278,1.195,All fragments measured,1.1,1.1,1.1,1.103,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80774,0.77614,0.57362,0.96059,0.52457,0.98659,0.84844,0.84757,0.82734,390.7,1,4.75,8.82
50-04-4,CORTISONE ACETATE,CORTONE,PF-00932448,734,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,MERCK,major pharma,18601,1950,Drugs@FDA,NO,NO,,,NA,NA,0.1,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,402.4807,1,5,1,6,0,4,97.74,0.739130435,1.82,1.894,2.022,Valid estimate for difficult structure,1.8,1.8,2.22,2.219,12.32,,12,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74484,0.70275,0.55569,0.90444,0.52457,0.98659,0.7103,0.96969,0.47245,415.9,12.9,41.9,118
877399-52-5,CRIZOTINIB,XALKORI,PF-02341066,4187,C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4,CAPSULE,YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,40781,2011,Drugs@FDA,NO,NO,0.43,,High,Reported bioavailability,0.09,25.3,42,,,,478649380,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Less,FEARS Addition ,1,C,Less,C (probable cause of clinically apparent acute liver injury),Less,0,,NO,NO,NO,4ANQ,450.3367,3,4,2,6,0,5,77.99,0.333333333,1.71,1.787,4.288,Benzyl approx. based on a priori value,4.3,1.8,4.29,2.109,,9.81,,9.7,Basic,Class 4,0,1,0,0,2,0,0,3,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,3,0,0,0,0,NO,0.56236,0.61482,0.32023,0.93127,0.72615,0.79222,0.88961,0.84757,0.25672,413.1,2.58,17.5,33.2
16110-51-3,CROMOLYN SODIUM,GASTROCROM,PF-00345499,741,c1cc2c(c(c1)OCC(COc3cccc4c3c(=O)cc(o4)C(=O)O)O)c(=O)cc(o2)C(=O)O,CONCENTRATE,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,35124,1996,Drugs@FDA,NO,NO,0.01,,Low,Reported bioavailability,0.24,0.13,1.5,,,,,YES,Autoimmune Disease,NO,NO,,YES,NO,NO,NO,,None,,,,,,Less,1,Michael_acceptor,NO,YES,NO,,468.3665,3,9,3,11,1,8,173.71,0.130434783,-2.34,-2.34,1.481,All fragments measured,2,-3.4,1.8,-2.947,1.94,,1.3,,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44184,0.29704,0.25656,0.9274,0.03975,0.37866,0.15194,0.39983,0.93773,461.2,0.372,3.46,14.9
3485-14-1,CYCLACILLIN,CYCLAPEN-W,PF-00344701,632,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,2000,Discontinued,,NO,NO,,,,,WYETH,major pharma,29111,1979,Drugs@FDA,NO,NO,,0.7,High,Fa estimated from reported excretion data,0.75,,0.5,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Beta_Lactams,NO,NO,NO,,341.4258,4,6,3,7,0,3,112.73,0.8,-0.87,-0.87,-0.823,Approximated fragment value used,1.2,-0.61,0.89,-2.351,2.45,7.36,2.8,8.5,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.46617,0.41799,0.91244,0.0824,0.52457,0.37866,0.31825,0.99269,0.47245,408,0.399,2.47,6.78
303-53-7,CYCLOBENZAPRINE HYDROCHLORIDE,FLEXERIL,PF-00344868,751,CN(C)CCC=C1c2ccccc2C=Cc3c1cccc3,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,30,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,28363,1977,Drugs@FDA,NO,NO,0.33,,High,Reported bioavailability,0.07,,18,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (Unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,275.3874,0,1,0,1,1,3,3.24,0.2,2.79,2.875,5.097,All fragments measured,5.1,3.5,4.64,2.895,,9.15,,9.1,Basic,Class 2,0,0,0,0,0,0,0,3,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79432,0.58713,0.92927,0.75787,0.23327,0.59178,0.26577,0.99269,0.93773,176.5,17.7,15,23.2
50-18-0,CYCLOPHOSPHAMIDE,CYTOXAN,PF-00344700,758,C1CNP(=O)(OC1)N(CCCl)CCCl,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,350,Prescription,,NO,NO,,,,,BAXTER HLTHCARE,pharma,21870,1959,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.76,0.5,,,,,1007,NO,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,261.086,1,1,1,4,0,5,41.57,1,0.823,0.7658,0.803,Valid estimate for difficult structure,0.79,0.79,0.53,0.526,,2.84,,2.7,Neutral,Class 2,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,2,0,0,0,0,NO,0.74195,0.77124,0.85458,0.517,0.93048,0.98659,0.99928,0.84757,0.47245,272.7,24.8,3.52,8.15
68-41-7,CYCLOSERINE,SEROMYCIN,RS-006775,759,C1[C@H](C(=O)NO1)N,CAPSULE,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,PURDUE PHARMA LP,pharma,23557,1964,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,,0.22,10,Suicide,,,182580,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,1XQL,102.0919,3,2,2,4,0,0,64.35,0.666666667,-1.43,-1.43,-1.192,Benzyl approx. based on a priori value,-2.1,-2.1,-1.83,-1.846,,5.93,7.2,6.6,Basic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.29403,0.39719,0.10379,0.10603,0.9848,0.79222,0.97325,0.39503,0.47245,144.3,4.87,2.07,6.65
59865-13-3,CYCLOSPORINE,SANDIMMUNE,PF-02375678,760,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,1050,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,30634,1983,Drugs@FDA,NO,NO,0.3,0.86,Moderate,Reported bioavailability,0.1,4.2,8.4,,,,,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,1202.6112,5,12,5,23,3,15,278.8,0.790322581,3.97,8.133,14.36,Very high LogP unrealistic in nature,6.6,6.6,1.8,1.805,,,13,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,YES,0.08889,0.07388,0.02683,0.75564,0.02915,0.05547,0.02081,0.03725,0.47245,1359,1.8,7.01,44.6
2259-96-3,CYCLOTHIAZIDE,ANHYDRON,PF-02299130,761,c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C3CC4CC3C=C4,TABLET,YES,NO,NO,NO,ORAL,6,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,23243,1963,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,FEARS Addition ,1,,,,,1,Aniline,YES,NO,NO,,389.8775,4,4,3,7,0,2,118.36,0.428571429,2.19,2.416,1.976,All fragments measured,1.5,1.5,1.32,1.318,9.39,,8.8,0.85,Neutral,Class 4,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,2,4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.65782,0.62048,0.63144,0.82862,0.72615,0.37866,0.34179,0.87038,0.82734,440.5,0.892,5.26,12.6
77-39-4,CYCRIMINE HYDROCHLORIDE,PAGITANE,VC-001229554,763,c1ccc(cc1)C(CCN2CCCCC2)(C3CCCC3)O,TABLET,YES,NO,NO,NO,ORAL,3.75,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,19562,1953,Drugs@FDA,NO,NO,,,NA,NA,0.79,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,287.4397,1,2,1,2,0,5,23.47,0.684210526,1.42,1.416,4.592,All fragments measured,4.2,2.2,4.08,2.17,,9.33,16,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.90008,0.87025,0.97339,0.87327,0.93048,0.98659,0.69082,0.84757,0.82734,213.2,15.7,32.1,36.9
129-03-3,CYPROHEPTADINE HYDROCHLORIDE,PERIACTIN,PF-00344538,765,CN1CCC(=C2c3ccccc3C=Cc4c2cccc4)CC1,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,MERCK,major pharma,22571,1961,Drugs@FDA,NO,NO,,0.4,High,Fa estimated from reported excretion data,,,16,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,287.3981,0,1,0,1,1,0,3.24,0.238095238,2.69,3.172,5.302,All fragments measured,4.8,3.6,5.05,3.509,,8.95,,9.2,Basic,Class 2,0,0,0,0,0,0,0,3,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65419,0.51683,0.97327,0.74471,0.23327,0.59178,0.26577,0.39503,0.93773,191.3,10.6,15.3,8.56
60-23-1,CYSTEAMINE BITARTRATE,CYSTAGON,PF-00345800,768,C(CS)N,"CAPSULE; CAPSULE, DELAYED RELEASE",YES,YES,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,34561,1994,Drugs@FDA,NO,NO,,,NA,NA,0.48,5.5,1.5,,,,,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,D[HD],Less,D [HD] (possible cause of liver injury when given in high doses),,1,Thiol_Disulfide,NO,NO,NO,,77.1487,2,2,1,1,0,1,26.02,1,-0.981,-0.981,-0.252,All fragments measured,-0.18,-1.7,-0.03,-1.546,8.32,10.34,10,9.5,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.37285,0.4871,0.07438,0.40592,0.93048,0.79222,0.97116,0.63709,0.47245,33.81,35.3,9.56,15.8
211915-06-9,DABIGATRAN ETEXILATE MESYLATE,PRADAXA,PF-06700219,776,CCCCCCOC(=O)NC(=N)c1ccc(cc1)NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c4ccccn4,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,BOEHRINGER INGELHEIM,major pharma,40470,2010,Drugs@FDA,NO,YES,0.07,,Low,Reported bioavailability,0.65,0.86,12,,,83,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,LiverTox Additions,1,D,Less,D (possible rare cause of clinically apparent liver injury),,2,1_4_Diketones; Aniline,YES,NO,NO,,627.7332,3,6,3,12,2,19,151.53,0.352941176,4.32,4.97,4.709,Calculated fragment value,4.7,4.7,4.94,4.917,9.88,5.98,,5.4,Neutral,Class 4,0,0,0,0,0,0,0,4,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.08474,0.09359,0.04866,0.19947,0.06191,0.79222,0.21003,0.01822,0.03452,585.9,0.7,50.2,318
1195765-45-7,DABRAFENIB MESYLATE,TAFINLAR,PF-06708359,4801,CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,NOVARTIS,major pharma,41423,2013,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.03,1,8,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,4XV2,519.5624,3,5,2,7,1,5,110.86,0.173913043,3.68,2.834,4.61,All fragments measured,5.3,4,3.84,2.942,6.62,2.24,6.7,3.8,Acidic,Class 1B,0,3,0,0,0,0,0,4,0,2,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.26383,0.27082,0.13737,0.31497,0.52457,0.79222,0.24995,0.6885,0.03452,510,8.06,35.3,50.5
1009119-64-5,DACLATASVIR DIHYDROCHLORIDE,DAKLINZA,PF-05087573,4875,CC(C)[C@@H](C(=O)N1CCC[C@H]1c2[nH]c(cn2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,TABLET,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,BRISTOL MYERS SQUIBB,major pharma,42209,2015,Drugs@FDA,NO,NO,0.67,,High,Reported bioavailability,0.01,0.7,12,,,73,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury in patients with cirrhosis or preexisting hepatitis B virus coinfection),,0,,NO,NO,NO,,738.875,4,6,4,14,2,15,174.64,0.45,4.07,4.71,4.722,Approximated fragment value used,5,5,4.51,4.488,10.92,6.39,12,7.2,Neutral,Class 2,0,0,0,0,0,0,0,4,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.08269,0.10076,0.03084,0.38963,0.19128,0.14694,0.11954,0.07566,0.03452,797.1,2.61,5.88,25.9
1110813-31-4,DACOMITINIB,VIZIMPRO,PF-00299804,,COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F,TABLET,YES,NO,NO,NO,ORAL,45,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,43370,2018,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.02,27,70,,,,656767,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,2,Aniline; Michael_acceptor,YES,YES,NO,,469.939,2,5,2,7,1,7,79.38,0.291666667,3.44,3.8,5.899,All fragments measured,5.1,3.5,4.23,3.377,12.05,8.31,12,8.8,Basic,Class 4,0,1,0,0,1,0,0,3,1,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,0,0,0,0,NO,0.42706,0.47671,0.25162,0.44478,0.52457,0.79222,0.87884,0.53315,0.25672,441.7,0.696,17.1,27.2
504-24-5,DALFAMPRIDINE,AMPYRA,PF-01002716,4163,c1cnccc1N,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,20,Prescription,,NO,NO,,,Elan (Perrigo),pharma,ACORDA,pharma,40200,2010,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.99,5,,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven although suspected rare cause of clinically apparent liver injury),Less,1,Pyridine,NO,NO,NO,,94.1145,2,1,1,2,0,0,38.91,0,-0.318,-0.318,0.318,All fragments measured,-0.12,-1.7,0.31,-1.463,,9.26,,8.4,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.41036,0.53024,0.09289,0.45057,0.93048,0.98659,0.93854,0.39503,0.82734,71.48,34.5,2.95,23.6
17230-88-5,DANAZOL,DANOCRINE,PF-00344870,779,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=Cc5c(cno5)C[C@]34C,CAPSULE,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,27932,1976,Drugs@FDA,NO,NO,,,High,Based on textual comment,,,,,,,,NO,"Genitourinary, Metabolic Disease",NO,NO,,NO,YES,NO,YES,Most,Most,DILIRank,1,,,,Moderate,1,Alkynes,NO,NO,NO,,337.4553,1,2,1,3,0,0,46.26,0.681818182,3.63,4.24,3.927,All fragments measured,3.7,3.7,4.33,4.329,,,15,-1.2,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,8,0,0,0,8,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70185,0.75868,0.92984,0.52528,0.93048,0.98659,0.98731,0.39503,0.82734,369.7,8.38,54.3,53.7
117-10-2,DANTHRON,DORBANE,PF-01000876,3125,c1cc2c(c(c1)O)C(=O)c3c(cccc3O)C2=O,N/A,N/A,N/A,N/A,NO,ORAL,100,Discontinued,1987,YES,NO,"Carcinogen, rats and mice",WITHDRAWN,,,3M,pharma,21551,1959,DrugCentral,NO,NO,,,NA,NA,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,240.2109,2,4,2,4,0,0,74.6,0,1.97,1.97,3.738,All fragments measured,2.4,2.4,3.83,2.257,6.27,,6.4,,Acidic,Class 1A,0,0,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71069,0.77506,0.71786,0.98388,0.88651,0.79222,0.91441,0.39503,0.93773,195.7,6.1,37.7,14.2
7261-97-4,DANTROLENE SODIUM,DANTRIUM,PF-00344542,780,c1cc(ccc1c2ccc(o2)/C=N/N3CC(=O)NC3=O)N(=O)=O,CAPSULE,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,PAR STERILE PRODUCTS,pharma,27044,1974,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,,0.5,8.7,,,,851323,NO,Musculoskeletal/Pain,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (Well established cause of clinically apparent liver injury),Less,2,Furan; Nitroorganics,NO,NO,NO,,314.253,1,4,1,9,0,4,120.73,0.071428571,1.88,2.043,1.631,Estimated fragment value used,1.4,1,1.52,1.334,7.68,,7.3,0,Acidic,Class 2,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.94418,0.74657,0.99487,0.99206,0.33223,0.98659,0.43945,0.96969,0.93773,346,2.83,3.93,12.8
461432-26-8,DAPAGLIFLOZIN,FARXIGA,PF-04750365,4304,CCOc1ccc(cc1)Cc2cc(ccc2Cl)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,ASTRAZENECA AB,major pharma,41647,2014,Drugs@FDA,NO,NO,0.78,,High,Reported bioavailability,0.09,,10.2,,,150,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,Less,,,D,Less,D (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,408.8726,4,6,4,6,0,6,99.38,0.428571429,2.07,3.4,3.369,All fragments measured,2.3,2.3,2.48,2.481,,,12,,Neutral,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.52116,0.56203,0.51898,0.98892,0.52457,0.14694,0.69359,0.6885,0.93773,424.3,5.01,3.13,9.51
80-08-0,DAPSONE,DAPSONE,PF-00344702,782,c1cc(ccc1N)S(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,JACOBUS,pharma,29039,1979,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.25,0.83,28,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,248.3009,4,2,2,4,0,2,86.18,0,0.925,0.8627,0.886,All fragments measured,0.97,0.97,1.08,1.075,,1.24,,2.3,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83954,0.83669,0.77335,0.8725,0.88651,0.79222,0.74218,0.87038,0.93773,176,13.9,14.2,6.65
133099-04-4,DARIFENACIN HYDROBROMIDE,ENABLEX,PF-02586636,784,c1ccc(cc1)C(c2ccccc2)([C@@H]3CCN(C3)CCc4ccc5c(c4)CCO5)C(=O)N,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,15,Prescription,,NO,NO,,,Novartis,major pharma,ALLERGAN,major pharma,38343,2004,Drugs@FDA,NO,NO,0.19,,Moderate,Reported bioavailability,0.02,2.3,16,,,,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,426.55,2,3,1,4,0,7,55.56,0.321428571,1.98,1.67,3.621,All fragments measured,3.8,2.5,4.16,2.328,,9.32,15,8.7,Basic,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.54149,0.62585,0.42534,0.66587,0.9848,0.98659,0.9985,0.53315,0.25672,335.1,4.14,15.6,67.3
1297538-32-9,DAROLUTAMIDE,NUBEQA,PF-07239901,,O=C(C1=NNC(C(O)C)=C1)N[C@@H](C)CN2N=C(C3=CC=C(C#N)C(Cl)=C3)C=C2,TABLET,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Orion,pharma,BAYER HEALTHCARE,major pharma,43676,2019,Drugs@FDA,NO,NO,0.3,0.65,Moderate,Reported bioavailability,0.08,1.7,20,,,,,NO,Oncology,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,398.8461,3,5,3,8,0,6,119.62,0.263,2.73,2.86,1.935,All fragments measured,2.1,2.1,1.17,1.046,11.66,1.06,11,1.5,Neutral,Class 2,0,0,0,0,1,0,0,3,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.52538,0.54086,0.57714,0.99638,0.72615,0.37866,0.48446,0.6885,0.25672,431.3,8.46,12.1,8.69
206361-99-1,DARUNAVIR ETHANOLATE,PREZISTA,PF-06780731,4143,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)c4ccc(cc4)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,JANSSEN PHARMS,major pharma,38891,2006,Drugs@FDA,NO,NO,0.37,,High,Reported bioavailability,0.05,,15,,,55,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,D,Less,"D (possible, rare cause of clinically apparent liver injury)",,1,Aniline,YES,NO,NO,4HLA,547.6636,4,4,3,10,1,12,140.42,0.518518519,2.97,2.87,2.887,All fragments measured,2.8,2.8,3.09,3.264,11.43,1.75,12,1.6,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.28156,0.29064,0.0998,0.99769,0.19128,0.37866,0.24142,0.10729,0.93773,586.5,12.1,28.2,255
1132935-63-7,DASABUVIR SODIUM,VIEKIRA PAK (COPACKAGED),PF-06950293,4914,CC(C)(C)c1cc(cc(c1OC)c2ccc3cc(ccc3c2)NS(=O)(=O)C)n4ccc(=O)[nH]c4=O,TABLET,YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,41992,2014,Drugs@FDA,YES,NO,0.7,,High,Reported bioavailability,0.005,,6,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,C,Less,C (probable cause of liver injury arising in patients with pre-existing cirrhosis),,0,,NO,NO,NO,,493.5747,2,5,2,8,0,5,110.26,0.230769231,3.46,4.64,4.073,All fragments measured,4.3,4.2,3.4,3.37,8.61,,8.4,,Neutral,Class 3B,0,0,0,0,0,0,0,4,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47506,0.51871,0.18793,0.96146,0.72615,0.79222,0.54994,0.6885,0.25672,466.6,2.75,18.3,32.5
302962-49-8,DASATINIB,SPRYCEL,PF-04571508,785,Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl,TABLET,YES,NO,NO,NO,ORAL,140,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,BRISTOL MYERS SQUIBB,major pharma,38896,2006,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.04,35.8,4,,,59,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Moderate,2,Aminothiazole; Aniline,YES,NO,NO,3QLG,488.0055,3,6,3,9,0,7,106.51,0.363636364,2.96,3.44,2.529,All fragments measured,3.3,2.6,2.58,2.177,10.94,7.29,8.6,7.9,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,NO,0.38001,0.35172,0.20125,0.96774,0.19128,0.37866,0.34486,0.53315,0.25672,484,2.21,27.4,82.4
201530-41-8,DEFERASIROX,EXJADE,PF-06438824,3128,c1ccc(c(c1)c2nc(n(n2)c3ccc(cc3)C(=O)O)c4ccccc4O)O,"GRANULE, TABLET, TABLET, FOR SUSPENSION",YES,NO,NO,NO,ORAL,1400,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,38658,2005,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.01,0.2,8,,,133,,YES,Cardiovascular,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,373.3615,3,5,3,7,0,4,108.47,0,1.38,1.38,3.668,All fragments measured,4.5,1.5,4.26,0.742,3.54,2.22,4.3,1.5,Acidic,Class 3A,0,0,0,0,0,0,0,4,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.42056,0.4242,0.7339,0.84534,0.52457,0.37866,0.59909,0.96969,0.03452,331.4,2.13,24.1,8.32
30652-11-0,DEFERIPRONE,FERRIPROX,PF-00346100,4188,Cc1c(c(=O)ccn1C)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,5250,Prescription,,NO,NO,,,BTG,pharma,APOPHARMA INC,pharma,40830,2011,Drugs@FDA,NO,NO,,0.75,High,Fa estimated from reported excretion data,0.9,1.6,1.6,,,,,YES,Cardiovascular,NO,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,139.1519,1,2,1,3,0,0,42.23,0.285714286,-0.162,-0.162,-0.903,All fragments measured,-0.63,-0.63,-0.44,-0.447,9.9,2.15,9.5,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.43158,0.53985,0.18027,0.42892,0.9848,0.98659,0.95307,0.39503,0.47245,135.3,6.87,44.8,12.4
14484-47-0,DEFLAZACORT,EMFLAZA,PF-00371245,793,CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,63,Prescription,,NO,NO,,,Sanofi,major pharma,PTC THERAP,pharma,42775,2017,Drugs@FDA,NO,YES,,0.86,High,Fa estimated from reported excretion data,0.6,,,,,,647,YES,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,None,,,,,,Moderate,0,,NO,NO,NO,,441.5167,1,5,1,7,0,4,102.26,0.68,2.47,2.793,2.86,A priori fragment value used,3.2,3.2,2.43,2.427,,3.84,12,7.1,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,8,0,0,0,8,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66965,0.61271,0.35634,0.91258,0.33223,0.98659,0.6639,0.96969,0.47245,535.1,12.1,36.4,136
189279-58-1,DELAFLOXACIN MEGLUMINE,BAXDELA,PF-00318443,5238,c1c2c(c(c(c1F)N3CC(C3)O)Cl)n(cc(c2=O)C(=O)O)c4c(cc(c(n4)N)F)F,TABLET,YES,NO,NO,NO,ORAL,900,Prescription,,NO,NO,,,Wakunaga,pharma,MELINTA,pharma,42905,2017,Drugs@FDA,NO,NO,0.59,,High,Reported bioavailability,0.16,0.6,6.4,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,,440.7605,4,5,3,8,0,3,121.68,0.166666667,-0.0437,-0.0437,1.954,All fragments measured,2.5,1,0.77,-2.156,4.58,,5.5,2.4,Acidic,Class 3B,0,3,0,0,1,0,0,2,0,0,0,0,0,4,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,2,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,1,1,0,1,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.61781,0.52932,0.35959,0.99879,0.19128,0.37866,0.48077,0.99269,0.93773,437.5,3.21,3.58,7.27
136817-59-9,DELAVIRDINE MESYLATE,RESCRIPTOR,PF-00596729,799,CC(C)Nc1cccnc1N2CCN(CC2)C(=O)c3cc4cc(ccc4[nH]3)NS(=O)(=O)C,TABLET,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,VIIV HLTHCARE,pharma,35524,1997,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.02,,5.8,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,1KLM,456.5611,3,4,3,9,0,7,110.43,0.363636364,2.48,2.48,2.412,All fragments measured,2.5,2.4,1.86,1.514,9.11,8.37,7.3,5.7,Neutral,Class 3B,0,0,0,0,0,0,0,3,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44983,0.46963,0.29675,0.98174,0.52457,0.37866,0.49256,0.6885,0.25672,472.6,2.81,12.7,37.4
127-33-3,DEMECLOCYCLINE HYDROCHLORIDE,DECLOMYCIN,PF-00344979,802,CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](c4c(ccc(c4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)Cl)O,"CAPSULE, SYRUP, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,LEDERLE,major pharma,21929,1960,Drugs@FDA,NO,NO,,0.66,High,Fa estimated from reported excretion data,0.1,,10,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,,464.853,7,9,6,10,1,2,181.62,0.380952381,-0.366,-0.947,-0.576,Valid estimate for difficult structure,-0.19,-3.1,-0.46,-3.406,4.5,11,3.3,9.5,Zwitter,Class 3B,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.25219,0.20678,0.26794,0.34389,0.10671,0.02306,0.09897,0.87038,0.82734,522.6,1.08,2.15,7.37
131-01-1,DESERPIDINE,HARMONYL,PF-01507060,810,COc1cc(cc(c1OC)OC)C(=O)O[C@@H]2C[C@@H]3CN4CCc5c6ccccc6[nH]c5[C@H]4C[C@@H]3[C@@H]([C@H]2OC)C(=O)OC,TABLET,YES,NO,NO,NO,ORAL,1,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,20929,1957,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,578.6527,1,7,1,10,1,9,108.55,0.5,3.31,4.04,3.838,All fragments measured,3.9,3.5,4.21,3.736,,7.7,9.8,6.9,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,8,0,0,0,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.31365,0.30915,0.0727,0.78278,0.10671,0.98659,0.59826,0.29329,0.25672,627.7,5.57,55.1,46
50-47-5,DESIPRAMINE HYDROCHLORIDE,NORPRAMIN,PF-00344781,812,CNCCCN1c2ccccc2CCc3c1cccc3,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,23701,1964,Drugs@FDA,NO,NO,0.4,0.7,High,Reported bioavailability,0.16,38,17.1,,,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,266.3807,1,1,1,2,0,4,15.27,0.333333333,1.2,0.976,4.468,All fragments measured,3.8,1.1,4.28,1.556,,10.4,,9.9,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92448,0.85558,0.88464,0.8997,0.93048,0.98659,0.50512,0.96969,0.93773,204.3,6.55,10.9,66.2
100643-71-8,DESLORATADINE,CLARINEX,PF-00346598,814,c1cc2c(nc1)C(=C3CCNCC3)c4ccc(cc4CC2)Cl,"SOLUTION, SYRUP, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,Sepracor (SunovionPharmaceuticals),pharma,MERCK,major pharma,37246,2001,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.18,32,,,106,,850100,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,310.8206,1,2,1,2,0,0,24.92,0.315789474,1.55,1.7,3.826,All fragments measured,4.1,2.7,4.8,1.843,,10.27,,9.3,Basic,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.77142,0.79205,0.99825,0.79827,0.93048,0.98659,0.72166,0.39503,0.93773,230.1,8.35,5.62,14.1
16679-58-6,DESMOPRESSIN ACETATE,DDAVP,PF-01266468,817,c1ccc(cc1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N2)Cc3ccc(cc3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,TABLET,YES,NO,NO,NO,ORAL,0.8,Prescription,,NO,NO,,,,,FERRING PHARMS INC,pharma,34948,1995,Drugs@FDA,NO,NO,0.002,0.52,Low,Reported bioavailability,,0.37,1.2,,,,,YES,"Cardiovascular, Metabolic Disease",NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,,,,Less,1,Thiol_Disulfide,NO,NO,NO,,1069.217,18,15,14,26,3,21,435.41,0.47826087,-2.28,-2.74,-3.144,Approximated fragment value used,-3.9,-7.4,-5.34,-7.345,9.9,,9.7,11,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,11,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,YES,0.02601,0.02739,0.02685,0.03153,0.02075,0.00627,0.01795,0.00623,0.93773,1202,0.117,1.98,11.8
54024-22-5,DESOGESTREL,DESOGEN,PF-02400190,818,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34,TABLET,YES,NO,NO,NO,ORAL,0.15,Prescription,,NO,NO,,,,,ORGANON USA INC,pharma,33948,1992,Drugs@FDA,YES,NO,0.6,,High,Reported bioavailability,,1.5,30,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,FEARS Addition ,1,A,Most,A (well established cause of clniically apparent liver injury),Less,1,Alkynes,NO,NO,NO,,310.473,1,1,1,1,1,1,20.23,0.727272727,3.44,4.72,5.683,All fragments measured,5.6,5.6,5.92,5.924,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59331,0.49932,0.9985,0.18083,0.23327,0.98659,0.61872,0.63709,0.47245,289,5.09,59.8,146
93413-62-8,DESVENLAFAXINE SUCCINATE,PRISTIQ,PF-05212375,4380,CN(C)CC(c1ccc(cc1)O)C2(CCCCC2)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,50,Prescription,,NO,NO,,,Pfizer,major pharma,WYETH,major pharma,39507,2008,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.7,3.4,10,,,177,223325696,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,4MM7,263.3752,2,3,2,3,0,4,43.7,0.625,0.365,0.06706,2.683,All fragments measured,2.9,1.2,2.64,1.006,10.04,9.33,10,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.88917,0.9132,0.86788,0.99997,0.9848,0.79222,0.97499,0.96969,0.82734,171.2,20.7,4.36,7.4
1392826-25-3,DEUTETRABENAZINE,AUSTEDO,VC-001215249,5226,[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])[C@H]3CC(=O)[C@@H](CN3CC2)CC(C)C,TABLET,YES,NO,NO,YES,ORAL,48,Prescription,,NO,NO,,,Auspex Pharmaceuticals,pharma,TEVA,major pharma,42828,2017,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,,,,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,323.4596,0,4,0,4,0,6,38.77,0.631578947,2.29,2.406,-3.361,Calculated fragment value,2.9,1.8,3.43,3.122,,6.46,,7.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,6,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79268,0.8281,0.9774,0.97543,0.88651,0.59178,0.9373,0.6885,0.82734,335.3,23.6,37.2,51.4
50-02-2,DEXAMETHASONE,DECADRON,PF-00345215,824,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,"ELIXIR, TABLET",YES,NO,NO,NO,ORAL,6,Prescription,,NO,NO,,,,,MERCK,major pharma,21488,1958,Drugs@FDA,NO,NO,0.86,,High,Reported bioavailability,0.23,2,4,,179,,4247639,NO,"Autoimmune Disease, Cardiovascular, Metabolic Disease, Respiratory",NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,,,,Moderate,0,,NO,NO,NO,1M2Z,392.4611,3,5,3,5,0,2,94.83,0.727272727,1.92,2.281,1.785,All fragments measured,1.7,1.7,1.92,1.916,12.13,,11,,Neutral,Class 2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.61663,0.64664,0.61563,0.91839,0.72615,0.37866,0.73951,0.87038,0.47245,458.5,9.14,9.17,7.52
132-21-8,DEXBROMPHENIRAMINE MALEATE,DISOMER,PF-00345213,830,CN(C)CC[C@@H](c1ccc(cc1)Br)c2ccccn2,TABLET,YES,NO,NO,NO,ORAL,18,Discontinued,,NO,NO,,,,,SCHERING,major pharma,23302,1963,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),None,0,,NO,NO,NO,,319.2395,0,3,0,2,0,5,16.13,0.3125,1.56,1.7,3.298,All fragments measured,3.5,1.8,3.33,1.4,,9.33,,9,Basic,Class 2,0,0,0,0,0,1,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.83085,0.79869,0.98689,0.9148,0.93048,0.59178,0.52472,0.84757,0.93773,196.9,20.6,5.72,10.8
3239-45-0,DEXFENFLURAMINE HYDROCHLORIDE,REDUX,PF-00579943,832,CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,30,Discontinued,1997,YES,YES,Valvular heart disease,FederalRegister,,,INTERNEURON,pharma,35186,1996,PharmaCircle,NO,NO,,,NA,NA,0.012,0.6,1.5,,,,,NO,Metabolic Disease,NO,NO,,NO,YES,YES,NO,,,,,,,,,0,,NO,NO,NO,,231.2573,1,1,1,1,0,4,12.03,0.5,1.42,1.299,3.3,All fragments measured,3.5,1.4,3.34,0.691,,10.23,,9.5,Basic,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.81156,0.64145,0.65493,0.97619,0.23327,0.98659,0.43308,0.84757,0.82734,163.8,25.3,6.1,13.6
138530-94-6,DEXLANSOPRAZOLE,DEXILANT,PF-06263993,4162,Cc1c(ccnc1C[S@+](c2[nH]c3ccccc3n2)[O-])OCC(F)(F)F,"CAPSULE, DELAYED RELEASE, TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE",NO,YES,NO,NO,ORAL,60,Prescription,,NO,NO,,,Takeda,major pharma,TAKEDA PHARMS USA,major pharma,39843,2009,Drugs@FDA,NO,NO,,0.51,High,Fa estimated from reported excretion data,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,369.3615,1,3,1,5,0,5,72.86,0.25,2.03,2.457,3.681,Calculated fragment value,0.53,0.39,2.41,2.4,9.04,4.29,12,5.6,Neutral,Class 2,0,3,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.68048,0.70623,0.75852,0.91878,0.88651,0.98659,0.81335,0.6885,0.25672,354.6,13.6,8.71,18
40431-64-9,DEXMETHYLPHENIDATE HYDROCHLORIDE,FOCALIN,PF-04122714,836,COC(=O)[C@H](c1ccccc1)[C@H]2CCCCN2,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,40,Prescription,,NO,NO,,,Celgene,major pharma,NOVARTIS,major pharma,37208,2001,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.85,2.65,2.2,,176,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,233.3062,1,2,1,3,0,4,38.33,0.5,0.0387,0.0387,2.556,All fragments measured,2.1,1.6,2.33,0.272,,9.51,,8.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87353,0.89877,0.66937,0.9732,0.9848,0.98659,0.93296,0.96969,0.82734,197.6,25,12.5,11.7
51-64-9,DEXTROAMPHETAMINE SULFATE,DEXEDRINE,PF-00345361,841,C[C@@H](Cc1ccccc1)N,"CAPSULE, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,60,Prescription,,NO,NO,,,,,IMPAX LABS INC,pharma,27974,1976,Drugs@FDA,NO,NO,,,NA,NA,,6.1,12,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,4XP9,135.2062,2,1,1,1,0,2,26.02,0.333333333,-0.571,-0.571,1.742,All fragments measured,1.8,-0.58,1.82,-0.616,,9.94,,9.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60436,0.5676,0.16968,0.90687,0.23327,0.98659,0.74426,0.87038,0.82734,95.93,49.4,5.67,9.39
125-71-3,DEXTROMETHORPHAN POLISTIREX,DELSYM,PF-02450388,842,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc4c3cc(cc4)OC,"SUSPENSION, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,120,Over-the-counter,,NO,NO,,,,,RB HLTH,pharma,30232,1982,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,8346238,NO,Respiratory,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,271.3972,0,2,0,2,0,1,12.47,0.666666667,1.69,2.356,3.945,All fragments measured,3.5,1.6,3.58,1.861,,9.13,,9.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75125,0.72892,0.9106,0.93459,0.93048,0.59178,0.44264,0.63709,0.82734,259.8,15.9,30.3,18.1
51-49-0,DEXTROTHYROXINE SODIUM,CHOLOXIN,PF-02592014,846,c1c(cc(c(c1I)Oc2cc(c(c(c2)I)O)I)I)C[C@H](C(=O)O)N,TABLET,YES,NO,NO,NO,ORAL,8,Discontinued,1997,YES,NO,cardiac side-effects,Micromedex,,,ABBVIE,major pharma,24576,1967,Drugs@FDA,NO,NO,,,NA,NA,,,18,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,YES,,,,,C,Less,C (probable rare cause of clinically apparent liver injury),,1,Organic_Iodide,NO,NO,NO,1Y0X,776.87,4,4,3,5,1,5,92.78,0.133333333,1.22,1.22,3.508,All fragments measured,5.4,2.9,4.8,1.76,2.12,8.27,2.1,8.5,Zwitter,Class 3B,0,0,0,0,0,0,4,2,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,4,1,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.35005,0.46396,0.02907,0.95873,0.72615,0.37866,0.75966,0.84757,0.93773,312.7,0.623,16.6,15.3
439-14-5,DIAZEPAM,VALIUM,PF-00345121,852,CN1c2ccc(cc2C(=NCC1=O)c3ccccc3)Cl,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,23330,1963,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.02,1,48,,,,13612846,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D  (Possible but rare cause of clinically apparent liver injury) ,Less,0,,NO,NO,NO,,284.7402,0,1,0,3,0,1,32.67,0.125,2.6,3,2.961,All fragments measured,2.8,2.8,2.92,2.917,,3.4,,3.1,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7942,0.82988,0.96522,0.99018,0.93048,0.59178,0.86219,0.63709,0.93773,249.6,31.3,5.46,14.5
364-98-7,DIAZOXIDE,PROGLYCEM,PF-00344877,854,CC1=NS(=O)(=O)c2cc(ccc2N1)Cl,"CAPSULE, SUSPENSION",YES,NO,NO,NO,ORAL,1050,Prescription,,NO,NO,,,,,TEVA,major pharma,27908,1976,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.06,0.21,28,,,,312027,NO,Cardiovascular,NO,NO,,YES,NO,YES,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,230.6714,1,3,1,4,0,0,58.53,0.125,1.48,1.629,1.421,Approximated fragment value used,1.2,1.2,0.99,0.983,8.99,,8.8,5.5,Neutral,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.69512,0.7718,0.6508,0.82136,0.9848,0.98659,0.96104,0.39503,0.82734,237.1,33.9,2.25,9.6
120-97-8,DICHLORPHENAMIDE,DARANIDE,PF-00344981,864,c1c(cc(c(c1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,STRONGBRIDGE US,pharma,21388,1958,Drugs@FDA,NO,NO,,,NA,NA,0.45,,,,,,,YES,"Metabolic Disease, Musculoskeletal/Pain",YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Moderate,0,,NO,NO,NO,,305.1588,4,4,2,6,0,2,120.32,0,0.301,0.301,0.241,All fragments measured,0.41,0.18,0.9,0.881,8.95,,7.5,,Neutral,Class 3A,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.8187,0.72695,0.99993,0.65097,0.88651,0.79222,0.32589,0.87038,0.82734,283.6,1.16,2.28,12.2
15307-86-5,DICLOFENAC SODIUM,VOLTAREN,PF-00344545,865,c1ccc(c(c1)CC(=O)O)Nc2c(cccc2Cl)Cl,"CAPSULE; TABLET, DELAYED RELEASE; TABLET, EXTENDED RELEASE",YES,YES,YES,NO,ORAL,200,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,32352,1988,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.01,1.4,2,,184,,120753065,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,3N8Y,296.1486,2,2,2,3,0,4,49.33,0.071428571,1.38,1.187,4.726,All fragments measured,4,1,4.48,1.372,4.18,,4.2,0.93,Acidic,Class 1A,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.89269,0.91068,0.99242,0.74051,0.9848,0.79222,0.99636,0.96969,0.93773,213.5,31,40.5,29.3
3116-76-5,DICLOXACILLIN SODIUM,PATHOCIL,PF-00345271,866,Cc1c(c(no1)c2c(cccc2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,WYETH,major pharma,24950,1968,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.02,0.16,0.7,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely but rare cause of clinically apparent liver injury),Less,1,Beta_Lactams,NO,NO,NO,,470.3264,2,6,2,8,0,4,112.74,0.368421053,-0.00344,-0.00344,2.981,Approximated fragment value used,3.3,0.017,3.08,-0.652,2.44,,2.8,-5.6,Acidic,Class 3B,0,0,0,0,2,0,0,2,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.6657,0.60615,0.25041,0.99833,0.52457,0.79222,0.31825,0.96969,0.93773,544.4,1.2,3.68,7.7
66-76-2,DICUMAROL,DICUMAROL,PF-00344706,867,c1ccc2c(c1)c(c(c(=O)o2)Cc3c(c4ccccc4oc3=O)O)O,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,16284,1944,Drugs@FDA,NO,NO,,,NA,NA,0.01,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,Suzuki Additions,1,,,,,1,Michael_acceptor,NO,YES,NO,,336.295,2,2,2,6,0,2,100.88,0.052631579,1.32,1.32,3.658,All fragments measured,2.9,-0.88,2.43,-0.613,4.2,,4.3,,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.88681,0.81554,0.93463,0.99995,0.52457,0.79222,0.75693,0.87038,0.93773,305.7,4.74,17.9,10.8
77-19-0,DICYCLOMINE HYDROCHLORIDE,BENTYL,PF-00344704,868,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,"CAPSULE, SYRUP, TABLET",YES,NO,NO,NO,ORAL,160,Prescription,,NO,NO,,,,,ALLERGAN,major pharma,18394,1950,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,,3.6,1.8,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,309.4867,0,2,0,3,1,8,29.54,0.947368421,3.12,3.78,6.138,All fragments measured,4.6,3,5.24,3.431,,9.24,,8.5,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56698,0.62619,0.99909,0.42321,0.9848,0.59178,0.81105,0.39983,0.47245,186.3,6.54,69.7,80.5
69655-05-6,DIDANOSINE,VIDEX,PF-00345685,869,c1[nH]c(=O)c2c(n1)n(cn2)[C@H]3CC[C@H](O3)CO,"CAPSULE, DELAYED REL PELLETS; FOR SOLUTION; TABLET, CHEWABLE",NO,YES,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,33520,1991,Drugs@FDA,NO,NO,0.37,,High,Reported bioavailability,0.95,0.77,1.5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of several forms of clinically apparent liver injury),Less,0,,NO,NO,NO,,236.2273,2,5,2,7,0,2,93.03,0.5,-0.382,-0.382,-1.924,All fragments measured,-0.93,-0.95,-1.11,-1.124,9.03,1.58,7.5,2,Neutral,Class 3A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.74001,0.70305,0.68995,0.4807,0.52457,0.79222,0.75468,0.87038,0.93773,339.2,5.41,1.66,7.7
65928-58-7,DIENOGEST,NATAZIA,PF-06456084,871,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,Bayer,major pharma,BAYER HEALTHCARE,major pharma,40304,2010,Drugs@FDA,YES,NO,0.91,,High,Reported bioavailability,0.1,,9,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,None,0,,NO,NO,NO,,311.418,1,2,1,3,0,1,61.09,0.7,2.61,2.224,2.125,Valid estimate for difficult structure,2.1,2.1,2.64,2.64,,,17,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79908,0.83646,0.99779,0.99596,0.9848,0.98659,0.98581,0.63709,0.47245,298.3,26.2,53.6,24.7
90-89-1,DIETHYLCARBAMAZINE CITRATE,HETRAZAN,PF-00344876,873,CCN(CC)C(=O)N1CCN(CC1)C,TABLET,YES,NO,NO,NO,ORAL,420,Discontinued,,NO,NO,,,,,LEDERLE,major pharma,18580,1950,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,1,3.2,8,,,,2164768,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,Gerren Additions,1,,,,,0,,NO,NO,NO,,199.2932,0,2,0,4,0,4,26.79,0.9,0.129,0.129,1.616,All fragments measured,0.7,0.2,1.06,0.912,,7.07,,8.2,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59198,0.64476,0.44173,0.6097,0.93048,0.59178,0.75963,0.87038,0.47245,170.1,13.6,4.47,8.53
90-84-6,DIETHYLPROPION HYDROCHLORIDE,TENUATE,PF-04769725,874,CCN(CC)C(C)C(=O)c1ccccc1,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,75,Prescription,,NO,NO,,,,,TEVA,major pharma,21768,1959,Drugs@FDA,NO,NO,,0.75,High,Fa estimated from reported excretion data,,,6,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,205.2961,0,2,0,2,0,5,20.31,0.461538462,0.916,0.916,2.85,All fragments measured,2.7,1.7,2.78,1.662,,8.49,,8.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70531,0.73393,0.47883,0.99977,0.93048,0.59178,0.62053,0.84757,0.82734,160.1,35.1,11.7,15.7
56-53-1,DIETHYLSTILBESTROL,DIETHYLSTILBESTROL,PF-00344543,875,CC/C(=C(/CC)\c1ccc(cc1)O)/c2ccc(cc2)O,"TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,30,Discontinued,1973,YES,YES,Adenocarcinoma of the vagina in the offspring of the patient when used in early pregnancy,FederalRegister,,,ELI LILLY AND CO,major pharma,26814,1973,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,"Genitourinary, Oncology",NO,NO,,NO,NO,NO,YES,,Less,,,,,,None,0,,NO,NO,NO,1S9P,268.3502,2,2,2,2,0,4,40.46,0.222222222,4.08,4.8,4.956,All fragments measured,5,5,4.79,4.798,10.18,,9.1,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79453,0.81266,0.89515,0.40963,0.93048,0.79222,0.95241,0.96969,0.93773,155.7,3.79,45.3,36.3
28782-42-5,DIFENOXIN HYDROCHLORIDE,MOTOFEN HALF-STRENGTH,PF-01035610,878,c1ccc(cc1)C2(CCN(CC2)CCC(C#N)(c3ccccc3)c4ccccc4)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,8.72,Prescription,,NO,NO,,,,,SEBELA IRELAND LTD,pharma,28685,1978,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,,NO,Anti-infective,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,424.5341,1,3,1,4,0,7,64.33,0.285714286,2.01,2.01,2.127,All fragments measured,5.2,2.3,4.96,2.452,3.55,9.13,3.4,8.1,Zwitter,Class 3B,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57511,0.64979,0.43538,0.96417,0.88651,0.98659,0.9733,0.53315,0.25672,274.6,4.95,11.3,16.3
22494-42-4,DIFLUNISAL,DOLOBID,PF-00345032,880,c1cc(c(cc1c2ccc(cc2F)F)C(=O)O)O,TABLET,YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,,,MERCK,major pharma,30060,1982,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,7.52,10,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,250.1976,2,3,2,3,0,2,57.53,0,0.481,0.481,4.397,All fragments measured,3.7,0.31,4.31,1.162,2.94,,2.8,,Acidic,Class 1A,0,2,0,0,0,0,0,2,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.86606,0.90415,0.786,0.9915,0.9848,0.79222,0.99536,0.87038,0.93773,203.8,11.2,24.9,6.76
20830-75-5,DIGOXIN,LANOXICAPS,PF-00344881,882,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,"CAPSULE, ELIXIR, TABLET",YES,NO,NO,NO,ORAL,0.5,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,30158,1982,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.75,6.8,36,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,4RET,780.9385,6,13,6,14,3,7,203.06,0.926829268,1.9,1.657,1.423,All fragments measured,0.21,0.21,1.26,1.258,,,14,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,NO,0.14237,0.11057,0.02894,0.95586,0.02183,0.02306,0.05756,0.53315,0.47245,1086,1.47,2.02,8.08
125-28-0,DIHYDROCODEINE BITARTRATE,SYNALGOS-DC,PF-00345362,886,CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC,CAPSULE,YES,NO,NO,NO,ORAL,96,Prescription,,NO,NO,,,,,SUN PHARM INDUSTRIES,pharma,21373,1958,Drugs@FDA,YES,NO,0.2,,Moderate,Reported bioavailability,,,,,,,115088,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,,,FEARS Addition ,1,,,,Moderate,0,,NO,NO,NO,,301.3801,1,4,1,4,0,1,41.93,0.666666667,0.328,0.328,1.261,All fragments measured,2,0.43,1.54,0.416,,8.43,13,9.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86661,0.88385,0.99831,0.95005,0.88651,0.98659,0.96367,0.63709,0.82734,370.2,22.8,5.36,11.2
25447-65-8,DIHYDROERGOCORNINE,HYDERGINE,PF-00346424,3184,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@@H]5c6cccc7c6c(c[nH]7)C[C@H]5N(C4)C)O,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,0.999,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,28489,1977,Drugs@FDA,NO,NO,0.08,,Low,Reported bioavailability,,,3.5,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,,,,,,,None,1,3_Methyl_Indole,NO,NO,NO,,563.6877,3,6,3,10,2,4,118.21,0.64516129,2.78,3.207,5.072,All fragments measured,4,3.6,2.67,2.404,9.6,7.22,9.6,7.6,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,10,0,0,0,10,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.44958,0.49417,0.08426,0.94835,0.52457,0.37866,0.4986,0.96969,0.93773,780.2,6.26,23.4,393
17479-19-5,DIHYDROERGOCRISTINE,HYDERGINE,PF-00345654,887,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)Cc4ccccc4)NC(=O)[C@@H]5C[C@@H]6c7cccc8c7c(c[nH]8)C[C@H]6N(C5)C,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,3,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,28489,1977,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,,0.7,,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,,,,,,,None,1,3_Methyl_Indole,NO,NO,NO,,611.7305,3,6,3,10,2,5,118.21,0.514285714,3.4,4.6,5.562,All fragments measured,4.6,2.1,3.53,3.257,9.61,7.22,9.4,7.6,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,10,0,0,0,10,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.31122,0.36742,0.05466,0.76741,0.52457,0.37866,0.4986,0.84757,0.25672,815.3,1.82,15,363
42399-41-7,DILTIAZEM HYDROCHLORIDE,CARDIZEM,PF-00249692,897,CC(=O)O[C@@H]1[C@@H](Sc2ccccc2N(C1=O)CCN(C)C)c3ccc(cc3)OC,"CAPSULE, EXTENDED RELEASE, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,540,Prescription,,NO,NO,,,,,VALEANT,pharma,30260,1982,Drugs@FDA,NO,NO,0.4,0.95,High,Reported bioavailability,0.18,4.1,,,,,10996290,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,414.5178,0,5,0,6,0,7,59.08,0.363636364,2,2.026,3.647,Approximated fragment value used,3.1,2.6,3.43,2.056,,8.94,,7.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65005,0.67373,0.48773,0.9941,0.52457,0.59178,0.83735,0.53315,0.93773,409.8,24.5,27.6,40.7
624-49-7,DIMETHYL FUMARATE,TECFIDERA,PF-01486069,4757,COC(=O)/C=C/C(=O)OC,"CAPSULE, DELAYED RELEASE",NO,YES,NO,NO,ORAL,480,Prescription,,NO,NO,,,Biogen,major pharma,BIOGEN IDEC INC,pharma,41360,2013,Drugs@FDA,NO,YES (Presystemic),,0.76,High,Fa estimated from reported excretion data,0.55,0.9,1,Parent CRG,,16,,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,NO,,,,,C,Less,C (probable rare cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,,144.1253,0,2,0,4,0,4,52.6,0.333333333,0.14,0.14,0.784,All fragments measured,0.7,0.7,0.5,0.5,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50975,0.60394,0.1946,0.62658,0.88651,0.59178,0.99994,0.96969,0.47245,113.4,38.8,37.7,22.8
58-73-1,DIPHENHYDRAMINE HYDROCHLORIDE,BENADRYL,PF-00344546,916,CN(C)CCOC(c1ccccc1)c2ccccc2,"CAPSULE, ELIXIR",YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,MCNEIL CONSUMER,pharma,16865,1946,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.18,4.5,6,,,,193585,NO,"Neurological, Respiratory",NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,255.3547,0,2,0,2,0,6,12.47,0.294117647,1.7,1.721,3.452,All fragments measured,3.5,2.1,3.71,2.338,,8.76,,8.4,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.76651,0.74346,0.81945,0.97357,0.93048,0.59178,0.44264,0.6885,0.93773,156.8,19,15.8,17
972-02-1,DIPHENIDOL HYDROCHLORIDE,VONTROL,PF-00345500,313,c1ccc(cc1)C(CCCN2CCCCC2)(c3ccccc3)O,TABLET,YES,NO,NO,NO,ORAL,300,Discontinued,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,24567,1967,Drugs@FDA,NO,NO,,0.84,High,Fa estimated from reported excretion data,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,None,,,,,,Less,0,,NO,NO,NO,,309.4452,1,2,1,2,0,6,23.47,0.428571429,1.58,1.444,4.067,All fragments measured,4.4,2.7,3.85,1.58,,9.74,15,9.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85916,0.84195,0.99911,0.73318,0.93048,0.98659,0.69082,0.6885,0.93773,188.3,18,19.8,38.2
915-30-0,DIPHENOXYLATE HYDROCHLORIDE,LOMOTIL,PF-00345418,918,CCOC(=O)C1(CCN(CC1)CCC(C#N)(c2ccccc2)c3ccccc3)c4ccccc4,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,22174,1960,Drugs@FDA,YES,NO,0.9,,High,Reported bioavailability,,4.9,12,,,,2778487,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,452.5873,0,2,0,4,1,9,53.33,0.333333333,4.73,5.34,5.331,All fragments measured,6.9,6.8,5.72,5.477,,7.28,,6.8,Basic,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.33464,0.42855,0.31156,0.21572,0.88651,0.59178,0.99998,0.29329,0.25672,297.7,2.22,35.5,61.8
147-20-6,DIPHENYLPYRALINE HYDROCHLORIDE,HISPRIL,PF-00344879,920,CN1CCC(CC1)OC(c2ccccc2)c3ccccc3,"CAPSULE, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,10,Discontinued,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,20271,1955,PharmaPendium,NO,NO,,,NA,NA,0.01,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,281.392,0,2,0,2,0,4,12.47,0.368421053,1.86,2.011,3.206,All fragments measured,4.1,2.2,4.24,3.187,,8.42,,9.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.85487,0.79815,0.95368,0.97629,0.93048,0.59178,0.44264,0.96969,0.93773,179.2,30.4,22.8,13.1
58-32-2,DIPYRIDAMOLE,PERSANTINE,PF-00344983,924,C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CCO)N4CCCCC4)nc(n2)N(CCO)CCO,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,22621,1961,Drugs@FDA,NO,NO,0.37,,High,Reported bioavailability,0.01,2.9,10,,185,,,NO,Cardiovascular,YES,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,504.6256,4,10,4,12,2,12,145.44,0.75,1.31,3.2,1.492,All fragments measured,2,1.6,0.33,0.433,,6.47,13,8.5,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.25112,0.21084,0.16424,0.99256,0.02915,0.14694,0.26363,0.10729,0.93773,463.7,1.1,15.6,70.7
68-89-3,DIPYRONE,NOVALDIN,PF-00345717,4659,Cc1c(c(=O)n(n1C)c2ccccc2)N(C)CS(=O)(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,1000,Discontinued,1965,YES,YES,Agranulocytosis,FederalRegister,,,STERLING WIMTHROP,pharma,8037,1922,Wikipedia,NO,NO,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,311.3568,1,3,1,7,0,4,84.54,0.307692308,-1.6,-1.6,-1.189,All fragments measured,-0.76,-4.2,-1.1,-4.591,1.32,3.9,-0.23,5,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87132,0.79087,0.99784,0.59078,0.52457,0.98659,0.79064,0.96969,0.82734,303.8,1.05,3.6,8.65
62013-04-1,DIRITHROMYCIN,DYNABAC,PF-00346428,925,CC[C@@H]1[C@@]([C@H]2C([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)O[C@H]4[C@@H]([C@H](C[C@H](O4)C)N(C)C)O)(C)O)C)N[C@H](O2)COCCOC)C)(C)O,"TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,500,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,34869,1995,Drugs@FDA,NO,NO,0.06,,Low,Reported bioavailability,0.7,11,44,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,835.0737,5,15,5,16,2,12,196.33,0.976190476,1.22,1.319,2.783,All fragments measured,2.7,1.4,2.78,2.053,12.94,8.16,13,8.8,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,8,0,0,YES,0.11887,0.10009,0.02775,0.94063,0.02025,0.05547,0.06769,0.10729,0.47245,1165,0.526,6.12,39.4
1577222-14-0,DIROXIMEL FUMARATE,VUMERITY,VC-001274378,,O=C(OC)/C=C/C(OCCN1C(CCC1=O)=O)=O,"CAPSULE, DELAYED RELEASE",NO,YES,NO,NO,ORAL,924,Prescription,,NO,NO,,,Alkermes,pharma,BIOGEN,major pharma,43767,2019,Drugs@FDA,NO,YES (Presystemic),,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,,,,,,,,,1,Michael_acceptor,NO,YES,NO,,255.22406,0,4,0,7,0,7,89.98,0.455,0.224,0.224,0.256,Valid estimate for difficult structure,-0.25,-0.25,0.04,0.043,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56356,0.5699,0.81862,0.38781,0.52457,0.59178,0.7865,0.53315,0.47245,247.3,20.6,15,6.65
22059-60-5,DISOPYRAMIDE PHOSPHATE,NORPACE,PF-00344548,926,CC(C)N(CCC(c1ccccc1)(c2ccccn2)C(=O)N)C(C)C,"CAPSULE; CAPSULE, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,800,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,28369,1977,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.35,1.3,6.7,,,,6014012,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (rare but likely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,339.4745,2,3,1,4,0,8,59.22,0.428571429,0.68,-1.2,2.576,All fragments measured,2.2,-0.097,2.76,0.35,,10.1,14,9.4,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78887,0.85082,0.92118,0.97016,0.9848,0.98659,0.99142,0.39983,0.93773,265.9,18.9,2.35,7.16
97-77-8,DISULFIRAM,ANTABUSE,PF-00345037,928,CCN(CC)C(=S)SSC(=S)N(CC)CC,TABLET,YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,,,TEVA,major pharma,18868,1951,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.04,,12,Parent CRG,,,7267,NO,Neurological,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Less,1,Thiol_Disulfide,NO,NO,NO,,296.5392,0,0,0,2,0,9,6.48,0.8,3.15,2.9,3.88,All fragments measured,3.8,3.8,3.59,3.59,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47872,0.50301,0.99301,0.24106,0.88651,0.59178,0.4682,0.29329,0.47245,202.3,11.7,15.8,59.8
115256-11-6,DOFETILIDE,TIKOSYN,PF-00345691,942,CN(CCc1ccc(cc1)NS(=O)(=O)C)CCOc2ccc(cc2)NS(=O)(=O)C,CAPSULE,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,,,PFIZER,major pharma,36434,1999,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.36,3.5,10,,,,40304321,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,441.5648,2,6,2,8,0,11,104.81,0.368421053,1.07,0.6558,1.994,All fragments measured,1.9,0.93,1.69,0.687,9.1,8.28,8.1,8,Zwitter,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47656,0.50964,0.35613,0.91397,0.52457,0.79222,0.46515,0.15134,0.93773,397.8,3.39,14.1,12.7
115956-12-2,DOLASETRON MESYLATE,ANZEMET,PF-02433972,3931,c1ccc2c(c1)c(c[nH]2)C(=O)O[C@@H]3C[C@@H]4CC5C[C@H](C3)[N@]4CC5=O,TABLET,YES,NO,NO,NO,ORAL,100,Discontinued,,NO,NO,,,,,US PHARM HOLDINGS,pharma,35684,1997,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,1,8.19,0.2,,,,,NO,Gastrointestinal,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,324.3737,1,3,1,5,0,3,62.4,0.473684211,1.05,1.05,2.344,All fragments measured,3.3,1.8,2.66,2.626,,6.22,11,7.4,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.97124,0.95927,0.97503,0.95966,0.88651,0.98659,0.98116,0.99269,0.93773,340.2,17.7,14.6,20.3
1051375-16-6,DOLUTEGRAVIR SODIUM,TIVICAY,PF-05299617,4805,C[C@@H]1CCO[C@@H]2N1C(=O)c3c(c(=O)c(cn3C2)C(=O)NCc4ccc(cc4F)F)O,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Shionogi,pharma,VIIV HLTHCARE,pharma,41498,2013,Drugs@FDA,NO,NO,,0.31,High,Fa estimated from reported excretion data,0.011,0.2,14,,,48,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,D,Less,D (possible cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,,419.3788,2,5,2,8,0,3,100.87,0.35,0.835,0.835,-0.407,Approximated fragment value used,0.77,0.73,-0.44,-3.101,4.5,,9.9,,Acidic,Class 2,0,2,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,NO,0.69912,0.67238,0.46182,0.56666,0.52457,0.79222,0.69563,0.99269,0.82734,515.8,3.46,7.46,14
120014-06-4,DONEPEZIL HYDROCHLORIDE,ARICEPT,PF-00346601,946,COc1cc2c(cc1OC)C(=O)C(C2)CC3CCN(CC3)Cc4ccccc4,"SOLUTION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,EISAI INC,pharma,35394,1996,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.04,12,70,,44,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,4EY7,379.492,0,4,0,4,0,6,38.77,0.458333333,3.21,1.704,4.598,All fragments measured,4.5,3.6,4.23,2.816,,8.83,,8.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70615,0.75964,0.69582,0.66076,0.88651,0.59178,0.9373,0.6885,0.93773,298.8,6.21,33.3,14.1
1338225-97-0,DORAVIRINE,PIFELTRO,VC-000639250,,Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,43342,2018,Drugs@FDA,NO,NO,0.64,,High,Reported bioavailability,0.34,0.9,15,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,,425.7491,1,4,1,8,0,4,105.7,0.176470588,2.77,2.752,2.666,Calculated fragment value,2,2,2.02,1.968,8.32,1.48,9,5.7,Acidic,Class 2,0,3,0,0,1,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.75319,0.75496,0.42931,0.91627,0.72615,0.98659,0.70736,0.84757,0.82734,417.8,8.9,6.68,8.86
74191-85-8,DOXAZOSIN MESYLATE,CARDURA,PF-00346603,954,COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)C4COc5ccccc5O4,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,16,Prescription,,NO,NO,,,,,PFIZER,major pharma,33179,1990,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.02,1.3,16,,,,143841307,NO,"Cardiovascular, Genitourinary",NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,451.4751,2,7,1,10,0,5,112.27,0.347826087,1.79,2.513,3.532,Approximated fragment value used,2.6,2.5,1.51,1.456,,6.52,,7.3,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.58511,0.46351,0.31582,0.99264,0.10671,0.98659,0.55947,0.96969,0.25672,501.7,13.9,13.1,24.3
1668-19-5,DOXEPIN HYDROCHLORIDE,SINEQUAN,PF-00344620,956,CN(C)CC/C=C\1/c2ccccc2COc3c1cccc3,"CAPSULE, CONCENTRATE, TABLET",YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,PFIZER,major pharma,25469,1969,Drugs@FDA,NO,NO,0.3,,Moderate,Reported bioavailability,0.2,24,15,,,,439751,NO,Neurological,NO,NO,,NO,YES,YES,NO,Less,Less,DILIRank,1,C,Less,C (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,3RZE,279.3761,0,2,0,2,0,3,12.47,0.263157895,1.98,2.2,4.092,Benzyl approx. based on a priori value,4.2,2.5,4.27,2.496,,9.19,,9.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.845,0.78896,0.94601,0.88648,0.93048,0.59178,0.44264,0.99269,0.93773,204.5,16.5,22.6,14.9
54573-75-0,DOXERCALCIFEROL,HECTOROL,PF-06852501,957,C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,CAPSULE,YES,NO,NO,NO,ORAL,0.0086,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,36320,1999,Drugs@FDA,NO,YES,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,,,,None,0,,NO,NO,NO,,412.6478,2,2,2,2,1,5,40.46,0.714285714,4.65,6.28,8.16,Very high LogP unrealistic in nature,6.7,6.7,6.77,6.774,,,14,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.48354,0.53964,0.49795,0.09519,0.93048,0.79222,0.95241,0.84757,0.47245,341.3,4.15,67.7,83.5
564-25-0,DOXYCYCLINE HYCLATE,VIBRAMYCIN,PF-00344784,961,C[C@H]1c2cccc(c2C(=O)C3=C([C@]4([C@@H]([C@H]([C@H]13)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O,"CAPSULE; CAPSULE, DELAYED RELEASE; TABLET; TABLET, DELAYED RELEASE",YES,YES,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,PFIZER,major pharma,24811,1967,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.12,0.69,18,,,,29925493,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely but rare cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,,444.4346,7,9,6,10,1,2,181.62,0.409090909,-0.466,-0.03905,-0.499,Valid estimate for difficult structure,-0.64,-5.7,-0.47,-3.288,4.5,10.28,3.2,9.1,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.2561,0.2065,0.34402,0.26536,0.10671,0.02306,0.09897,0.87038,0.82734,517.7,0.483,2.33,7.56
469-21-6,DOXYLAMINE SUCCINATE,DECAPRYN,PF-00344984,962,CC(c1ccccc1)(c2ccccn2)OCCN(C)C,TABLET,YES,NO,NO,NO,ORAL,25,Over-the-counter,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,17630,1948,Drugs@FDA,NO,NO,,,NA,NA,,2.6,12,,,,,NO,"Neurological, Respiratory",NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,270.3694,0,3,0,3,0,6,25.36,0.352941176,0.738,0.738,2.354,All fragments measured,2.6,1.3,2.82,1.462,,8.68,,8.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.79572,0.81983,0.9055,0.99979,0.9848,0.59178,0.73079,0.6885,0.93773,243.7,26,6.24,6.65
8/3/1972,DRONABINOL,MARINOL,PF-05205049,4109,CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]2C=C(CC3)C)(C)C)O,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,ABBVIE,major pharma,31198,1985,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,0.03,10,5.6,,,,,YES,"Gastrointestinal, Musculoskeletal/Pain",NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,1,1_4_Diketones,NO,NO,NO,,314.4617,1,2,1,2,1,4,29.46,0.619047619,5,5.87,7.238,Very high LogP unrealistic in nature,7,7,7.25,7.252,9.81,,10,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69261,0.69058,0.99461,0.12629,0.93048,0.98659,0.80963,0.96969,0.82734,236,1.92,70.4,158
141626-36-0,DRONEDARONE HYDROCHLORIDE,MULTAQ,PF-05331353,4112,CCCCc1c(c2cc(ccc2o1)NS(=O)(=O)C)C(=O)c3ccc(cc3)OCCCN(CCCC)CCCC,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Sanofi,major pharma,SANOFI AVENTIS US,major pharma,39995,2009,Drugs@FDA,NO,NO,0.04,,Low,Reported bioavailability,0.02,20,13,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),,1,Benzofuran,NO,NO,NO,,556.7565,1,5,1,7,2,18,88.85,0.516129032,4.32,4.98,8.567,Very high LogP unrealistic in nature,7.3,4.9,6.16,4.007,7.49,9.44,8,9.6,Zwitter,Class 3B,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.1112,0.18406,0.09054,0.04714,0.72615,0.98659,0.71557,0.01273,0.25672,448,0.184,62.5,62.8
67392-87-4,DROSPIRENONE,YASMIN,PF-04440810,968,C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C,TABLET,YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,Schering ,major pharma,BAYER HEALTHCARE,major pharma,37022,2001,Drugs@FDA,YES,NO,0.76,,High,Reported bioavailability,0.03,4,30,,,184,462741,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,Ambiguous,,,,,,Less,0,,NO,NO,NO,,366.4932,0,2,0,3,0,0,43.37,0.833333333,3.18,2.671,2.84,Valid estimate for difficult structure,2.6,2.6,3.46,3.473,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,10,0,0,0,10,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.61048,0.69706,0.77597,0.97367,0.9848,0.59178,0.97306,0.39503,0.47245,426.4,15.8,35.3,18.2
23651-95-8,DROXIDOPA,NORTHERA,PF-06786780,971,c1cc(c(cc1[C@H]([C@@H](C(=O)O)N)O)O)O,CAPSULE,YES,NO,NO,NO,ORAL,1800,Prescription,,NO,NO,,,Sumitomo Dainippon Pharma,pharma,LUNDBECK PHARMS LLC,pharma,41688,2014,Drugs@FDA,NO,YES,,0.75,High,Fa estimated from reported excretion data,,2.9,2.5,,,,844414,YES,Cardiovascular,YES,NO,,NO,YES,NO,NO,,None,FEARS Addition ,1,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Quinones,NO,NO,NO,,213.1873,6,6,5,6,1,3,124.01,0.222222222,-1.1,-1.1,-2.484,All fragments measured,-1.4,-3.1,-1.06,-3.575,2.09,8.55,2.2,8.2,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.2805,0.30713,0.53012,0.04609,0.52457,0.05547,0.44147,0.99269,0.82734,224,2.48,4.61,10.5
116539-59-4,DULOXETINE HYDROCHLORIDE,CYMBALTA,PF-00346559,972,CNCC[C@@H](c1cccs1)Oc2cccc3c2cccc3,"CAPSULE, DELAYED REL PELLETS",NO,YES,NO,YES,ORAL,60,Prescription,,NO,NO,,,Eli Lilly ,major pharma,ELI LILLY AND CO,major pharma,38202,2004,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.1,23.4,12,,35,135,418139,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,NO,NO,YES,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,1,Thiophene,NO,NO,YES,4MM6,297.4146,1,2,1,2,0,6,21.26,0.222222222,1.73,1.807,4.258,Benzyl approx. based on a priori value,4,2.3,4.03,1.529,,10.02,,9.2,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.724,0.7588,0.99423,0.90082,0.93048,0.98659,0.9967,0.6885,0.25672,257.9,5.34,26.9,84.2
164656-23-9,DUTASTERIDE,AVODART,PF-02768590,973,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)Nc4cc(ccc4C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C,CAPSULE,YES,NO,NO,NO,ORAL,0.5,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,GLAXOSMITHKLINE,major pharma,37215,2001,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.01,4.3,840,Suicide,146,161,,NO,Genitourinary,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,2,Aniline; Michael_acceptor,YES,YES,NO,,528.5297,2,2,2,4,1,2,58.2,0.62962963,4.77,5.96,4.94,Estimated fragment value used,5.4,5.4,4.99,4.994,,,13,,Neutral,Class 4,0,6,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.4533,0.55097,0.12372,0.21195,0.93048,0.79222,0.99393,0.96969,0.82734,495.5,2.31,13.8,29.6
1201438-56-3,DUVELISIB,COPIKTRA,PF-06734032,,C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c(nc[nH]5)ncn4,CAPSULE,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,Intellikine ,pharma,VERASTEM INC,pharma,43367,2018,Drugs@FDA,NO,NO,0.42,,High,Reported bioavailability,0.02,0.4,4.7,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproved but suspected cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4XEO,416.863,2,4,2,7,0,4,88.49,0.090909091,3.35,3.62,4.39,Valid estimate for difficult structure,3.5,3.5,4.19,4.187,10.05,3.25,10,4.3,Neutral,Class 2,0,0,0,0,1,0,0,5,2,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,2,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,NO,0.45699,0.49237,0.47511,0.93961,0.72615,0.79222,0.81589,0.96969,0.03452,440.3,14.2,12,39.6
152-62-5,DYDROGESTERONE,GYNOREST,PF-00345223,975,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C,TABLET,YES,NO,NO,NO,ORAL,30,Discontinued,,NO,NO,,,,,SOLVAY,pharma,28752,1978,PharmaPendium,NO,NO,0.28,,Moderate,Reported bioavailability,,,6,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,FEARS Addition ,1,A,Most,A (well established cause of clniically apparent liver injury),,0,,NO,NO,NO,,312.4458,0,2,0,2,0,1,34.14,0.714285714,3.11,3.37,3.541,Valid estimate for difficult structure,2.9,2.9,3.3,3.303,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71414,0.75636,0.99687,0.97037,0.93048,0.59178,0.88329,0.63709,0.47245,287.9,16,60.4,77
479-18-5,DYPHYLLINE,NEOTHYLLINE,PF-00344785,976,Cn1c2c(c(=O)n(c1=O)C)n(cn2)CC(CO)O,"ELIXIR, TABLET",YES,NO,NO,NO,ORAL,6300,Discontinued,,NO,NO,,,,,TEVA,major pharma,18694,1951,Drugs@FDA,NO,NO,,0.88,High,Fa estimated from reported excretion data,,,,,,,,NO,Respiratory,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,,0,,NO,NO,NO,,254.2426,2,5,2,8,0,3,102.28,0.5,-0.563,-0.563,-1.286,Valid estimate for difficult structure,-1.2,-1.2,-0.94,-0.944,,,12,1.3,Neutral,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.67122,0.65203,0.81237,0.18689,0.72615,0.79222,0.6985,0.99269,0.82734,320,3.28,4.97,6.65
480449-70-5,EDOXABAN TOSYLATE,SAVAYSA,VC-001215213,4897,CN1CCc2c(sc(n2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)Nc4ccc(cn4)Cl)C(=O)N(C)C)C1,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,Daiichi Sankyo,pharma,DAIICHI SANKYO,pharma,42012,2015,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,0.45,1.53,11.5,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury),,0,,NO,NO,NO,,548.0575,3,7,3,11,2,7,136.63,0.5,0.525,0.525,0.152,Calculated fragment value,1.5,1.5,1.19,0.592,6.87,6.58,11,7.8,Basic,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,4,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.4029,0.3685,0.09937,0.73166,0.33223,0.37866,0.15626,0.6885,0.93773,631.1,0.505,2.49,17.4
154598-52-4,EFAVIRENZ,SUSTIVA,PF-00342257,989,c1cc2c(cc1Cl)[C@@](OC(=O)N2)(C#CC3CC3)C(F)(F)F,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,36055,1998,Drugs@FDA,NO,NO,,0.24,Moderate,Fa estimated from reported excretion data,0.005,,40,,110,35,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Moderate,1,Alkynes,NO,NO,NO,1JKH,315.675,1,1,1,3,0,0,38.33,0.357142857,3.9,4.81,3.726,Benzyl approx. based on a priori value,4.3,4.3,4.38,4.383,9.81,,11,,Neutral,Class 2,0,3,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.91725,0.90957,0.99296,0.73743,0.93048,0.98659,0.93296,0.99269,0.82734,289.9,6.36,17.6,21.9
832720-36-2,ELAGOLIX SODIUM,ORILISSA,VC-001215212,,Cc1c(c(=O)n(c(=O)n1Cc2c(cccc2F)C(F)(F)F)C[C@@H](c3ccccc3)NCCCC(=O)O)c4cccc(c4F)OC,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,Neurocrine Biosciences,pharma,ABBVIE,major pharma,43304,2018,Drugs@FDA,NO,NO,,,NA,NA,0.2,12.6,5,,,,,NO,Metabolic Disease,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,631.5897,2,6,2,8,1,12,102.56,0.28125,1.84,1.84,4.172,Benzyl approx. based on a priori value,5.7,2.9,5.8,3.298,4.4,8.51,3.1,6.4,Zwitter,Class 3B,0,5,0,0,0,0,0,4,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,5,0,0,0,0,NO,0.2169,0.30854,0.04742,0.99973,0.52457,0.79222,0.69563,0.07566,0.25672,565.6,2.48,7.93,32.5
1370468-36-2,ELBASVIR,ZEPATIER,VC-001215211,5080,CC(C)[C@@H](C(=O)N1CCC[C@H]1c2[nH]c(cn2)c3ccc4c(c3)cc-5n4[C@@H](Oc6c5ccc(c6)c7cnc([nH]7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)c9ccccc9)NC(=O)OC,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,42397,2016,Drugs@FDA,YES,NO,0.32,,High,Reported bioavailability,0.001,9.7,24,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,882.0171,4,7,4,16,3,15,188.8,0.387755102,4.62,6.14,6.655,Benzyl approx. based on a priori value,7,7,5.88,5.83,11.22,6.52,13,6,Basic,Class 4,0,0,0,0,0,0,0,6,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,3,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.04499,0.05168,0.02728,0.03559,0.10671,0.14694,0.0819,0.07566,0.01044,1021,1.55,6.3,10.9
143322-58-1,ELETRIPTAN HYDROBROMIDE,RELPAX,PF-01614157,995,CN1CCC[C@@H]1Cc2c[nH]c3c2cc(cc3)CCS(=O)(=O)c4ccccc4,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,37616,2002,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.15,1.97,4,,140,,135841542,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,1,3_Methyl_Indole,NO,NO,NO,,382.519,1,3,1,4,0,6,53.17,0.363636364,2.1,0.7087,3.355,All fragments measured,3.7,2,3.81,1.057,,10.35,12,9,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64182,0.69935,0.67698,0.71504,0.9848,0.98659,0.98425,0.6885,0.25672,336.7,9.46,23.9,41.6
2216712-66-0,ELEXACAFTOR,TRIKAFTA,VC-001274380,,O=C(C1=CC=C(N2N=C(OCC(C)(C)C(F)(F)F)C=C2)N=C1N3C(C)(C)C[C@H](C)C3)NS(=O)(C4=CN(C)N=C4C)=O,TABLET,YES,NO,NO,YES,ORAL,200,Prescription,,NO,NO,,,Vertex Pharmaceuticals,pharma,VERTEX PHARMS,pharma,43759,2019,Drugs@FDA,YES,NO,0.8,,High,Reported bioavailability,0.01,0.8,29.8,,,,,YES,Respiratory,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,597.6541496,1,7,1,11,2,8,124.24,0.538,2.67,2.67,4.434,Benzyl approx. based on a priori value,5.2,2.6,4.19,2.049,3.8,1.33,4.4,2.6,Acidic,Class 3B,0,3,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.26826,0.27382,0.06127,0.36533,0.19128,0.98659,0.36291,0.29329,0.25672,601.6,3.2,13.2,46.4
491833-29-5,ELIGLUSTAT TARTRATE,CERDELGA,PF-06952299,4834,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](c2ccc3c(c2)OCCO3)O,CAPSULE,YES,NO,NO,NO,ORAL,168,Prescription,,NO,NO,,,Genzyme,major pharma,GENZYME CORP,pharma,41870,2014,Drugs@FDA,NO,NO,0.05,0.42,Low,Reported bioavailability,0.17,11.9,6.5,,,,,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,,,,E,None,"E (unlikely cause of clinically apparent liver injury, but experience with its use is limited)",,1,1_4_Diketones,NO,NO,NO,,404.5429,2,5,2,6,0,11,71.03,0.695652174,2.72,3.098,4.831,All fragments measured,3.2,2.3,3.66,2.129,,8.71,11,7.8,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.52278,0.61529,0.5437,0.90902,0.72615,0.79222,0.93777,0.15134,0.82734,383.5,4.59,22.9,86.5
496775-61-2,ELTROMBOPAG OLAMINE,PROMACTA,PF-03322295,4399,Cc1ccc(cc1C)N2C(=O)/C(=N\Nc3cccc(c3O)c4cccc(c4)C(=O)O)/C(=N2)C,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,75,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,NOVARTIS,major pharma,39772,2008,Drugs@FDA,NO,NO,0.52,,High,Reported bioavailability,0.001,8.7,21,,,,,YES,Cardiovascular,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,E*,Ambiguous,"E* (suspected, but unproven cause of clinically apparent liver injury)",,0,,NO,NO,NO,,442.4666,3,5,3,8,1,5,114.59,0.12,1.19,1.19,5.249,Calculated fragment value,5,0.64,3.94,0.618,,,3.7,1.3,Acidic,Class 3B,0,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.45074,0.43839,0.35229,0.60262,0.33223,0.37866,0.53549,0.84757,0.25672,410.4,0.96,17.8,9.6
864821-90-9,ELUXADOLINE,VIBERZI,VC-001215215,5001,Cc1cc(cc(c1C[C@@H](C(=O)N(Cc2ccc(c(c2)C(=O)O)OC)[C@@H](C)c3[nH]c(cn3)c4ccccc4)N)C)C(=O)N,TABLET,YES,NO,NO,YES,ORAL,200,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,ALLERGAN,major pharma,42151,2015,Drugs@FDA,NO,NO,0.011,,Low,Reported bioavailability,0.19,,3.7,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,Less,,,C,Less,"C (probable cause of acute liver injury, likely due to bile duct spasm or obstruction)",Less,0,,NO,NO,NO,,569.6508,6,7,4,10,2,12,164.63,0.25,0.997,0.997,0.72,Vinyl approx. based on a priori value,3.3,1.5,3.44,0.883,4.01,6.82,3.3,7.7,Zwitter,Class 4,0,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.13587,0.16008,0.07935,0.84608,0.33223,0.14694,0.15729,0.15134,0.03452,539.2,0.351,10.8,12.8
697761-98-1,ELVITEGRAVIR,VITEKTA,PF-04269440,4300,CC(C)[C@@H](CO)n1cc(c(=O)c2c1cc(c(c2)Cc3cccc(c3F)Cl)OC)C(=O)O,TABLET,YES,NO,NO,YES,ORAL,150,Discontinued,,NO,NO,,,Japan Tobacco,major pharma,GILEAD SCIENCES INC,major pharma,41906,2014,Drugs@FDA,NO,NO,,,NA,NA,0.01,,8.7,,,54,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E,None,"E (unlikely cause of clinically apparent liver injury, but experience with its use is limited)",Less,0,,NO,NO,NO,,447.8838,2,5,2,6,0,7,88.76,0.304347826,1.7,1.7,4.559,All fragments measured,4.6,3.5,4.29,1.963,,,6.5,3.2,Acidic,Class 1B,0,1,0,0,1,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,2,0,0,0,0,NO,0.58766,0.61823,0.32994,0.61902,0.52457,0.79222,0.81345,0.53315,0.93773,392.1,4.59,8.63,24.6
864070-44-0,EMPAGLIFLOZIN,JARDIANCE,PF-04732403,4830,c1cc(ccc1Cc2cc(ccc2Cl)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O[C@H]4CCOC4,TABLET,YES,NO,NO,YES,ORAL,25,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,BOEHRINGER INGELHEIM,major pharma,41852,2014,Drugs@FDA,NO,NO,,0.54,High,Fa estimated from reported excretion data,0.138,1,12.4,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,450.9093,4,7,4,7,0,6,108.61,0.47826087,1.49,1.87,2.585,All fragments measured,1.8,1.8,2.46,2.468,,,12,,Neutral,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,1,0,2,0,0,NO,0.45858,0.47691,0.31801,0.93677,0.33223,0.14694,0.59763,0.6885,0.93773,497.6,3.23,2.99,9.73
143491-57-0,EMTRICITABINE,EMTRIVA,PF-06700206,1003,c1c(c(nc(=O)n1[C@@H]2CS[C@@H](O2)CO)N)F,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,240,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,37804,2003,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.96,,10,,66,19,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Moderate,0,,NO,NO,NO,,247.2467,3,5,2,6,0,2,90.37,0.5,0.0869,0.0869,-1.291,Approximated fragment value used,-1.1,-1.1,-0.73,-0.708,,2.4,13,2.6,Neutral,Class 4,0,1,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.62015,0.57264,0.76625,0.28176,0.52457,0.79222,0.54725,0.87038,0.47245,341.7,0.608,4.89,7.78
75847-73-3,ENALAPRIL MALEATE,VASOTEC,PF-00344786,1005,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,"FOR SOLUTION, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,VALEANT,pharma,31405,1985,Drugs@FDA,NO,YES,0.6,,High,Reported bioavailability,0.45,1.7,,,,,892791,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,376.4467,2,5,2,7,0,11,95.94,0.55,-0.244,-0.7275,0.667,Approximated fragment value used,2.2,-1.2,2,-1.43,3.15,5.43,3.1,5.5,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50236,0.53151,0.71477,0.31599,0.52457,0.79222,0.72844,0.21184,0.82734,383.1,0.867,28,8.01
1446502-11-9,ENASIDENIB MESYLATE,IDHIFA,VC-000914860,5251,CC(C)(CNc1nc(nc(n1)Nc2ccnc(c2)C(F)(F)F)c3cccc(n3)C(F)(F)F)O,TABLET,YES,NO,NO,YES,ORAL,100,Prescription,,NO,NO,,,Agios Pharmaceuticals,pharma,CELGENE,major pharma,42948,2017,Drugs@FDA,NO,NO,0.57,,High,Reported bioavailability,,,,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,,473.375,3,6,3,8,0,6,108.74,0.315789474,4.24,4.19,3.906,All fragments measured,4.3,3.6,3.73,3.758,,2.2,14,4.5,Neutral,Class 2,0,6,0,0,0,0,0,3,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,5,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,6,0,0,0,0,NO,0.34148,0.34309,0.24114,0.52347,0.19128,0.37866,0.59627,0.39983,0.25672,433.8,4.92,20.7,24.6
66794-74-9,ENCAINIDE HYDROCHLORIDE,ENKAID,PF-05165057,1007,CN1CCCCC1CCc2ccccc2NC(=O)c3ccc(cc3)OC,N/A,N/A,N/A,N/A,NO,ORAL,200,Discontinued,1991,YES,YES,"Cardiovascular, proarrhythmic",FederalRegister,Bristol-Meyers Squibb,major pharma,BRISTOL MYERS SQUIBB,major pharma,31413,1986,NIH NCATS,NO,NO,0.3,0.95,Moderate,Reported bioavailability,0.26,2.2,,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,352.4699,1,3,1,4,0,6,41.57,0.409090909,1.97,1.858,3.516,All fragments measured,4.7,2.7,4.48,2.05,,9.94,12,9.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8365,0.8703,0.85696,0.73201,0.9848,0.98659,0.96107,0.6885,0.93773,304.6,6.93,28,16.4
1269440-17-6,ENCORAFENIB,BRAFTOVI,VC-001215214,,C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC,CAPSULE,YES,NO,NO,NO,ORAL,450,Prescription,,NO,NO,,,Novartis ,major pharma,ARRAY BIOPHARMA INC,pharma,43278,2018,Drugs@FDA,NO,NO,0.86,,High,Reported bioavailability,0.14,2.3,3.5,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,540.0107,3,6,3,11,2,10,140.13,0.363636364,3.22,3.9,2.812,All fragments measured,3.6,2.5,2.9,1.494,5.91,2.67,7.8,3.2,Acidic,Class 3B,0,1,0,0,1,0,0,3,0,2,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,NO,0.26759,0.2674,0.10859,0.93945,0.19128,0.37866,0.24327,0.21184,0.25672,563.5,7.45,7.53,28.4
74011-58-8,ENOXACIN,PENETREX,PF-00345503,1013,CCn1cc(c(=O)c2c1nc(c(c2)F)N3CCNCC3)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,800,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,33603,1991,Drugs@FDA,NO,NO,0.87,,High,Reported bioavailability,0.6,2,5.4,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Quinolones_Naphthyridinones,NO,NO,NO,,320.3189,2,5,2,7,0,3,87.46,0.4,-0.91,-0.91,-1.596,All fragments measured,1.4,-1.1,-0.63,-2.834,6.04,8.19,6.2,8.4,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.66243,0.58824,0.98469,0.13876,0.33223,0.79222,0.82513,0.99269,0.82734,314,1.24,2.94,7.21
130929-57-6,ENTACAPONE,COMTAN,PF-04440348,1018,CCN(CC)C(=O)/C(=C\c1cc(c(c(c1)O)O)N(=O)=O)/C#N,TABLET,YES,NO,NO,NO,ORAL,1600,Prescription,,NO,NO,,,,,ORION PHARMA,pharma,36452,1999,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.02,0.27,0.5,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,"D (possible, rare cause of clinically apparent liver injury)",Less,3,Michael_acceptor; Nitroorganics; Quinones,NO,YES,NO,,305.286,2,5,2,8,0,6,130.38,0.285714286,0.536,0.536,1.761,All fragments measured,1.6,-0.093,1.99,-0.035,5.15,,4.2,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85262,0.72123,0.99995,0.9107,0.52457,0.79222,0.38251,0.84757,0.82734,289.7,6.08,14.8,10
142217-69-4,ENTECAVIR,BARACLUDE,PF-06700532,1019,C=C1[C@H](C[C@@H]([C@H]1CO)O)n2cnc3c2[nH]c(nc3=O)N,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,BRISTOL MYERS SQUIBB,major pharma,38440,2005,Drugs@FDA,NO,NO,,0.62,High,Fa estimated from reported excretion data,0.87,,,,,104,1530996,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver rinjury),Less,0,,NO,NO,NO,,277.2792,5,5,4,8,0,2,130.05,0.416666667,-0.581,-0.581,-2.759,Valid estimate for difficult structure,-0.66,-0.67,-0.74,-0.738,,3.63,8.1,3.6,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44932,0.41402,0.93746,0.14893,0.33223,0.14694,0.42483,0.87038,0.82734,353,1.13,3.33,7
1108743-60-7,ENTRECTINIB,ROZLYTREK,PF-05768567,,O=C(NC1=NNC2=C1C=C(CC3=CC(F)=CC(F)=C3)C=C2)C4=CC=C(N5CCN(C)CC5)C=C4NC6CCOCC6,CAPSULE,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,Nerviano Medical Sciences,pharma,GENENTECH,major pharma,43692,2019,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.01,7.9,20,,,,,YES,Oncology,NO,YES,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,560.6377064,3,4,3,8,2,7,85.52,0.355,3.44,3.95,5.22,All fragments measured,5.6,4.5,5.31,4.843,12.01,7.75,12,8.4,Basic,Class 4,0,2,0,0,0,0,0,4,1,0,0,1,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,NO,0.21247,0.27819,0.08695,0.49025,0.52457,0.37866,0.82735,0.53315,0.03452,505.6,0.572,33.5,50.4
915087-33-1,ENZALUTAMIDE,XTANDI,PF-04998299,4628,CC1(C(=O)N(C(=S)N1c2ccc(c(c2)F)C(=O)NC)c3ccc(c(c3)C(F)(F)F)C#N)C,CAPSULE,YES,NO,NO,YES,ORAL,240,Prescription,,NO,NO,,,UCLA,nonprofit,ASTELLAS,major pharma,41152,2012,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,0.02,1.6,139,,,42,,NO,Oncology,NO,NO,,NO,NO,NO,YES,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,2,Aniline; Thiourea,YES,NO,NO,,464.436,1,3,1,6,0,3,76.44,0.238095238,3.09,3.426,3.354,Calculated fragment value,3.4,3.4,2.35,2.354,,,13,,Neutral,Class 2,0,4,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.64759,0.6733,0.26933,0.48936,0.88651,0.98659,0.59847,0.96969,0.93773,435,17.6,3.49,12.3
107724-20-9,EPLERENONE,INSPRA,PF-02845980,1032,C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Pfizer,major pharma,GD SEARLE,major pharma,37526,2002,Drugs@FDA,NO,NO,0.69,,High,Reported bioavailability,0.54,0.95,4.5,,,,127338716,NO,Cardiovascular,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspect rare cause of clinically apparent liver injury),Less,1,Epoxide,NO,NO,NO,,414.4914,0,4,0,6,0,2,82.2,0.791666667,1.76,0.8987,0.475,Valid estimate for difficult structure,1.6,1.6,1.66,1.359,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.64579,0.65512,0.48788,0.9715,0.52457,0.59178,0.85602,0.87038,0.47245,511.2,11.4,20.9,41.1
133040-01-4,EPROSARTAN MESYLATE,TEVETEN,PF-01468991,1037,CCCCc1ncc(n1Cc2ccc(cc2)C(=O)O)/C=C(\Cc3cccs3)/C(=O)O,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,ABBVIE,major pharma,35786,1997,Drugs@FDA,NO,NO,0.13,,Moderate,Reported bioavailability,0.02,4.4,20,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (Unproved but suspected rare cause of clinically apparent liver injury),Less,2,Michael_acceptor; Thiophene,NO,YES,YES,,424.5127,2,5,2,6,0,10,92.42,0.260869565,0.145,-1.332,4.804,All fragments measured,4.4,-0.011,4.68,1.062,3.63,8.31,4.2,6.9,Zwitter,Class 3B,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.40386,0.44609,0.43548,0.54423,0.72615,0.79222,0.47412,0.21184,0.25672,343,0.578,18.4,16.6
1346242-81-6,ERDAFITINIB,BALVERSA,PF-07223509,,CN1N=CC(C2=NC3=CC(N(C4=CC(OC)=CC(OC)=C4)CCNC(C)C)=CC=C3N=C2)=C1,TABLET,YES,NO,NO,NO,ORAL,9,Prescription,,NO,NO,,,Astex Therapeutics,pharma,JANSSEN BIOTECH,major pharma,43567,2019,Drugs@FDA,NO,NO,,0.69,High,Fa estimated from reported excretion data,0.002,0.4,59,,,,,NO,Oncology,NO,YES,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,446.54494,1,6,1,8,0,9,77.33,0.32,2.62,2.701,4.271,All fragments measured,4.4,2.6,3.89,1.812,,9.45,,8,Basic,Class 2,0,0,0,0,0,0,0,4,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.33321,0.36567,0.33534,0.87785,0.33223,0.98659,0.8946,0.29329,0.03452,444.5,6.6,19.8,69.4
50-14-6,ERGOCALCIFEROL,DRISDOL,PF-00345506,2838,C[C@H](C=C[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,CAPSULE,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,14987,1941,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,396.6484,1,1,1,1,1,5,20.23,0.714285714,4.73,5.87,9.391,Very high LogP unrealistic in nature,8.4,8.4,8.49,8.498,,,15,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.43211,0.37866,0.59028,0.03316,0.23327,0.98659,0.61872,0.84757,0.47245,299.1,1.16,43.6,27.5
113-15-5,ERGOTAMINE TARTRATE,CAFERGOT,PF-00344883,1043,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)Cc4ccccc4)NC(=O)[C@H]5CN([C@@H]6Cc7c[nH]c8c7c(ccc8)C6=C5)C,TABLET,YES,NO,NO,NO,ORAL,6,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,17863,1948,Drugs@FDA,YES,NO,0.05,,Low,Reported bioavailability,0.1,1.85,2,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,,,LiverTox Additions,0,E,None,E (unlikely cause of clinically apparent liver injury),None,1,3_Methyl_Indole,NO,NO,NO,4IAR,581.6615,3,6,3,10,1,4,118.21,0.424242424,2.74,3.61,4.661,All fragments measured,3.6,0.1,2.63,2.421,9.62,6.94,8.8,6.4,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,10,0,0,0,10,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.35339,0.40335,0.07067,0.99692,0.52457,0.37866,0.4986,0.96969,0.25672,797.8,1.81,23.8,380
183321-74-6,ERLOTINIB HYDROCHLORIDE,TARCEVA,PF-01527112,1045,COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,Pfizer,major pharma,OSI PHARMS,pharma,38309,2004,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.07,2.85,36.2,,126,126,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely but uncommon cause of clinically apparent liver injury),Moderate,2,Alkynes; Aniline,YES,NO,NO,4HJO,393.4357,1,6,1,7,0,10,74.73,0.272727273,3.13,3.4,4.342,All fragments measured,3.8,3.8,3.05,3.042,,4.51,,5,Neutral,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,NO,0.47993,0.49793,0.60969,0.7645,0.33223,0.98659,0.91343,0.21184,0.25672,370.8,12.2,11.6,28
1210344-57-2,ERTUGLIFLOZIN,STEGLATRO,PF-04971729,5270,CCOc1ccc(cc1)Cc2cc(ccc2Cl)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,Pfizer,major pharma,MERCK,major pharma,43088,2017,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.064,1.2,16.6,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,436.8827,4,7,4,7,0,6,108.61,0.454545455,2.3,3.6,3.189,All fragments measured,1.8,1.8,3.95,4.09,12.95,,11,,Neutral,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,1,0,2,0,0,NO,0.47846,0.49076,0.37666,0.96636,0.33223,0.14694,0.59763,0.6885,0.93773,492.6,2.53,3.27,9.47
1264-62-6,ERYTHROMYCIN ETHYLSUCCINATE,E.E.S.,PF-00346430,1051,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,"GRANULE, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,4000,Prescription,,NO,NO,,,,,ARBOR PHARMS LLC,pharma,23834,1965,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.1,0.57,1.5,,,,322873,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,862.0527,4,14,4,17,2,14,226.28,0.906976744,2.56,3.504,3.232,All fragments measured,2.9,2.4,3.41,3.003,,7.59,12,7.9,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,YES,0.12369,0.09549,0.02744,0.99658,0.02002,0.14694,0.03583,0.05315,0.47245,1109,1.89,16.9,165
128196-01-0,ESCITALOPRAM OXALATE,LEXAPRO,PF-00988288,1053,CN(C)CCC[C@@]1(c2ccc(cc2CO1)C#N)c3ccc(cc3)F,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Lundbeck,pharma,ALLERGAN,major pharma,37482,2002,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.44,19,22,,10,,795652,NO,Neurological,NO,NO,,NO,NO,YES,NO,,Less,,,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,5I71,324.3919,0,3,0,3,0,5,36.26,0.35,1.31,1.201,3.132,All fragments measured,4.1,2.5,3.39,1.269,,9.57,,9,Basic,Class 2,0,1,0,0,0,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.8403,0.87116,0.97498,0.92621,0.9848,0.59178,0.91035,0.84757,0.93773,277.6,23.4,2.36,14.1
236395-14-5,ESLICARBAZEPINE ACETATE,APTIOM,PF-04798310,4303,CC(=O)O[C@H]1Cc2ccccc2N(c3c1cccc3)C(=O)N,TABLET,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Bial,pharma,SUNOVION PHARMS INC,pharma,41586,2013,Drugs@FDA,NO,YES,1,,High,Reported bioavailability,0.562,0.9,16,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,D,Less,D (possible rare cause of clinically apparent liver injury),,0,,NO,NO,NO,,296.3205,2,2,1,5,0,3,72.63,0.176470588,1.56,1.955,1.503,All fragments measured,2.3,2.3,2.24,2.242,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.95241,0.95449,0.99268,0.98843,0.9848,0.98659,0.92762,0.87038,0.93773,297.1,25.3,12,11
119141-88-7,ESOMEPRAZOLE MAGNESIUM,NEXIUM,PF-00579913,1055,Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3cc(ccc3n2)OC,"CAPSULE, DELAYED REL PELLETS; CAPSULE, DELAYED RELEASE; FOR SUSPENSION, DELAYED RELEASE; TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,20,Over-the-counter,,NO,NO,,,AstraZeneca,major pharma,ASTRAZENECA AB,major pharma,36942,2001,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.03,0.2,1.3,Prodrug,2,51,101229697,NO,Gastrointestinal,NO,NO,,NO,NO,YES,NO,Less,Less,,,B,Most,B (rare but likely cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,345.4161,1,5,1,6,0,5,77.1,0.294117647,1.95,2.15,2.565,Benzyl approx. based on a priori value,2.2,2.2,2.09,2.086,9.81,5.39,9.3,4.7,Neutral,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74398,0.72059,0.8935,0.9994,0.72615,0.98659,0.72473,0.84757,0.25672,402.8,21.1,10.1,21.2
29975-16-4,ESTAZOLAM,PROSOM,PF-01458096,1056,c1ccc(cc1)C2=NCc3nncn3-c4c2cc(cc4)Cl,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,,,ABBOTT,major pharma,33233,1990,Drugs@FDA,NO,NO,,0.96,High,Fa estimated from reported excretion data,0.07,,16,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,294.7383,0,2,0,4,0,1,43.07,0.0625,1.96,2.061,2.286,Benzyl approx. based on a priori value,2.1,2.1,2.5,2.501,,1.79,,9.1,Neutral,Class 2,0,0,0,0,1,0,0,3,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.64948,0.70925,0.99011,0.98493,0.9848,0.59178,0.97123,0.63709,0.25672,272.1,31.8,9.4,9.07
50-28-2,ESTRADIOL,ESTRANCE,PF-00344987,1057,C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CC[C@@H]2O)O,TABLET,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,27598,1975,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,115959217,NO,Genitourinary,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,3OLL,272.382,2,2,2,2,0,0,40.46,0.666666667,2.9,3.75,3.784,All fragments measured,3.7,3.7,3.62,3.617,10.27,,11,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72654,0.78854,0.91538,0.90258,0.93048,0.79222,0.95241,0.39503,0.82734,257.4,18.2,36.6,22.2
4245-41-4,ESTRADIOL ACETATE,FEMTRACE,RS-291179,4497,CC(=O)Oc1ccc2c(c1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,TABLET,YES,NO,NO,NO,ORAL,1,Discontinued,,NO,NO,,,,,APIL,pharma,14611,1940,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,314.4186,1,1,1,3,0,2,46.53,0.65,3.37,3.76,3.8,All fragments measured,4.1,4.1,3.82,3.82,,,16,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92156,0.93387,0.99467,0.90059,0.9848,0.98659,0.98835,0.87038,0.82734,299.7,15.7,95.5,38.6
4891-15-0,ESTRAMUSTINE PHOSPHATE SODIUM,EMCYT,PF-02784135,1066,C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O)OC(=O)N(CCCl)CCCl,CAPSULE,YES,NO,NO,NO,ORAL,1120,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,29944,1981,Drugs@FDA,NO,YES (Presystemic),0.75,,High,Reported bioavailability,,,20,Parent CRG,,,2540223,NO,Oncology,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,520.383,2,4,2,7,1,9,96.3,0.695652174,1.42,1.42,4.386,Calculated fragment value,5,0.35,3.55,-0.692,1.88,,2.3,,Acidic,Class 3B,0,0,0,1,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,2,0,0,0,0,NO,0.40271,0.454,0.13605,0.34073,0.52457,0.79222,0.62388,0.39983,0.82734,446.3,0.564,21.1,18
7280-37-7,ESTROPIPATE,OGEN,PF-06182625,4857,C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CCC2=O)OS(=O)(=O)O,TABLET,YES,NO,NO,NO,ORAL,9,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,28264,1977,Drugs@FDA,NO,YES,,,High,Based on textual comment,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,350.4293,1,3,1,5,0,2,80.67,0.611111111,0.795,0.795,1.822,Approximated fragment value used,1.5,-2,1.6,-1.89,,,-0.72,,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,6,0,0,0,6,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8936,0.85713,0.86789,0.95451,0.72615,0.98659,0.79532,0.87038,0.82734,307.2,2.69,33.9,22.8
138729-47-2,ESZOPICLONE,LUNESTA,PF-05182193,1068,CN1CCN(CC1)C(=O)O[C@H]2c3c(nccn3)C(=O)N2c4ccc(cn4)Cl,TABLET,YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,Sepracor (Sunovion Pharmaceuticals),pharma,SUNOVION PHARMS INC,pharma,38336,2004,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,0.48,,6,,61,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,388.8083,0,7,0,9,0,4,91.76,0.352941176,1.17,1.188,1.253,Approximated fragment value used,0.77,0.46,0.64,0.568,,6.69,,7.7,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.76611,0.69391,0.63802,0.86213,0.33223,0.59178,0.76953,0.99269,0.93773,477.8,16.9,6.32,13.5
58-54-8,ETHACRYNIC ACID,EDECRIN,PF-00344547,1071,CCC(=C)C(=O)c1ccc(c(c1Cl)Cl)OCC(=O)O,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,VALEANT,pharma,24482,1967,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.1,,2,Parent CRG,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,LiverTox Additions,0,E,None,E (unlikely causes of clinically apparent liver injury),Less,0,,NO,NO,NO,,303.138,1,4,1,4,0,6,63.6,0.230769231,0.00817,0.00817,3.445,All fragments measured,2.8,-0.46,3.38,-0.31,2.81,,3.2,,Acidic,Class 1A,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.87038,0.88472,0.99934,0.87275,0.88651,0.98659,0.97641,0.6885,0.82734,226.4,18,13,16.3
74-55-5,ETHAMBUTOL HYDROCHLORIDE,MYAMBUTOL,PF-00344710,1073,CC[C@@H](CO)NCCN[C@@H](CC)CO,TABLET,YES,NO,NO,NO,ORAL,1700,Prescription,,NO,NO,Abuse potential,,,,STI PHARMA LLC,pharma,24782,1967,Drugs@FDA,NO,NO,,0.65,High,Fa estimated from reported excretion data,0.8,2.8,,,,,8,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,204.3098,4,4,4,4,0,9,64.52,1,-1.43,-1.43,0.119,All fragments measured,-0.38,-2.5,0.15,-2.131,,9.59,15,9.4,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.34712,0.45757,0.47261,0.50622,0.88651,0.14694,0.97246,0.29329,0.47245,187,1.59,5.16,6.65
113-18-8,ETHCHLORVYNOL,PLACIDYL,PF-05236347,1078,CCC(/C=C/Cl)(C#C)O,CAPSULE,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,22411,1961,Drugs@FDA,NO,NO,,0.33,High,Fa estimated from reported excretion data,0.5,3.5,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,2,Alkyl_halide_Sulfate_ester; Alkynes,NO,NO,NO,,144.5988,1,1,1,1,0,2,20.23,0.428571429,1.76,1.927,1.571,All fragments measured,2.4,2.4,1.99,1.99,12.06,,14,,Neutral,Class 2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.57474,0.5267,0.19603,0.97968,0.23327,0.98659,0.61872,0.87038,0.47245,115.9,42.8,19,12.1
126-52-3,ETHINAMATE,VALMID,PF-01441744,1081,C#CC1(CCCCC1)OC(=O)N,CAPSULE,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,DISTA,pharma,20166,1955,Drugs@FDA,NO,NO,,0.36,High,Fa estimated from reported excretion data,,,2.5,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Alkynes,NO,NO,NO,,167.205,2,2,1,3,0,2,52.32,0.666666667,1.27,1.286,1.917,All fragments measured,1.7,1.7,1.29,1.289,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64356,0.7243,0.27724,0.99934,0.93048,0.98659,0.99986,0.87038,0.47245,124.7,31.1,7.89,14
57-63-6,ETHINYL ESTRADIOL,ESTINYL,PF-00344549,1082,C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CC[C@]2(C#C)O)O,TABLET,YES,NO,NO,NO,ORAL,0.025,Prescription,,NO,NO,,,,,SCHERING,major pharma,15882,1943,Drugs@FDA,NO,NO,0.43,,High,Reported bioavailability,0.03,,,,95,184,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,Less,1,Alkynes,NO,NO,NO,,296.4034,2,2,2,2,0,0,40.46,0.6,2.73,4.1,3.864,All fragments measured,3.5,3.5,3.87,3.873,10.24,,11,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.67918,0.73729,0.99281,0.51987,0.93048,0.79222,0.95241,0.39503,0.82734,290,23.3,73.1,33.3
536-33-4,ETHIONAMIDE,TRECATOR,PF-00344711,1083,CCc1cc(ccn1)C(=S)N,TABLET,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,WYETH,major pharma,23862,1965,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.7,1.34,1.9,,,,448208,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Thioamide,NO,NO,NO,,166.2434,2,1,1,2,0,2,38.91,0.25,0.878,1.598,1.729,All fragments measured,1.3,1.2,1.43,1.43,12.14,4.34,11,4.3,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68812,0.76237,0.27323,0.88352,0.93048,0.98659,0.93795,0.87038,0.82734,136.1,41.3,4.51,14.4
522-00-9,ETHOPROPAZINE HYDROCHLORIDE,PARSIDOL,PF-00345228,1086,CCN(CC)C(C)CN1c2ccccc2Sc3c1cccc3,TABLET,YES,NO,NO,NO,ORAL,800,Discontinued,,NO,NO,,,,,PARKE DAVIS,major pharma,19668,1953,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,312.4723,0,2,0,2,1,5,6.48,0.368421053,2.78,2.709,5.458,All fragments measured,5.1,3,5.19,2.852,,9.88,,9.4,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7489,0.77548,0.99685,0.4305,0.9848,0.59178,0.84849,0.84757,0.93773,276.8,2.53,36.7,91.5
77-67-8,ETHOSUXIMIDE,ZARONTIN,PF-00344988,1087,CCC1(CC(=O)NC1=O)C,CAPSULE,YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,,,PARKE DAVIS,major pharma,22222,1960,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.78,0.7,,,,,6101608,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,141.1677,1,2,1,3,0,1,46.17,0.714285714,-0.021,-0.021,0.395,Estimated fragment value used,0.45,0.44,0.33,0.329,9.7,,9.3,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.51358,0.61321,0.18594,0.64299,0.93048,0.98659,0.98696,0.63709,0.47245,147.6,44.6,5.96,6.65
86-35-1,ETHOTOIN,PEGANONE,PF-00344992,1088,CCN1C(=O)C(NC1=O)c2ccccc2,TABLET,YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,RECORDATI RARE,pharma,20932,1957,Drugs@FDA,NO,NO,,,NA,NA,0.588,,7.5,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Moderate,1,Hydantoin,NO,NO,NO,,204.2252,1,2,1,4,0,2,49.41,0.272727273,1.11,1.146,1.482,Valid estimate for difficult structure,1.4,1.4,1.1,1.005,8.01,,4.2,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76637,0.82003,0.47208,0.80181,0.93048,0.98659,0.99652,0.87038,0.82734,220.4,57.1,4.91,18.1
452-35-7,ETHOXZOLAMIDE,ETHAMIDE,PF-00344709,1089,CCOc1ccc2c(c1)sc(n2)S(=O)(=O)N,TABLET,YES,NO,NO,NO,ORAL,750,Discontinued,,NO,NO,,,,,ALLERGAN,major pharma,24392,1966,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.11,,,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Reactive_HeteroCycle,NO,NO,NO,3DD0,258.3173,2,4,1,5,0,3,82.28,0.222222222,1.88,2.074,2.047,All fragments measured,2,1.9,1.84,1.81,8.02,,8,2.6,Acidic,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91413,0.84038,0.83791,0.88261,0.88651,0.98659,0.49166,0.99269,0.93773,268.8,42,10.3,41.1
965-90-2,ETHYLESTRENOL,MAXIBOLIN,PF-00835111,1094,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,"ELIXIR, TABLET",YES,NO,NO,NO,ORAL,2,Discontinued,,NO,NO,,,,,ORGANON USA INC,pharma,23525,1964,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,288.4675,1,1,1,1,1,1,20.23,0.9,4,4.6,6.087,All fragments measured,5.7,5.7,5.75,5.753,,,17,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68452,0.57052,0.97622,0.47024,0.23327,0.98659,0.61872,0.63709,0.47245,270.4,6.33,70.1,58.2
297-76-7,ETHYNODIOL DIACETATE,OVULEN,PF-00345230,1095,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,TABLET,YES,NO,NO,NO,ORAL,0.5,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,24189,1966,Drugs@FDA,YES,NO,,,NA,NA,,,25,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,Gerren Additions,1,,,,Less,1,Alkynes,NO,NO,NO,,384.5085,0,2,0,4,1,4,52.6,0.75,3.61,4.52,5.134,All fragments measured,4.9,4.9,5.27,5.272,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64283,0.69307,0.66462,0.48089,0.88651,0.59178,0.99994,0.96969,0.47245,400.8,7.2,36.5,78.5
2809-21-4,ETIDRONATE DISODIUM,DIDRONEL,PF-00344622,1098,CC(O)(P(=O)(O)O)P(=O)(O)O,TABLET,YES,NO,NO,NO,ORAL,1400,Prescription,,NO,NO,,,,,APIL,pharma,28369,1977,Drugs@FDA,NO,NO,0.03,,Low,Reported bioavailability,,1.37,4,,,,,YES,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,None,None,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury)  ,Moderate,0,,NO,NO,NO,,206.0282,5,3,5,7,0,2,135.29,1,0.377,0.377,-2.543,A priori fragment value used,-2.5,-8.5,-4.08,-9.395,1.97,,1.2,,Acidic,Class 3A,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,NO,0.31458,0.29785,0.48347,0.27684,0.33223,0.05547,0.20505,0.87038,0.47245,161.8,0.515,2.73,8.99
41340-25-4,ETODOLAC,LODINE,PF-00345040,1103,CCc1cccc2c1[nH]c3c2CCOC3(CC)CC(=O)O,"CAPSULE, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1000,Prescription,,NO,NO,,,,,WYETH,major pharma,33269,1991,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.01,5.2,6,,,,212,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable rare cause clinically apparent liver injury),Moderate,0,,NO,NO,NO,,287.3535,2,3,2,4,0,4,62.32,0.470588235,1.17,0.7884,3.432,All fragments measured,2.5,0.19,3.42,0.436,4.31,,5,,Acidic,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.91981,0.93556,0.97314,0.92584,0.9848,0.79222,0.98146,0.96969,0.93773,273.5,20.4,18.9,10.2
33419-42-0,ETOPOSIDE,VEPESID,PF-00344552,1112,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@@H]3c4cc5c(cc4[C@H]([C@@H]6[C@@H]3COC6=O)c7cc(c(c(c7)OC)O)OC)OCO5)O)O,CAPSULE,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,DAVA PHARMS INC,pharma,31776,1986,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.03,0.18,7,,,,342490,NO,Oncology,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,1,BenzoDioxolane,NO,NO,NO,5GWK,588.5566,3,10,3,13,2,5,160.83,0.551724138,0.96,0.9494,0.03,All fragments measured,-0.43,-0.43,0.66,0.658,9.94,,12,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,8,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,4,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,NO,0.37155,0.25154,0.06634,0.75649,0.02416,0.37866,0.17456,0.84757,0.93773,760.1,0.812,23,36.1
269055-15-4,ETRAVIRINE,INTELENCE,PF-01281634,1115,Cc1cc(cc(c1Oc2c(c(nc(n2)Nc3ccc(cc3)C#N)N)Br)C)C#N,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,JANSSEN PHARMS,major pharma,39465,2008,Drugs@FDA,NO,NO,,,NA,NA,,,9,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,435.2767,3,5,2,7,1,4,120.64,0.1,4.25,5.19,5.224,All fragments measured,5.5,5.5,4.05,4.055,,,,2.9,Neutral,Class 4,0,0,0,0,0,1,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.48645,0.44174,0.38392,0.27502,0.33223,0.79222,0.47442,0.96969,0.25672,343.8,1.53,53.3,36.6
54350-48-0,ETRETINATE,TEGISON,PF-01450218,1116,CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/c1c(cc(c(c1C)C)OC)C,CAPSULE,YES,NO,NO,NO,ORAL,105,Discontinued,1992,YES,YES,High risk of birth defects,FederalRegister,,,HOFFMANN LA ROCHE,major pharma,31685,1986,Drugs@FDA,NO,YES,0.4,,High,Reported bioavailability,0.01,1.5,2880,,,,,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,YES,,,Suzuki Additions,1,B,Most,B (highly likely cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,,354.4825,0,2,0,3,1,8,35.53,0.347826087,4.44,6.15,6.82,All fragments measured,7.2,7.2,6.14,6.143,,,,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.4846,0.55271,0.84593,0.10718,0.9848,0.59178,0.90148,0.39983,0.82734,234,5.57,38,67.4
159351-69-6,EVEROLIMUS,AFINITOR,CAT-774569,1118,C[C@@H]1CC[C@H]2C[C@@H](/C(=C\C=C\C=C[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC,"TABLET, TABLET, FOR SUSPENSION",YES,NO,NO,YES,ORAL,2,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,39902,2009,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,0.26,1.5,30,,,78,,YES,"Autoimmune Disease, Oncology",YES,YES,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven and also unlikely cause of clinically apparent liver injury but capable of inducing reactivation of hepatitis B),Less,0,,NO,NO,NO,,958.2244,3,13,3,15,3,9,204.66,0.754716981,3.03,6.61,7.103,A priori fragment value used,5.7,4.9,4.25,4.245,10.4,,9,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,1,0,4,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,YES,0.15787,0.11057,0.02697,0.11783,0.02183,0.37866,0.05548,0.29329,0.47245,1031,0.327,22.7,68.5
107868-30-4,EXEMESTANE,AROMASIN,PF-00835121,1122,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,36454,1999,Drugs@FDA,NO,NO,0.42,,High,Reported bioavailability,0.1,,8.9,Suicide,,,161203388,YES,Oncology,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,0,,NO,NO,NO,3S7S,296.4034,0,2,0,2,0,0,34.14,0.6,3.06,2.56,3.278,All fragments measured,2.7,2.7,3.01,3.008,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64006,0.70343,0.99281,0.94563,0.93048,0.59178,0.88329,0.39503,0.47245,273.4,21.8,76.6,32.3
163222-33-1,EZETIMIBE,ZETIA,PF-00835592,1125,c1cc(ccc1[C@@H]2[C@H](C(=O)N2c3ccc(cc3)F)CC[C@@H](c4ccc(cc4)F)O)O,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,37554,2002,Drugs@FDA,NO,NO,,0.3,Moderate,Fa estimated from reported excretion data,0.1,0.7,22,,32,36,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,2,Aniline; Beta_Lactams,YES,NO,NO,,409.4252,2,3,2,4,0,6,60.77,0.208333333,3.27,4.37,3.958,Valid estimate for difficult structure,3.8,3.8,3.68,3.674,9.72,,10,,Neutral,Class 2,0,2,0,0,0,0,0,3,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.56682,0.64096,0.51587,0.63308,0.9848,0.79222,0.98686,0.6885,0.25672,373.8,11.1,54.8,81.3
150812-12-7,EZOGABINE,POTIGA,PF-02543547,4181,CCOC(=O)Nc1ccc(cc1N)NCc2ccc(cc2)F,TABLET,YES,NO,NO,NO,ORAL,1200,Discontinued,,NO,NO,,,Asta Medica,pharma,GLAXOSMITHKLINE,major pharma,40704,2011,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.12,2.5,9,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,303.3314,4,1,3,5,0,6,76.38,0.1875,2.47,2.985,2.003,All fragments measured,3.1,3.1,2.25,2.084,,4.78,9.6,4.5,Neutral,Class 2,0,1,0,0,0,0,0,2,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.74395,0.7919,0.99942,0.99997,0.88651,0.37866,0.90164,0.6885,0.93773,266.5,22.5,7.99,8.68
104227-87-4,FAMCICLOVIR,FAMVIR,PF-00345684,1128,CC(=O)OCC(CCn1cnc2c1nc(nc2)N)COC(=O)C,TABLET,YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,34514,1994,Drugs@FDA,NO,YES,0.77,,High,Reported bioavailability,0.8,1.08,2.3,,172,,469480,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,321.3318,2,5,1,9,0,9,122.22,0.5,0.739,0.739,0.085,All fragments measured,0.26,0.26,0.26,0.254,,4,,4.5,Neutral,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62022,0.50993,0.98249,0.38321,0.19128,0.98659,0.45879,0.29329,0.93773,319.8,4.15,44.4,17.2
76824-35-6,FAMOTIDINE,PEPCID,PF-00344625,1129,c1c(nc(s1)NC(=N)N)CSCCC(=N)NS(=O)(=O)N,"FOR SUSPENSION, TABLET, TABLET, CHEWABLE, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,40,Over-the-counter,,NO,NO,,,,,VALEANT,pharma,31700,1986,Drugs@FDA,NO,NO,0.43,,High,Reported bioavailability,0.8,1.5,2.5,,,,734650,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,1,Aminothiazole,NO,NO,NO,,337.4454,8,7,6,9,1,9,170.83,0.375,-1.33,-1.33,-1.167,Calculated fragment value,-0.63,-0.73,-0.76,-2.952,7.51,11.32,9.9,6.9,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.29413,0.20677,0.92988,0.15945,0.19128,0.05547,0.03105,0.39983,0.82734,305.7,0.456,2.1,14
144060-53-7,FEBUXOSTAT,ULORIC,PF-01214528,1137,Cc1c(sc(n1)c2ccc(c(c2)C#N)OCC(C)C)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Teijin Pharma ,pharma,TAKEDA PHARMS USA,major pharma,39857,2009,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.01,0.7,7,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,1N5X,316.3748,1,5,1,5,0,5,83.21,0.3125,0.768,1.205,4.097,All fragments measured,4.5,1.2,3.83,0.704,,2.48,3.5,0.72,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92905,0.84569,0.99191,0.96439,0.72615,0.98659,0.56799,0.84757,0.93773,283.1,5.91,4.19,7.62
1374744-69-0,FEDRATINIB HYDROCHLORIDE,INREBIC,PF-04997004,,O=S(C1=CC=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O,CAPSULE,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,TargeGen,pharma,CELGENE,major pharma,43693,2019,Drugs@FDA,NO,NO,,0.59,High,Fa estimated from reported excretion data,0.08,25.3,114,,,,,YES,Oncology,NO,YES,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,524.67938,3,6,3,9,2,10,108.48,0.407,3.13,2.782,6.545,All fragments measured,6.5,5.1,4.26,2.048,10.98,9.66,9.3,8.6,Basic,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,NO,0.23124,0.25868,0.12937,0.41555,0.19128,0.37866,0.51227,0.15134,0.25672,479.8,0.761,36.9,59.5
25451-15-4,FELBAMATE,FELBATOL,PF-00345502,1140,c1ccc(cc1)C(COC(=O)N)COC(=O)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,3600,Prescription,,NO,NO,"Aplastic anemia, liver failure (reinstated, limited use allowed)",,,,MYLAN PHARMS INC,pharma,34179,1993,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.52,0.76,18,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,238.2399,4,4,2,6,0,7,104.64,0.272727273,0.52,0.52,0.497,All fragments measured,0.69,0.69,1.04,1.041,12.99,,14,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70768,0.72693,0.70408,0.76941,0.88651,0.79222,0.63913,0.53315,0.82734,195.7,6.39,6.2,6.8
72509-76-3,FELODIPINE,PLENDIL,PF-00346433,1142,CCOC(=O)C1=C(NC(=C(C1c2cccc(c2Cl)Cl)C(=O)OC)C)C,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,10,Prescription,,NO,NO,,,,,ASTRAZENECA AB,major pharma,33444,1991,Drugs@FDA,NO,NO,0.16,0.62,Moderate,Reported bioavailability,0.01,10,11,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,YES,Less,Less,DILIRank,1,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,384.2538,1,3,1,5,1,6,64.63,0.333333333,3.99,4.56,5.297,Estimated fragment value used,4.2,4.2,4.86,4.863,,2.73,,1.4,Neutral,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,2,NO,0.80363,0.82131,0.6662,0.95396,0.72615,0.98659,0.97197,0.6885,0.82734,312.6,14.8,40.3,225
404-82-0,FENFLURAMINE HYDROCHLORIDE,PONDIMIN,PF-00344551,1150,CCNC(C)Cc1cccc(c1)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,30,Discontinued,1997,YES,YES,Valvular heart disease,FederalRegister,,,WYETH,major pharma,26829,1973,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,YES,YES,NO,,,,,,,,,0,,NO,NO,NO,,231.2573,1,1,1,1,0,4,12.03,0.5,1.42,1.299,3.3,All fragments measured,3.5,1.4,3.34,0.691,,10.23,,9.5,Basic,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.81156,0.64145,0.65493,0.97619,0.23327,0.98659,0.43308,0.84757,0.82734,163.8,25.3,6.1,7.65
49562-28-9,FENOFIBRATE,LIPIDIL,PF-00345505,1152,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,130,Prescription,,NO,NO,,,,,ABBVIE,major pharma,34334,1993,Drugs@FDA,NO,YES,0.6,,High,Reported bioavailability,0.01,0.9,20,,40,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,B,Most,B (very likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,360.8313,0,3,0,4,1,7,52.6,0.3,3.38,5.26,5.233,All fragments measured,5.1,5.1,5.01,5.01,,,,,Neutral,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.64478,0.70818,0.8097,0.42065,0.88651,0.59178,0.99994,0.53315,0.93773,248.3,1.43,40.2,61
29679-58-1,FENOPROFEN CALCIUM,NALFON,PF-00345124,1154,CC(c1cccc(c1)Oc2ccccc2)C(=O)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,3200,Prescription,,NO,NO,,,,,XSPIRE PHARMA,pharma,27835,1976,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.01,,3,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,242.2699,1,2,1,3,0,4,46.53,0.133333333,0.698,0.698,3.821,All fragments measured,3.2,0.57,3.19,0.099,4.2,,4.5,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.90822,0.9324,0.73217,0.95827,0.9848,0.98659,0.98835,0.96969,0.93773,187.1,24.1,21.8,21.5
437-38-7,FENTANYL CITRATE,FENTANYL,PF-00345423,1164,CCC(=O)N(c1ccccc1)C2CCN(CC2)CCc3ccccc3,TROCHE/LOZENGE,YES,NO,NO,NO,ORAL,0.8,Discontinued,,NO,NO,Abuse potential,,,,CEPHALON,pharma,34246,1993,Drugs@FDA,NO,NO,0.65,0.85,High,Reported bioavailability,0.15,5,,,,,51317421,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,NO,YES,NO,NO,,Less,LiverTox Additions,0,E,None,E (all four are unlikely cases of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,336.4705,0,2,0,3,0,7,23.55,0.409090909,2.38,2.801,3.621,All fragments measured,4.1,3,4.09,3.011,,8.92,,8.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.787,0.79881,0.93392,0.90258,0.93048,0.59178,0.69255,0.6885,0.93773,247.1,17.7,48.8,58.1
286930-02-7,FESOTERODINE FUMARATE,TOVIAZ,PF-00695838,4191,CC(C)C(=O)Oc1ccc(cc1[C@H](CCN(C(C)C)C(C)C)c2ccccc2)CO,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,8,Prescription,,NO,NO,,,Schwarz Pharma ,pharma,PFIZER,major pharma,39752,2008,Drugs@FDA,NO,YES,0.52,,High,Reported bioavailability,0.5,2.4,5.5,,,,399349896,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,None,None,LiverTox Additions,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,411.5769,1,2,1,4,0,11,49.77,0.5,1.89,2.193,4.357,All fragments measured,4.8,1.9,5.12,1.904,,10.6,14,9.7,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.43935,0.53833,0.50386,0.21009,0.88651,0.98659,0.99719,0.15134,0.93773,275.4,6.9,36.2,158
83799-24-0,FEXOFENADINE HYDROCHLORIDE,ALLEGRA,PF-00345624,1170,CC(C)(c1ccc(cc1)C(CCCN2CCC(CC2)C(c3ccccc3)(c4ccccc4)O)O)C(=O)O,"CAPSULE, SUSPENSION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,120,Over-the-counter,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35271,1996,Drugs@FDA,NO,NO,0.33,,High,Reported bioavailability,0.35,5.4,14.4,,103,,2186492,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,501.6564,3,5,3,5,1,10,81,0.40625,1.36,0.3166,1.957,All fragments measured,4.8,2,4.93,2.427,4.43,9.42,4.7,9,Zwitter,Class 3B,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31316,0.41715,0.17026,0.99705,0.72615,0.37866,0.86585,0.21184,0.25672,337.7,1.68,2.32,12.2
98319-26-7,FINASTERIDE,PROSCAR,PF-00346437,1171,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,TABLET,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,,,MERCK,major pharma,33774,1992,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,0.1,1.1,4.5,Suicide,173,,27515767,NO,"Autoimmune Disease, Genitourinary",YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,,372.5441,2,2,2,4,0,1,58.2,0.826086957,3.36,3.71,3.013,Estimated fragment value used,3.2,3.2,3.01,3.015,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76374,0.8057,0.73895,0.99001,0.93048,0.79222,0.99393,0.87038,0.47245,382.3,16.2,4.7,9.74
162359-55-9,FINGOLIMOD HYDROCHLORIDE,GILENYA,PF-01945559,4167,CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N,CAPSULE,YES,NO,NO,NO,ORAL,0.5,Prescription,,NO,NO,,,Mitsubishi Tanabe Pharma,pharma,NOVARTIS,major pharma,40442,2010,Drugs@FDA,NO,YES,0.93,,High,Reported bioavailability,0.003,17.1,136,,,26,,NO,Autoimmune Disease,NO,NO,,NO,YES,NO,NO,,,,,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury),,1,1_4_Diketones,NO,NO,NO,,307.4708,4,3,3,3,1,12,66.48,0.684210526,2.15,2.829,5.058,All fragments measured,3.7,2.6,4.62,2.17,12.2,8.71,13,8.4,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47068,0.59242,0.99984,0.80329,0.9848,0.37866,0.96322,0.10729,0.82734,163.7,3.63,37.7,30.5
15301-69-6,FLAVOXATE HYDROCHLORIDE,URISPAS,PF-00345507,1175,Cc1c(=O)c2cccc(c2oc1c3ccccc3)C(=O)OCCN4CCCCC4,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,ORTHO MCNEIL JANSSEN,major pharma,25583,1970,Drugs@FDA,NO,NO,,0.57,High,Fa estimated from reported excretion data,,,,,,,,NO,Genitourinary,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,391.4596,0,3,0,5,0,6,59.75,0.333333333,2.1,2.782,4.97,All fragments measured,5.4,4.4,4.69,3.832,,8.2,,8.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69224,0.73797,0.62174,0.69228,0.72615,0.59178,0.99815,0.6885,0.93773,317.4,12.7,44,124
54143-55-4,FLECAINIDE ACETATE,TAMBOCOR,PF-00344553,1176,c1cc(c(cc1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,CNTY LINE PHARMS,pharma,31351,1985,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.6,7.5,7,,,,2521192,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,414.3427,2,4,2,5,0,7,59.59,0.588235294,1.33,0.9582,3.66,Benzyl approx. based on a priori value,3.1,1.6,3.14,1.063,,9.69,15,9.2,Basic,Class 2,0,6,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.59691,0.69518,0.48869,0.95128,0.88651,0.79222,0.99041,0.29329,0.82734,354.6,7.27,6.12,8.46
167933-07-5,FLIBANSERIN,ADDYI,PF-00797664,5022,c1ccc2c(c1)[nH]c(=O)n2CCN3CCN(CC3)c4cccc(c4)C(F)(F)F,TABLET,YES,NO,NO,YES,ORAL,100,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,SPROUT PHARMS,pharma,42234,2015,Drugs@FDA,NO,NO,0.33,,High,Reported bioavailability,0.02,,11,,,,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,390.4021,1,2,1,5,0,4,44.27,0.35,3.81,4.6,4.733,All fragments measured,3.7,3.6,3.5,3.443,12.12,7.66,10,6.4,Basic,Class 2,0,3,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.84963,0.88641,0.62822,0.94517,0.9848,0.98659,0.93778,0.84757,0.93773,357.4,8.53,20.9,50.4
76568-02-0,FLOSEQUINAN,MANOPLAX,PNU-0084911,1182,Cn1cc(c(=O)c2c1cc(cc2)F)S(=O)C,N/A,N/A,N/A,N/A,NO,ORAL,150,Discontinued,1993,YES,YES,Increased mortality ,FederalRegister,,,ABBOTT,major pharma,33968,1992,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,239.266,0,2,0,3,0,1,39.07,0.181818182,0.174,0.174,-0.753,All fragments measured,-2.1,-2.1,0.92,0.92,,,,-1.3,Neutral,Class 2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.71009,0.78292,0.71126,0.82772,0.9848,0.59178,0.99706,0.63709,0.82734,230.8,28.4,12,6.65
86386-73-4,FLUCONAZOLE,DIFLUCAN,PF-00345508,1187,c1cc(c(cc1F)F)C(Cn2cncn2)(Cn3cncn3)O,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,PFIZER,major pharma,32902,1990,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.89,0.75,30,,,,183356013,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,1,Imidazole_Triazole,NO,NO,NO,5ESM,306.2708,1,3,1,7,0,5,81.65,0.230769231,0.705,0.4822,-0.44,All fragments measured,0.19,0.19,0.7,0.698,11.01,3.32,14,2.7,Neutral,Class 2,0,2,0,0,0,0,0,3,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.7252,0.71396,0.99999,0.70495,0.72615,0.98659,0.86051,0.84757,0.25672,312.7,4.04,5.88,8.78
2022-85-7,FLUCYTOSINE,ANCOBON,PF-00344715,1188,c1c(c([nH]c(=O)n1)N)F,CAPSULE,YES,NO,NO,NO,ORAL,10500,Prescription,,NO,NO,,,,,VALEANT,pharma,26263,1971,Drugs@FDA,NO,NO,0.84,,High,Reported bioavailability,0.96,0.68,5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury.,Moderate,0,,NO,NO,NO,,129.0925,3,2,2,4,0,0,71.77,0,-0.776,-0.776,-1.635,All fragments measured,-2,-2,-1.71,-2.451,6.72,2.9,10,2.4,Neutral,Class 4,0,1,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.35562,0.46089,0.15456,0.20486,0.9848,0.79222,0.95814,0.39503,0.47245,144.7,6.96,2.44,9.51
75607-67-9,FLUDARABINE PHOSPHATE,OFORTA,PF-06700528,1189,c1nc2c(nc(nc2n1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,TABLET,YES,NO,NO,NO,ORAL,,Discontinued,2011,YES,NO,Neutropenia and thrombocytopenia. Low commercial demand.,Micromedex,Southern Research Institute,nonprofit,SANOFI AVENTIS US,major pharma,39800,2008,Drugs@FDA,NO,YES,0.5,,High,Reported bioavailability,0.76,,20,,,,338294,YES,Oncology,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (Unproven but suspected cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,365.2117,6,8,5,12,2,4,186.07,0.5,-1.23,-1.23,-3.073,Calculated fragment value,-1.9,-6.3,-2.35,-6.615,1.86,1.3,1.4,3.1,Acidic,Class 3A,0,1,0,1,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,NO,0.34443,0.20703,0.7837,0.15163,0.03975,0.05547,0.06843,0.96969,0.93773,500.1,0.685,2.82,6.73
514-36-3,FLUDROCORTISONE ACETATE,FLORINEF,PF-00345234,1191,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,TABLET,YES,NO,NO,NO,ORAL,0.2,Prescription,,NO,NO,,,,,CASPER PHARMA LLC,pharma,20319,1955,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.58,,3.5,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,1GS4,422.487,2,5,2,6,0,4,100.9,0.782608696,1.77,1.978,2.267,Valid estimate for difficult structure,1.8,1.8,2.25,2.245,12.06,,12,,Neutral,Class 2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.6803,0.65821,0.44574,0.93033,0.52457,0.79222,0.67796,0.96969,0.47245,481,17.4,19.5,27
54910-89-3,FLUOXETINE HYDROCHLORIDE,PROZAC,PF-00344556,1209,CNCCC(c1ccccc1)Oc2ccc(cc2)C(F)(F)F,"CAPSULE; CAPSULE, DELAYED RELEASE",YES,YES,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,ELI LILLY AND CO,major pharma,32140,1987,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.055,58.6,96,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,309.3261,1,2,1,2,0,6,21.26,0.294117647,2,2,4.566,Benzyl approx. based on a priori value,4.3,2,4.27,1.71,,10.05,,9.6,Basic,Class 4,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.83059,0.82099,0.99917,0.8539,0.93048,0.98659,0.64201,0.53315,0.93773,218.4,3.45,7.93,23
76-43-7,FLUOXYMESTERONE,HALOTESTIN,PF-00346547,1210,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@]4(C)O)C)O)F,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,20743,1956,Drugs@FDA,NO,NO,0.44,,High,Reported bioavailability,0.01,,9.2,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,,,,None,0,,NO,NO,NO,,336.4409,2,3,2,3,0,0,57.53,0.85,2.18,2.357,2.844,Valid estimate for difficult structure,2.4,2.4,2.7,2.696,,,14,,Neutral,Class 2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.67831,0.75127,0.93404,0.99784,0.9848,0.79222,0.99536,0.39503,0.47245,392.3,31.2,23,29.2
69-23-8,FLUPHENAZINE HYDROCHLORIDE,PERMITIL,PF-00345041,1212,c1ccc2c(c1)N(c3cc(ccc3S2)C(F)(F)F)CCCN4CCN(CC4)CCO,"CONCENTRATE, ELIXIR, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,10,Prescription,,NO,NO,,,,,SCHERING,major pharma,21802,1959,Drugs@FDA,NO,NO,0.027,,Low,Reported bioavailability,,463,12.2,,,,,NO,Neurological,NO,NO,,NO,YES,NO,YES,Ambiguous,Ambiguous,DILIRank,0,C,Less,C (probable cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,437.5215,1,4,1,4,0,6,29.95,0.454545455,3.29,4.3,4.118,All fragments measured,4.5,3.9,4.46,4.115,,7.39,14,8.2,Basic,Class 4,0,3,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.65273,0.71527,0.3738,0.71624,0.72615,0.98659,0.99884,0.53315,0.93773,367.2,1.62,38,53.7
53-34-9,FLUPREDNISOLONE,ALPHADROL,RS-292564,1216,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)C[C@@H](C4=CC(=O)C=C[C@]34C)F)O,TABLET,YES,NO,NO,NO,ORAL,15,Discontinued,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,22087,1960,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,378.4345,3,5,3,5,0,2,94.83,0.714285714,1.53,1.631,1.466,All fragments measured,1.5,1.5,1.43,1.43,12.31,,11,,Neutral,Class 2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.62131,0.64586,0.7024,0.79817,0.72615,0.37866,0.73951,0.87038,0.47245,435.5,7.13,5.03,7.71
17617-23-1,FLURAZEPAM HYDROCHLORIDE,DALMANE,PF-00344628,1218,CCN(CC)CCN1c2ccc(cc2C(=NCC1=O)c3ccccc3F)Cl,CAPSULE,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,VALEANT,pharma,25665,1970,Drugs@FDA,NO,NO,,,NA,NA,0.028,,2.3,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (Possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,387.8782,0,2,0,4,0,6,35.91,0.333333333,1.92,2.449,4.215,All fragments measured,3.8,3,3.55,1.2,,9.79,,8.1,Basic,Class 2,0,1,0,0,1,0,0,2,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,NO,0.71545,0.77972,0.64375,0.79827,0.9848,0.59178,0.90616,0.6885,0.93773,343.3,15.2,17.7,30.7
5104-49-4,FLURBIPROFEN,ANSAID,PF-00344626,1219,CC(c1ccc(c(c1)F)c2ccccc2)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,32447,1988,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,0.01,0.12,4.7,,,,8507504,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,5JVZ,244.2609,1,2,1,2,0,3,37.3,0.133333333,0.834,0.9516,3.754,All fragments measured,3.6,0.59,3.82,0.683,4.14,,4.2,,Acidic,Class 1A,0,1,0,0,0,0,0,2,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.91081,0.91782,0.7459,0.93355,0.93048,0.98659,0.92207,0.99269,0.93773,175.2,30.3,30.4,49.3
13311-84-7,FLUTAMIDE,EULEXIN,PF-00344885,1223,CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)N(=O)=O,CAPSULE,YES,NO,NO,NO,ORAL,750,Prescription,,NO,NO,,,,,SCHERING,major pharma,32535,1989,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.05,,7.8,,,,3295998,NO,Oncology,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,A,Most,A (well know cause of clinically apparent liver injury),Less,2,Aniline; Nitroorganics,YES,NO,NO,,276.2118,1,3,1,5,0,3,74.92,0.363636364,3.36,3.27,3.335,All fragments measured,3,3,3.14,3.14,,,12,,Neutral,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.94383,0.94293,0.9329,0.99923,0.9848,0.98659,0.9121,0.96969,0.82734,233.2,57.5,19.6,22.8
93957-54-1,FLUVASTATIN SODIUM,LESCOL,PF-04960204,1229,CC(C)n1c2ccccc2c(c1/C=C/[C@@H](C[C@@H](CC(=O)O)O)O)c3ccc(cc3)F,"CAPSULE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,80,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,34334,1993,Drugs@FDA,NO,NO,0.24,0.95,Moderate,Reported bioavailability,0.02,0.42,,,151,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,1HWI,411.4659,3,4,3,5,0,8,82.69,0.291666667,1.37,1.413,4.048,All fragments measured,2.9,-0.21,3.65,0.531,4.27,,4.2,,Acidic,Class 1B,0,1,0,0,0,0,0,3,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.44302,0.52945,0.50448,0.78766,0.88651,0.37866,0.85183,0.39983,0.25672,359.8,5.45,8.61,14.9
54739-18-3,FLUVOXAMINE MALEATE,LUVOX,PF-00346380,1230,COCCCC/C(=N/OCCN)/c1ccc(cc1)C(F)(F)F,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,300,Prescription,,NO,NO,,,,,SOLVAY,pharma,34673,1994,Drugs@FDA,NO,NO,0.53,,High,Reported bioavailability,0.2,25,15.6,,,,550473,NO,Neurological,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,6AWP,318.3346,2,2,1,4,0,9,56.84,0.533333333,1.51,1.581,3.321,Valid estimate for difficult structure,3.1,1.6,3.04,1.166,,9.39,,9.4,Basic,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,NO,0.68493,0.76283,0.9886,0.99527,0.88651,0.98659,0.99665,0.21184,0.82734,223.5,6.38,4.11,18.2
59-30-3,FOLIC ACID,FOLIC ACID,PF-00345729,1231,c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2c[nH]c-3nc(nc(=O)c3n2)N,TABLET,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,,,ELI LILLY AND CO,major pharma,17320,1947,Drugs@FDA,NO,NO,0.76,,High,Reported bioavailability,,,,,,,9964119,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of liver injury),Less,1,Aniline,YES,NO,NO,,441.3975,7,9,6,13,2,9,213.28,0.210526316,-1.89,-1.89,-2.042,Valid estimate for difficult structure,-0.54,-6.3,-1.54,-6.276,3.59,1.79,3.5,4.4,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.21366,0.14477,0.35685,0.40121,0.02915,0.02306,0.05033,0.29329,0.93773,480.4,0.257,2.04,6.89
226700-79-4,FOSAMPRENAVIR CALCIUM,LEXIVA,VC-001215217,1240,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)c3ccc(cc3)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,2800,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,VIIV HLTHCARE,pharma,37914,2003,Drugs@FDA,NO,YES (Presystemic),,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,585.6068,5,4,4,12,2,14,177.72,0.48,-0.697,-0.697,3.036,Calculated fragment value,2.5,-2,2.09,-2.196,1.77,1.67,0.14,1.6,Acidic,Class 3B,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,NO,0.17435,0.15431,0.06814,0.98595,0.06191,0.14694,0.06838,0.05315,0.93773,569.4,1,22.2,20.6
23155-02-4,FOSFOMYCIN TROMETHAMINE,MONUROL,PF-00345504,1243,C[C@H]1[C@H](O1)P(=O)(O)O,FOR SOLUTION,YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,ZAMBON SPA,pharma,35418,1996,Drugs@FDA,NO,NO,0.37,,High,Reported bioavailability,1,1.9,5.7,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),,1,Epoxide,NO,NO,NO,,138.059,2,2,2,4,0,1,70.06,1,-0.0159,-0.0159,-0.228,A priori fragment value used,-0.62,-5.6,-2.18,-5.996,3.2,,0.23,,Acidic,Class 3A,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,NO,0.44559,0.53368,0.17726,0.37607,0.88651,0.79222,0.87496,0.63709,0.47245,183.2,1.39,1.66,9.73
98048-97-6,FOSINOPRIL SODIUM,MONOPRIL,PF-06242283,1245,CCC(=O)O[C@H](C(C)C)OP(=O)(CCCCc1ccccc1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,33374,1991,Drugs@FDA,NO,YES,0.36,,High,Reported bioavailability,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,563.6625,1,5,1,8,2,16,110.21,0.7,2.03,2.03,7.445,Very high LogP unrealistic in nature,5.7,2.5,5.46,1.921,3.38,,4,,Acidic,Class 3B,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,NO,0.21068,0.2676,0.08428,0.24017,0.33223,0.98659,0.48047,0.03725,0.82734,549.7,2.3,83.9,20.9
1025687-58-4,FOSTAMATINIB DISODIUM,TAVALISSE,PF-05240706,,CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Rigel,pharma,RIGEL PHARMS INC,pharma,43207,2018,Drugs@FDA,NO,YES (Presystemic),,,NA,NA,,,,,,,,YES,Cardiovascular,NO,YES,I,NO,NO,NO,NO,,None,,,E*,Ambiguous,E* (suspected but unproven cause of idiosyncratic clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,3FQS,580.4595,4,10,4,15,2,10,186.72,0.304347826,-0.0959,-0.0959,2.524,Calculated fragment value,3.9,-0.15,1.19,-3.094,1.7,2.99,0.95,5.5,Acidic,Class 3B,0,1,0,1,0,0,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,NO,0.18939,0.13485,0.07147,0.96557,0.02183,0.14694,0.06735,0.21184,0.25672,594.9,0.185,5.76,25.9
158747-02-5,FROVATRIPTAN SUCCINATE,FROVA,PF-06731050,1251,CN[C@@H]1CCc2c(c3cc(ccc3[nH]2)C(=O)N)C1,TABLET,YES,NO,NO,NO,ORAL,7.5,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,ENDO PHARMS,pharma,37203,2001,Drugs@FDA,NO,NO,0.26,0.4,Moderate,Reported bioavailability,0.85,3.6,26,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,243.3043,4,2,3,4,0,2,70.91,0.357142857,-0.104,-0.104,0.718,All fragments measured,1.3,-0.89,1.32,-1.536,,10.38,11,11,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60119,0.69537,0.73931,0.9657,0.9848,0.14694,0.93232,0.87038,0.93773,244.9,5.31,4.44,8.14
67-45-8,FURAZOLIDONE,FUROXONE,PF-00344713,1257,c1cc(oc1/C=N/N2CCOC2=O)N(=O)=O,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,400,Discontinued,1986,YES,NO,Mutagens or carcinogen,PharmaCircle,,,SHIRE,major pharma,21205,1958,Drugs@FDA,NO,NO,,0.65,High,Fa estimated from reported excretion data,,,,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,Gerren Additions,1,,,,,2,Furan; Nitroorganics,NO,NO,NO,,225.1583,0,3,0,8,0,3,100.86,0.25,0.181,0.181,-0.038,Valid estimate for difficult structure,0.13,0.13,0.43,0.429,,,,2.7,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74295,0.73606,0.61208,0.79866,0.72615,0.59178,0.67848,0.99269,0.82734,274.8,16.5,8.27,10.3
54-31-9,FUROSEMIDE,LASIX,PF-00344554,1258,c1cc(oc1)CNc2cc(c(cc2C(=O)O)S(=O)(=O)N)Cl,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,24289,1966,Drugs@FDA,NO,NO,0.64,,High,Reported bioavailability,0.01,0.2,,,,,18435333,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,2,Aniline; Furan,YES,NO,NO,,330.7441,4,4,3,7,0,5,122.63,0.083333333,-0.591,-0.7695,1.9,All fragments measured,1.8,-1.2,2.35,-0.776,3.04,,3.7,-0.88,Acidic,Class 3A,0,0,0,0,1,0,0,2,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.73814,0.68129,0.95553,0.86551,0.72615,0.37866,0.37694,0.84757,0.93773,313.6,0.972,2.96,10.5
60142-96-3,GABAPENTIN,NEURONTIN,PF-00345043,1264,C1CCC(CC1)(CC(=O)O)CN,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,3600,Prescription,,NO,NO,,,,,PFIZER,major pharma,34333,1993,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,1,0.71,6,,,,337944053,YES,"Musculoskeletal/Pain, Neurological",NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,171.2368,3,3,2,3,0,3,63.32,0.888888889,-0.824,-0.1172,-0.66,All fragments measured,0.55,-1.7,1.1,-1.416,4.72,10.27,4,10,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47274,0.54664,0.29464,0.13838,0.9848,0.79222,0.9776,0.99269,0.47245,97.98,2.98,4.67,7.27
357-70-0,GALANTAMINE HYDROBROMIDE,RAZADYNE,PF-00345731,1272,CN1CC[C@@]23C=C[C@@H](C[C@@H]2Oc4c3c(ccc4OC)C1)O,"CAPSULE, EXTENDED RELEASE, SOLUTION, TABLET",YES,NO,YES,NO,ORAL,24,Prescription,,NO,NO,,,Sanochemia (Johnson & Johnson),pharma,JANSSEN PHARMS,major pharma,36950,2001,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.82,2.3,7,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinicallyapparent liver injury),Moderate,0,,NO,NO,NO,4EY6,287.3535,1,4,1,4,0,1,41.93,0.529411765,0.561,0.1298,1.025,All fragments measured,1.8,0.45,1.55,0.917,,7.92,15,8.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8505,0.87006,0.97314,0.87307,0.88651,0.98659,0.96367,0.63709,0.82734,320,32.8,2.13,12.6
82410-32-0,GANCICLOVIR,CYTOVENE,PF-00346566,1277,c1nc2c(=O)[nH]c(nc2n1COC(CO)CO)N,CAPSULE,YES,NO,NO,NO,ORAL,2000,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,34690,1994,Drugs@FDA,NO,NO,0.05,,Low,Reported bioavailability,0.99,0.74,4.8,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury) ,Moderate,0,,NO,NO,NO,1KI2,255.2306,5,6,4,9,0,5,139.28,0.444444444,-1.24,-0.2,-2.545,All fragments measured,-2.6,-2.6,-1.72,-1.726,9.32,2.53,8.8,1.6,Neutral,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.40163,0.36715,0.81866,0.0936,0.33223,0.14694,0.34287,0.84757,0.82734,283.2,0.539,1.77,6.65
112811-59-3,GATIFLOXACIN,TEQUIN,PF-00579952,1280,CC1CN(CCN1)c2c(cc3c(c2OC)n(cc(c3=O)C(=O)O)C4CC4)F,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,2006,YES,YES,Dysglycemia,FederalRegister,,,BRISTOL MYERS SQUIBB,major pharma,36161,1999,NIH NCATS,NO,NO,0.96,,High,Reported bioavailability,0.8,1.7,10,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Less,,,,,,Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,5BTD,375.3941,2,5,2,7,0,4,83.8,0.473684211,-0.627,-1.181,-0.266,All fragments measured,2.1,-0.65,0.19,-2.252,5.98,8.72,6.2,8.6,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.66626,0.60657,0.72131,0.23154,0.33223,0.79222,0.85669,0.96969,0.82734,400.5,1.79,3.01,8.53
184475-35-2,GEFITINIB,IRESSA,PF-01514191,1282,COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F,TABLET,YES,NO,NO,NO,ORAL,250,Prescription,,NO,NO,,,AstraZeneca,major pharma,ASTRAZENECA AB,major pharma,37746,2003,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.1,20,48,,,,11663,YES,Oncology,NO,YES,I,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liverinjury),Moderate,1,Aniline,YES,NO,NO,4I22,446.9024,1,4,1,7,1,8,68.74,0.363636364,3.33,3.9,5.602,All fragments measured,4.3,3.9,3.7,3.662,,7,,7.6,Basic,Class 4,0,1,0,0,1,0,0,3,1,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,0,1,0,0,NO,0.4864,0.50662,0.33389,0.80162,0.33223,0.98659,0.95124,0.39983,0.25672,419.4,5.61,15.9,74.5
25812-30-0,GEMFIBROZIL,LOPID,PF-00344631,1285,Cc1ccc(c(c1)OCCCC(C)(C)C(=O)O)C,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,PFIZER,major pharma,29941,1981,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.014,0.14,1.5,,,,17639318,NO,Cardiovascular,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,250.3334,1,3,1,3,0,6,46.53,0.533333333,2,1.855,3.937,All fragments measured,3.8,1.5,4.19,1.576,4.75,,5.1,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81781,0.86053,0.7869,0.81184,0.9848,0.98659,0.98835,0.6885,0.82734,164.2,16.8,59.7,15.9
175463-14-6,GEMIFLOXACIN MESYLATE,FACTIVE,PF-06263877,1286,CO/N=C\1/CN(CC1CN)c2c(cc3c(=O)c(cn(c3n2)C4CC4)C(=O)O)F,TABLET,YES,NO,NO,NO,ORAL,320,Prescription,,NO,NO,,,LG Chem,pharma,LG CHEM LTD,pharma,37715,2003,Drugs@FDA,NO,NO,0.71,,High,Reported bioavailability,0.35,4.18,7,,,,1279718,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),,1,Quinolones_Naphthyridinones,NO,NO,NO,,389.3809,3,5,2,9,0,5,123.04,0.444444444,-0.505,-0.505,-1.245,Approximated fragment value used,1.7,-0.27,-0.22,-2.694,6.02,9.15,6.3,9.3,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.53667,0.40518,0.63449,0.10199,0.10671,0.79222,0.46732,0.84757,0.82734,414.6,4.62,3.27,8.92
1254053-84-3,GILTERITINIB FUMARATE,XOSPATA,PF-06876366,,CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5,TABLET,YES,NO,NO,NO,ORAL,120,Prescription,,NO,NO,,,Kotobuki Pharmaceutical ,pharma,ASTELLAS,major pharma,43432,2018,Drugs@FDA,NO,NO,,0.16,Moderate,Fa estimated from reported excretion data,0.06,15.6,113,,,,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproved but suspected cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,3AC1,552.7115,4,8,3,11,2,9,121.11,0.620689655,1.9,1.743,2.271,All fragments measured,3.4,1.8,3.84,2.884,,8.14,11,8.7,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,4,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,4,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.34424,0.31125,0.09451,0.98849,0.06191,0.37866,0.46978,0.29329,0.93773,528.2,1.37,8.73,43.5
1095173-27-5,GLASDEGIB,DAURISMO,PF-04449913,,CN1CC[C@H](C[C@@H]1c2[nH]c3ccccc3n2)NC(=O)Nc4ccc(cc4)C#N,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,43425,2018,Drugs@FDA,NO,NO,0.77,,High,Reported bioavailability,0.09,2.7,,,,,1001436,YES,Oncology,NO,NO,,NO,YES,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproved but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,374.439,3,4,3,7,0,3,96.84,0.285714286,3.13,2.929,2.275,All fragments measured,2.6,2.1,2.36,1.61,11.84,7.92,12,7,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60507,0.64034,0.72723,0.98631,0.88651,0.37866,0.7194,0.99269,0.25672,413.3,2.46,4.53,8.23
1365970-03-1,GLECAPREVIR,MAVYRET,VC-001215421,5243,CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C\C(c6c(nc7ccccc7n6)O4)(F)F)C(C)(C)C,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Enanta,pharma,ABBVIE,major pharma,42950,2017,Drugs@FDA,YES,NO,,,NA,NA,0.025,,7.8,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury due to reactivation of hepatitis B),None,0,,NO,NO,NO,,838.8653,3,10,3,15,2,6,195.22,0.631578947,2.79,2.79,4.002,Benzyl approx. based on a priori value,5.5,2.8,2.3,0.708,5.59,,4.8,1.4,Acidic,Class 3B,0,4,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,8,0,0,0,4,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,6,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,1,0,0,YES,0.28102,0.19552,0.0277,0.92149,0.03975,0.37866,0.05685,0.53315,0.93773,1012,1.94,14.2,46.3
93479-97-1,GLIMEPIRIDE,AMARYL,PF-00345553,1300,CCC1=C(CN(C1=O)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@@H](CC3)C)C,TABLET,YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35033,1995,Drugs@FDA,NO,NO,,1,High,Fa estimated from reported excretion data,0.005,0.19,3,,,,955473,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,,490.6156,3,5,3,9,0,8,124.68,0.541666667,1.83,1.83,3.962,A priori fragment value used,4.2,2.1,3.17,1.2,5.19,,5.3,,Acidic,Class 1B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.46253,0.49957,0.19489,0.91459,0.72615,0.37866,0.35922,0.53315,0.82734,461.5,8.17,25.8,34.3
29094-61-9,GLIPIZIDE,GLUCOTROL,PF-00344887,1301,Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,40,Prescription,,NO,NO,,,,,PFIZER,major pharma,30810,1984,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.02,0.16,4,,,,21392982,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Less,Less,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,445.5352,3,6,3,9,0,7,130.15,0.428571429,0.429,0.403,2.571,All fragments measured,2.1,0.01,1.82,-0.111,5.16,1.33,5.3,2.6,Acidic,Class 1B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53226,0.51803,0.33947,0.94472,0.52457,0.37866,0.31432,0.53315,0.93773,431.2,1.4,4.6,10
77-21-4,GLUTETHIMIDE,DORIDEN,PF-00345424,1313,CCC1(CCC(=O)NC1=O)c2ccccc2,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,500,Discontinued,,NO,NO,Abuse potential,,,,SANOFI AVENTIS US,major pharma,20926,1957,Drugs@FDA,NO,NO,,,NA,NA,0.458,,12,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,Gerren Additions,1,,,,,0,,NO,NO,NO,,217.2637,1,2,1,3,0,2,46.17,0.384615385,1.52,1.616,1.993,Estimated fragment value used,1.6,1.5,2.2,2.203,11.36,,9.7,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81748,0.86036,0.55757,0.95925,0.93048,0.98659,0.98696,0.87038,0.82734,191.9,37.2,6.84,6.81
10238-21-8,GLYBURIDE,MICRONASE,PF-00344714,1314,COc1ccc(cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3)Cl,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,30803,1984,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.01,,10,,,,,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,,Most,FEARS Addition ,1,B,Most,B (likely rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,6BAA,494.0035,3,5,3,8,0,8,113.6,0.391304348,1.77,2.148,4.239,All fragments measured,4.1,2,3.79,1.856,5.19,,5.3,,Acidic,Class 1B,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.43409,0.49524,0.18695,0.82206,0.72615,0.37866,0.46114,0.39983,0.93773,426.7,6.84,9.64,77.3
611168-24-2,GLYCEROL PHENYLBUTYRATE,RAVICTI,VC-001215216,4745,c1ccc(cc1)CCCC(=O)OCC(COC(=O)CCCc2ccccc2)OC(=O)CCCc3ccccc3,LIQUID,YES,NO,NO,NO,ORAL,19,Prescription,,NO,NO,,,Ucyclyd (Bausch Health),pharma,HORIZON THERAPS INC,pharma,41306,2013,Drugs@FDA,NO,YES (Presystemic),,,NA,NA,,,,,,,,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,,None,,,,,,Less,0,,NO,NO,NO,,530.6512,0,3,0,6,2,20,78.9,0.363636364,4.8,6.42,7.874,Very high LogP unrealistic in nature,7.2,7.2,6.86,6.874,,,,,Neutral,,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.08632,0.15058,0.12073,0.03316,0.52457,0.59178,0.8826,0.00623,0.25672,349.7,1.75,21,96.5
596-51-0,GLYCOPYRROLATE,ROBINUL,PF-06287731,4302,C[N+]1(CCC(C1)OC(=O)C(c2ccccc2)(C3CCCC3)O)C,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,,,CASPER PHARMA LLC,pharma,22504,1961,Drugs@FDA,NO,NO,0.03,,Low,Reported bioavailability,0.6,1.2,3.2,,,,,YES,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,318.4305,1,3,1,4,0,5,46.53,0.631578947,0.0533,0.0533,0.121,Approximated fragment value used,-0.23,-0.23,-0.72,-0.772,12.1,,15,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91101,0.92581,0.98843,0.87592,0.9848,0.98659,0.98835,0.84757,0.82734,293.1,0.959,9.11,6.65
109889-09-0,GRANISETRON HYDROCHLORIDE,KYTRIL,PF-06180758,1329,Cn1c2ccccc2c(n1)C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,34774,1995,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.35,3.9,,,,,697054,NO,Gastrointestinal,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,312.4094,1,3,1,5,0,2,50.16,0.555555556,0.482,0.482,1.715,All fragments measured,2.8,0.98,2.12,-0.782,12.34,10.5,14,9.1,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.95473,0.96508,0.99691,0.98849,0.9848,0.98659,0.99783,0.87038,0.93773,374.7,12.9,6.82,7.37
1350514-68-9,GRAZOPREVIR,ZEPATIER,VC-000486005,5081,CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)Oc5c(nc6ccc(cc6n5)OC)CCCCC[C@@H]7C[C@H]7OC(=O)N1,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,42397,2016,Drugs@FDA,YES,NO,0.27,,Moderate,Reported bioavailability,0.012,17.9,31,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,766.9034,3,10,3,15,3,7,195.22,0.631578947,1.65,1.65,6.316,All fragments measured,5.9,3.1,3.65,2.346,5.61,3.07,3.9,1.5,Acidic,Class 3B,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,8,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,YES,0.26508,0.18772,0.02944,0.86963,0.03975,0.37866,0.05684,0.39983,0.93773,940.4,1.64,18.6,29.8
119914-60-2,GREPAFLOXACIN HYDROCHLORIDE,RAXAR,PF-04551811,1330,Cc1c2c(cc(c1F)N3CCNC(C3)C)n(cc(c2=O)C(=O)O)C4CC4,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,1999,YES,YES,QTc prolongation ,FederalRegister,,,OTSUKA,pharma,35740,1997,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.5,6.6,12.9,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,,359.3947,2,4,2,6,0,3,74.57,0.473684211,0.0961,0.0961,0.293,All fragments measured,2.8,-0.018,0.37,-1.845,6.22,8.74,6.1,8.7,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.74161,0.71,0.81807,0.35178,0.52457,0.79222,0.92598,0.99269,0.82734,372.2,3.3,4.3,7.72
126-07-8,GRISEOFULVIN,GRISACTIN,PF-04270616,1331,C[C@@H]1CC(=O)C=C([C@]12C(=O)c3c(cc(c(c3O2)Cl)OC)OC)OC,"CAPSULE, SUSPENSION",YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,,,WYETH,major pharma,22880,1962,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,,,,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,352.7663,0,6,0,6,0,3,71.06,0.411764706,2.17,2.166,2.053,Valid estimate for difficult structure,1.5,1.5,2.88,3.165,,,,,Neutral,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,NO,0.82866,0.79632,0.85535,0.99308,0.52457,0.59178,0.93758,0.99269,0.82734,377.2,29.5,25.8,11.3
93-14-1,GUAIFENESIN,MUCINEX,PF-00344789,1336,COc1ccccc1OCC(CO)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,1200,Over-the-counter,,NO,NO,,,Elan (Perrigo),pharma,RB HLTH,pharma,37449,2002,Drugs@FDA,NO,NO,,,High,Based on textual comment,,1.7,1,,,,7820395,NO,Respiratory,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,198.2158,2,4,2,4,0,5,58.92,0.4,0.222,0.222,0.102,All fragments measured,0.35,0.35,0.84,0.839,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70044,0.76242,0.43526,0.70408,0.88651,0.79222,0.9922,0.84757,0.82734,186.7,37.7,19.5,23.2
5051-62-7,GUANABENZ ACETATE,WYTENSIN,PF-01008352,3952,c1cc(c(c(c1)Cl)/C=N/NC(=N)N)Cl,TABLET,YES,NO,NO,NO,ORAL,64,Prescription,,NO,NO,,,,,WYETH,major pharma,30201,1982,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.1,10.4,6,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,None,,,,,,None,0,,NO,NO,NO,,231.0819,4,2,3,4,0,3,74.26,0,0.914,0.914,2.979,All fragments measured,2.1,1.1,1.93,1.117,,8.17,,9.3,Basic,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.71664,0.77567,0.65369,0.97419,0.93048,0.37866,0.91676,0.99269,0.82734,163.7,6.64,19.5,11.6
40580-59-4,GUANADREL SULFATE,HYLOREL,PF-00344791,1339,C1CCC2(CC1)OCC(O2)CNC(=N)N,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,30314,1982,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,0.8,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,213.2768,4,5,3,5,0,3,80.36,0.9,-0.311,-0.311,0.635,All fragments measured,1.3,0.58,0.38,-1.579,,12.59,,9.8,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.57432,0.64343,0.53072,0.56475,0.9848,0.37866,0.87104,0.99269,0.47245,195.3,3.7,7.07,7.48
55-65-2,GUANETHIDINE MONOSULFATE,ISMELIN,PF-00344632,1342,C1CCCN(CCC1)CCNC(=N)N,TABLET,YES,NO,NO,NO,ORAL,100,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,22102,1960,Drugs@FDA,NO,NO,0.03,,Low,Reported bioavailability,,,50,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,,0,,NO,NO,NO,,198.3085,4,4,3,4,0,4,65.14,0.9,-1.63,-1.63,1.354,All fragments measured,1.7,-2.9,1.09,-2.602,,,,12,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.58002,0.66226,0.43581,0.81906,0.93048,0.37866,0.96966,0.96969,0.47245,139.2,1.31,3.18,12.4
29110-47-2,GUANFACINE HYDROCHLORIDE,TENEX,PF-00344716,1343,c1cc(c(c(c1)Cl)CC(=O)NC(=N)N)Cl,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,3,Prescription,,NO,NO,,,,,PROMIUS PHARMA,pharma,31712,1986,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.28,6.3,17,,,,,NO,"Cardiovascular, Neurological",NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,246.0933,4,3,3,4,0,3,78.97,0.111111111,0.996,1.35,1.37,Approximated fragment value used,2.1,1.2,1.57,1.565,11.07,6,,10,Basic,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.73834,0.7862,0.75842,0.95915,0.93048,0.37866,0.88205,0.99269,0.82734,182.9,10.8,14.2,16.5
113-00-8,GUANIDINE HYDROCHLORIDE,GUANIDINE HYDROCHLORIDE,PF-01013423,1344,C(=N)(N)N,TABLET,YES,NO,NO,NO,ORAL,2450,Prescription,,NO,NO,,,,,MERCK,major pharma,14520,1939,Drugs@FDA,NO,NO,,,NA,NA,,,7,,,,,NO,Autoimmune Disease,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,59.0705,5,3,3,3,0,0,75.89,0,-1.33,-1.33,-2.387,Calculated fragment value,-0.9,-4.4,-1.22,-3.217,,,,8.6,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.2436,0.29492,0.06019,0.21603,0.23327,0.37866,0.9052,0.39503,0.47245,31.93,0.876,2.93,8.41
23092-17-3,HALAZEPAM,PAXIPAM,PF-00345367,1348,c1ccc(cc1)C2=NCC(=O)N(c3c2cc(cc3)Cl)CC(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,160,Discontinued,,NO,NO,,,,,SCHERING,major pharma,29853,1981,Drugs@FDA,NO,NO,,,High,Based on textual comment,,,14,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,352.7382,0,1,0,3,0,2,32.67,0.176470588,2.94,3.939,3.754,Benzyl approx. based on a priori value,3.6,3.6,3.63,3.629,,2.61,,1.9,Neutral,Class 2,0,3,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.82589,0.84445,0.85551,0.80988,0.93048,0.59178,0.86219,0.99269,0.93773,290.5,17.3,7.5,33.3
69756-53-2,HALOFANTRINE HYDROCHLORIDE,HALFAN,PF-00346441,1350,CCCCN(CCCC)CCC(c1cc2c(cc(cc2Cl)Cl)c3c1ccc(c3)C(F)(F)F)O,TABLET,YES,NO,NO,NO,ORAL,1500,Discontinued,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,33809,1992,Drugs@FDA,NO,NO,,,Moderate,Based on textual comment,0.17,,,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,None,FEARS Addition ,1,,,,Less,0,,NO,NO,NO,,500.4237,1,2,1,2,2,10,23.47,0.461538462,4.83,5.17,9.31,Very high LogP unrealistic in nature,9,7,7.69,5.721,,9.44,12,9.1,Basic,Class 4,0,3,0,0,2,0,0,3,2,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,5,0,0,0,0,NO,0.2033,0.2739,0.17284,0.02715,0.93048,0.98659,0.69082,0.15134,0.25672,340.9,0.384,44.7,47.6
52-86-8,HALOPERIDOL,HALDOL,PF-00344555,1353,c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,ORTHO MCNEIL,major pharma,24574,1967,Drugs@FDA,NO,NO,0.86,,High,Reported bioavailability,0.1,17,,,,,1887114,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,375.8642,1,3,1,3,0,6,40.54,0.380952381,2.39,2.205,3.849,All fragments measured,4.3,3.3,3.48,2.653,,8.04,15,8.7,Basic,Class 2,0,1,0,0,1,0,0,2,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,NO,0.82913,0.87184,0.71839,0.89147,0.9848,0.98659,0.95307,0.6885,0.93773,252.6,8.15,24.1,31
3511-16-8,HETACILLIN,VERSAPEN,PF-00345245,1363,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)c4ccccc4)C(=O)O)C,FOR SUSPENSION,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,24894,1968,PharmaPendium,NO,YES,,,NA,NA,,,,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Beta_Lactams,NO,NO,NO,,389.4686,2,6,2,7,0,3,89.95,0.526315789,-0.365,-0.365,0.812,Approximated fragment value used,0.57,0.81,1.51,-2.195,2.45,5.09,3,12,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56199,0.52096,0.63395,0.09104,0.52457,0.79222,0.52871,0.99269,0.82734,487,0.913,4.48,6.91
6004-98-4,HEXOCYCLIUM METHYLSULFATE,TRAL,VC-001224817,1371,C[N+]1(CCN(CC1)CC(c2ccccc2)(C3CCCCC3)O)C,TABLET,YES,NO,NO,NO,ORAL,75,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,20864,1957,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,317.4888,1,3,1,3,0,4,23.47,0.7,0.768,0.768,1.408,Approximated fragment value used,-0.2,-0.2,-0.36,-0.314,,4.16,16,5.2,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.94428,0.90144,0.9901,0.96018,0.93048,0.98659,0.69082,0.96969,0.82734,244.5,0.869,5.16,12.8
80-49-9,HOMATROPINE METHYLBROMIDE,HYCODAN,VC-001224818,1380,C[N+]1([C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(c3ccccc3)O)C,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,9,Discontinued,,NO,NO,Abuse potential,,,,GENUS LIFESCIENCES,pharma,15788,1943,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,350414,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,LiverTox Additions,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,290.3774,1,3,1,4,0,4,46.53,0.588235294,-0.939,-0.939,-2.897,Approximated fragment value used,-2.1,-2.1,-1.96,-1.963,12.04,,13,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87875,0.88886,0.98107,0.58,0.9848,0.98659,0.98835,0.96969,0.82734,321,1.19,5.26,6.65
86-54-4,HYDRALAZINE HYDROCHLORIDE,APRESOLINE,PF-00345047,1384,c1ccc\2c(c1)cn[nH]/c2=N\N,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,19374,1953,Drugs@FDA,NO,NO,0.44,,High,Reported bioavailability,0.13,,3,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,160.1759,3,1,2,4,0,0,67.06,0,0.271,0.271,0.655,A priori fragment value used,2.4,2.2,0.99,0.982,,5.58,,6.6,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59958,0.69346,0.24909,0.75649,0.88651,0.79222,0.97545,0.63709,0.93773,137.9,20,8.32,38.9
58-93-5,HYDROCHLOROTHIAZIDE,ESIDRIX,PF-00344792,1385,c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)NCN2,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,21593,1959,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.6,3.5,11,,84,118,2,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,297.7391,4,4,3,7,0,1,118.36,0.142857143,-0.166,0.09738,-0.365,All fragments measured,-0.22,-0.24,0.01,0.003,9.39,,8.7,0.29,Neutral,Class 4,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.60413,0.56802,0.99466,0.38724,0.72615,0.37866,0.34179,0.63709,0.82734,318.6,0.234,1.91,6.67
125-29-1,HYDROCODONE BITARTRATE,ZOHYDRO ER,PF-00345368,1386,CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)OC,"CAPSULE, EXTENDED RELEASE, TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,120,Prescription,,NO,NO,,,Elan (Perrigo),pharma,PERNIX IRELAND PAIN,pharma,41572,2013,Drugs@FDA,NO,NO,,,NA,NA,0.65,5.7,8,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,,,LiverTox Additions,0,,,,Moderate,0,,NO,NO,NO,,299.3642,0,4,0,4,0,1,38.77,0.611111111,0.375,0.375,1.126,All fragments measured,1.7,0.35,1.32,0.173,,8.52,,8.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.77942,0.81806,0.99654,0.94936,0.88651,0.59178,0.9372,0.63709,0.82734,353.2,24.3,5.88,14.5
50-23-7,HYDROCORTISONE,HYDROCORTONE,PF-00344557,1388,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,TABLET,YES,NO,NO,NO,ORAL,240,Prescription,,NO,NO,,,,,MERCK,major pharma,19211,1952,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,0.1,0.5,1.5,,,,112313119,NO,"Autoimmune Disease, Cardiovascular, Metabolic Disease",NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,4P6X,362.4599,3,5,3,5,0,2,94.83,0.80952381,1.38,1.524,1.887,Valid estimate for difficult structure,1.5,1.5,1.66,1.659,12.47,,11,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64473,0.66289,0.80011,0.84073,0.72615,0.37866,0.73951,0.87038,0.47245,390.6,10.3,4.11,13.6
508-99-6,HYDROCORTISONE CYPIONATE,CORTEF,PF-04217801,1390,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC5CCCC5)O)C)O,SUSPENSION,YES,NO,NO,NO,ORAL,175,Discontinued,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,20219,1955,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,0.1,0.5,1,,,,,NO,"Autoimmune Disease, Cardiovascular, Metabolic Disease",NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,486.6402,2,5,2,6,1,7,100.9,0.827586207,3.6,4.97,5.044,Valid estimate for difficult structure,4.2,4.2,4.38,4.377,12.33,,12,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.49539,0.5341,0.20467,0.85362,0.52457,0.79222,0.67796,0.53315,0.47245,474.1,13,39.8,180
135-09-1,HYDROFLUMETHIAZIDE,SALURON,PF-00345049,1392,c1c(c(cc2c1NCNS2(=O)=O)S(=O)(=O)N)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,SHIRE,major pharma,21753,1959,Drugs@FDA,NO,NO,,0.46,High,Fa estimated from reported excretion data,0.26,3.5,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,,,,Less,1,Aniline,YES,NO,NO,,331.292,4,4,3,7,0,1,118.36,0.25,0.467,0.4559,-0.21,All fragments measured,0.047,0.022,0.24,0.231,9.29,,8.9,1.3,Neutral,Class 4,0,3,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.66054,0.6071,0.95362,0.47101,0.72615,0.37866,0.34179,0.87038,0.82734,333.8,0.442,3.47,7.08
466-99-9,HYDROMORPHONE HYDROCHLORIDE,DILAUDID,PF-00345426,1393,CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)O,"CAPSULE, EXTENDED RELEASE, SOLUTION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,24,Prescription,,NO,NO,,,,,RHODES PHARMS,pharma,33945,1992,Drugs@FDA,NO,NO,0.24,,Moderate,Reported bioavailability,0.92,2.9,2.3,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,285.3377,1,4,1,4,0,0,49.77,0.588235294,0.413,0.413,0.72,All fragments measured,1.5,0.16,1.29,0.242,9.34,8.53,10,8.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.77167,0.82195,0.96712,0.91944,0.88651,0.98659,0.99719,0.39503,0.82734,340,19.5,22.2,11.1
118-42-3,HYDROXYCHLOROQUINE SULFATE,PLAQUENIL,PF-00344886,1395,CCN(CCCC(C)Nc1ccnc2c1ccc(c2)Cl)CCO,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,CONCORDIA PHARMS INC,pharma,20197,1955,Drugs@FDA,NO,NO,0.746,,High,Reported bioavailability,,6.2,172,,,,,NO,"Anti-infective, Autoimmune Disease",NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,"C (probable rare cause of idiosyncratic, clinically apparent liver injury, but capable of causing acute hepatoxicity with high doses in patients with porphyria)",Moderate,0,,NO,NO,NO,,335.8715,2,3,2,4,0,9,48.39,0.5,1.08,1.102,4.116,All fragments measured,4.1,1.6,3.5,1.787,,8.87,15,9.3,Basic,Class 4,0,0,0,0,1,0,0,2,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,NO,0.7055,0.77872,0.93634,0.96568,0.88651,0.79222,0.99421,0.29329,0.93773,297.2,3.77,11,8.18
127-07-1,HYDROXYUREA,HYDREA,PF-00344629,1399,C(=O)(N)NO,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,1050,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,24813,1967,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.2,0.52,3.2,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,76.0547,4,1,3,4,0,0,75.35,0,-1.25,-1.25,-1.8,All fragments measured,-1.5,-1.5,-1.54,-1.541,10.56,,10,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.25909,0.36795,0.07338,0.20815,0.93048,0.37866,0.90907,0.39503,0.47245,72.92,1.17,3,7.04
68-88-2,HYDROXYZINE HYDROCHLORIDE,ATARAX,PF-00345246,1400,c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCCO,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,PFIZER,major pharma,20557,1956,Drugs@FDA,NO,NO,,,NA,NA,0.07,16,,,,,,NO,"Gastrointestinal, Neurological, Respiratory",NO,NO,,NO,YES,NO,NO,None,None,,,E,None,E (unlikely to be a cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,374.9043,1,4,1,4,0,8,35.94,0.428571429,2.28,1.7,3.995,All fragments measured,3.1,2.9,2.74,2.655,,6.62,14,7.6,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.74448,0.79889,0.72434,0.96451,0.88651,0.98659,0.90652,0.39983,0.93773,288.3,6.58,16.9,54.4
114084-78-5,IBANDRONATE SODIUM,BONIVA,PF-01738746,1404,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,TABLET,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,Roche and Chugai Pharmaceutical ,major pharma,HOFFMANN LA ROCHE,major pharma,37757,2003,Drugs@FDA,NO,NO,0.006,0.6,Low,Reported bioavailability,0.14,1.3,,,119,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury)  ,Moderate,0,,NO,NO,NO,2F94,319.2289,5,4,5,8,0,9,138.53,1,-1.76,-1.76,-3.373,A priori fragment value used,-0.58,-6,-1.68,-6.08,1.6,9.5,0.04,8.6,Zwitter,Class 3A,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,NO,0.33068,0.29333,0.98691,0.68562,0.19128,0.05547,0.1878,0.29329,0.47245,237.2,0.468,4.19,9.06
936563-96-1,IBRUTINIB,IMBRUVICA,PF-05022372,4810,C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,560,Prescription,,NO,NO,,,Pharmacyclics,pharma,PHARMACYCLICS INC,pharma,41591,2013,Drugs@FDA,NO,NO,0.029,,Low,Reported bioavailability,0.027,143,5,Parent CRG,,57,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Less,,,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,4IFG,440.4971,2,4,1,8,0,6,99.16,0.2,3.33,4.4,4.069,Approximated fragment value used,4,4,2.86,2.861,,4.09,,4.3,Neutral,Class 2,0,0,0,0,0,0,0,4,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.42748,0.44201,0.36073,0.867,0.52457,0.98659,0.69584,0.84757,0.03452,444.4,8.24,55.7,145
15687-27-1,IBUPROFEN,MOTRIN,PF-00344559,1407,CC(C)Cc1ccc(cc1)C(C)C(=O)O,"CAPSULE, SUSPENSION, SUSPENSION/DROPS, TABLET, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,1200,Over-the-counter,,NO,NO,,,,,MCNEIL CONSUMER,pharma,27291,1974,Drugs@FDA,NO,NO,0.92,,High,Reported bioavailability,0.01,0.15,2,,,,346782886,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well known but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4PH9,206.2808,1,2,1,2,0,4,37.3,0.461538462,1.04,1.04,3.679,All fragments measured,3.2,0.37,3.37,0.452,4.41,,4.4,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80861,0.8465,0.48508,0.94548,0.93048,0.98659,0.92207,0.96969,0.82734,121.7,31.5,24.1,9.33
86227-47-6,ICOSAPENT ETHYL,VASCEPA,RS-350179,1413,CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCC(=O)OCC,CAPSULE,YES,NO,NO,NO,ORAL,4000,Prescription,,NO,NO,,,Amarin,pharma,AMARIN PHARMS,pharma,41116,2012,Drugs@FDA,NO,YES (Presystemic),,,NA,NA,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,330.5042,0,1,0,2,1,15,26.3,0.5,4.73,6.48,7.813,Very high LogP unrealistic in nature,7.6,7.6,6.65,6.649,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.25364,0.33816,0.95636,0.07275,0.93048,0.59178,0.74989,0.03725,0.47245,181.2,4.01,169,71.9
870281-82-6,IDELALISIB,ZYDELIG,PF-06276688,4878,CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Calistoga Pharmaeuticals (Gilead Sciences),pharma,GILEAD SCIENCES INC,major pharma,41843,2014,Drugs@FDA,NO,NO,,0.58,High,Fa estimated from reported excretion data,0.16,0.3,8.2,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Less,,,D,Less,D (possible cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4XE0,415.423,2,5,2,8,0,5,101.38,0.136363636,2.95,3.379,3.62,Valid estimate for difficult structure,2.9,2.9,2.99,2.991,10,2.87,10,4.5,Neutral,Class 2,0,1,0,0,0,0,0,5,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,6,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,NO,0.4417,0.45197,0.48284,0.94283,0.52457,0.79222,0.69584,0.84757,0.03452,466.8,24.4,8.92,15.8
133454-47-4,ILOPERIDONE,FANAPT,PF-01827219,3294,CC(=O)c1ccc(c(c1)OC)OCCCN2CCC(CC2)c3c4ccc(cc4on3)F,TABLET,YES,NO,NO,NO,ORAL,24,Prescription,,NO,NO,,,Sanofi,major pharma,VANDA PHARMS INC,pharma,39939,2009,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,0.05,29.6,18,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,426.4806,0,5,0,6,0,8,64.8,0.416666667,2.51,2.529,3.916,All fragments measured,4.3,3,3.79,2.721,,8.43,,8.7,Basic,Class 2,0,1,0,0,0,0,0,3,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.47354,0.55221,0.42568,0.85862,0.72615,0.59178,0.97121,0.39983,0.25672,392.2,3.13,25.2,68.6
152459-95-5,IMATINIB MESYLATE,GLEEVEC,PF-01677920,1423,Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,37021,2001,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.05,,18,,101,23,590905,YES,Oncology,NO,YES,II,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury as well as reactivation of hepatitis B),Moderate,2,Aniline; Pyridine,YES,NO,NO,1OPJ,493.6027,2,6,2,8,0,7,86.28,0.24137931,2.06,2.445,4.529,All fragments measured,4.4,3.5,3.1,2.652,,7.55,12,8.4,Basic,Class 2,0,0,0,0,0,0,0,4,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31382,0.34607,0.18787,0.7959,0.33223,0.79222,0.82057,0.53315,0.03452,464.6,5.38,14.9,22.5
50-49-7,IMIPRAMINE HYDROCHLORIDE,PRESAMINE,PF-00344560,1427,CN(C)CCCN1c2ccccc2CCc3c1cccc3,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,21656,1959,Drugs@FDA,NO,NO,0.94,,High,Reported bioavailability,0.11,18,6,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,B,Most,B (likely rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,280.4073,0,1,0,2,1,4,6.48,0.368421053,2.11,2.155,5.037,All fragments measured,4.3,2.5,4.69,2.678,,9.49,,9,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81215,0.73182,0.95,0.73512,0.93048,0.59178,0.32149,0.96969,0.93773,210.6,5.19,13.9,59.9
26807-65-8,INDAPAMIDE,LOZOL,PF-00344561,1433,CC1Cc2ccccc2N1NC(=O)c3ccc(c(c3)S(=O)(=O)N)Cl,TABLET,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,30503,1983,Drugs@FDA,NO,NO,0.99,,High,Reported bioavailability,0.21,0.4,14,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,365.8345,3,3,2,6,0,3,92.5,0.1875,1.9,2.229,2.957,Approximated fragment value used,1.8,1.7,2.15,2.146,9.35,1.87,8.6,5.6,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.88234,0.85905,0.77995,0.99844,0.88651,0.79222,0.67817,0.99269,0.93773,363.7,8.21,2.83,7.05
150378-17-9,INDINAVIR SULFATE,CRIXIVAN,PF-00346012,1437,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](Cc2ccccc2)C(=O)N[C@H]3c4ccccc4C[C@H]3O)O)Cc5cccnc5,CAPSULE,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,MERCK,major pharma,35137,1996,Drugs@FDA,NO,NO,0.3,,Moderate,Reported bioavailability,0.4,2.8,1.8,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,C,Less,C (frequent cause of serum bilirubin elevations and probable cause of rare instances of clinically apparent liver injury),,1,Pyridine,NO,NO,NO,1HSG,613.7895,4,7,4,9,1,11,118.03,0.472222222,2.97,3.697,3.681,All fragments measured,3,3,3.04,3.148,,5.19,7.7,6.9,Basic,Class 3B,0,0,0,0,0,0,0,3,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.1678,0.23185,0.0538,0.99457,0.33223,0.14694,0.50041,0.10729,0.25672,627.3,1.3,30.7,462
53-86-1,INDOMETHACIN,INDOCIN,PF-00344630,1440,Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O,"CAPSULE; CAPSULE, EXTENDED RELEASE; SUSPENSION",YES,NO,YES,NO,ORAL,200,Prescription,,NO,NO,,,,,IROKO PHARMS LLC,pharma,23903,1965,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,0.1,4.5,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4COX,357.7876,1,4,1,5,0,5,68.53,0.157894737,1.06,1.007,4.18,Valid estimate for difficult structure,3.4,0.5,4.02,0.748,3.96,,4.4,,Acidic,Class 1A,0,0,0,0,1,0,0,3,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.73288,0.75174,0.82731,0.79077,0.88651,0.98659,0.95241,0.96969,0.25672,305.1,9.77,7.41,12.8
138402-11-6,IRBESARTAN,AVAPRO,PF-00346555,1481,CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5[nH]nnn5,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35703,1997,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.1,0.72,11,,96,182,16678,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (Probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,428.5294,1,4,1,7,1,7,87.13,0.4,1.49,1.387,6.044,Calculated fragment value,4.9,2.6,3.22,1.243,4.16,2.75,4,4.6,Acidic,Class 1B,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53707,0.58326,0.41566,0.6931,0.72615,0.98659,0.8129,0.53315,0.25672,352.1,0.945,15.1,26.4
742049-41-8,ISAVUCONAZONIUM SULFATE,CRESEMBA,VC-001224819,4947,C[C@@H](c1nc(cs1)c2ccc(cc2)C#N)[C@](Cn3c[n+](cn3)C(C)OC(=O)N(C)c4c(cccn4)COC(=O)CNC)(c5cc(ccc5F)F)O,CAPSULE,YES,NO,NO,NO,ORAL,372,Prescription,,NO,NO,,,Roche,major pharma,ASTELLAS,major pharma,42069,2015,Drugs@FDA,NO,YES,0.98,,High,Reported bioavailability,0.01,6.4,130,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,,717.7648,2,9,2,13,2,16,159.37,0.285714286,2.95,3.828,-1.153,A priori fragment value used,2.5,2,-1.31,,11.45,7.35,15,7.3,Basic,Class 4,0,2,0,0,0,0,0,5,0,1,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.08475,0.08273,0.03237,0.43395,0.06191,0.79222,0.08449,0.03725,0.01222,782.5,2.59,64.2,198
59-63-2,ISOCARBOXAZID,MARPLAN,PF-00344892,1490,Cc1cc(no1)C(=O)NNCc2ccccc2,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,VALIDUS PHARMS,pharma,21732,1959,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible rare cause of clinically apparent liver injury),None,1,Hydrazines,NO,NO,NO,,231.2505,2,2,2,5,0,4,67.16,0.166666667,1.77,1.882,0.994,Benzyl approx. based on a priori value,1.4,1.4,1.22,1.219,10.84,3.32,10,0,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82505,0.86495,0.65488,0.81231,0.9848,0.79222,0.95976,0.96969,0.93773,224.1,45,10.9,18.8
54-85-3,ISONIAZID,ISONIAZID,PF-00344562,1497,c1cnccc1C(=O)NN,TABLET,YES,NO,NO,NO,ORAL,386,Prescription,,NO,NO,,,,,SANDOZ,pharma,19315,1952,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,1,0.67,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Moderate,2,Hydrazines; Pyridine,NO,NO,NO,5KSG,137.1393,3,3,2,4,0,1,68.01,0,-0.613,-0.613,-0.668,All fragments measured,-1,-1,-0.63,-0.635,11.4,3.79,11,3.8,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.4587,0.56017,0.17478,0.25208,0.9848,0.79222,0.95526,0.63709,0.82734,117.6,6.17,2.26,18.5
7492-32-2,ISOPROPAMIDE IODIDE,DARBID,PF-00345128,1500,CC(C)[N+](C)(CCC(c1ccccc1)(c2ccccc2)C(=O)N)C(C)C,TABLET,YES,NO,NO,NO,ORAL,20,Discontinued,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,21102,1957,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,353.5209,2,2,1,3,0,8,43.09,0.434782609,0.741,0.741,-0.195,Approximated fragment value used,1.3,1.3,-1.25,-1.257,,,15,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75981,0.68579,0.85123,0.99994,0.23327,0.98659,0.97135,0.39983,0.93773,225,1.39,14.4,17.8
652-67-5,ISOSORBIDE,ISMOTIC,PF-05785875,1501,C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O)O,SOLUTION,YES,NO,NO,NO,ORAL,8400,Discontinued,,NO,NO,,,,,ALCON,pharma,27059,1974,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,Less,0,,NO,NO,NO,,146.1412,2,4,2,4,0,0,58.92,1,-1.73,-1.73,-1.53,All fragments measured,-1.6,-1.6,-1.07,-1.078,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.35815,0.45233,0.20074,0.1484,0.88651,0.79222,0.9922,0.39503,0.47245,235.1,7.42,3.15,6.65
87-33-2,ISOSORBIDE DINITRATE,ISORDIL,PF-00344720,1505,C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)ON(=O)=O)ON(=O)=O,"CAPSULE, EXTENDED RELEASE, TABLET, TABLET, CHEWABLE",YES,NO,YES,NO,ORAL,120,Prescription,,NO,NO,,,,,VALEANT,pharma,21863,1959,Drugs@FDA,NO,NO,0.22,,Moderate,Reported bioavailability,0.72,3.1,1,,,,2076329,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely causes of clinically apparent acute liver injury),None,0,,NO,NO,NO,,236.1363,0,6,0,10,0,4,128.56,1,1.35,1.378,0.219,All fragments measured,0.82,0.82,1.22,1.222,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.69116,0.54256,0.68931,0.97058,0.19128,0.59178,0.39889,0.96969,0.47245,344.3,11.9,1.83,10.4
16051-77-7,ISOSORBIDE MONONITRATE,ISMO,PF-00798716,1506,C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)ON(=O)=O)O,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,40,Prescription,,NO,NO,,,,,PROMIUS PHARMA,pharma,33602,1991,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.95,0.7,5,,,,2516150,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely causes of clinically apparent acute liver injury),Less,0,,NO,NO,NO,,191.1388,1,5,1,7,0,2,93.74,1,-0.56,-0.56,-0.655,All fragments measured,-0.38,-0.38,-0.08,-0.084,,,15,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.65876,0.6495,0.39435,0.77433,0.52457,0.98659,0.75027,0.87038,0.47245,289.7,9.93,2.81,9.96
4759-48-2,ISOTRETINOIN,ACCUTANE,PF-00344991,1508,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C,CAPSULE,YES,NO,NO,NO,ORAL,140,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,30078,1982,Drugs@FDA,NO,NO,,0.65,High,Fa estimated from reported excretion data,0.001,,15.7,,,,,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,,300.4351,1,2,1,2,1,5,37.3,0.45,3.35,3.35,6.744,All fragments measured,6.6,3.7,5.9,3.292,4.76,,4.2,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68759,0.70501,0.99756,0.25603,0.93048,0.98659,0.92207,0.84757,0.47245,167.4,5.73,46.7,38.5
75695-93-1,ISRADIPINE,DYNACIRC,PF-00345053,1511,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)c2cccc3c2non3)C(=O)OC,"CAPSULE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,20,Prescription,,NO,NO,,,,,SMITHKLINE BEECHAM,major pharma,33227,1990,Drugs@FDA,NO,NO,0.92,,High,Reported bioavailability,0.05,4,,,,,217,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,371.3871,1,5,1,8,0,6,103.55,0.368421053,3.31,3.53,3.916,Estimated fragment value used,3,3,3.75,3.749,,2.56,,1.9,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,NO,0.82568,0.71953,0.74609,0.97218,0.33223,0.98659,0.65049,0.6885,0.93773,366.9,26.2,139,154
155270-99-8,ISTRADEFYLLINE,NOURIANZ,PF-06878033,4882,O=C(N1CC)N(CC)C2=C(N(C)C(/C=C/C3=CC=C(OC)C(OC)=C3)=N2)C1=O,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Kyowa Hakko Kogyo,pharma,KYOWA KIRIN,pharma,43704,2019,Drugs@FDA,NO,NO,,0.39,High,Fa estimated from reported excretion data,0.02,8,83,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,384.42912,0,5,0,8,0,6,80.28,0.35,2.62,2.587,3.368,Valid estimate for difficult structure,3.7,3.7,2.54,2.543,,,,1.7,Neutral,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,2,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60193,0.64268,0.66511,0.99849,0.72615,0.59178,0.89781,0.6885,0.25672,408.8,27,21,24.9
84625-61-6,ITRACONAZOLE,SPORANOX,PF-00346444,1513,CCC(C)n1c(=O)n(cn1)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC[C@H]5CO[C@](O5)(Cn6cncn6)c7ccc(cc7Cl)Cl,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,YES,ORAL,400,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,33858,1992,Drugs@FDA,NO,NO,0.55,,High,Reported bioavailability,0.002,10,16,,,,2897647,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,2,Aniline; Imidazole_Triazole,YES,NO,NO,5JLC,705.6334,0,6,0,12,3,11,104.7,0.371428571,4.59,5.94,5.99,A priori fragment value used,5.8,5.8,5.02,5.136,,6.47,,5.6,Neutral,Class 4,0,0,0,0,2,0,0,5,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,2,0,0,2,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,2,0,0,NO,0.10568,0.13027,0.03349,0.08483,0.10671,0.59178,0.6791,0.15134,0.03452,735.8,0.793,27.4,50.7
155974-00-8,IVABRADINE HYDROCHLORIDE,CORLANOR,PF-05166420,3312,CN(CCCN1CCc2cc(c(cc2CC1=O)OC)OC)C[C@H]3Cc4c3cc(c(c4)OC)OC,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,Servier,pharma,AMGEN,major pharma,42109,2015,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,0.3,1.4,6,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,468.5851,0,6,0,7,0,10,60.47,0.518518519,1.59,1.587,3.266,Benzyl approx. based on a priori value,3,1.6,3.45,2.228,,8.77,,8.5,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.46036,0.54984,0.25587,0.97485,0.52457,0.59178,0.98781,0.21184,0.93773,433.6,10.3,15.4,41.3
873054-44-5,IVACAFTOR,KALYDECO,PF-05234929,4228,CC(C)(C)c1cc(c(cc1NC(=O)c2c[nH]c3ccccc3c2=O)O)C(C)(C)C,TABLET,YES,NO,NO,YES,ORAL,300,Prescription,,NO,NO,,,Vertex Pharmaceuticals,pharma,VERTEX PHARMS,pharma,40939,2012,Drugs@FDA,NO,NO,,0.65,High,Fa estimated from reported excretion data,0.01,5,12,,,128,,YES,Respiratory,NO,NO,,NO,NO,YES,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspectedrare cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,392.4907,3,3,3,5,0,2,82.19,0.333333333,3.87,4.841,3.823,All fragments measured,5.5,5.5,5.42,5.418,11.08,1.15,7.4,,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.67846,0.73304,0.61545,0.68315,0.88651,0.37866,0.88624,0.96969,0.93773,311.4,1.84,35.7,88
71827-03-7,IVERMECTIN,STROMECTOL,PF-00345511,3972,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C,TABLET,YES,NO,NO,NO,ORAL,17500,Prescription,,NO,NO,,,,,MERCK,major pharma,35391,1996,Drugs@FDA,NO,NO,,,NA,NA,0.01,0.7,18,,,,,NO,Anti-infective,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,875.0928,3,13,3,14,3,8,170.06,0.8125,4.27,8.45,5.388,All fragments measured,5.5,5.5,6.21,6.211,12.42,,12,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,3,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,YES,0.22109,0.16535,0.02733,0.5843,0.02183,0.37866,0.1355,0.39983,0.47245,1162,0.306,31.3,38.6
1448347-49-6,IVOSIDENIB,TIBSOVO,VC-001215220,,c1ccc(c(c1)[C@@H](C(=O)NC2CC(C2)(F)F)N(c3cc(cnc3)F)C(=O)[C@@H]4CCC(=O)N4c5cc(ccn5)C#N)Cl,TABLET,YES,NO,NO,YES,ORAL,500,Prescription,,NO,NO,,,Agios Pharmaceuticals,pharma,AGIOS PHARMS INC,pharma,43301,2018,Drugs@FDA,NO,NO,,0.27,Moderate,Fa estimated from reported excretion data,0.06,3.3,93,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,1,Pyridine,NO,NO,NO,,582.9609,1,6,1,9,1,8,119.29,0.285714286,2.56,2.771,1.814,Benzyl approx. based on a priori value,2.5,2.5,1.21,1.681,11.58,1.39,12,0.61,Neutral,Class 2,0,3,0,0,1,0,0,3,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.37626,0.42257,0.06982,0.99731,0.52457,0.98659,0.48776,0.53315,0.25672,620.8,7.62,9.86,98.5
1072833-77-2,IXAZOMIB CITRATE,NINLARO,PF-06708362,5067,O=C1C(CC(O)=O)(CC(O)=O)OB([C@@H](NC(CNC(C2=CC(Cl)=CC=C2Cl)=O)=O)CC(C)C)O1,CAPSULE,YES,NO,NO,NO,ORAL,0.57,Prescription,,NO,NO,,,Millennium Pharmaceuticals,pharma,TAKEDA PHARMS USA,major pharma,42328,2015,Drugs@FDA,NO,YES,0.58,,High,Reported bioavailability,0.01,7.8,228,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,,517.122,4,7,4,11,2,11,168.33,0.45,-1.12,-1.12,1.942,Calculated fragment value,0.22,-5,0.99,,3.8,,3.59,,Acidic,,1,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.27744,0.24505,0.14139,0.96084,0.10671,0.14694,0.14213,0.21184,0.82734,550.8,,4.94,8.86
65277-42-1,KETOCONAZOLE,NIZORAL,PF-00344571,1527,CC(=O)N1CCN(CC1)c2ccc(cc2)OC[C@H]3CO[C@](O3)(Cn4ccnc4)c5ccc(cc5Cl)Cl,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,29749,1981,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.01,,2,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause cause of clinically apparent liver injury),Less,2,Aniline; Imidazole_Triazole,YES,NO,NO,3LD6,531.4309,0,5,0,8,1,8,69.06,0.384615385,3.59,4.61,3.635,Approximated fragment value used,4,3.9,3.61,3.545,,6.88,,5.7,Basic,Class 4,0,0,0,0,2,0,0,3,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,1,0,0,2,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,2,0,0,NO,0.3838,0.46301,0.11966,0.94502,0.52457,0.59178,0.94943,0.53315,0.25672,546,7.01,29.3,40.3
22071-15-4,KETOPROFEN,ORUDIS,PF-00344989,1528,CC(c1cccc(c1)C(=O)c2ccccc2)C(=O)O,"CAPSULE; CAPSULE, EXTENDED RELEASE; TABLET",YES,NO,YES,NO,ORAL,300,Prescription,,NO,NO,,,,,WYETH,major pharma,31421,1986,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.01,0.13,2.1,,,,14296,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,254.2806,1,3,1,3,0,4,54.37,0.125,0.0969,-0.05348,2.761,All fragments measured,2.9,-0.064,3.12,0.054,4.23,,4.1,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.93233,0.95037,0.81261,0.97581,0.9848,0.98659,0.99957,0.96969,0.93773,184,24.2,8.92,27
74103-06-3,KETOROLAC TROMETHAMINE,TORADOL,PF-00345127,1529,c1ccc(cc1)C(=O)c2ccc3n2CCC3C(=O)O,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,33592,1991,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,13,5.2,,,,22000194,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,"E* (unproven but suspected cause of clinically apparent liver injury, largely due to bleeding episodes)",Moderate,1,Pyrrole,NO,NO,NO,,255.2686,1,3,1,4,0,3,59.3,0.2,-0.511,-0.6069,1.622,All fragments measured,2.5,-0.74,2.58,-0.444,4.29,,3.5,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.94213,0.9568,0.81891,0.99997,0.9848,0.98659,0.9912,0.99269,0.93773,233.1,12.1,2.83,7.41
36894-69-6,LABETALOL HYDROCHLORIDE,NORMODYNE,PF-02299185,1531,CC(CCc1ccccc1)NCC(c2ccc(c(c2)C(=O)N)O)O,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,SCHERING,major pharma,30895,1984,Drugs@FDA,NO,NO,0.25,0.95,Moderate,Reported bioavailability,0.5,9.4,5,,,,5156661,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable although rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,328.4055,5,4,4,5,0,8,95.58,0.315789474,0.371,0.8782,2.5,All fragments measured,1.8,0.59,2.74,0.845,8.21,9.3,7.2,8.8,Zwitter,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53593,0.61677,0.96327,0.98583,0.88651,0.14694,0.73204,0.39983,0.93773,293.3,12.8,32,21.8
175481-36-4,LACOSAMIDE,VIMPAT,PF-04448885,4310,CC(=O)N[C@H](COC)C(=O)NCc1ccccc1,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,UCB,pharma,UCB INC,pharma,39749,2008,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.86,0.6,13,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,250.2936,2,3,2,5,0,6,67.43,0.384615385,0.3,0.3,0.392,All fragments measured,-0.2,-0.2,0.83,0.825,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.71974,0.76981,0.78664,0.4782,0.9848,0.79222,0.95835,0.6885,0.82734,240.5,8.8,6.69,8.06
134678-17-4,LAMIVUDINE,EPIVIR,PF-00219084,1539,c1cn(c(=O)nc1N)[C@@H]2CS[C@@H](O2)CO,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,VIIV HLTHCARE,pharma,35020,1995,Drugs@FDA,NO,NO,0.87,,High,Reported bioavailability,0.64,1.3,,,99,48,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury although flares of hepatitis B can occur during or following therapy),Most,0,,NO,NO,NO,,229.2562,3,5,2,6,0,2,90.37,0.5,-0.389,-0.1,-1.462,Approximated fragment value used,-1,-1,-0.98,-0.948,,4.18,13,4.2,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.60293,0.56419,0.64083,0.30361,0.52457,0.79222,0.54725,0.87038,0.47245,319.3,1.55,3.74,7.92
84057-84-1,LAMOTRIGINE,LAMICTAL,PF-01072776,1540,c1cc(c(c(c1)Cl)Cl)c2c(nc(nn2)N)N,"TABLET, TABLET, CHEWABLE, TABLET, EXTENDED RELEASE, TABLET, ORALLY DISINTEGRATING",YES,NO,YES,NO,ORAL,375,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,34695,1994,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.44,1.1,31,,26,170,,YES,Neurological,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury)  ,Most,0,,NO,NO,NO,,256.0914,4,3,2,5,0,1,90.71,0,1.77,1.65,2.534,All fragments measured,1.6,1.6,1.68,1.674,,5.39,,5.3,Neutral,Class 2,0,0,0,0,2,0,0,2,0,1,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.80905,0.80473,0.8241,0.98982,0.72615,0.79222,0.77959,0.63709,0.93773,220.9,40.3,3.51,7.27
103577-45-3,LANSOPRAZOLE,PREVACID,PF-00346589,1547,Cc1c(ccnc1CS(=O)c2[nH]c3ccccc3n2)OCC(F)(F)F,"CAPSULE, DELAYED REL PELLETS; FOR SUSPENSION, DELAYED RELEASE; TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE",NO,YES,NO,NO,ORAL,15,Over-the-counter,,NO,NO,,,,,TAKEDA PHARMS USA,major pharma,34829,1995,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.03,0.28,1.5,Prodrug,3,,8671668,NO,Gastrointestinal,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,369.3615,1,4,1,5,0,5,67.87,0.25,1.98,3.233,2.598,Benzyl approx. based on a priori value,2.5,2.4,2.41,2.4,9.04,4.29,9.1,3.5,Neutral,Class 2,0,3,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.68593,0.71146,0.75852,0.9674,0.88651,0.98659,0.81335,0.6885,0.25672,401.6,24,6.07,7.89
231277-92-2,LAPATINIB DITOSYLATE,TYKERB,PF-01672112,1548,CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F,TABLET,YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,NOVARTIS,major pharma,39154,2007,Drugs@FDA,NO,NO,,,NA,NA,0.01,,,,,,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent acute liver injury),,2,Aniline; Furan,YES,NO,NO,1XKK,581.0575,2,6,2,8,2,11,106.35,0.172413793,4.22,5,5.965,Benzyl approx. based on a priori value,5.3,5.3,5.22,5.188,,6.34,,5.6,Neutral,Class 4,0,1,0,0,1,0,0,5,1,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,2,0,0,0,0,NO,0.12261,0.15879,0.07107,0.13769,0.33223,0.79222,0.53415,0.15134,0.01222,539,0.377,12,93.5
1223403-58-4,LAROTRECTINIB,VITRAKVI,VC-001215219,,c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Array BioPharma,pharma,LOXO ONCOLOGY INC,pharma,43430,2018,Drugs@FDA,NO,NO,0.34,,High,Reported bioavailability,0.3,0.7,2.9,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),None,0,,NO,NO,NO,,428.4352,2,4,2,8,0,4,86,0.380952381,2.63,2.842,1.999,Valid estimate for difficult structure,2.3,2.3,1.59,1.235,8.41,1.84,8.6,4.9,Neutral,Class 2,0,2,0,0,0,0,0,3,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.61836,0.64784,0.41611,0.95389,0.72615,0.79222,0.82308,0.99269,0.25672,503.8,10.2,13.1,48.9
439239-92-6,LASMIDITAN SUCCINATE,REYVOW,PF-06838911,,O=C(NC1=NC(C(C2CCN(C)CC2)=O)=CC=C1)C3=C(F)C=C(F)C=C3F,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Eli Lilly,major pharma,ELI LILLY AND CO,major pharma,43749,2019,Drugs@FDA,NO,NO,,0.69,High,Fa estimated from reported excretion data,0.42,,5.7,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,377.3604496,1,4,1,5,0,4,62.3,0.316,1.91,2.015,1.976,All fragments measured,3.5,2,2.25,1.178,7.3,8.21,9.9,9.2,Basic,Class 4,0,3,0,0,0,0,0,2,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.90182,0.91505,0.70909,0.97048,0.88651,0.98659,0.98154,0.96969,0.93773,338.7,4.22,11.8,26.6
1256388-51-8,LEDIPASVIR,HARVONI,VC-001215218,4899,CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1c3[nH]c(cn3)c4ccc-5c(c4)C(c6c5ccc(c6)c7ccc8c(c7)[nH]c(n8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)(F)F)NC(=O)OC,TABLET,YES,NO,NO,NO,ORAL,90,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,41922,2014,Drugs@FDA,YES,NO,,0.3,Moderate,Fa estimated from reported excretion data,0.002,,47,,,2,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury in susceptible individuals),None,0,,NO,NO,NO,,888.9999,4,6,4,14,3,14,174.64,0.469387755,5.07,6.79,6.715,Benzyl approx. based on a priori value,7.2,7.1,6.38,6.376,11.23,5.56,13,5.8,Neutral,Class 4,0,2,0,0,0,0,0,5,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,3,0,8,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.0519,0.06516,0.02723,0.04155,0.19128,0.14694,0.11957,0.10729,0.01222,977.7,0.455,16.7,15.9
1350636-82-6,LEFAMULIN ACETATE,XENLETA,PF-06969289,,O=C(O[C@H]1[C@@]([C@H](C)CC2)(C)[C@@](C(CC3)=O)([H])[C@]32[C@@H](C)[C@H](O)[C@](C)(C=C)C1)CS[C@H]4[C@H](O)C[C@H](N)CC4,TABLET,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Nabriva Therapeutics,pharma,NABRIVA,pharma,43696,2019,Drugs@FDA,NO,NO,0.25,0.69,Moderate,Reported bioavailability,0.04,1.2,8,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,507.72664,4,6,3,6,1,6,109.85,0.857,1.09,1.127,4.235,All fragments measured,3.4,0.82,3.4,0.822,,10.06,15,10,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.42641,0.41749,0.1582,0.99984,0.33223,0.37866,0.34154,0.6885,0.47245,559.8,2.72,10.2,37.2
75706-12-6,LEFLUNOMIDE,ARAVA,PF-00345513,1552,Cc1c(cno1)C(=O)Nc2ccc(cc2)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,36048,1998,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,,0.2,432,,,,,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (well known cause of idiosyncratic clinically apparent liver injury as well as reactivation of hepatitis B),Moderate,1,Aniline,YES,NO,NO,,270.2073,1,2,1,4,0,2,55.13,0.166666667,2.9,3.223,2.324,All fragments measured,2.2,2.2,2.2,2.202,11.45,,12,-3.4,Neutral,Class 2,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.9581,0.95974,0.90469,0.97115,0.93048,0.98659,0.99896,0.99269,0.93773,239.3,18.6,19.9,23.6
1369764-02-2,LEMBOREXANT,DAYVIGO,VC-001275220,,O=C([C@H]1[C@@](C2=CC=CC(F)=C2)(COC3=CN=C(C)N=C3C)C1)NC4=NC=C(F)C=C4,TABLET,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,Eisai,pharma,EISAI INC ,pharma,43819,2019,Drugs@FDA,NO,NO,,0.291,Moderate,Fa estimated from reported excretion data,0.06,28.1,17,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,410.4167664,1,5,1,6,0,6,77,0.273,3.43,3.66,3.991,All fragments measured,2.9,2.9,3.29,3.29,9.96,2.47,11,2.9,Neutral,Class 2,0,2,0,0,0,0,0,3,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.62996,0.66526,0.51031,0.9948,0.72615,0.98659,0.89707,0.6885,0.25672,432.1,10.2,47.8,100
191732-72-6,LENALIDOMIDE,REVLIMID,PF-06700569,3317,c1cc2c(c(c1)N)CN(C2=O)C3CCC(=O)NC3=O,CAPSULE,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Celgene,major pharma,CELGENE,major pharma,38713,2005,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.7,,,,,3,,YES,Autoimmune Disease,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (well known but rare cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,5FQD,259.2606,3,3,2,6,0,1,92.5,0.307692308,0.019,0.019,-0.412,Approximated fragment value used,0.047,-0.15,-0.48,-0.487,10.75,2.77,8.1,3.1,Neutral,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.67192,0.69309,0.84366,0.3227,0.88651,0.79222,0.76238,0.63709,0.82734,307.4,5.09,3.75,7.01
417716-92-8,LENVATINIB MESYLATE,LENVIMA,PF-06700173,4942,COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4,CAPSULE,YES,NO,NO,NO,ORAL,24,Prescription,,NO,NO,,,Eisai,pharma,EISAI INC,pharma,42048,2015,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,0.01,,28,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,D,Less,D (possible cause of clinically apparent liver injury),,0,,NO,NO,NO,3WZD,426.853,4,4,3,8,0,6,115.57,0.19047619,3.17,3.13,3.347,All fragments measured,2.9,2.9,2.98,2.905,,4.63,11,4.2,Neutral,Class 4,0,0,0,0,1,0,0,3,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.49162,0.52383,0.42385,0.99997,0.72615,0.37866,0.52543,0.6885,0.25672,423.2,4.2,3.76,18.6
878672-00-5,LESINURAD,ZURAMPIC,PF-06480567,5075,c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4,TABLET,YES,NO,NO,YES,ORAL,200,Prescription,,NO,NO,,,AstraZeneca,major pharma,IRONWOOD PHARMS INC,pharma,42360,2015,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.02,0.3,5,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,404.281,1,6,1,5,0,5,68.01,0.235294118,1.04,0.4531,4.012,All fragments measured,2.4,-0.65,4.62,0.939,2.91,,3.4,1.4,Acidic,Class 3B,0,0,0,0,0,1,0,3,1,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.64245,0.65224,0.54522,0.78313,0.72615,0.98659,0.75449,0.84757,0.25672,317.2,10.9,6.72,11.8
917389-32-3,LETERMOVIR,PREVYMIS,VC-001215222,5262,COc1cccc(c1)N2CCN(CC2)C3=Nc4c(cccc4F)[C@@H](N3c5cc(ccc5OC)C(F)(F)F)CC(=O)O,TABLET,YES,NO,NO,YES,ORAL,480,Prescription,,NO,NO,,,AiCuris,pharma,MERCK,major pharma,43047,2017,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.01,0.65,12,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,1,Aniline,YES,NO,NO,,572.5506,1,5,1,8,2,7,77.84,0.310344828,2.54,2.54,7.058,Calculated fragment value,4.4,1.3,4.16,1.217,4,6.1,5.5,6.6,Zwitter,Class 3B,0,4,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.29667,0.32516,0.07711,0.28882,0.19128,0.98659,0.89075,0.39983,0.25672,542.5,0.825,6.79,72.7
112809-51-5,LETROZOLE,FEMARA,PF-00346482,1556,c1cc(ccc1C#N)C(c2ccc(cc2)C#N)n3cncn3,TABLET,YES,NO,NO,NO,ORAL,2.5,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,35636,1997,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.41,1.9,48,,130,,766403,NO,Oncology,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Imidazole_Triazole,NO,NO,NO,,285.3027,0,3,0,5,0,3,78.29,0.058823529,1.68,1.882,1.429,All fragments measured,2.1,2.1,2.22,2.215,,1.61,,3.4,Neutral,Class 2,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71102,0.73392,0.96701,0.9997,0.88651,0.59178,0.88739,0.99269,0.25672,234.7,36.3,10.7,6.65
58-05-9,LEUCOVORIN CALCIUM,LEUCOVORIN CALCIUM,PF-00344995,1232,c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2CNc3c(c(=O)nc([nH]3)N)N2C=O,"FOR SOLUTION, TABLET",YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,,,HOSPIRA,pharma,19165,1952,Drugs@FDA,NO,NO,0.97,,High,Reported bioavailability,,,,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,1,Aniline,YES,NO,NO,,473.4393,8,8,7,14,2,10,219.84,0.3,-1.8,-1.8,-3.49,Valid estimate for difficult structure,-2,-7.7,-2.41,-7.026,3.61,5.66,3.8,3.1,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,NO,0.17277,0.12222,0.24095,0.44016,0.02915,0.01196,0.04007,0.29329,0.93773,531.6,0.229,1.91,7.91
14769-73-4,LEVAMISOLE HYDROCHLORIDE,ERGAMISOL,PF-00345282,1561,c1ccc(cc1)[C@H]2CN3CCSC3=N2,TABLET,YES,NO,NO,NO,ORAL,150,Discontinued,1999,YES,NO,"Neutropenia, agranulocytosis and thrombotic vasculopathy",WITHDRAWN,,,JANSSEN PHARMA,major pharma,33042,1990,Drugs@FDA,NO,NO,,0.95,High,Fa estimated from reported excretion data,,,4.5,,,,,NO,Anti-infective,NO,NO,,YES,NO,NO,NO,,,LiverTox Additions,0,,,,,0,,NO,NO,NO,,204.2914,0,2,0,2,0,1,15.6,0.363636364,1.04,1.041,1.844,All fragments measured,1.8,1.2,2.15,0.304,,10,,8.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66518,0.75216,0.4725,0.9816,0.9848,0.59178,0.95596,0.63709,0.82734,208.7,31.9,9.33,8.69
102767-28-2,LEVETIRACETAM,KEPPRA,PF-02434000,1563,CC[C@@H](C(=O)N)N1CCCC1=O,"SOLUTION, TABLET, TABLET, EXTENDED RELEASE, TABLET, FOR SUSPENSION",YES,NO,YES,NO,ORAL,3000,Prescription,,NO,NO,,,,,UCB INC,pharma,36494,1999,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.966,0.7,7,,81,,8621430,NO,Neurological,NO,NO,,YES,NO,YES,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,170.209,2,2,1,4,0,3,63.4,0.75,-0.494,-0.2,-0.344,All fragments measured,-0.48,-0.48,-0.74,-0.739,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57582,0.64497,0.29012,0.38034,0.93048,0.98659,0.97723,0.99269,0.47245,189.4,15.9,2.72,6.67
541-15-1,LEVOCARNITINE,CARNITOR,PF-00345284,513,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,2970,Prescription,,NO,NO,,,,,LEADIANT BIOSCI INC,pharma,31408,1985,Drugs@FDA,NO,NO,0.15,,Moderate,Reported bioavailability,,0.39,17.4,,,,,YES,Gastrointestinal,YES,NO,,NO,NO,NO,NO,None,None,,,,,,Less,0,,NO,NO,NO,,161.1989,1,4,1,4,0,4,60.36,0.857142857,-2.23,-2.23,-7.727,Approximated fragment value used,-4.6,-4,-4.21,-3.607,3.8,,3.8,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.38986,0.4585,0.25302,0.03827,0.9848,0.98659,0.98815,0.96969,0.47245,131.8,1.89,1.66,12.1
130018-77-8,LEVOCETIRIZINE DIHYDROCHLORIDE,XYZAL,PF-04087759,1566,c1ccc(cc1)[C@H](c2ccc(cc2)Cl)N3CCN(CC3)CCOCC(=O)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,5,Over-the-counter,,NO,NO,,,Sumitomo Dainippon Pharma,pharma,SANOFI AVENTIS US,major pharma,39227,2007,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.05,0.4,7.5,,,,261,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,388.8878,1,5,1,5,0,8,53.01,0.380952381,1.23,1.23,2.08,All fragments measured,3.4,0.37,2.52,-0.552,3.27,6.71,3.2,8.1,Zwitter,Class 3A,0,0,0,0,1,0,0,2,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.67402,0.72503,0.63753,0.61503,0.72615,0.98659,0.99999,0.39983,0.93773,307.5,4.78,2.02,8
59-92-7,LEVODOPA,BENDOPA,PF-00344566,1567,c1cc(c(cc1C[C@@H](C(=O)O)N)O)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,420,Discontinued,,NO,NO,,,,,VALEANT,pharma,25723,1970,PharmaPendium,NO,NO,0.7,,High,Reported bioavailability,,1.7,2.3,,,,,YES,Neurological,NO,NO,,NO,YES,NO,NO,,None,LiverTox Additions,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Quinones,NO,NO,NO,,197.1879,5,5,4,5,0,3,103.78,0.222222222,-0.782,-0.782,-2.82,All fragments measured,-0.25,-1.9,-0.18,-2.698,2.24,8.85,2.3,9.2,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.36241,0.41176,0.42915,0.08233,0.72615,0.14694,0.6481,0.99269,0.82734,181.9,0.55,4.16,7.71
100986-85-4,LEVOFLOXACIN,LEVAQUIN,PF-00579980,1569,C[C@H]1COc2c3n1cc(c(=O)c3cc(c2N4CCN(CC4)C)F)C(=O)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,750,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,35419,1996,Drugs@FDA,NO,NO,0.99,,High,Reported bioavailability,0.69,1.2,7,,25,,6159013,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,5EIX,361.3675,1,5,1,7,0,2,75.01,0.444444444,-0.736,-0.736,-0.508,All fragments measured,1.9,-0.41,0.17,-2.076,5.19,7.37,6.1,8.3,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.65541,0.59655,0.80655,0.153,0.33223,0.98659,0.92306,0.87038,0.82734,392.7,5.21,3.56,8.01
31690-09-2,LEVOMEFOLATE CALCIUM,BEYAZ,VC-000054920,4621,CN1c2c([nH]c(nc2=O)N)NC[C@@H]1CNc3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,Cox Biosciences,pharma,BAYER HEALTHCARE,major pharma,40445,2010,Drugs@FDA,YES,NO,,,NA,NA,0.44,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,None,1,Aniline,YES,NO,NO,,459.4558,8,7,7,13,2,9,202.77,0.35,-1.71,-1.71,-2.252,Valid estimate for difficult structure,-1,-7.6,-1.6,-5.094,3.61,9.3,3.5,5.8,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,NO,0.16415,0.12732,0.28638,0.25579,0.03975,0.01196,0.0642,0.29329,0.82734,506.6,0.213,2.02,8.1
1477-40-3,LEVOMETHADYL ACETATE HYDROCHLORIDE,ORLAAM,PF-00345371,1571,CC[C@@H](C(C[C@H](C)N(C)C)(c1ccccc1)c2ccccc2)OC(=O)C,CONCENTRATE,YES,NO,NO,NO,ORAL,17.1,Discontinued,2003,YES,NO,Ventricular rhythm disorders,Inxight,,,ROXANE,pharma,34159,1993,Drugs@FDA,NO,NO,,,NA,NA,0.2,,35,,,,,YES,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,353.4977,0,2,0,3,0,9,29.54,0.434782609,2.2,2.602,4.587,All fragments measured,4.5,2.9,5.13,3.155,,9.4,,8.4,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60082,0.6766,0.85136,0.58654,0.9848,0.59178,0.81105,0.29329,0.93773,265.7,15.5,19.2,24.2
96847-54-0,LEVOMILNACIPRAN HYDROCHLORIDE,FETZIMA,PF-00569806,4864,CCN(CC)C(=O)[C@]1(C[C@H]1CN)c2ccccc2,"CAPSULE, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,120,Prescription,,NO,NO,,,Pierre Fabre,pharma,ALLERGAN,major pharma,41480,2013,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,0.78,6.1,12,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,,,,,D,Less,"D (possible, rare cause of clinically apparent liver injury)",,0,,NO,NO,NO,,246.348,2,2,1,3,0,6,46.33,0.533333333,-0.598,-0.598,1.906,Benzyl approx. based on a priori value,0.9,-1.9,1.66,-0.647,,10.36,,9.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85327,0.87942,0.76016,0.84181,0.93048,0.98659,0.98759,0.84757,0.82734,203.2,12.6,8.19,7.79
797-63-7,LEVONORGESTREL,PLAN B,PF-00345735,1572,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,TABLET,YES,NO,NO,NO,ORAL,1.5,Over-the-counter,,NO,NO,,,,,FDN CONSUMER,pharma,26960,1973,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,1.8,13.9,,,,2145157,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Alkynes,NO,NO,NO,3D90,312.4458,1,2,1,2,0,1,37.3,0.761904762,3.19,3.48,3.499,Valid estimate for difficult structure,3.5,3.5,3.32,3.317,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73142,0.75907,0.99687,0.57172,0.93048,0.98659,0.92207,0.63709,0.47245,305.1,15.7,57.2,76.3
2338-37-6,LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS,NOVRAD,PF-00345288,1573,CCC(=O)O[C@@](Cc1ccccc1)(c2ccccc2)[C@@H](C)CN(C)C,"CAPSULE, SUSPENSION",YES,NO,NO,NO,ORAL,,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,22726,1962,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,339.4712,0,2,0,3,1,9,29.54,0.409090909,2.44,2.85,5.21,All fragments measured,4.1,3.1,4.86,3.08,,9.19,,8.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.61344,0.68634,0.9212,0.59906,0.9848,0.59178,0.81105,0.29329,0.93773,263.2,13.6,20.7,50.6
77-07-6,LEVORPHANOL TARTRATE,LEVO-DROMORAN,PF-00345372,1574,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc4c3cc(cc4)O,TABLET,YES,NO,NO,NO,ORAL,12,Prescription,,NO,NO,,,,,VALEANT,pharma,19367,1953,Drugs@FDA,NO,NO,,,NA,NA,0.6,11.5,11,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,257.3706,1,2,1,2,0,0,23.47,0.647058824,1.27,1.273,3.529,All fragments measured,3,1.1,3.22,1.668,10.07,9.06,10,9.4,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74718,0.7742,0.83208,0.96672,0.93048,0.98659,0.69082,0.39503,0.82734,246.7,19.4,25.3,16.8
51-48-9,LEVOTHYROXINE SODIUM,UNITHROID,PF-00344997,2646,c1c(cc(c(c1I)Oc2cc(c(c(c2)I)O)I)I)C[C@@H](C(=O)O)N,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,0.3,Prescription,,NO,NO,,,,,STEVENS J,pharma,36759,2000,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.01,9.2,144,,62,169,33593362,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,1,Organic_Iodide,NO,NO,NO,1Y0X,776.87,4,4,3,5,1,5,92.78,0.133333333,3.16,1.148,3.508,All fragments measured,5.4,2.9,4.8,1.76,2.12,8.27,2.1,8.5,Zwitter,Class 3B,0,0,0,0,0,0,4,2,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,4,1,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.35005,0.46396,0.02907,0.95873,0.72615,0.37866,0.75966,0.84757,0.93773,312.7,0.623,16.6,15.3
56-85-9,L-GLUTAMINE,NUTRESTORE,PF-01386485,1311,C(CC(=O)N)[C@@H](C(=O)O)N,"POWDER, FOR SOLUTION",YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,Eisai,pharma,EMMAUS MEDCL,pharma,38148,2004,Drugs@FDA,NO,NO,,,NA,NA,,0.2,1,,,,,YES,"Cardiovascular, Gastrointestinal",NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,,0,,NO,NO,NO,,146.1445,5,4,3,5,0,4,106.41,0.6,-1.5,-1.5,-3.375,All fragments measured,-2.4,-4,-1.39,-3.902,2.27,9.13,2.2,9.3,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.28903,0.34369,0.20075,0.02956,0.88651,0.37866,0.62064,0.96969,0.47245,143.8,0.672,1.66,6.91
137-58-6,LIDOCAINE HYDROCHLORIDE,XYLOCAINE VISCOUS,PF-00344797,1579,CCN(CC)CC(=O)Nc1c(cccc1C)C,SOLUTION,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,FRESENIUS KABI USA,pharma,19969,1954,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.3,1.5,1.5,,,,52845259,NO,"Cardiovascular, Neurological",NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,234.3373,1,2,1,3,0,5,32.34,0.5,1.8,1.45,1.954,All fragments measured,2.7,2,2.33,1.806,,7.96,14,7.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8512,0.86841,0.67664,0.99756,0.93048,0.98659,0.85719,0.84757,0.82734,174,30.5,11.3,17.9
668270-12-0,LINAGLIPTIN,TRADJENTA,PF-06708369,4175,CC#CCn1c2c(nc1N3CCC[C@H](C3)N)n(c(=O)n(c2=O)Cc4nc(c5ccccc5n4)C)C,TABLET,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,BOEHRINGER INGELHEIM,major pharma,40665,2011,Drugs@FDA,NO,NO,0.3,,Moderate,Reported bioavailability,0.75,15.9,100,,,102,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,Less,,,D,Less,D (possible rare cause of clinically apparent acute liver injury),Less,1,Alkynes,NO,NO,NO,2RGU,472.5422,2,7,1,10,0,4,116.86,0.4,1.29,1.447,1.909,Benzyl approx. based on a priori value,3.1,2.1,2.17,-0.16,,10.01,,9.4,Basic,Class 4,0,0,0,0,0,0,0,4,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.54697,0.51415,0.24364,0.99936,0.33223,0.98659,0.54694,0.84757,0.25672,543.3,2.25,5.29,39.4
154-21-2,LINCOMYCIN HYDROCHLORIDE,LINCOCIN,PF-00345052,1582,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CAPSULE,YES,NO,NO,NO,ORAL,180,Discontinued,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,23740,1964,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.3,1.2,5.4,,,,20518880,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,None,0,,NO,NO,NO,,406.5374,5,8,5,8,0,7,122.49,0.944444444,0.299,-0.06749,1.28,All fragments measured,0.001,-0.4,0.63,-0.44,12.91,8.78,12,8.5,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.31408,0.29043,0.53223,0.49422,0.19128,0.05547,0.24793,0.53315,0.47245,558.4,0.434,8.51,26.6
165800-03-3,LINEZOLID,ZYVOX,PF-00184033,1584,CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(c2)F)N3CCOCC3,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Pfizer,major pharma,PHARMACIA AND UPJOHN,major pharma,36634,2000,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.69,0.58,4.7,,139,,318143146,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury usually in association with lactic acidosis),Moderate,1,Aniline,YES,NO,NO,,337.3461,1,2,1,7,0,4,71.11,0.5,0.878,0.5581,0.168,Estimated fragment value used,1.1,1.1,0.83,0.829,,4.23,11,2.6,Neutral,Class 2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.89727,0.86878,0.9303,0.74543,0.72615,0.98659,0.93728,0.96969,0.82734,376.4,13.8,5.46,9.18
55-06-1,LIOTHYRONINE SODIUM,CYTOMEL,PF-00344894,1585,c1cc(c(cc1Oc2c(cc(cc2I)C[C@@H](C(=O)O)N)I)I)O,TABLET,YES,NO,NO,NO,ORAL,0.1,Prescription,,NO,NO,,,,,KING PHARMS,pharma,20583,1956,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,,0.6,60,,,,27038561,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,C,Less,C (probable rare cause of clinically apparent liver injury),Less,1,Organic_Iodide,NO,NO,NO,2H79,650.9735,4,4,3,5,1,5,92.78,0.133333333,2.38,2.38,2.631,All fragments measured,4.4,2.7,4.12,1.539,2.13,8.27,2.1,8.7,Zwitter,Class 3B,0,0,0,0,0,0,3,2,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.37479,0.48285,0.04216,0.87422,0.72615,0.37866,0.75966,0.84757,0.93773,306.2,1.09,13.4,14
608137-32-2,LISDEXAMFETAMINE DIMESYLATE,VYVANSE,VC-001215221,4135,C[C@@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)N,"CAPSULE, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,70,Prescription,,NO,NO,,,Shire (Takeda),major pharma,SHIRE,major pharma,39136,2007,Drugs@FDA,NO,NO,,0.96,High,Fa estimated from reported excretion data,,,1,,,52,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,,,,,0,,NO,NO,NO,,263.3785,5,3,3,4,0,8,81.14,0.533333333,-1.63,-1.63,0.81,All fragments measured,0.95,-2,0.68,-2.423,,10.48,13,11,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60637,0.68927,0.8679,0.79841,0.9848,0.37866,0.86471,0.39983,0.82734,230,1.19,4.54,12.2
76547-98-3,LISINOPRIL,PRINIVIL,PF-00344570,1587,c1ccc(cc1)CC[C@@H](C(=O)O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,MERCK,major pharma,32140,1987,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,1,1.8,12,,,,142328,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,1O86,405.4879,5,7,4,8,0,13,132.96,0.571428571,-1.83,0.1184,-1.822,Approximated fragment value used,0.66,-3.1,1.21,-1.805,2.18,10.5,2.2,11,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.19831,0.22339,0.53825,0.03306,0.33223,0.14694,0.35999,0.10729,0.82734,392.5,0.418,3.86,8.1
31036-80-3,LOFEXIDINE HYDROCHLORIDE,LUCEMYRA,PF-02400222,1593,CC(C1=NCCN1)Oc2c(cccc2Cl)Cl,TABLET,YES,NO,NO,NO,ORAL,2.88,Prescription,,NO,NO,,,Britannia (Genus Pharmaceuticals),pharma,US WORLDMEDS LLC,nonprofit,43236,2018,Drugs@FDA,NO,NO,0.72,,High,Reported bioavailability,0.45,6.9,12,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,259.1318,1,2,1,3,0,3,33.62,0.363636364,1.11,1.134,3.463,All fragments measured,2.1,0.17,2.88,1.153,,9.8,,9.4,Basic,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.92685,0.92717,0.84288,0.99983,0.9848,0.98659,0.8759,0.99269,0.82734,229.4,8.72,2.2,11.6
98079-51-7,LOMEFLOXACIN HYDROCHLORIDE,MAXAQUIN,PF-00345518,1594,CCn1cc(c(=O)c2c1c(c(c(c2)F)N3CCNC(C3)C)F)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,2008,YES,NO,Phototoxicity and QTc prolongation,Micromedex,,,PHARMACIA,major pharma,33655,1992,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.85,2.2,7.75,,,,19,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,,351.3479,2,4,2,6,0,3,74.57,0.411764706,-0.387,-0.387,-0.112,All fragments measured,2.4,-0.33,-0.38,-2.891,,8.57,5.8,8.4,Zwitter,Class 3A,0,2,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.71111,0.68076,0.86301,0.24842,0.52457,0.79222,0.92598,0.99269,0.82734,375.4,2.35,4.11,7.91
182431-12-5,LOMITAPIDE MESYLATE,JUXTAPID,PF-00579905,4721,c1ccc(c(c1)c2ccc(cc2)C(F)(F)F)C(=O)NC3CCN(CC3)CCCCC4(c5ccccc5-c6c4cccc6)C(=O)NCC(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,AEGERION,pharma,41264,2012,Drugs@FDA,NO,NO,0.07,,Low,Reported bioavailability,0.002,14,,,,,,YES,Cardiovascular,NO,NO,,NO,NO,NO,NO,,,,,C,Less,C (probable cause of clinically significant liver injury),,0,,NO,NO,NO,,693.7204,2,3,2,5,2,10,61.44,0.333333333,3.86,5.97,7.001,Very high LogP unrealistic in nature,8.7,7.5,7.43,5.864,12.66,8.7,12,8.6,Basic,Class 4,0,6,0,0,0,0,0,4,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,4,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.09359,0.16254,0.03482,0.03025,0.9848,0.79222,0.98463,0.10729,0.03452,501.3,1.18,11.3,75.8
13010-47-4,LOMUSTINE,GLEOSTINE,PF-00346528,1596,C1CCC(CC1)NC(=O)N(CCCl)N=O,CAPSULE,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,CORDEN PHARMA,pharma,27976,1976,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.5,,1.5,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),None,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,233.6952,1,2,1,5,0,5,61.77,0.888888889,2.41,2.925,2.755,All fragments measured,2.6,2.6,2.51,2.514,10.88,,13,,Neutral,Class 2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.80137,0.83821,0.67212,0.9881,0.9848,0.98659,0.98347,0.96969,0.47245,173.7,44.7,11.7,27.7
192725-17-0,LOPINAVIR,KALETRA,PF-01369926,1601,Cc1cccc(c1OCC(=O)N[C@@H](Cc2ccccc2)[C@H](C[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O)C,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,36784,2000,Drugs@FDA,YES,NO,,,Moderate,Based on textual comment,0.01,,,,100,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,LiverTox Additions,1,D,Less,"D (possible, rare cause of clinically apparent liver injury)",Moderate,0,,NO,NO,NO,1MUI,628.8008,4,5,4,9,2,15,120,0.432432432,4.05,5.4,6.095,Estimated fragment value used,5.1,5.1,5.24,4.754,,,11,,Neutral,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.11836,0.19791,0.04831,0.50189,0.72615,0.14694,0.48067,0.03725,0.25672,598,1.68,28,162
76470-66-1,LORACARBEF,LORABID,PF-00579879,1603,c1ccc(cc1)[C@H](C(=O)N[C@H]2[C@H]3CCC(=C(N3C2=O)C(=O)O)Cl)N,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,800,Discontinued,,NO,NO,,,,,KING PHARMS,pharma,33603,1991,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.75,0.33,1,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,,3,Alkyl_halide_Sulfate_ester; Beta_Lactams; Michael_acceptor,NO,YES,NO,,349.7689,4,5,3,7,0,4,112.73,0.3125,-0.531,-0.531,-0.472,Benzyl approx. based on a priori value,0.49,-1.1,-0.89,-4.138,3.1,6.87,2.1,7.4,Zwitter,Class 3A,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,NO,0.48817,0.48744,0.87137,0.06132,0.72615,0.37866,0.5547,0.96969,0.82734,399,0.317,4.19,7.13
79794-75-5,LORATADINE,CLARITIN,PF-00346581,1605,CCOC(=O)N1CCC(=C2c3ccc(cc3CCc4c2nccc4)Cl)CC1,"CAPSULE, SUSPENSION, SYRUP, TABLET, TABLET, CHEWABLE, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,10,Over-the-counter,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,34071,1993,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.03,,,,,,4381818,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),None,0,,NO,NO,NO,,382.8832,0,3,0,4,1,3,42.43,0.363636364,3.96,4.89,5.051,All fragments measured,5.3,5.3,5.32,5.319,,4.27,,4.7,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.70174,0.75932,0.67472,0.46891,0.9848,0.59178,0.96711,0.87038,0.93773,310.6,5.89,29.6,64
846-49-1,LORAZEPAM,ATIVAN,PF-00345101,1606,c1ccc(c(c1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)O)Cl,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,VALEANT,pharma,28398,1977,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.09,1.3,13,,,,109522434,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,321.1581,2,2,2,4,0,1,61.69,0.066666667,2.36,2.836,2.368,All fragments measured,2.9,2.9,2.49,2.49,10.8,,8.2,0.63,Neutral,Class 1A,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.84556,0.8871,0.98288,0.95931,0.9848,0.79222,0.98375,0.63709,0.93773,323.2,23.2,7.07,8.35
616202-92-7,LORCASERIN HYDROCHLORIDE,BELVIQ,PF-03609190,4374,C[C@H]1CNCCc2c1cc(cc2)Cl,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,20,Prescription,,NO,NO,,,Arena Pharmaceuticals,pharma,EISAI INC,pharma,41087,2012,Drugs@FDA,NO,NO,,0.92,High,Fa estimated from reported excretion data,0.3,,11.9,,,,,NO,Metabolic Disease,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,195.6886,1,1,1,1,0,0,12.03,0.454545455,0.462,0.462,3.236,All fragments measured,2.9,0.65,2.81,0.276,,9.99,,10,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.62454,0.5417,0.42034,0.99968,0.23327,0.98659,0.43308,0.39503,0.82734,141.9,16.6,8.69,19.4
1454846-35-5,LORLATINIB,LORBRENA,PF-06463922,,C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,43406,2018,Drugs@FDA,NO,NO,0.81,,High,Reported bioavailability,0.34,4.4,24,,,,21320972,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,406.413,2,5,1,8,0,0,110.06,0.238095238,2.28,2.318,1.865,Benzyl approx. based on a priori value,2.7,2.7,1.35,1.339,,6.05,,5.1,Neutral,Class 2,0,1,0,0,0,0,0,3,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,6,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,YES,0.55446,0.55416,0.53294,0.98509,0.52457,0.98659,0.58248,0.39503,0.25672,445.8,22.7,5.23,7.82
114798-26-4,LOSARTAN POTASSIUM,COZAAR,PF-00579890,1610,CCCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)CO)Cl,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,MERCK,major pharma,34803,1995,Drugs@FDA,NO,NO,0.33,,High,Reported bioavailability,0.013,0.5,2,,56,,5231996,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (Probable causeof rare instances of clinically apparent liver injury),Less,0,,NO,NO,NO,,422.9106,2,5,2,7,0,8,92.51,0.272727273,1.68,1.68,3.852,All fragments measured,4.5,1,3.27,1.426,4.16,2.94,4.4,3.8,Acidic,Class 3B,0,0,0,0,1,0,0,4,0,2,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,NO,0.36033,0.41494,0.44358,0.7887,0.72615,0.79222,0.76228,0.39983,0.03452,343.8,3.22,18.9,41
75330-75-5,LOVASTATIN,MEVACOR,PF-00345293,1612,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,80,Prescription,,NO,NO,,,,,MERCK,major pharma,32020,1987,Drugs@FDA,NO,YES,0.05,,Low,Reported bioavailability,0.04,0.87,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,404.5396,1,3,1,5,0,7,72.83,0.75,3.16,5.133,4.082,All fragments measured,4.4,4.4,4.14,4.142,,,15,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64457,0.68723,0.54372,0.79658,0.72615,0.98659,0.92631,0.53315,0.47245,410.3,12,37.6,318
27833-64-3,LOXAPINE SUCCINATE,LOXITANE,PF-00345001,1613,CN1CCN(CC1)C2=Nc3ccccc3Oc4c2cc(cc4)Cl,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,250,Prescription,,NO,NO,,,,,ACTAVIS LABS UT INC,pharma,27450,1975,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.054,,7.6,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury),,0,,NO,NO,NO,,327.808,0,2,0,4,0,1,28.07,0.277777778,2.72,3.55,3.981,Approximated fragment value used,4.2,4,3.11,2.906,,7.32,,7.7,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7893,0.81049,0.96515,0.96841,0.88651,0.59178,0.78426,0.63709,0.93773,301,8.63,10,32.8
333963-40-9,LUBIPROSTONE,AMITIZA,VC-001215225,4123,CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,48,Prescription,,NO,NO,,,Sucampo Pharmaceuticals(Mallinckrodt),pharma,SUCAMPO PHARMA LLC,pharma,38748,2006,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.06,,,,,,,NO,Gastrointestinal,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,390.4619,2,5,2,5,0,11,83.83,0.9,1.1,1.1,3.832,All fragments measured,4.5,2,2.86,0.268,4.77,,4.8,,Acidic,Class 3A,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,1,0,0,NO,0.49124,0.57013,0.62785,0.90037,0.72615,0.79222,0.84211,0.15134,0.47245,346.3,5.78,33.1,12
936727-05-8,LUMACAFTOR,ORKAMBI,PF-05235345,5010,Cc1ccc(nc1c2cccc(c2)C(=O)O)NC(=O)C3(CC3)c4ccc5c(c4)OC(O5)(F)F,"GRANULE, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Vertex Pharmaceuticals,pharma,VERTEX PHARMS,pharma,42187,2015,Drugs@FDA,YES,NO,,0.49,High,Fa estimated from reported excretion data,0.01,1.2,,,,128,,YES,Respiratory,NO,NO,,NO,NO,YES,NO,,,,,E*,Ambiguous,E* (unproven but suspectedrare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,452.4069,2,4,2,7,1,5,97.75,0.208333333,2.44,2.561,6.054,All fragments measured,6.3,3.2,4.8,1.902,10.82,4.44,4.3,3.4,Acidic,Class 1B,0,2,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.3836,0.4037,0.31224,0.08715,0.52457,0.79222,0.7102,0.84757,0.25672,418.9,8.48,12.6,12.8
313368-91-1,LUMATEPERONE,CAPLYTA,VC-001275221,,O=C(C1=CC=C(F)C=C1)CCCN2CC[C@@](N3CCN(C)C4=C3C5=CC=C4)([H])[C@@]5([H])C2,CAPSULE,YES,NO,NO,NO,ORAL,42,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,INTRA-CELLULAR THERAPIES INC,pharma,43819,2019,Drugs@FDA,NO,NO,0.044,0.58,Low,Reported bioavailability,0.026,4.1,18,,,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,,,,,,,,,1,Aniline,YES,NO,NO,,393.4971432,0,2,0,4,0,5,26.79,0.458,2.88,2.814,4.435,All fragments measured,4.1,2.4,3.99,1.9,,9.1,,9,Basic,Class 4,0,1,0,0,0,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.75179,0.78093,0.60932,0.91779,0.88651,0.59178,0.75963,0.84757,0.93773,387.8,1.83,43,92.6
82186-77-4,LUMEFANTRINE,COARTEM,PF-06369820,1617,CCCCN(CCCC)CC(c1cc(cc\2c1-c3ccc(cc3/C2=C/c4ccc(cc4)Cl)Cl)Cl)O,TABLET,YES,NO,NO,NO,ORAL,240,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,39910,2009,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,,,,Less,0,,NO,NO,NO,,528.9402,1,2,1,2,2,10,23.47,0.333333333,5.27,5.29,10.202,Very high LogP unrealistic in nature,9,8.6,9.37,8.123,,8.71,13,8.7,Basic,Class 4,0,0,0,0,3,0,0,4,2,1,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,3,0,0,0,3,0,0,0,0,NO,0.19997,0.2701,0.12313,0.02469,0.93048,0.98659,0.69082,0.21184,0.25672,360.4,0.426,33.1,48.6
367514-87-2,LURASIDONE HYDROCHLORIDE,LATUDA,PF-06708379,4168,c1ccc2c(c1)c(ns2)N3CCN(CC3)C[C@@H]4CCCC[C@H]4CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,TABLET,YES,NO,NO,NO,ORAL,160,Prescription,,NO,NO,,,Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma),pharma,SUNOVION PHARMS INC,pharma,40479,2010,Drugs@FDA,NO,NO,0.09,,Low,Reported bioavailability,0.01,88,18,,,109,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,492.676,0,4,0,6,1,5,56.75,0.678571429,3.77,5.4,5.614,Valid estimate for difficult structure,4.7,3.8,4.82,4.684,,6.58,,7.8,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,6,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.52986,0.59949,0.19002,0.51537,0.72615,0.59178,0.83202,0.84757,0.93773,517.7,3.69,60.4,250
1110766-97-6,LUSUTROMBOPAG,MULPLETA,VC-001215224,5059,CCCCCCO[C@@H](C)c1cccc(c1OC)c2csc(n2)NC(=O)c3cc(c(c(c3)Cl)/C=C(\C)/C(=O)O)Cl,TABLET,YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,Shionogi,pharma,SHIONOGI INC,pharma,43312,2018,Drugs@FDA,NO,NO,,0.67,High,Fa estimated from reported excretion data,0.001,0.6,27,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,"E* (suspected, but unproven cause of clinically apparent liver injury)",None,3,1_4_Diketones; Aminothiazole; Michael_acceptor,NO,YES,NO,,591.5458,2,6,2,7,2,13,97.75,0.344827586,4.23,4.23,7.925,Very high LogP unrealistic in nature,8.1,4.5,7.82,4.005,4.33,1.3,4.5,0.9,Acidic,Class 3B,0,0,0,0,2,0,0,3,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,2,0,1,0,0,NO,0.13347,0.18179,0.0646,0.02977,0.52457,0.79222,0.42267,0.07566,0.25672,493.1,0.345,35.4,38.8
381231-18-1,MACIMORELIN ACETATE,MACRILEN,VC-001215223,5271,CC(C)(C(=O)N[C@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@H](Cc3c[nH]c4c3cccc4)NC=O)N,FOR SOLUTION,YES,NO,NO,NO,ORAL,35,Prescription,,NO,NO,,,Aeterna Zentaris,pharma,NOVO,pharma,43089,2017,Drugs@FDA,NO,NO,,,NA,NA,,,4.1,,,,,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,,,,,,,,,1,3_Methyl_Indole,NO,NO,NO,,474.5548,7,4,6,9,1,10,144.9,0.269230769,2.18,1.82,1.143,All fragments measured,2.2,1.5,2,1.202,,8.24,10,8,Basic,Class 4,0,0,0,0,0,0,0,4,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.14307,0.19898,0.23765,0.93872,0.88651,0.02306,0.26735,0.29329,0.03452,494.2,0.215,7.34,68.4
441798-33-0,MACITENTAN,OPSUMIT,PF-06681660,4809,CCCNS(=O)(=O)Nc1c(c(ncn1)OCCOc2ncc(cn2)Br)c3ccc(cc3)Br,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Actelion,pharma,ACTELION PHARMS LTD,pharma,41565,2013,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.01,0.7,14,,,153,,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unlikely but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,588.2729,2,10,2,10,1,11,128.22,0.263157895,3.09,3.09,4.3,Benzyl approx. based on a priori value,5.3,3.6,4.06,2.128,4.99,1.58,5.8,2.6,Acidic,Class 1B,0,0,0,0,0,2,0,3,0,1,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.26085,0.27558,0.06651,0.9351,0.19128,0.79222,0.32967,0.15134,0.25672,454.9,3.85,20.5,120
10262-69-8,MAPROTILINE HYDROCHLORIDE,LUDIOMIL,PF-06700198,1634,CNCCCC12CCC(c3c1cccc3)c4c2cccc4,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,29556,1980,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.12,22.6,43,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,,,,Moderate,0,,NO,NO,NO,,277.4033,1,1,1,1,0,4,12.03,0.4,1.66,2.1,4.524,All fragments measured,4.1,1.7,4.95,2.098,,10.62,,10,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.90079,0.68465,0.93798,0.82952,0.23327,0.98659,0.43308,0.96969,0.93773,177.8,6.96,11.6,24.2
376348-65-1,MARAVIROC,SELZENTRY,PF-03419979,1635,Cc1nnc(n1[C@@H]2C[C@H]3CC[C@@H](C2)N3CC[C@@H](c4ccccc4)NC(=O)C5CCC(CC5)(F)F)C(C)C,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Pfizer,major pharma,VIIV HLTHCARE,pharma,39300,2007,Drugs@FDA,NO,NO,0.23,,Moderate,Reported bioavailability,0.24,2.77,14,,,,614174,NO,Anti-infective,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4MBS,513.6655,1,4,1,6,1,8,63.05,0.689655172,2.02,2.754,3.262,All fragments measured,4.5,2.4,4.02,1.824,,9.72,14,9.2,Basic,Class 4,0,2,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.51631,0.63529,0.14732,0.88332,0.88651,0.98659,0.97864,0.39983,0.93773,472,2.06,4.79,26.5
22232-71-9,MAZINDOL,SANOREX,PF-00345374,1640,c1ccc2c(c1)C3=NCCN3C2(c4ccc(cc4)Cl)O,TABLET,YES,NO,NO,NO,ORAL,8,Discontinued,,NO,NO,,,,,HEXIM,pharma,26829,1973,Drugs@FDA,NO,NO,,0.88,High,Fa estimated from reported excretion data,,,40,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,284.7402,1,2,1,3,0,1,35.83,0.1875,1.99,2.005,3.385,Vinyl approx. based on a priori value,3,0.79,1.94,-0.066,9.82,12.86,13,11,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.88495,0.90735,0.96522,0.99835,0.9848,0.98659,0.90518,0.63709,0.93773,299.2,21.3,20.9,9.95
31431-39-7,MEBENDAZOLE,VERMOX,PF-00344727,1641,COC(=O)Nc1[nH]c2ccc(cc2n1)C(=O)c3ccccc3,"TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,27208,1974,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,0.09,1.2,,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Moderate,1,2_AminoImidazole_2_AminoThiazole,NO,NO,NO,,295.2927,2,3,2,6,0,4,84.08,0.0625,2.85,2.802,3.077,All fragments measured,3,2.9,2.76,2.725,7.44,3.64,11,2.8,Neutral,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75385,0.75885,0.99106,0.99563,0.88651,0.79222,0.83995,0.96969,0.25672,280.7,8.18,56.3,17.5
64-55-1,MEBUTAMATE,DORMATE,CL-56871,1644,CCC(C)C(C)(COC(=O)N)COC(=O)N,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,,NO,NO,,,,,MEDPOINTE PHARM HLC,pharma,22472,1961,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,232.2768,4,4,2,6,0,8,104.64,0.8,0.773,0.773,1.314,All fragments measured,1.3,1.3,1.14,1.136,,,15,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.6121,0.65149,0.66212,0.88731,0.88651,0.79222,0.63913,0.39983,0.47245,193.8,16.8,4.45,6.65
60-40-2,MECAMYLAMINE HYDROCHLORIDE,INVERSINE,VC-001230244,1646,CC1(C2CCC(C2)C1(C)NC)C,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,,,TARGACEPT,pharma,20515,1956,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.6,,,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,167.2911,1,1,1,1,0,1,12.03,1,0.878,0.878,2.825,All fragments measured,2.2,-1,3.01,-0.035,,11.35,,11,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57522,0.50265,0.2776,0.97345,0.23327,0.98659,0.43308,0.63709,0.47245,160.3,8.55,13.2,11.7
569-65-3,MECLIZINE HYDROCHLORIDE,ANTIVERT,PF-00344801,1649,Cc1cccc(c1)CN2CCN(CC2)C(c3ccccc3)c4ccc(cc4)Cl,"TABLET, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,CASPER PHARMA LLC,pharma,20865,1957,Drugs@FDA,NO,NO,,,NA,NA,,,5,,,,,NO,"Gastrointestinal, Neurological",NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely to be a cause of clinically apparent liver injury),None,0,,NO,NO,NO,,390.9483,0,2,0,2,1,5,6.48,0.28,3.65,6.6,6.732,All fragments measured,5.8,5.7,4.77,4.537,,6.73,,7.2,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.43523,0.42931,0.62487,0.11166,0.93048,0.59178,0.32149,0.84757,0.25672,287.5,0.843,40.4,50.1
644-62-2,MECLOFENAMATE SODIUM,MECLOMEN,PF-00344723,1650,Cc1ccc(c(c1Cl)Nc2ccccc2C(=O)O)Cl,CAPSULE,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,PARKE DAVIS,major pharma,29397,1980,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,23.3,1.3,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Moderate,1,Aniline,YES,NO,NO,,296.1486,2,2,2,3,1,3,49.33,0.071428571,1.87,1.87,6.406,All fragments measured,4.8,1.8,6.02,2.955,3.59,,4.2,-1.5,Acidic,Class 1A,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.85636,0.87523,0.99242,0.54784,0.9848,0.79222,0.99636,0.99269,0.93773,225.9,19.9,71.1,27.9
71-58-9,MEDROXYPROGESTERONE ACETATE,PROVERA,PF-00345005,1659,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,21719,1959,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,0.14,847.1,14.1,,196,,254945904,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,A,Most,A (well established cause of clniically apparent liver injury),Less,0,,NO,NO,NO,,386.5244,0,3,0,4,0,3,60.44,0.791666667,2.76,3.675,4.196,Valid estimate for difficult structure,3.7,3.7,4.04,4.04,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71122,0.75951,0.65212,0.91975,0.88651,0.59178,0.9879,0.99269,0.47245,393.1,16.7,46.5,115
61-68-7,MEFENAMIC ACID,PONSTEL,PF-00344800,1663,Cc1cccc(c1C)Nc2ccccc2C(=O)O,CAPSULE,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,SHIONOGI INC,pharma,24559,1967,Drugs@FDA,NO,NO,,0.52,High,Fa estimated from reported excretion data,0.1,1.06,2.5,,,,53015164,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Aniline,YES,NO,NO,5IKR,241.2851,2,2,2,3,1,3,49.33,0.133333333,1.64,1.526,5.287,All fragments measured,4.6,1.6,5,2.041,3.73,,4.4,-0.22,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85771,0.89373,0.72533,0.86779,0.9848,0.79222,0.99636,0.99269,0.93773,187.8,29.8,81,50.7
53230-10-7,MEFLOQUINE HYDROCHLORIDE,MEFLOQUINE HYDROCHLORIDE,PF-04131598,1665,c1cc2c(cc(nc2c(c1)C(F)(F)F)C(F)(F)F)[C@@H]([C@H]3CCCCN3)O,TABLET,YES,NO,NO,NO,ORAL,1250,Prescription,,NO,NO,,,,,US ARMY WALTER REED,nonprofit,32630,1989,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.02,20,504,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,378.3122,2,3,2,3,0,2,45.15,0.470588235,2.25,2.781,3.669,All fragments measured,3.5,3,3.19,1.384,12.81,9.24,14,8.7,Basic,Class 2,0,6,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.83118,0.86957,0.70317,0.76705,0.9848,0.79222,0.98253,0.96969,0.93773,328.5,9.94,10.1,25.7
595-33-5,MEGESTROL ACETATE,MEGACE,PF-07052400,1667,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,320,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,26163,1971,Drugs@FDA,NO,NO,,0.66,High,Fa estimated from reported excretion data,,,34,,,,,YES,"Genitourinary, Metabolic Disease, Oncology",NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,A,Most,A (well established cause of clniically apparent liver injury),Less,0,,NO,NO,NO,,384.5085,0,3,0,4,0,3,60.44,0.708333333,2.73,2.695,3.772,Valid estimate for difficult structure,3,3,3.83,3.828,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71896,0.76622,0.66462,0.95982,0.88651,0.59178,0.9879,0.99269,0.47245,384.7,19.1,48.8,145
71125-38-7,MELOXICAM,MOBIC,PF-00346297,1676,Cc1cnc(s1)NC(=O)C2=C(c3ccccc3S(=O)(=O)N2C)O,"CAPSULE, SUSPENSION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,BOEHRINGER INGELHEIM,major pharma,36629,2000,Drugs@FDA,NO,NO,0.89,,High,Reported bioavailability,0.006,0.15,22,,75,,58586,YES,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,2,Aminothiazole; Michael_acceptor,NO,YES,NO,4M11,351.4007,2,3,2,7,0,2,99.6,0.142857143,0.182,0.5011,2.292,A priori fragment value used,2.6,-2.7,2.38,-1.022,3.01,3.18,3.8,3.1,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,2,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.78586,0.69,0.86272,0.55233,0.72615,0.79222,0.33284,0.87038,0.93773,396.2,21.6,2.84,20.7
148-82-3,MELPHALAN,ALKERAN,PF-00345054,1678,c1cc(ccc1C[C@@H](C(=O)O)N)N(CCCl)CCCl,TABLET,YES,NO,NO,NO,ORAL,6,Prescription,,NO,NO,,,,,APOTEX INC,pharma,23393,1964,Drugs@FDA,NO,NO,0.56,,High,Reported bioavailability,0.08,0.5,1.5,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,2,Alkyl_halide_Sulfate_ester; Aniline,YES,NO,NO,,305.2002,3,3,2,4,0,8,66.56,0.461538462,0.232,0.3086,-0.207,All fragments measured,2,0.36,1.47,-1.034,2.12,9.54,2.3,9.2,Zwitter,Class 3A,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.66352,0.7173,0.99994,0.4368,0.88651,0.79222,0.96282,0.39983,0.82734,217.5,1.42,6.78,9.58
19982-08-2,MEMANTINE HYDROCHLORIDE,NAMENDA,PF-00345664,1679,CC12CC3CC(C1)(CC(C3)(C2)N)C,"CAPSULE, EXTENDED RELEASE, SOLUTION, TABLET",YES,NO,YES,NO,ORAL,20,Prescription,,NO,NO,,,Merz,pharma,ALLERGAN,major pharma,37910,2003,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.55,10,70,,92,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,179.3018,2,1,1,1,0,0,26.02,1,-0.0446,0.2766,3.033,All fragments measured,3.1,0.095,3.48,0.554,,10.79,,10,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.54267,0.51825,0.33227,0.94533,0.23327,0.98659,0.74426,0.39503,0.47245,136.8,25.9,7.64,9.6
6700-42-1,MENADIOL SODIUM DIPHOSPHATE,SYNKAYVITE,PF-00579903,5032,Cc1cc(c2ccccc2c1OP(=O)(O)O)OP(=O)(O)O,TABLET,YES,NO,NO,NO,ORAL,10,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,15172,1941,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,334.1557,4,4,4,8,0,4,133.52,0.090909091,-2.15,-2.15,0.077,Calculated fragment value,1.7,-3.9,-1.16,-6.024,1.23,,1.6,,Acidic,Class 3A,0,0,0,2,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,NO,0.61479,0.47001,0.94309,0.97729,0.19128,0.14694,0.21512,0.96969,0.93773,255.6,0.776,18.2,8.57
58-27-5,MENADIONE,MENADIONE,PF-00344802,1683,CC1=CC(=O)c2ccccc2C1=O,TABLET,YES,NO,NO,NO,ORAL,30,Discontinued,1983,YES,NO,Unspecified toxicity,NA,,,ELI LILLY AND CO,major pharma,14734,1940,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,172.18,0,2,0,2,0,0,34.14,0.090909091,1.31,1.372,2.446,All fragments measured,2,2,2.02,2.018,,,,,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5392,0.64477,0.29885,0.97516,0.93048,0.59178,0.88329,0.39503,0.82734,136.2,16.6,21.6,59.1
24360-97-2,MEPAZINE ACETATE,N/A,PF-06615419,1688,CN1CCCC(C1)CN2c3ccccc3Sc4c2cccc4,N/A,N/A,N/A,N/A,NO,ORAL,,Discontinued,1970,YES,YES,"Granulocytopenia, granulocytosis, paralytic ileus, urinary retention, seizures, hypotension, and jaundice",FederalRegister,,,N/A,,20821,1957,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,0,,NO,NO,NO,,310.4564,0,2,0,2,1,2,6.48,0.368421053,2.83,3.04,5.068,All fragments measured,4.8,3.4,4.9,2.956,,9.42,,9,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80532,0.82784,0.99851,0.66119,0.9848,0.59178,0.84849,0.87038,0.93773,273.1,5.42,26.7,61.3
25990-43-6,MEPENZOLATE BROMIDE,CANTIL,PF-00345003,1689,C[N+]1(CCCC(C1)OC(=O)C(c2ccccc2)(c3ccccc3)O)C,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,20773,1956,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,340.436,1,3,1,4,0,5,46.53,0.380952381,-0.0991,-0.0991,0.157,Approximated fragment value used,0.3,0.3,-0.5,-0.5,11.19,,14,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92476,0.94235,0.91692,0.943,0.9848,0.98659,0.98835,0.84757,0.93773,268.2,1.71,11.3,6.65
57-42-1,MEPERIDINE HYDROCHLORIDE,DEMEROL,PF-00345376,1690,CCOC(=O)C1(CCN(CC1)C)c2ccccc2,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,15655,1942,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.2,4.1,5,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,247.3327,0,2,0,3,0,4,29.54,0.533333333,1.28,1.28,2.227,All fragments measured,3,1.7,2.45,1.877,,7.84,,8.4,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81055,0.83713,0.76683,0.99078,0.9848,0.59178,0.81105,0.96969,0.82734,167.4,17.5,41.3,13.9
50-12-4,MEPHENYTOIN,MESANTOIN,PF-00345055,1695,CCC1(C(=O)N(C(=O)N1)C)c2ccccc2,TABLET,YES,NO,NO,NO,ORAL,800,Discontinued,2010,YES,NO,Fatal blood dyscrasia,Wikipedia,,,NOVARTIS,major pharma,17098,1946,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.404,1.4,17,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,,,,,1,Hydantoin,NO,NO,NO,,218.2518,1,2,1,4,0,2,49.41,0.333333333,1.34,1.445,2.001,Valid estimate for difficult structure,2,2,1.5,1.42,8.07,,8.6,,Acidic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81193,0.85535,0.5643,0.90114,0.93048,0.98659,0.99652,0.87038,0.82734,239.3,49.1,3.29,7.63
1247-42-3,MEPREDNISONE,BETAPAR,PF-00344806,1702,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C,TABLET,YES,NO,NO,NO,ORAL,8,Discontinued,,NO,NO,,,,,SCHERING,major pharma,28516,1978,DrugCentral,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,372.4547,2,5,2,5,0,2,91.67,0.681818182,1.9,2.152,2.18,All fragments measured,1.7,1.7,1.93,1.931,12.38,,12,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74445,0.73867,0.7395,0.89033,0.72615,0.79222,0.7704,0.87038,0.47245,393.4,19.9,21.9,44.7
57-53-4,MEPROBAMATE,MILTOWN,PF-00345377,1704,CCCC(C)(COC(=O)N)COC(=O)N,TABLET,YES,NO,NO,NO,ORAL,2400,Prescription,,NO,NO,,,,,MEDPOINTE PHARM HLC,pharma,20207,1955,Drugs@FDA,NO,NO,,,NA,NA,0.7,0.65,9,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,,,,Moderate,0,,NO,NO,NO,,218.2502,4,4,2,6,0,8,104.64,0.777777778,0.39,0.39,0.915,All fragments measured,0.91,0.91,0.82,0.824,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.58544,0.63152,0.56429,0.83726,0.88651,0.79222,0.63913,0.39983,0.47245,176.3,12.3,3.93,6.65
50-44-2,MERCAPTOPURINE,PURINETHOL,PF-00345379,1708,c1[nH]c2c(n1)c(=S)[nH]cn2,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,175,Prescription,,NO,NO,,,,,STASON PHARMS,pharma,19613,1953,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.81,0.9,2,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),None,1,Thioamide,NO,NO,NO,,152.1771,2,2,2,4,0,0,57.36,0,-0.156,-0.156,-1.612,All fragments measured,-1.4,-1.7,-0.5,-0.689,8.38,3.08,7.6,1.2,Acidic,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.51408,0.60413,0.2203,0.67879,0.88651,0.79222,0.75497,0.39503,0.93773,178,12.4,6.29,9.03
89-57-6,MESALAMINE,ASACOL,PF-00345380,1710,c1cc(c(cc1N)C(=O)O)O,"CAPSULE, DELAYED RELEASE, CAPSULE, EXTENDED RELEASE, TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,4.8,Prescription,,NO,NO,,,,,APIL,pharma,33634,1992,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.57,0.2,7,,91,159,,NO,Gastrointestinal,YES,NO,,NO,NO,NO,YES,,Less,,,C,Less,C (probable cause of clinically apparent liver injury),Moderate,2,Aniline; Hydroxy_Aniline,YES,NO,NO,,153.1354,4,3,3,4,0,1,83.55,0,-0.785,-0.785,1.056,All fragments measured,0.67,-2.6,1.14,-1.983,1.9,5.43,2.8,5.9,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47665,0.57482,0.22357,0.62066,0.88651,0.37866,0.84452,0.63709,0.82734,127.7,4.49,3.55,8.4
3375-50-6,MESNA,MESNEX,PF-00345737,1711,C(CS(=O)(=O)O)S,TABLET,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,Baxtor Oncology,pharma,BAXTER HLTHCARE,pharma,37336,2002,Drugs@FDA,NO,NO,0.58,,High,Reported bioavailability,0.72,0.64,0.36,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Moderate,1,Thiol_Disulfide,NO,NO,NO,,142.1972,1,3,1,3,0,2,54.37,1,-0.476,-0.476,-1.554,All fragments measured,-0.71,-4.2,-1.33,-4.827,1.5,,0.64,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.49938,0.56095,0.18891,0.47726,0.88651,0.79222,0.67125,0.87038,0.47245,95.21,3.01,1.99,6.65
5588-33-0,MESORIDAZINE BESYLATE,SERENTIL,PF-00344897,1712,CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)S(=O)C,"CONCENTRATE, TABLET",YES,NO,NO,NO,ORAL,400,Discontinued,2004,YES,NO,Irregular heart beat and QT-prolongation,Martindale,,,NOVARTIS,major pharma,25626,1970,Drugs@FDA,NO,NO,,0.4,High,Fa estimated from reported excretion data,0.09,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,,,,,0,,NO,NO,NO,,386.5739,0,3,0,3,0,4,23.55,0.428571429,2.53,2.476,4.441,All fragments measured,4.3,2.6,4.32,1.919,,9.84,,9.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,2,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75879,0.80058,0.65181,0.70982,0.88651,0.59178,0.95499,0.96969,0.93773,420.1,6.8,25.9,107
72-33-3,MESTRANOL,ENOVID,PF-00345011,1714,C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CC[C@]2(C#C)O)OC,TABLET,YES,NO,NO,NO,ORAL,0.1,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,22349,1961,Drugs@FDA,YES,YES,,,NA,NA,,,,,,,67682,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,1,Alkynes,NO,NO,NO,,310.4299,1,2,1,2,0,1,29.46,0.619047619,3.33,4.92,4.45,All fragments measured,4,4,4.28,4.287,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76173,0.77264,0.99853,0.42023,0.93048,0.98659,0.80963,0.63709,0.82734,303.1,8.52,77.2,43.3
586-06-1,METAPROTERENOL SULFATE,ALUPENT,PF-00345008,1720,CC(C)NCC(c1cc(cc(c1)O)O)O,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,27162,1974,Drugs@FDA,NO,NO,,0.44,High,Fa estimated from reported excretion data,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,211.2576,4,4,4,4,0,4,72.72,0.454545455,-1.04,-0.8356,0.083,All fragments measured,0.56,-0.66,0.12,-1.78,9.11,9.3,9.5,8.8,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.54003,0.63142,0.51734,0.79841,0.88651,0.14694,0.92703,0.96969,0.82734,176.1,0.442,5.68,13.4
1665-48-1,METAXALONE,SKELAXIN,PF-00345552,1722,Cc1cc(cc(c1)OCC2CNC(=O)O2)C,TABLET,YES,NO,NO,YES,ORAL,3200,Prescription,,NO,NO,,,,,KING PHARMS,pharma,22871,1962,Drugs@FDA,NO,NO,,,NA,NA,,11.4,8,,82,,5455071,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,221.2524,1,2,1,4,0,3,47.56,0.416666667,2.12,2.6,2.145,All fragments measured,2.3,2.3,2.29,2.288,12.26,,14,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85567,0.89477,0.58492,0.99188,0.9848,0.98659,0.99187,0.99269,0.82734,214.1,37.2,11.7,26
657-24-9,METFORMIN HYDROCHLORIDE,GLUCOPHAGE,PF-00345168,1725,CN(C)C(=N)NC(=N)N,"SOLUTION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,2550,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,34761,1995,Drugs@FDA,NO,NO,0.55,,High,Reported bioavailability,1,8.9,5.2,,199,,23294,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,129.1636,5,5,4,5,0,3,88.99,0.5,-1.73,-1.716,-1.633,Calculated fragment value,-0.46,-4,-1.37,-3.109,,12.25,,13,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31935,0.41475,0.15473,0.2674,0.93048,0.14694,0.79579,0.99269,0.47245,102.8,1.09,2.59,7.35
76-99-3,METHADONE HYDROCHLORIDE,DOLOPHINE HYDROCHLORIDE,PF-05236373,1728,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2,"CONCENTRATE, SYRUP, TABLET, TABLET, FOR SUSPENSION",YES,NO,NO,NO,ORAL,120,Prescription,,NO,NO,,,,,WEST-WARD PHARMS INT,pharma,17392,1947,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.1,4.4,23,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Less,0,,NO,NO,NO,,309.4452,0,2,0,2,0,7,20.31,0.380952381,1.75,2.103,4.167,All fragments measured,3.7,2.1,4.44,2.794,,9.05,,8.4,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72569,0.7392,0.99911,0.70659,0.93048,0.59178,0.62053,0.53315,0.93773,206.3,5.32,12.3,21.8
537-46-2,METHAMPHETAMINE HYDROCHLORIDE,DESOXYN,PF-00345381,1732,C[C@@H](Cc1ccccc1)NC,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,25,Prescription,,NO,NO,,,,,RECORDATI RARE,pharma,16071,1943,Drugs@FDA,NO,NO,,0.62,High,Fa estimated from reported excretion data,,,4,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,4XP6,149.2328,1,1,1,1,0,3,12.03,0.4,-0.524,-0.524,1.888,All fragments measured,2.1,-0.33,2.17,-0.57,,10.38,,9.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65146,0.5568,0.21053,0.9628,0.23327,0.98659,0.43308,0.99269,0.82734,108.6,28.5,9.29,14.4
72-63-9,METHANDROSTENOLONE,DIANABOL,PF-02885465,1734,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC(=O)C=C[C@]34C,N/A,N/A,N/A,N/A,NO,ORAL,5,Discontinued,,NO,NO,Abuse potential,,,,CIBA,pharma,21916,1960,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,300.4351,1,2,1,2,0,0,37.3,0.75,3.22,3.39,4.104,All fragments measured,3.8,3.8,3.76,3.759,,,17,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71137,0.76099,0.99756,0.9378,0.93048,0.98659,0.92207,0.39503,0.47245,304.4,16.5,54.2,50.4
5818-17-7,METHANTHELINE BROMIDE,BANTHINE,PF-00345292,1736,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc3c1cccc3,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,,NO,NO,,,,,SHIRE,major pharma,18812,1951,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,340.436,0,2,0,4,0,7,35.53,0.380952381,0.911,0.911,0.875,Approximated fragment value used,0.16,0.16,-0.52,-0.524,,,,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75654,0.81478,0.91692,0.98982,0.9848,0.59178,0.90148,0.53315,0.93773,271.1,1.52,27.1,10.9
91-80-5,METHAPYRILENE,N/A,PF-00345010,1738,CN(C)CCN(Cc1cccs1)c2ccccn2,N/A,N/A,N/A,N/A,NO,ORAL,200,Discontinued,1979,YES,YES,"Carcinogen, rats",FederalRegister,,,N/A,,17168,1947,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,NO,NO,NO,,,Gerren Additions,1,,,,,1,Thiophene,NO,NO,YES,,261.3858,0,2,0,3,0,6,19.37,0.357142857,1.21,1.189,2.952,Benzyl approx. based on a priori value,2.7,1.9,2.86,0.993,,8.9,,7.8,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79079,0.84964,0.85634,0.99994,0.9848,0.59178,0.99202,0.6885,0.93773,225.6,21.5,10.1,17.8
50-11-3,METHARBITAL,GEMONIL,PF-00346541,1740,CCC1(C(=O)NC(=O)N(C1=O)C)CC,TABLET,YES,NO,NO,NO,ORAL,300,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,19053,1952,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,198.2191,1,3,1,5,0,2,66.48,0.666666667,0.678,0.678,1.141,All fragments measured,1.3,1.2,1.38,1.323,8.27,,8.4,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68209,0.74501,0.43528,0.76048,0.9848,0.98659,0.96322,0.87038,0.47245,198.2,30.8,1.83,7.42
554-57-4,METHAZOLAMIDE,NEPTAZANE,PF-00344724,1741,CC(=O)/N=c\1/n(nc(s1)S(=O)(=O)N)C,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,LEDERLE,major pharma,21576,1959,Drugs@FDA,NO,NO,,,NA,NA,0.45,0.3,14,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,1BZM,236.272,2,5,1,7,0,2,107.41,0.4,0.162,0.162,0.088,Valid estimate for difficult structure,0.13,-0.26,0.32,-0.025,7.31,,6.3,9.8,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.631,0.51948,0.69026,0.48102,0.33223,0.98659,0.31167,0.63709,0.47245,271.2,19.8,2.83,8.69
1982-37-2,METHDILAZINE,TACARYL,PF-00344804,1742,CN1CCC(C1)CN2c3ccccc3Sc4c2cccc4,"TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,32,Discontinued,,NO,NO,,,,,WESTWOOD SQUIBB,pharma,22091,1960,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,296.4298,0,2,0,2,0,2,6.48,0.333333333,2.45,2.581,4.509,All fragments measured,4.4,2.7,4.75,2.271,,10.09,,9.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83325,0.85459,0.99284,0.83075,0.9848,0.59178,0.84849,0.87038,0.93773,267.1,4.57,20.7,47.3
100-97-0,METHENAMINE HIPPURATE,UREX,PF-00344726,3344,C1N2CN3CN1CN(C2)C3,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,,,CNTY LINE PHARMS,pharma,24658,1967,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,,0.56,4.3,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,140.1863,0,4,0,4,0,0,12.96,1,-0.536,-0.536,2.435,All fragments measured,1.6,1.6,0.99,0.995,,5.28,,11,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.39247,0.45523,0.18315,0.49832,0.88651,0.59178,0.45338,0.39503,0.47245,67.26,8.68,6.72,17.1
60-56-0,METHIMAZOLE,TAPAZOLE,PF-00344638,1745,Cn1cc[nH]c1=S,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,KING PHARMS,pharma,18435,1950,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,,0.5,,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Less,1,Thiourea,NO,NO,NO,4IG5,114.1688,1,0,1,2,0,0,20.72,0.25,0.393,0.393,-0.34,All fragments measured,-0.12,-0.12,-0.11,-0.048,12.37,,11,,Neutral,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47135,0.59641,0.12358,0.72606,0.93048,0.98659,0.99701,0.39503,0.82734,112.9,11.9,12.1,12.2
1553-34-0,METHIXENE HYDROCHLORIDE,TREST,PF-00346452,1780,CN1CCCC(C1)CC2c3ccccc3Sc4c2cccc4,TABLET,YES,NO,NO,NO,ORAL,60,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,23743,1965,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,309.4683,0,2,0,1,1,2,3.24,0.4,3.13,3.6,5.841,All fragments measured,5.3,3.9,5.48,3.46,,9.46,,9.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75363,0.7666,0.9991,0.43697,0.93048,0.59178,0.79301,0.87038,0.93773,234.7,12.9,37.5,30.3
532-03-6,METHOCARBAMOL,ROBAXIN,PF-00345009,1747,COc1ccccc1OCC(COC(=O)N)O,TABLET,YES,NO,NO,NO,ORAL,4000,Prescription,,NO,NO,,,,,AUXILIUM PHARMS LLC,pharma,21017,1957,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.5,0.7,1.14,,,,3047853,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,241.2405,3,5,2,6,0,7,91.01,0.363636364,0.454,0.454,0.146,All fragments measured,0.26,0.26,0.65,0.647,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71011,0.72704,0.72502,0.7514,0.72615,0.79222,0.77673,0.53315,0.82734,243.7,19.2,9.94,7.95
2154-02-1,METHOPHOLINE,VERSIDYNE,PF-04767949,1749,CN1CCc2cc(c(cc2C1CCc3ccc(cc3)Cl)OC)OC,N/A,N/A,N/A,N/A,NO,ORAL,,Discontinued,1965,YES,YES,"Ophthalmic, dogs",FederalRegister,,,N/A,,23377,1964,Federal Register,NO,NO,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,345.8631,0,3,0,3,1,5,21.7,0.4,2.71,3.445,5.098,All fragments measured,4.6,3.9,4.73,4.022,,8.02,,8.3,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.73641,0.74411,0.89129,0.46935,0.9848,0.59178,0.65187,0.84757,0.93773,281.8,9.55,27.5,67.1
59-05-2,METHOTREXATE SODIUM,METHOTREXATE SODIUM,PF-00344600,1751,CN(Cc1cnc2c(n1)c(nc(n2)N)N)c3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,DAVA PHARMS INC,pharma,19700,1953,Drugs@FDA,NO,NO,0.6,0.7,High,Reported bioavailability,0.5,0.4,8,,,,148421437,YES,"Autoimmune Disease, Oncology",YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Aniline,YES,NO,NO,1U72,454.4393,7,9,5,13,2,9,210.54,0.25,-2.65,-1.91,-0.529,Benzyl approx. based on a priori value,-0.25,-6.7,-0.56,-5.22,3.56,5.55,3.5,5.6,Acidic,Class 3B,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.20763,0.13721,0.30457,0.50749,0.02915,0.05547,0.04865,0.29329,0.25672,482.4,0.255,2.56,7.09
298-81-7,METHOXSALEN,8-MOP,PF-00345384,30,COc1c2c(ccc(=O)o2)cc3c1occ3,CAPSULE,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,VALEANT,pharma,20061,1954,Drugs@FDA,NO,NO,,0.95,High,Fa estimated from reported excretion data,,,,,,,74,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,2,Furocoumarins; Michael_acceptor,NO,YES,NO,,216.1895,0,1,0,4,0,1,52.58,0.083333333,1.93,1.953,2.305,All fragments measured,2.1,2.1,1.98,1.979,,,,,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70186,0.78617,0.55028,0.97378,0.9848,0.59178,0.99491,0.63709,0.93773,217.2,17.6,42.3,71.2
13265-10-6,METHSCOPOLAMINE BROMIDE,PAMINE,PF-00345294,1757,C[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)c4ccccc4)C,TABLET,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,FOUGERA PHARMS,pharma,19458,1953,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (Unlikely cause of clinically apparent liver injury),Less,1,Epoxide,NO,NO,NO,,318.3875,1,3,1,5,0,5,59.06,0.611111111,-0.952,-0.952,-2.474,Approximated fragment value used,-3.3,-3.3,-2.14,-2.138,,,14,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.7776,0.78971,0.98851,0.31856,0.88651,0.98659,0.99184,0.84757,0.82734,399.8,0.822,10.2,6.65
77-41-8,METHSUXIMIDE,CELONTIN,PF-00344803,1758,CC1(CC(=O)N(C1=O)C)c2ccccc2,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,PARKE DAVIS,major pharma,20859,1957,Drugs@FDA,NO,NO,,,NA,NA,,,1.4,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,203.2371,0,2,0,3,0,1,37.38,0.333333333,0.933,0.933,1.461,Valid estimate for difficult structure,0.81,0.81,1.33,1.325,,,,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64736,0.72575,0.4659,0.84966,0.93048,0.59178,0.92305,0.63709,0.82734,194,46,8.21,10.9
135-07-9,METHYCLOTHIAZIDE,ENDURON,PF-00344731,1759,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CCl,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,ABBVIE,major pharma,22210,1960,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,2,Alkyl_halide_Sulfate_ester; Aniline,YES,NO,NO,,360.2373,3,2,2,7,0,2,109.57,0.333333333,1.48,1.55,0.937,All fragments measured,1.3,1.3,1.2,1.193,9.29,,9.4,1,Neutral,Class 4,0,0,0,0,2,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,2,0,0,0,0,NO,0.79589,0.72168,0.81317,0.72155,0.72615,0.79222,0.41948,0.87038,0.82734,386.4,1.1,4.18,8.93
555-30-6,METHYLDOPA,ALDOMET,PF-00344805,1762,C[C@](Cc1ccc(c(c1)O)O)(C(=O)O)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,MERCK,major pharma,23000,1962,Drugs@FDA,NO,NO,0.32,,High,Reported bioavailability,0.85,0.6,,,,,448,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Quinones,NO,NO,NO,,211.2145,5,5,4,5,0,3,103.78,0.3,-0.632,-0.632,-2.264,Approximated fragment value used,0.66,-2.1,0.18,-2.335,2.28,8.99,2.5,9.2,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.39334,0.43897,0.51706,0.10695,0.72615,0.14694,0.6481,0.99269,0.82734,204.8,0.768,3.94,7.62
113-42-8,METHYLERGONOVINE MALEATE,METHERGINE,PF-00345295,1764,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4c3c(ccc4)C2=C1)C,TABLET,YES,NO,NO,NO,ORAL,0.8,Prescription,,NO,NO,,,,,EDISON THERAPS LLC,pharma,17125,1946,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,,0.2,3.4,,,,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,1,3_Methyl_Indole,NO,NO,NO,,339.4314,3,3,3,5,0,4,68.36,0.45,1.72,1.911,1.758,All fragments measured,1.7,1.6,1.94,1.671,,7.14,8.8,6.9,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,6,0,0,0,6,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78512,0.83654,0.92137,0.9625,0.9848,0.37866,0.95335,0.96969,0.93773,362.9,10.3,12.5,14.1
83387-25-1,METHYLNALTREXONE BROMIDE,RELISTOR,PF-05236803,4616,C[N+]1(CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O)CC6CC6,TABLET,YES,NO,NO,NO,ORAL,450,Prescription,,NO,NO,,,Progenics Pharmaceuticals,pharma,SALIX PHARMS INC,pharma,42570,2016,Drugs@FDA,NO,NO,,,NA,NA,0.89,1.1,15,,,,246853,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,,0,,NO,NO,NO,,356.4354,2,5,2,5,0,2,66.76,0.666666667,-0.262,-0.262,-2.639,Approximated fragment value used,-2.7,-1.8,-2.68,-2.637,8.63,,8.6,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78699,0.81083,0.835,0.56729,0.88651,0.79222,0.96181,0.87038,0.82734,464.5,0.743,3.21,7
113-45-1,METHYLPHENIDATE HYDROCHLORIDE,RITALIN,PF-05237359,1767,COC(=O)C(c1ccccc1)C2CCCCN2,"CAPSULE, EXTENDED RELEASE, FOR SUSPENSION, EXTENDED RELEASE, SOLUTION, TABLET, TABLET, CHEWABLE, TABLET, EXTENDED RELEASE, TABLET, EXTENDED RELEASE, CHEWABLE",YES,NO,YES,YES,ORAL,60,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,20428,1955,Drugs@FDA,NO,NO,0.22,,Moderate,Reported bioavailability,0.78,2.65,4,,41,143,142,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,233.3062,1,2,1,3,0,4,38.33,0.5,0.0387,0.0387,2.556,All fragments measured,2.1,1.6,2.33,0.272,,9.51,,8.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87353,0.89877,0.66937,0.9732,0.9848,0.98659,0.93296,0.96969,0.82734,197.6,20.6,12.5,18.3
83-43-2,METHYLPREDNISOLONE,MEDROL,PF-00345299,1768,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,21117,1957,Drugs@FDA,NO,NO,0.82,,High,Reported bioavailability,0.22,1.5,2.5,,,,567949615,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,374.4706,3,5,3,5,0,2,94.83,0.727272727,1.73,2.414,1.742,All fragments measured,2,2,1.97,1.967,12.46,,11,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.6363,0.65881,0.72703,0.88606,0.72615,0.37866,0.73951,0.87038,0.47245,410.4,9.36,5.1,8.14
58-18-4,METHYLTESTOSTERONE,ORETON METHYL,PF-00345739,3356,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,SCHERING,major pharma,14965,1940,PharmaPendium,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.02,,1,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,302.451,1,2,1,2,0,0,37.3,0.85,3.1,3.25,3.928,Valid estimate for difficult structure,3.7,3.7,3.53,3.527,,,17,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71113,0.76069,0.999,0.9339,0.93048,0.98659,0.92207,0.39503,0.47245,302,16.7,59.3,54.3
125-64-4,METHYPRYLON,NOLUDAR,PF-05237362,1774,CCC1(C(=O)C(CNC1=O)C)CC,"CAPSULE, ELIXIR, TABLET",YES,NO,NO,NO,ORAL,400,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,20107,1955,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.4,0.97,6,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,183.2475,1,2,1,3,0,2,46.17,0.8,1.22,1.191,1.78,All fragments measured,1.3,1.3,0.6,0.601,12.11,,12,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66511,0.73446,0.35206,0.87892,0.93048,0.98659,0.98696,0.87038,0.47245,151.1,26.9,7.41,16.1
361-37-5,METHYSERGIDE MALEATE,SANSERT,PF-00625952,1775,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2Cc3cn(c4c3c(ccc4)C2=C1)C)C,TABLET,YES,NO,NO,NO,ORAL,8,Discontinued,,NO,NO,Retroperitoneal/retropulmonary fibrosis and increased risk of cardiac valve dysfunction,,,,NOVARTIS,major pharma,22689,1962,Drugs@FDA,NO,NO,,0.3,Moderate,Fa estimated from reported excretion data,,,1,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,,0,,NO,NO,NO,,353.458,2,3,2,5,0,4,57.5,0.476190476,1.87,1.957,2.224,All fragments measured,1.7,1.6,2.47,2.366,,7.15,13,7.1,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,6,0,0,0,6,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.9011,0.92725,0.85158,0.98005,0.9848,0.79222,0.99542,0.96969,0.93773,377.1,18.6,9.56,26.3
364-62-5,METOCLOPRAMIDE HYDROCHLORIDE,REGLAN,PF-00345007,1782,CCN(CC)CCNC(=O)c1cc(c(cc1OC)N)Cl,"SOLUTION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,ANI PHARMS,pharma,29585,1980,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.7,3.5,5.5,,,,11488875,NO,Gastrointestinal,NO,NO,,YES,YES,NO,NO,Less,Less,DILIRank,1,,,,None,1,Aniline,YES,NO,NO,,299.7964,3,3,2,5,0,7,67.59,0.5,0.0904,0.933,2.229,All fragments measured,1.9,0.27,2.41,0.551,,9.08,13,8.9,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.79354,0.83135,0.99697,0.92811,0.88651,0.79222,0.9575,0.53315,0.82734,251,11.7,5.78,11.9
17560-51-9,METOLAZONE,ZAROXOLYN,PF-00344728,1783,Cc1ccccc1N2C(Nc3cc(c(cc3C2=O)S(=O)(=O)N)Cl)C,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,LANNETT CO INC,pharma,26995,1973,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.05,1.6,8,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,365.8345,3,3,2,6,0,2,92.5,0.1875,2.77,2.334,2.056,All fragments measured,3.5,3.5,2.42,2.506,10,,9.7,1.1,Neutral,Class 4,0,0,0,0,1,0,0,2,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.8564,0.84225,0.77995,0.99164,0.88651,0.79222,0.67817,0.87038,0.93773,376.6,6.84,3.14,40.3
51384-51-1,METOPROLOL TARTRATE,LOPRESSOR,PF-00274011,1786,CC(C)NCC(COc1ccc(cc1)CCOC)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,450,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,28709,1978,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.9,4.4,3.5,,,,2200358,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,267.3639,2,4,2,4,0,9,50.72,0.6,-0.186,-0.2638,1.486,All fragments measured,1.9,-0.035,1.85,-0.293,,9.43,16,9.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.67918,0.75526,0.88993,0.92556,0.88651,0.79222,0.9986,0.29329,0.82734,207.2,28,6.76,11.7
443-48-1,METRONIDAZOLE,FLAGYL,PF-00344568,1790,Cc1ncc(n1CCO)N(=O)=O,"CAPSULE, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,2250,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,23210,1963,Drugs@FDA,NO,NO,0.99,,High,Reported bioavailability,0.8,0.55,6,,,,16510310,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,1,Nitroorganics,NO,NO,NO,,171.154,1,4,1,6,0,3,83.87,0.5,0.464,-0.293,-0.457,All fragments measured,-0.44,-0.44,0.05,0.05,,2.58,11,2.8,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62755,0.67822,0.29428,0.37097,0.88651,0.98659,0.84177,0.99269,0.82734,183.8,24.5,5.91,6.65
54-36-4,METYRAPONE,METOPIRONE,PF-00344807,1791,CC(C)(c1cccnc1)C(=O)c2cccnc2,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,4500,Prescription,,NO,NO,,,,,LABORATORIE HRA,pharma,22619,1961,Drugs@FDA,NO,NO,,0.44,High,Fa estimated from reported excretion data,,,1.9,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,1,Pyridine,NO,NO,NO,1W0G,226.2738,0,3,0,3,0,3,42.85,0.214285714,1.36,1.452,1.459,Benzyl approx. based on a priori value,1.6,1.6,1.7,1.712,,4.61,,4.8,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78912,0.84431,0.61988,0.93781,0.9848,0.59178,0.96985,0.99269,0.93773,188.5,32.3,34.9,53.6
672-87-7,METYROSINE,DEMSER,PF-00344730,1792,C[C@](Cc1ccc(cc1)O)(C(=O)O)N,CAPSULE,YES,NO,NO,NO,ORAL,4000,Prescription,,NO,NO,,,,,ATON,pharma,29131,1979,Drugs@FDA,NO,NO,,0.53,High,Fa estimated from reported excretion data,,,3.4,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,195.2151,4,4,3,4,0,3,83.55,0.3,-0.734,-0.734,-1.667,Approximated fragment value used,0.82,-1.9,0.76,-1.743,2.29,9.22,2.5,9.3,Zwitter,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47501,0.53694,0.41758,0.13234,0.88651,0.37866,0.84452,0.99269,0.82734,170.8,0.63,3.33,7.89
31828-71-4,MEXILETINE HYDROCHLORIDE,MEXITIL,PF-00345060,1794,Cc1cccc(c1OCC(C)N)C,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,31411,1985,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.4,7,6,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,,,,Most,0,,NO,NO,NO,,179.2588,2,2,1,2,0,3,35.25,0.454545455,0.58,0.58,2.569,All fragments measured,2.2,0.44,2.43,1.23,,8.58,,9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75141,0.80618,0.33206,0.98452,0.93048,0.98659,0.89795,0.99269,0.82734,137.9,39.4,7.89,7.61
116666-63-8,MIBEFRADIL DIHYDROCHLORIDE,POSICOR,PF-00138642,1797,CC(C)[C@H]1c2ccc(cc2CC[C@@]1(CCN(C)CCCc3[nH]c4ccccc4n3)OC(=O)COC)F,N/A,N/A,N/A,N/A,NO,ORAL,50,Discontinued,1998,YES,YES,Potential for drug interactions,FederalRegister,,,HOFFMANN-LA ROCHE,major pharma,35551,1997,NIH NCATS,NO,NO,0.67,,High,Reported bioavailability,0.005,2.57,,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,,,Gerren Additions,0,,,,,0,,NO,NO,NO,,495.6287,1,4,1,6,1,12,67.45,0.517241379,3.12,3.67,6.364,All fragments measured,5.9,5.7,6.13,4.183,11.93,9.26,12,9.5,Basic,Class 2,0,1,0,0,0,0,0,3,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,NO,0.2801,0.3777,0.18326,0.31643,0.72615,0.98659,0.9583,0.10729,0.25672,458.7,2.64,39,98.1
59467-70-8,MIDAZOLAM HYDROCHLORIDE,VERSED,PF-00346487,1802,Cc1ncc2n1-c3ccc(cc3C(=NC2)c4ccccc4F)Cl,SYRUP,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,36083,1998,Drugs@FDA,NO,NO,0.36,,High,Reported bioavailability,0.03,1.1,3.6,,,,20219965,YES,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,325.7673,0,1,0,3,0,1,30.18,0.111111111,2.94,3.172,3.422,Benzyl approx. based on a priori value,3.1,3.1,3.37,3.342,,6.26,,6.2,Neutral,Class 2,0,1,0,0,1,0,0,3,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,NO,0.62665,0.66813,0.9712,0.82644,0.93048,0.59178,0.82217,0.63709,0.25672,312.5,17.3,13.5,30.2
42794-76-3,MIDODRINE HYDROCHLORIDE,PROAMATINE,PF-00345522,1803,COc1ccc(c(c1)C(CNC(=O)CN)O)OC,TABLET,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,SHIRE,major pharma,35314,1996,Drugs@FDA,NO,YES,0.93,,High,Reported bioavailability,1,4,0.5,,,,,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,254.2823,4,5,3,6,0,6,93.81,0.416666667,-0.909,-0.909,-0.354,All fragments measured,-1.3,-2.1,-0.55,-0.724,,7.75,12,7.7,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57787,0.60589,0.81262,0.3142,0.72615,0.37866,0.74958,0.6885,0.82734,251.5,2.09,4.48,8.72
120685-11-2,MIDOSTAURIN,RYDAPT,PF-02730598,5231,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC,CAPSULE,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,42853,2017,Drugs@FDA,NO,NO,,0.96,High,Fa estimated from reported excretion data,0.002,1.36,21,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,0,,NO,NO,NO,4NCT,570.6371,1,4,1,8,2,4,77.73,0.257142857,3.58,4.22,5.491,Approximated fragment value used,3.6,3.6,4.79,4.794,,,10,,Neutral,Class 2,0,0,0,0,0,0,0,6,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,14,0,0,0,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.22924,0.30095,0.07858,0.35193,0.88651,0.98659,0.89166,0.99269,0.01044,738.8,3.8,12.1,117
84371-65-3,MIFEPRISTONE,MIFEPREX,PF-00345738,1805,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)c5ccc(cc5)N(C)C)C)O,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Sanofi,major pharma,DANCO LABS LLC,pharma,36797,2000,Drugs@FDA,NO,NO,0.69,,High,Reported bioavailability,0.08,1.5,85,,,,,YES,Genitourinary,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,D,Less,D (possible cause of clinically apparent liver injury),Less,2,Alkynes; Aniline,YES,NO,NO,5UC3,429.5937,1,2,1,3,0,2,40.54,0.551724138,3.9,5.06,4.648,Valid estimate for difficult structure,4.8,4.8,5.16,5.158,12.94,5.49,13,3.7,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62811,0.68433,0.41052,0.22512,0.9848,0.98659,0.95307,0.99269,0.82734,378.3,4.5,36.5,84.7
108147-54-2,MIGALASTAT HYDROCHLORIDE,GALAFOLD,PF-02840182,5110,C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O,CAPSULE,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,Amicus,pharma,AMICUS THERAPS US,pharma,43322,2018,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,1,1.3,4,,,,,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,163.1717,5,5,5,5,0,1,92.95,1,-2.42,-2.42,-1.424,All fragments measured,-2.9,-3.6,-2.01,-2.372,,7.53,13,7.9,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.21182,0.28445,0.26075,0.06287,0.72615,0.05547,0.758,0.63709,0.47245,230,1.05,1.66,7.76
72432-03-2,MIGLITOL,GLYSET,PF-00579971,1806,C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,35417,1996,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.96,0.18,2,,,,582098,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,3L4W,207.2243,5,6,5,6,0,3,104.39,1,-2.22,-2.22,-1.256,All fragments measured,-3.1,-3.1,-2.04,-2.07,,6.49,14,7.1,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.26619,0.30911,0.49111,0.06269,0.52457,0.05547,0.64174,0.99269,0.47245,269.4,0.949,1.66,13.1
72599-27-0,MIGLUSTAT,ZAVESCA,PF-02837115,1807,CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Pfizer,major pharma,ACTELION PHARMS LTD,pharma,37833,2003,Drugs@FDA,NO,NO,0.97,,High,Reported bioavailability,1,1.3,7,,,,,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,219.278,4,5,4,5,0,4,84.16,1,-1.55,-1.55,0.906,All fragments measured,-0.89,-1.2,-0.69,-0.837,,6.94,13,7.8,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.43259,0.49419,0.57133,0.30711,0.72615,0.14694,0.83926,0.96969,0.47245,266.2,1.22,1.66,15
92623-85-3,MILNACIPRAN HYDROCHLORIDE,SAVELLA,PF-05166427,1808,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c2ccccc2,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Pierre Fabre,pharma,ALLERGAN,major pharma,39827,2009,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.87,5,7,,,,33286,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,YES,NO,Most,Most,DILIRank,1,D,Less,"D (possible, rare cause of clinically apparent liver injury)",,0,,NO,NO,NO,,246.348,2,2,1,3,0,6,46.33,0.533333333,-0.598,-0.598,1.906,Benzyl approx. based on a priori value,0.9,-1.9,1.66,-0.647,,10.36,,9.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85327,0.87942,0.76016,0.84181,0.93048,0.98659,0.98759,0.84757,0.82734,203.2,12.6,8.19,7.79
58066-85-6,MILTEFOSINE,IMPAVIDO,PF-05667708,1810,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,CAPSULE,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,Meda (Mylan),pharma,KNIGHT THERAPS,pharma,41717,2014,Drugs@FDA,NO,NO,,,NA,NA,0.02,,737,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,1,1_4_Diketones,NO,NO,NO,,407.568,0,2,0,5,0,20,58.59,1,1.66,1.66,-2.383,A priori fragment value used,1.4,-0.94,2.17,2.783,1.28,,1.4,,Acidic,Class 3B,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,NO,0.22362,0.3555,0.52636,0.92602,0.88651,0.59178,0.95313,0.00623,0.47245,243.8,2.73,35.6,6.65
10118-90-8,MINOCYCLINE HYDROCHLORIDE,MINOCIN,PF-00344732,1813,CN(C)c1ccc(c2c1C[C@H]3C[C@H]4[C@@H](C(=C(C(=O)[C@]4(C(=C3C2=O)O)O)C(=O)N)O)N(C)C)O,"CAPSULE; CAPSULE, EXTENDED RELEASE; SUSPENSION; TABLET; TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,200,Prescription,,NO,NO,,,,,TRIAX PHARMS,pharma,26114,1971,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.24,1.6,11,,,,17552140,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Moderate,3,Aniline; Hydroxy_Aniline; Michael_acceptor,YES,YES,NO,,457.4764,6,8,5,10,1,3,164.63,0.434782609,-0.101,0.1939,0.206,Valid estimate for difficult structure,0.36,-4.8,-0.06,-2.737,4.5,11.06,3.1,9.5,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.33946,0.27288,0.29343,0.50211,0.10671,0.05547,0.15729,0.99269,0.82734,498.5,1.82,3.49,8.12
38304-91-5,MINOXIDIL,LONITEN,UK-008663,1814,c1c(n(=O)c(nc1N2CCCCC2)N)N,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,29146,1979,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,1,2.7,4.2,,,,12288628,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,Moderate,0,,NO,NO,NO,,209.2483,4,4,2,6,0,1,93.63,0.555555556,1.53,1.295,0.021,All fragments measured,0.9,0.9,1.06,1.047,,5.54,,4.6,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.6566,0.68174,0.50419,0.59584,0.72615,0.79222,0.75135,0.63709,0.82734,202.8,5.98,4.52,20.3
223673-61-8,MIRABEGRON,MYRBETRIQ,PF-04275592,4382,c1ccc(cc1)[C@H](CNCCc2ccc(cc2)NC(=O)Cc3csc(n3)N)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,50,Prescription,,NO,NO,,,Astellas Pharma,major pharma,ASTELLAS,pharma,41088,2012,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.29,23.9,50,,,149,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,2,Aminothiazole; Aniline,YES,NO,NO,,396.5059,5,4,4,6,0,9,100.27,0.238095238,0.493,0.65,1.32,All fragments measured,1.8,0.34,2.05,0.358,,8.9,12,8.7,Basic,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.35842,0.40724,0.59113,0.97947,0.72615,0.14694,0.39935,0.29329,0.25672,355.8,1.67,6.33,10.6
85650-52-8,MIRTAZAPINE,REMERON,PF-00297424,1816,CN1CCN2c3c(cccn3)Cc4ccccc4C2C1,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,45,Prescription,,NO,NO,,,,,ORGANON USA INC,pharma,35230,1996,Drugs@FDA,NO,NO,0.5,0.75,High,Reported bioavailability,0.15,1.5,26,,,,206034,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,265.3529,0,2,0,3,0,0,19.37,0.352941176,1.71,2.567,2.814,All fragments measured,2.4,1.8,3.01,2.419,,8.1,,7.7,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69656,0.73237,0.879,0.99406,0.9848,0.59178,0.59909,0.39503,0.93773,268.9,22.1,9.65,18.1
59122-46-2,MISOPROSTOL,CYTOTEC,PF-00345521,1817,CCCCC(C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O,TABLET,YES,NO,NO,NO,ORAL,0.8,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,32504,1988,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.11,,,,184,,21699574,NO,"Gastrointestinal, Genitourinary",NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,382.5341,2,4,2,5,0,14,83.83,0.818181818,2.57,3.614,3.072,All fragments measured,4.5,4.5,3.28,3.275,,,15,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.3958,0.49457,0.67689,0.87886,0.72615,0.79222,0.84211,0.05315,0.47245,325.4,13.9,54.4,87.6
53-19-0,MITOTANE,LYSODREN,PF-00344808,1820,c1ccc(c(c1)C(c2ccc(cc2)Cl)C(Cl)Cl)Cl,TABLET,YES,NO,NO,NO,ORAL,6000,Prescription,,NO,NO,,,,,LABORATOIRE HRA,pharma,25757,1970,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,,,432,,,,,NO,Oncology,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,320.0412,0,0,0,0,1,3,0,0.142857143,3.55,6.06,6.06,All fragments measured,5.9,5.9,5.84,5.837,,,,,Neutral,Class 4,0,0,0,0,4,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,4,0,0,0,0,NO,0.62983,0.35236,0.98527,0.20099,0.02838,0.59178,0.21777,0.99269,0.93773,175.7,1.96,43.5,26.6
68693-11-8,MODAFINIL,PROVIGIL,PF-00242013,1826,c1ccc(cc1)C(c2ccccc2)S(=O)CC(=O)N,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,CEPHALON,pharma,36153,1998,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.4,0.9,7.5,,54,,,YES,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,E,None,E (unlikely causes of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,273.3501,2,2,1,3,0,5,60.16,0.133333333,1.5,1.593,0.937,Benzyl approx. based on a priori value,1.2,1.2,1.37,1.367,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91918,0.9167,0.91997,0.92209,0.93048,0.98659,0.87892,0.84757,0.93773,244.4,20,8.74,8.81
103775-10-6,MOEXIPRIL HYDROCHLORIDE,UNIVASC,VC-001215226,1827,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3cc(c(cc3C[C@H]2C(=O)O)OC)OC,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,UCB INC,pharma,34808,1995,Drugs@FDA,NO,YES,0.13,,Moderate,Reported bioavailability,,,1,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unlikely but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,498.5681,2,7,2,9,0,13,114.4,0.444444444,0.393,0.393,1.394,Approximated fragment value used,3,-0.38,3.36,-0.339,2.94,5.28,3.1,5.3,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.35529,0.37097,0.17679,0.66739,0.19128,0.79222,0.53744,0.10729,0.93773,500.1,1.26,39.1,8.77
7416-34-4,MOLINDONE HYDROCHLORIDE,MOBAN,PF-00344809,1830,CCc1c([nH]c2c1C(=O)C(CC2)CN3CCOCC3)C,"CAPSULE, CONCENTRATE, TABLET",YES,NO,NO,NO,ORAL,225,Prescription,,NO,NO,,,,,ENDO PHARMS,pharma,27047,1974,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,None,LiverTox Additions,1,,,,Less,1,Pyrrole,NO,NO,NO,,276.374,1,1,1,4,0,3,45.33,0.6875,2.51,1.425,2.572,All fragments measured,1.6,1,2.2,2.109,,6.57,9.2,7.1,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.94588,0.95233,0.9336,0.96974,0.9848,0.98659,0.98337,0.99269,0.82734,242.8,19.5,18.2,32.3
158966-92-8,MONTELUKAST SODIUM,SINGULAIR,PF-00346597,1836,CC(C)(c1ccccc1CC[C@H](c2cccc(c2)/C=C/c3ccc4ccc(cc4n3)Cl)SCC5(CC5)CC(=O)O)O,"GRANULE, TABLET, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,MERCK,major pharma,35846,1998,Drugs@FDA,NO,NO,0.64,,High,Reported bioavailability,0.01,0.15,4,,5,140,2283752,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,B,Most,B (rare but likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,586.1832,2,5,2,4,2,12,70.42,0.314285714,4.24,5.106,8.472,Very high LogP unrealistic in nature,8.3,5.4,7.56,4.938,4.76,3.63,4.5,3,Acidic,Class 3B,0,0,0,0,1,0,0,4,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.10529,0.16116,0.06778,0.02675,0.72615,0.79222,0.73064,0.10729,0.03452,441.7,0.639,24.8,15.9
31883-05-3,MORICIZINE HYDROCHLORIDE,ETHMOZINE,PF-00345131,1842,CCOC(=O)Nc1ccc2c(c1)N(c3ccccc3S2)C(=O)CCN4CCOCC4,TABLET,YES,NO,NO,NO,ORAL,900,Discontinued,,NO,NO,,,,,SHIRE,major pharma,33043,1990,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.05,9.5,6.4,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,,,,,1,Aniline,YES,NO,NO,,427.5166,1,3,1,7,0,7,71.11,0.363636364,2.58,2.596,2.636,All fragments measured,3.6,3.5,3.17,3.135,12.88,6.36,12,6.3,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.73675,0.7209,0.42059,0.99486,0.52457,0.98659,0.72373,0.6885,0.93773,424.7,6.11,34.9,54.7
57-27-2,MORPHINE SULFATE,MS CONTIN,PF-00345387,1845,CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O,"CAPSULE, EXTENDED RELEASE, SOLUTION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1600,Prescription,,NO,NO,,,,,PURDUE PHARMA LP,pharma,31926,1987,Drugs@FDA,NO,NO,0.24,,Moderate,Reported bioavailability,0.65,3.3,2,,183,,24509902,YES,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,285.3377,2,4,2,4,0,0,52.93,0.529411765,0.233,0.233,0.572,All fragments measured,1.1,0.017,0.69,-0.136,9.48,8.25,9.6,8.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73106,0.79028,0.96712,0.86727,0.88651,0.79222,0.99999,0.39503,0.82734,359.4,13.2,21.8,7.8
113507-06-5,MOXIDECTIN,MOXIDECTIN,PF-05208746,,C[C@@H]1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N/OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C,TABLET,YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,Pfizer,major pharma,MDGH,nonprofit,43264,2018,Drugs@FDA,NO,NO,,0.98,High,Fa estimated from reported excretion data,,34.6,559,,,,,YES,Anti-infective,NO,NO,,YES,NO,NO,NO,,Most,,,,,,Less,0,,NO,NO,NO,,639.8186,2,6,2,9,2,3,116.04,0.675675676,3.84,7.11,7.177,Very high LogP unrealistic in nature,6.8,6.6,7.29,7.297,12.6,,12,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,3,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,YES,0.35639,0.32986,0.045,0.45746,0.10671,0.79222,0.52062,0.99269,0.47245,733.6,1.41,49.2,19.1
151096-09-2,MOXIFLOXACIN HYDROCHLORIDE,AVELOX,PF-00835115,1854,COc1c2c(cc(c1N3C[C@@H]4CCCN[C@@H]4C3)F)c(=O)c(cn2C5CC5)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,36504,1999,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.6,2.2,12.7,,102,,245629,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,2XKK,401.4314,2,5,2,7,0,4,83.8,0.523809524,-0.541,-0.3792,-0.082,All fragments measured,2.4,-0.35,0.78,-1.72,6.04,10.63,6.2,8.5,Zwitter,Class 3B,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.64788,0.60036,0.56185,0.2766,0.33223,0.79222,0.85669,0.96969,0.82734,432,2.43,3.87,8.38
128794-94-5,MYCOPHENOLATE MOFETIL,CELLCEPT,PF-00345525,1859,Cc1c2c(c(c(c1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O)C(=O)OC2,"CAPSULE, SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,34822,1995,Drugs@FDA,NO,YES,0.94,,High,Reported bioavailability,0.03,,,,78,175,3820538,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,433.4947,1,4,1,8,0,10,94.53,0.565217391,3.21,3.8,2.98,All fragments measured,3.4,3.3,3.6,3.583,9.87,6,11,6.5,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.53964,0.51426,0.39211,0.98787,0.19128,0.98659,0.74248,0.21184,0.82734,358.5,14.4,19.7,83.5
37415-62-6,MYCOPHENOLIC ACID,MYFORTIC,PF-01322543,1860,Cc1c2c(c(c(c1OC)C/C=C(\C)/CCC(=O)O)O)C(=O)OC2,"TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,1440,Prescription,,NO,NO,,,Eli Lilly,major pharma,NOVARTIS,major pharma,38044,2004,Drugs@FDA,NO,NO,0.72,,High,Reported bioavailability,0.02,0.8,8,,,,,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,1JR1,320.3371,2,5,2,6,0,6,93.06,0.411764706,0.505,0.2095,2.291,All fragments measured,3.2,0.71,3.43,0.763,4.71,,4.6,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83403,0.77948,0.98466,0.99096,0.52457,0.79222,0.75693,0.6885,0.82734,254.5,5.14,11.2,9.57
51022-71-0,NABILONE,CESAMET,PF-04440702,1862,CCCCCCC(C)(C)c1cc(c2c(c1)OC([C@H]3[C@H]2CC(=O)CC3)(C)C)O,CAPSULE,YES,NO,NO,NO,ORAL,6,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,31407,1985,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,,12.5,2,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,1,1_4_Diketones,NO,NO,NO,,372.5408,1,3,1,3,1,6,46.53,0.708333333,4.91,5.86,6.72,All fragments measured,6.9,6.9,7.2,7.198,9.67,,9.2,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.611,0.66021,0.73897,0.13526,0.9848,0.98659,0.98835,0.6885,0.82734,274,3.82,67.8,84.6
42924-53-8,NABUMETONE,RELAFEN,PF-00345742,1863,CC(=O)CCc1ccc2cc(ccc2c1)OC,TABLET,YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,SMITHKLINE BEECHAM,major pharma,33596,1991,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.01,6.4,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Moderate,0,,NO,NO,NO,,228.2863,0,2,0,2,0,4,26.3,0.266666667,2.89,3.325,2.982,All fragments measured,3,3,2.92,2.916,,,,,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79187,0.81447,0.63401,0.99877,0.93048,0.59178,0.74989,0.96969,0.93773,166.5,17.1,52.8,105
42200-33-9,NADOLOL,CORGARD,PF-00345064,1865,CC(C)(C)NCC(COc1cccc2c1CC(C(C2)O)O)O,TABLET,YES,NO,NO,NO,ORAL,240,Prescription,,NO,NO,,,,,US WORLDMEDS LLC,nonprofit,29199,1979,Drugs@FDA,NO,NO,0.3,,Moderate,Reported bioavailability,0.7,1.9,22,,,,3024554,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,309.4006,4,5,4,5,0,5,81.95,0.647058824,-1.17,-1.17,0.379,All fragments measured,1.1,-0.86,1.24,-0.861,,9.54,14,9.3,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57836,0.63621,0.99913,0.80971,0.72615,0.14694,0.85802,0.6885,0.82734,299.7,0.71,4.22,7.06
916072-89-4,NALDEMEDINE TOSYLATE,SYMPROIC,VC-001215352,5220,CC(C)(c1nc(no1)c2ccccc2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)Cc7c6c(c(cc7)O)O4)CC8CC8)O,TABLET,YES,NO,NO,NO,ORAL,0.2,Prescription,,NO,NO,,,Shionogi,pharma,SHIONOGI INC,pharma,42817,2017,Drugs@FDA,NO,NO,,0.57,High,Fa estimated from reported excretion data,0.06,2.2,11,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,,570.6356,4,8,4,10,1,6,141.18,0.46875,2.12,2.12,2.825,Benzyl approx. based on a priori value,2,0.28,3.1,0.46,4.5,7.36,9.3,7,Zwitter,Class 3B,0,0,0,0,0,0,0,3,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,6,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.26894,0.27358,0.07858,0.99927,0.19128,0.14694,0.29409,0.6885,0.25672,664.1,1.78,8.31,29.8
389-08-2,NALIDIXIC ACID,NEGGRAM,PF-00344729,1875,CCn1cc(c(=O)c2c1nc(cc2)C)C(=O)O,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,4,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,23442,1964,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,0.1,0.47,1,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Moderate,1,Quinolones_Naphthyridinones,NO,NO,NO,,232.2353,1,4,1,5,0,2,72.19,0.25,-1.01,0.1589,1.024,All fragments measured,1.7,-0.18,1.24,-0.325,3.45,6.12,6.3,1.1,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82409,0.82603,0.66182,0.81675,0.72615,0.98659,0.941,0.87038,0.82734,223.3,14.4,4.71,10.6
854601-70-0,NALOXEGOL OXALATE,MOVANTIK,VC-001215351,4832,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3Cc4ccc(c5c4[C@]2([C@H]1O5)CCN3CC=C)O)O,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Nektar Therapeutics,pharma,ASTRAZENECA AB,major pharma,41898,2014,Drugs@FDA,NO,NO,,0.68,High,Fa estimated from reported excretion data,0.96,13.8,6,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,651.7847,2,12,2,12,2,24,126.77,0.764705882,0.701,0.701,0.441,All fragments measured,0.99,0.4,0.94,0.859,9.36,6.51,9.6,8,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,8,0,0,NO,0.09823,0.12144,0.04197,0.76101,0.02915,0.79222,0.41537,0.00153,0.82734,704.4,8.1,16,30.9
465-65-6,NALOXONE HYDROCHLORIDE,TALWIN NX,PF-01372407,1878,C=CCN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O,TABLET,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,30301,1982,Drugs@FDA,YES,NO,0.02,,Low,Reported bioavailability,0.55,2.1,,,198,,22071495,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,327.3743,2,5,2,5,0,2,70,0.526315789,0.552,1.119,0.159,All fragments measured,1.1,0.75,1.53,1.421,9.16,6.71,9.6,7.5,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8662,0.8538,0.96648,0.87516,0.72615,0.79222,0.94399,0.87038,0.82734,405.8,17.4,71.1,11.5
16590-41-3,NALTREXONE HYDROCHLORIDE,REVIA,PF-00345063,1765,c1cc(c2c3c1C[C@@H]4[C@]5([C@]3(CCN4CC6CC6)[C@@H](O2)C(=O)CC5)O)O,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,TEVA,major pharma,31006,1984,Drugs@FDA,NO,NO,0.23,0.79,Moderate,Reported bioavailability,0.79,19.29,,,,,,YES,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Less,0,,NO,NO,NO,,341.4009,2,5,2,5,0,2,70,0.65,0.934,0.934,0.359,All fragments measured,1.3,0.82,1.63,1.186,9.16,7.5,9.6,7.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86049,0.85164,0.91255,0.91054,0.72615,0.79222,0.94399,0.87038,0.82734,414.8,23.7,14.3,13
22204-53-1,NAPROXEN,NAPROSYN,PF-00344899,1883,C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O,"SUSPENSION, TABLET, TABLET, DELAYED RELEASE",YES,YES,NO,NO,ORAL,660,Prescription,,NO,NO,,,,,ATNAHS PHARMA US,pharma,27830,1976,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.003,0.16,15,,,,753208,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,3NT1,230.2592,1,3,1,3,0,3,46.53,0.214285714,0.427,0.2012,2.816,All fragments measured,2.9,0.088,2.98,0.452,4.84,,4.4,,Acidic,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.89429,0.92493,0.6479,0.9999,0.9848,0.98659,0.98835,0.99269,0.93773,181.2,29.3,16.7,8.29
121679-13-8,NARATRIPTAN HYDROCHLORIDE,AMERGE,PF-01063833,1884,CNS(=O)(=O)CCc1ccc2c(c1)c(c[nH]2)C3CCN(CC3)C,TABLET,YES,NO,NO,NO,ORAL,5,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,35836,1998,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.69,2.4,5.5,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,335.4643,2,3,2,5,0,5,65.2,0.529411765,0.0789,0.0789,1.696,A priori fragment value used,2.5,0.16,1.78,-0.225,11.52,9.3,10,9.5,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8899,0.90961,0.93797,0.9615,0.9848,0.79222,0.92132,0.84757,0.93773,290.2,7.85,5.85,10
105816-04-4,NATEGLINIDE,STARLIX,PF-00579945,1886,CC([C@H]1CC[C@@H](CC1)C(=O)N[C@@H](C(=O)O)Cc2ccccc2)C,TABLET,YES,NO,NO,NO,ORAL,360,Prescription,,NO,NO,,,Ajinomoto ,pharma,NOVARTIS,major pharma,36882,2000,Drugs@FDA,NO,NO,0.73,,High,Reported bioavailability,0.02,0.15,1.9,,,,,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,317.4226,2,3,2,4,0,6,66.4,0.578947368,0.951,1.077,4.298,All fragments measured,3.8,0.64,4.23,0.625,3.61,,3.9,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83088,0.86695,0.99021,0.86805,0.9848,0.79222,0.96362,0.6885,0.82734,245.9,4.28,10.7,16.3
118457-14-0,NEBIVOLOL HYDROCHLORIDE,BYSTOLIC,PF-04605975,1887,c1cc2c(cc1F)CC[C@@H](O2)[C@H](CNC[C@@H]([C@@H]3CCc4cc(ccc4O3)F)O)O,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,ALLERGAN,major pharma,39433,2007,Drugs@FDA,NO,NO,,0.96,High,Fa estimated from reported excretion data,0.02,,12,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinicallyapparent liver injury),,0,,NO,NO,NO,,405.435,3,5,3,5,0,6,70.95,0.454545455,2.36,3.278,3.5,All fragments measured,3.9,3.1,3.69,2.316,,8.65,16,8.1,Basic,Class 4,0,2,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.64197,0.70373,0.53856,0.95284,0.72615,0.37866,0.93826,0.6885,0.93773,446.6,3.53,19.4,81.6
83366-66-9,NEFAZODONE HYDROCHLORIDE,SERZONE,PF-00579891,1890,CCc1nn(c(=O)n1CCOc2ccccc2)CCCN3CCN(CC3)c4cccc(c4)Cl,TABLET,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,34690,1994,Drugs@FDA,NO,NO,0.19,,Moderate,Reported bioavailability,0.01,0.51,2,,,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,Most,Most,DILIRank,1,,,,Moderate,1,Aniline,YES,NO,NO,,470.0069,0,4,0,7,1,10,55.53,0.44,4.14,4.76,5.725,Calculated fragment value,4.4,4.3,4.09,3.88,,7.65,,7.2,Basic,Class 2,0,0,0,0,1,0,0,3,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.44044,0.55158,0.25141,0.72417,0.72615,0.59178,0.99948,0.21184,0.93773,415.8,7.06,48.4,180
159989-64-7,NELFINAVIR MESYLATE,VIRACEPT,PF-00346577,1893,Cc1c(cccc1O)C(=O)N[C@@H](CSc2ccccc2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,"POWDER, TABLET",YES,NO,NO,NO,ORAL,1250,Prescription,,NO,NO,,,,,AGOURON PHARMS,pharma,35503,1997,Drugs@FDA,NO,NO,,0.67,High,Fa estimated from reported excretion data,0.02,2,3.5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),,0,,NO,NO,NO,1OHR,567.7824,4,6,4,7,2,9,101.9,0.5625,4.58,6.075,5.842,All fragments measured,5.3,5.3,5.69,5.682,9.58,6.21,8.6,6.7,Zwitter,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.22437,0.29131,0.08084,0.34959,0.52457,0.14694,0.41138,0.21184,0.93773,540.9,1.07,18.6,279
66-86-4,NEOMYCIN SULFATE,MYCIFRADIN,PF-05588163,4247,C1[C@@H]([C@@H]([C@@H]([C@@H]([C@@H]1N)O[C@H]2[C@@H]([C@@H]([C@@H]([C@@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@@H](O3)CO)O[C@H]4[C@@H]([C@@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,SOLUTION,YES,NO,NO,NO,ORAL,12000,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,25854,1970,Drugs@FDA,NO,NO,0.006,0.01,Low,Reported bioavailability,0.8,0.25,3,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,4V52,614.6437,19,19,13,19,3,9,353.11,1,-2.15,-2.15,-6.466,All fragments measured,-9,-9,-4.88,-11.121,12.93,9.52,12,8.6,Basic,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,3,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,NO,0.06048,0.04553,0.05346,0.02417,0.01986,0.00627,0.01816,0.29329,0.47245,1009,,1.66,8.71
698387-09-6,NERATINIB MALEATE,NERLYNX,PF-05208767,5252,CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4,TABLET,YES,NO,NO,YES,ORAL,240,Prescription,,NO,NO,,,Pfizer,major pharma,PUMA BIOTECH,pharma,42933,2017,Drugs@FDA,NO,NO,,,NA,NA,0.01,91.9,7,Parent CRG,,,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,2,Aniline; Michael_acceptor,YES,YES,NO,2JIV,557.0427,2,7,2,9,2,11,112.4,0.2,3.25,3.23,5.147,Benzyl approx. based on a priori value,4.5,2.7,4.43,3.697,12.37,8.01,9.6,8.7,Basic,Class 4,0,0,0,0,1,0,0,4,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,NO,0.18641,0.21441,0.09027,0.52212,0.19128,0.79222,0.55812,0.15134,0.03452,537.1,0.321,29.1,63.6
290297-26-6,NETUPITANT,AKYNZEO,PF-06824408,4898,Cc1ccccc1c2cc(ncc2N(C)C(=O)C(C)(C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Roche,major pharma,HELSINN HLTHCARE,pharma,41922,2014,Drugs@FDA,YES,NO,,,NA,NA,0.005,28.3,80,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,None,0,,NO,NO,NO,,578.5917,0,3,0,5,2,6,39.68,0.4,4.51,5.28,6.505,Benzyl approx. based on a priori value,6.7,5.7,6.29,6.22,,7.17,,8,Basic,Class 4,0,6,0,0,0,0,0,3,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.2148,0.29875,0.07274,0.043,0.88651,0.59178,0.94573,0.53315,0.25672,437.3,0.405,28.8,57.3
129618-40-2,NEVIRAPINE,VIRAMUNE,PF-00346563,1904,Cc1ccnc2c1NC(=O)c3cccnc3N2C4CC4,"SUSPENSION, TABLET, TABLET, EXTENDED RELEASE, TABLET, FOR SUSPENSION",YES,NO,YES,NO,ORAL,400,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,35237,1996,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.4,1.2,45,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Most,0,,NO,NO,NO,2HND,266.2979,1,3,1,5,0,1,58.12,0.266666667,2.57,2.038,2.65,All fragments measured,1.3,1.3,2.1,2.103,12.05,4.25,10,2.4,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86573,0.89245,0.88419,0.98181,0.88651,0.98659,0.99411,0.63709,0.93773,285.7,10.7,10.6,17
59-67-6,NIACIN,WAMPOCAP,PF-00345527,2835,c1cc(cnc1)C(=O)O,"CAPSULE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,3000,Prescription,,NO,NO,,,,,MEDPOINTE PHARM HLC,pharma,21025,1957,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,,,0.5,,85,,,NO,"Cardiovascular, Metabolic Disease",NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Pyridine,NO,NO,NO,,123.1094,1,3,1,3,0,1,50.19,0,-1.92,-1.92,0.799,All fragments measured,0.69,-2.5,0.47,-2.604,2.2,4.8,2.2,4.9,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.51965,0.63382,0.14118,0.56952,0.9848,0.98659,0.99788,0.63709,0.82734,107,18.4,5.73,9.1
51-12-7,NIALAMIDE,NIAMID,PF-00345606,1907,c1ccc(cc1)CNC(=O)CCNNC(=O)c2ccncc2,TABLET,YES,NO,NO,NO,ORAL,450,Discontinued,1974,YES,NO,Hepatotoxicity,WITHDRAWN,,,PFIZER,major pharma,21758,1959,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,2,Hydrazines; Pyridine,NO,NO,NO,,298.3397,3,3,3,6,0,7,83.12,0.1875,1.13,1.105,0.909,All fragments measured,-0.19,-0.2,0.82,0.817,11.13,3.6,11,4.6,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64212,0.69674,0.9954,0.56252,0.88651,0.37866,0.84819,0.53315,0.93773,255.3,2.2,6.79,13.9
55985-32-5,NICARDIPINE HYDROCHLORIDE,CARDENE,PF-00249549,1909,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)Cc2ccccc2)c3cccc(c3)N(=O)=O)C(=O)OC,"CAPSULE; CAPSULE, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,120,Prescription,,NO,NO,,,,,CHIESI USA INC,pharma,32498,1988,Drugs@FDA,NO,NO,0.35,0.95,High,Reported bioavailability,0.01,8.3,14.4,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Nitroorganics,NO,NO,NO,,479.525,1,6,1,9,1,11,113.69,0.307692308,4.17,4.12,5.23,Estimated fragment value used,3.9,3.7,4.81,4.553,,7.3,,7.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,NO,0.44685,0.43888,0.22347,0.96196,0.19128,0.98659,0.54477,0.15134,0.93773,425.4,9.7,50.9,329
54-11-5,NICOTINE,NICOTROL,PF-00345015,1920,CN1CCC[C@H]1c2cccnc2,CHEWING GUM,YES,NO,NO,NO,ORAL,,Over-the-counter,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,35552,1997,Drugs@FDA,NO,NO,0.3,1,Moderate,Reported bioavailability,0.95,2.6,1.5,,,,51409207,NO,Neurological,NO,NO,,YES,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Pyridine,NO,NO,NO,5KXI,162.2316,0,2,0,2,0,1,16.13,0.5,0.0766,0.0766,0.883,All fragments measured,1.1,0.069,0.82,-0.366,,8,,9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.55894,0.61309,0.25704,0.83175,0.93048,0.59178,0.52472,0.63709,0.82734,165.1,38.3,4.5,10.6
21829-25-4,NIFEDIPINE,PROCARDIA,PF-00344573,1922,CC1=C(C(C(=C(N1)C)C(=O)OC)c2ccccc2N(=O)=O)C(=O)OC,"CAPSULE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,120,Prescription,,NO,NO,,,,,PFIZER,major pharma,29951,1981,Drugs@FDA,NO,NO,0.5,0.8,High,Reported bioavailability,0.04,1.47,2,,,,6601568,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,1,Nitroorganics,NO,NO,NO,,346.3346,1,5,1,8,0,6,110.45,0.294117647,3.64,2.55,3.125,Estimated fragment value used,2.4,2.4,3.45,3.445,,2.69,,2.1,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,NO,0.83308,0.70778,0.88895,0.92684,0.33223,0.98659,0.57841,0.6885,0.82734,304.8,38.1,60.4,161
923288-95-3,NILOTINIB HYDROCHLORIDE,TASIGNA,PF-05166423,1932,Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,39384,2007,Drugs@FDA,NO,NO,,0.24,Moderate,Fa estimated from reported excretion data,0.02,,17,,,63,,YES,Oncology,NO,YES,II,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,,2,Aniline; Pyridine,YES,NO,NO,3GP0,529.5158,2,5,2,8,2,6,97.62,0.107142857,4.12,4.88,5.844,All fragments measured,6,6,4.75,4.847,12.94,5.64,12,5.1,Neutral,Class 4,0,3,0,0,0,0,0,5,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.22051,0.269,0.12232,0.43222,0.52457,0.79222,0.71162,0.53315,0.01222,520.8,1.87,15.3,69.6
63612-50-0,NILUTAMIDE,NILANDRON,PF-00346022,1933,CC1(C(=O)N(C(=O)N1)c2ccc(c(c2)C(F)(F)F)N(=O)=O)C,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,CONCORDIA PHARMS INC,pharma,35327,1996,Drugs@FDA,NO,NO,,0.62,High,Fa estimated from reported excretion data,0.16,,38,,,,,NO,Oncology,NO,NO,,NO,NO,NO,YES,Most,Most,,,C,Less,C (probable cause of clinically apparent liver injury),Less,2,Hydantoin; Nitroorganics,NO,NO,NO,,317.2207,1,4,1,7,0,2,95.23,0.333333333,2.44,2.548,1.708,All fragments measured,2,2,2.24,2.032,7.59,,12,,Neutral,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.95253,0.90891,0.99055,0.97902,0.88651,0.98659,0.73563,0.99269,0.82734,316.7,23.9,2.23,13.7
66085-59-4,NIMODIPINE,NIMOTOP,PF-00248850,1937,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)c2cccc(c2)N(=O)=O)C(=O)OCCOC,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,360,Prescription,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,32505,1988,Drugs@FDA,NO,NO,0.13,,Moderate,Reported bioavailability,0.05,1.1,8,,,,,YES,Cardiovascular,NO,NO,,YES,NO,NO,YES,Ambiguous,Ambiguous,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,1,Nitroorganics,NO,NO,NO,,418.4403,1,6,1,9,0,10,119.68,0.428571429,4.15,3.61,4.003,Estimated fragment value used,3.2,3.2,4.13,4.125,,2.77,,1.8,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,NO,0.55597,0.49582,0.46675,0.98619,0.19128,0.98659,0.48386,0.21184,0.82734,378.4,25.7,64.1,311
656247-17-5,NINTEDANIB ESYLATE,OFEV,PF-06293544,4903,CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Boehringer Ingelheim,major pharma,BOEHRINGER INGELHEIM,major pharma,41927,2014,Drugs@FDA,NO,NO,0.047,,Low,Reported bioavailability,0.022,15,12.3,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,2,Aniline; Michael_acceptor,YES,YES,NO,3C7Q,539.6248,2,5,2,9,1,9,94.22,0.258064516,2.44,3.5,3.083,A priori fragment value used,3.8,3.5,2.81,2.478,11.06,7.43,9.4,7.8,Basic,Class 4,0,0,0,0,0,0,0,4,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.37329,0.41701,0.10906,0.99831,0.33223,0.79222,0.74554,0.39983,0.25672,491.6,1.11,12.8,61.8
1038915-60-4,NIRAPARIB TOSYLATE,ZEJULA,PF-05601436,5222,c1cc2cn(nc2c(c1)C(=O)N)c3ccc(cc3)[C@@H]4CCCNC4,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Merck,major pharma,TESARO INC,pharma,42821,2017,Drugs@FDA,NO,NO,0.73,,High,Reported bioavailability,0.17,15.3,36,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,,320.3883,3,3,2,5,0,3,72.94,0.263157895,0.433,0.3528,2.722,All fragments measured,2.2,-0.087,2.4,0.22,,9.8,11,9.9,Basic,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75965,0.78316,0.98455,0.99735,0.9848,0.79222,0.92558,0.99269,0.25672,294.2,5.97,4.26,8.73
63675-72-9,NISOLDIPINE,SULAR,PF-00345689,1942,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)c2ccccc2N(=O)=O)C(=O)OC,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,60,Prescription,,NO,NO,,,,,COVIS PHARMA BV,pharma,34732,1995,Drugs@FDA,NO,NO,0.05,0.9,Low,Reported bioavailability,0.01,5.5,13.7,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Nitroorganics,NO,NO,NO,,388.4144,1,5,1,8,0,8,110.45,0.4,4.38,4.01,4.582,Estimated fragment value used,3.7,3.7,4.27,4.275,,2.67,,2,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,NO,0.69565,0.63162,0.64045,0.99846,0.33223,0.98659,0.57841,0.39983,0.82734,344.9,30.9,43.8,249
55981-09-4,NITAZOXANIDE,ALINIA,PF-01422300,1943,CC(=O)Oc1ccccc1C(=O)Nc2ncc(s2)N(=O)=O,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,Romark,pharma,ROMARK,pharma,37582,2002,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.01,,1.5,,,,67949,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Nitroorganics,NO,NO,NO,,307.282,1,4,1,8,0,5,114.11,0.083333333,2.42,2.42,1.243,All fragments measured,2.2,1.4,2.07,0.09,4.19,,6.4,-1.9,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.89752,0.72122,0.99988,0.86452,0.52457,0.98659,0.28547,0.84757,0.93773,336.2,16.3,17.6,19.5
104206-65-7,NITISINONE,ORFADIN,PF-06101294,1944,c1cc(c(cc1C(F)(F)F)N(=O)=O)C(=O)C2C(=O)CCCC2=O,"CAPSULE, SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,140,Prescription,,NO,NO,,,AstraZeneca,major pharma,SWEDISH ORPHAN,pharma,37274,2002,Drugs@FDA,NO,NO,,,NA,NA,0.05,0.1,54,,,,,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,2,1_3_Diketones; Nitroorganics,NO,NO,NO,,329.2281,0,5,0,6,0,3,97.03,0.357142857,0.255,0.255,1.384,All fragments measured,2.3,-0.55,2.42,-0.075,3.13,,3.5,,Acidic,Class 1A,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.8462,0.81376,0.96063,0.9945,0.72615,0.59178,0.71749,0.96969,0.82734,269.3,26.1,20.1,14.1
67-20-9,NITROFURANTOIN,FURADANTIN,PF-00344812,1949,c1cc(oc1/C=N/N2CC(=O)NC2=O)N(=O)=O,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,PROCTER AND GAMBLE,pharma,19396,1953,Drugs@FDA,NO,NO,0.94,,High,Reported bioavailability,0.1,,0.5,,,,2541788,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clniically apparent liver injury),Moderate,2,Furan; Nitroorganics,NO,NO,NO,,238.157,1,4,1,9,0,3,120.73,0.125,0.0487,0.0487,-0.467,Estimated fragment value used,-0.64,-0.99,-0.03,-0.257,7.55,,7.3,0,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78696,0.71856,0.7035,0.50464,0.72615,0.98659,0.47353,0.99269,0.82734,305,0.341,3.44,10.6
76963-41-2,NIZATIDINE,AXID,PF-00345389,1955,CN/C(=C\N(=O)=O)/NCCSCc1csc(n1)CN(C)C,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,300,Over-the-counter,,NO,NO,,,,,SMITHKLINE BEECHAM,major pharma,32245,1988,Drugs@FDA,NO,NO,0.94,,High,Reported bioavailability,0.65,1,1.9,,,,58392,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,331.4574,2,7,2,7,0,10,86.01,0.583333333,0.511,0.511,-0.162,Estimated fragment value used,-0.17,-0.26,0.15,-0.052,,7.31,,6.7,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.58714,0.5108,0.95304,0.6734,0.33223,0.79222,0.3065,0.21184,0.82734,310.4,0.705,3.2,16.8
32795-47-4,NOMIFENSINE MALEATE,MERITAL,PF-00345303,1958,CN1Cc2c(cccc2N)C(C1)c3ccccc3,N/A,N/A,N/A,N/A,NO,ORAL,300,Discontinued,1986,YES,YES,Hemolytic/immunohemolytic anemia,FederalRegister,,,HOECHST,pharma,28126,1977,NIH NCATS,NO,NO,0.27,0.95,Moderate,Reported bioavailability,0.4,5.4,,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,1,Aniline,YES,NO,NO,,238.3275,2,1,1,2,0,1,29.26,0.25,1.38,2.158,2.372,All fragments measured,2.3,1.8,2.68,1.989,,7.85,,8.8,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82222,0.84609,0.70469,0.99634,0.93048,0.98659,0.80607,0.63709,0.93773,187.4,15.6,77,24.1
68-22-4,NORETHINDRONE,MICRONOR,PF-00344575,1962,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,TABLET,YES,NO,NO,NO,ORAL,0.35,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,26666,1973,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.39,4,8,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,A,Most,A (well established cause of clniically apparent liver injury),Less,1,Alkynes,NO,NO,NO,,298.4192,1,2,1,2,0,0,37.3,0.75,2.88,2.88,2.97,Valid estimate for difficult structure,3,3,2.98,2.982,,,15,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68858,0.73857,0.9955,0.7623,0.93048,0.98659,0.92207,0.39503,0.47245,299.1,16,72.7,41.3
51-98-9,NORETHINDRONE ACETATE,AYGESTIN,PF-00346454,1963,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,DURAMED RES,pharma,30062,1982,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.39,4,8,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,,,,Less,1,Alkynes,NO,NO,NO,,340.4559,0,2,0,3,0,2,43.37,0.727272727,3.11,3.88,3.926,Valid estimate for difficult structure,4.1,4.1,3.72,3.72,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69981,0.74684,0.91683,0.60618,0.9848,0.59178,0.97306,0.87038,0.47245,341.5,8.56,78.7,62.7
68-23-5,NORETHYNODREL,ENOVID,PF-00345133,1965,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3CCC(=O)C4,TABLET,YES,NO,NO,NO,ORAL,5,Discontinued,,NO,NO,,,,,GD SEARLE,major pharma,22349,1961,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,1,Alkynes,NO,NO,NO,,298.4192,1,2,1,2,0,0,37.3,0.75,2.58,3.362,2.83,All fragments measured,4.4,4.4,3.63,3.631,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69875,0.74863,0.9955,0.83799,0.93048,0.98659,0.92207,0.39503,0.47245,288.5,17.6,70.5,54.1
70458-96-7,NORFLOXACIN,NOROXIN,PF-00344811,1967,CCn1cc(c(=O)c2c1cc(c(c2)F)N3CCNCC3)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,800,Discontinued,,NO,NO,,,,,MERCK,major pharma,31716,1986,Drugs@FDA,NO,NO,0.35,,High,Reported bioavailability,0.85,0.4,3,,,,195046,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,,319.3308,2,4,2,6,0,3,74.57,0.375,-0.808,-0.9921,-0.78,All fragments measured,1.7,-0.72,-0.57,-3.047,,8.68,6,8.6,Zwitter,Class 3A,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.67613,0.64442,0.98671,0.148,0.52457,0.79222,0.92598,0.99269,0.82734,305.5,1.64,2.31,7.34
35189-28-7,NORGESTIMATE,ORTHO CYCLEN-21,PF-06193118,1968,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N\O)/CC[C@H]34,TABLET,YES,NO,NO,NO,ORAL,0.25,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,32871,1989,Drugs@FDA,YES,NO,,,NA,NA,,,,,95,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,A,Most,A (well established cause of clniically apparent liver injury),Less,1,Alkynes,NO,NO,NO,,369.4971,1,3,1,4,1,3,58.89,0.739130435,3.8,4.68,5.055,Benzyl approx. based on a priori value,5.5,5.5,4.84,4.84,11.26,,9.8,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,NO,0.71117,0.73512,0.75769,0.37616,0.88651,0.98659,0.99227,0.99269,0.47245,368.9,6.57,50.8,125
72-69-5,NORTRIPTYLINE HYDROCHLORIDE,AVENTYL HYDROCHLORIDE,PF-00344733,1971,CNCCC=C1c2ccccc2CCc3c1cccc3,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,ELI LILLY AND CO,major pharma,23687,1964,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.12,22,27,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Most,Most,DILIRank,1,,,,Less,0,,NO,NO,NO,4M48,263.3767,1,1,1,1,0,3,12.03,0.263157895,1.67,1.583,4.315,All fragments measured,4.1,1.8,4.76,2.278,,10,,9.7,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8833,0.6747,0.86789,0.79043,0.23327,0.98659,0.43308,0.99269,0.93773,167.8,4.36,13,23.5
303-81-1,NOVOBIOCIN SODIUM,ALBAMYCIN,PF-02919947,1974,Cc1c(ccc2c1oc(=O)c(c2O)NC(=O)c3ccc(c(c3)CC=C(C)C)O)O[C@H]4[C@@H]([C@@H]([C@H](C(O4)(C)C)OC)OC(=O)N)O,CAPSULE,YES,NO,NO,NO,ORAL,2000,Discontinued,2011,YES,YES,"Adverse reactions that included skin reactions, jaundice, hepatic failure, and blood dyscrasias (neutropenia, anemia, and thrombocytopenia).  Drug resistance and DDI.",FederalRegister,,,PHARMACIA AND UPJOHN,major pharma,23624,1964,Drugs@FDA,NO,NO,,,NA,NA,,,5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Michael_acceptor,NO,YES,NO,4URO,612.6243,6,9,5,13,3,9,200.01,0.387096774,1.81,1.503,3.976,All fragments measured,4.5,1.6,2.71,-0.024,4.5,,4.6,,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,NO,0.19513,0.15516,0.05428,0.96649,0.03975,0.05547,0.06805,0.29329,0.93773,657.7,0.669,31.9,37.8
459789-99-2,OBETICHOLIC ACID,OCALIVA,PF-04337610,5155,CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Universita degli di Perugia,nonprofit,INTERCEPT PHARMS INC,pharma,42517,2016,Drugs@FDA,NO,NO,0.171,,Moderate,Reported bioavailability,0.01,8.8,,,,,,YES,Gastrointestinal,NO,NO,,NO,NO,NO,YES,,Less,,,C,Less,"C (based upon FDA reporting, a suspected rare cause of clinically apparent liver injury occurring mostly in patients with preexisting cirrhosis)",Less,0,,NO,NO,NO,1OT7,420.6252,3,4,3,4,1,5,77.76,0.961538462,2.05,2.05,5.362,All fragments measured,5.2,2.7,4.42,1.817,4.76,,5,,Acidic,Class 3B,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53529,0.60803,0.45532,0.56317,0.88651,0.37866,0.89136,0.84757,0.47245,415.3,4.44,9.08,14.6
82419-36-1,OFLOXACIN,FLOXIN,PF-00344904,1981,CC1COc2c3n1cc(c(=O)c3cc(c2N4CCN(CC4)C)F)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,33235,1990,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.68,2.4,5,,,,166229,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,5EIX,361.3675,1,5,1,7,0,2,75.01,0.444444444,-0.109,-0.7538,-0.508,All fragments measured,1.9,-0.41,0.17,-2.076,5.19,7.37,6.1,8.3,Zwitter,Class 1A,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.65541,0.59655,0.80655,0.153,0.33223,0.98659,0.92306,0.87038,0.82734,392.7,5.21,3.56,7.97
132539-06-1,OLANZAPINE,ZYPREXA,PF-00346488,1982,Cc1cc2c(s1)Nc3ccccc3N=C2N4CCN(CC4)C,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,ELI LILLY AND CO,major pharma,35338,1996,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.07,14.3,30,,19,181,4091048,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,Moderate,2,Dibenzazepine; Thiophene,NO,NO,YES,,312.4325,1,2,1,4,0,1,30.87,0.352941176,2.36,1.861,3.009,Approximated fragment value used,3.5,3.3,2.61,1.903,,7.78,,7.7,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.89147,0.90981,0.99689,0.99893,0.88651,0.98659,0.99171,0.63709,0.93773,308.4,15.7,12.3,22.6
763113-22-0,OLAPARIB,LYNPARZA,PF-05269734,4907,c1ccc2c(c1)c(n[nH]c2=O)Cc3ccc(c(c3)C(=O)N4CCN(CC4)C(=O)C5CC5)F,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,AstraZeneca,major pharma,ASTRAZENECA AB,major pharma,41992,2014,Drugs@FDA,NO,NO,,0.44,High,Fa estimated from reported excretion data,0.18,2.3,,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,434.4628,1,4,1,7,0,6,86.37,0.333333333,1.85,1.55,1.236,Approximated fragment value used,1.4,1.4,1.04,1.037,12.07,,12,-0.3,Neutral,Class 2,0,1,0,0,0,0,0,3,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.78617,0.82307,0.38764,0.96858,0.88651,0.98659,0.85694,0.96969,0.93773,414.7,11.7,11.9,16.3
144689-63-4,OLMESARTAN MEDOXOMIL,BENICAR,PF-03911981,1985,CCCc1nc(c(n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)C(=O)OCc5c(oc(=O)o5)C)C(C)(C)O,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,Daiichi Sankyo,pharma,DAIICHI SANKYO,pharma,37371,2002,Drugs@FDA,NO,YES,0.26,,Moderate,Reported bioavailability,0.01,0.24,13,,104,,16518786,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (Possible rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,4ZUD,558.5851,2,7,2,12,2,11,162.16,0.310344828,0.855,0.855,2.66,Calculated fragment value,5.5,2,4.12,2.118,4.15,4.4,4,4.7,Acidic,Class 3B,0,0,0,0,0,0,0,4,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,8,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.18022,0.15944,0.08882,0.55235,0.06191,0.79222,0.20828,0.15134,0.03452,504.7,0.519,37.4,60.2
1075240-43-5,OMADACYCLINE TOSYLATE,NUZYRA,VC-001215367,,CC(C)(C)CNCc1cc(c2c(c1O)C(=O)C3=C([C@]4([C@@H](C[C@@H]3C2)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)N(C)C,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Paratek Pharmaceuticals,pharma,PARATEK PHARMS INC,pharma,43375,2018,Drugs@FDA,NO,NO,0.345,,High,Reported bioavailability,0.8,11.3,16,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,3,Aniline; Hydroxy_Aniline; Michael_acceptor,YES,YES,NO,,556.6505,7,9,6,11,3,6,176.66,0.551724138,0.937,0.937,1.38,Valid estimate for difficult structure,1.4,-2.7,0.94,-1.706,4.5,11.06,3.1,12,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.20156,0.17565,0.09064,0.79866,0.06191,0.02306,0.11314,0.53315,0.82734,554.6,0.872,2.84,20.8
1258226-87-7,OMBITASVIR,VIEKIRA PAK (COPACKAGED),VC-001215366,4912,CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,41992,2014,Drugs@FDA,YES,NO,0.48,,High,Reported bioavailability,0.001,2.5,,,,77,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,C,Less,C (probable cause of liver injury arising in patients with pre-existing cirrhosis),Less,1,Aniline,YES,NO,NO,,894.1091,4,6,4,15,3,17,178.72,0.52,4.42,6.89,8.031,Very high LogP unrealistic in nature,7.8,7.8,6.02,6.135,10.92,4.6,13,4.5,Neutral,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.06206,0.07506,0.0272,0.04395,0.10671,0.14694,0.10703,0.02606,0.25672,923.9,1.89,7.08,24.1
73590-58-6,OMEPRAZOLE,PRILOSEC,PF-00344640,1990,Cc1cnc(c(c1OC)C)CS(=O)c2[nH]c3ccc(cc3n2)OC,"CAPSULE, DELAYED REL PELLETS, TABLET, DELAYED RELEASE, TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE",NO,YES,NO,NO,ORAL,20,Over-the-counter,,NO,NO,,,,,ASTRAZENECA AB,major pharma,32765,1989,Drugs@FDA,NO,YES,0.35,,High,Reported bioavailability,0.04,0.35,0.75,Prodrug,159,,2374433,NO,Gastrointestinal,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,B,Most,B (rare but likely cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,345.4161,1,5,1,6,0,5,77.1,0.294117647,1.95,2.173,2.565,Benzyl approx. based on a priori value,2.2,2.2,2.09,2.079,8.89,5.39,9.3,4.7,Neutral,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74398,0.72059,0.8935,0.9994,0.72615,0.98659,0.72473,0.84757,0.25672,402.8,22.5,10.5,21.2
99614-02-5,ONDANSETRON HYDROCHLORIDE,ZOFRAN,PF-00345557,1992,Cc1nccn1CC2CCc3c(c4ccccc4n3C)C2=O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,24,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,33969,1992,Drugs@FDA,NO,NO,0.56,,High,Reported bioavailability,0.27,2.3,4.6,,53,,10424757,NO,Gastrointestinal,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,293.363,0,2,0,4,0,2,39.82,0.333333333,2.23,1.525,2.716,All fragments measured,2.1,1.9,2.79,2.434,,7.5,,7.9,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69535,0.73402,0.98757,0.99776,0.93048,0.59178,0.94697,0.87038,0.25672,298.5,17.1,8.84,10.5
83-98-7,ORPHENADRINE HYDROCHLORIDE,DISIPAL,PF-00344813,1999,Cc1ccccc1C(c2ccccc2)OCCN(C)C,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,3M,pharma,20950,1957,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,,,13,,,,,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,YES,YES,YES,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,269.3813,0,2,0,2,0,6,12.47,0.333333333,2.05,2.349,3.901,All fragments measured,3.9,2.5,4.05,2.63,,8.72,,8.4,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.77264,0.74456,0.90049,0.89518,0.93048,0.59178,0.44264,0.6885,0.93773,199.9,20.1,9.37,11.7
196618-13-0,OSELTAMIVIR PHOSPHATE,TAMIFLU,PF-04440269,2001,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,36460,1999,Drugs@FDA,NO,YES,0.75,,High,Reported bioavailability,,,,,,162,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,,312.4045,3,4,2,6,0,8,90.65,0.75,1.03,1.025,2.132,All fragments measured,1.1,0.71,1.44,0.631,,8.81,14,7.7,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.65821,0.67872,0.99691,0.78503,0.72615,0.79222,0.78016,0.39983,0.47245,321.5,3.86,16.2,8.67
1421373-65-0,OSIMERTINIB MESYLATE,TAGRISSO,PF-06719696,5062,Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,AstraZeneca,major pharma,ASTRAZENECA AB,major pharma,42321,2015,Drugs@FDA,NO,NO,,0.78,High,Fa estimated from reported excretion data,0.05,14.2,48,Parent CRG,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,2,Aniline; Michael_acceptor,YES,YES,NO,4ZAU,499.6073,2,5,2,9,0,10,87.55,0.25,3.01,3.15,4.754,All fragments measured,4.5,3,3.74,2.633,12.68,9.06,10,7.9,Basic,Class 4,0,0,0,0,0,0,0,4,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.24241,0.28881,0.17456,0.61637,0.33223,0.79222,0.80907,0.21184,0.03452,502.9,3.03,28.4,32.6
128607-22-7,OSPEMIFENE,OSPHENA,VC-001215427,4749,c1ccc(cc1)/C(=C(\c2ccccc2)/c3ccc(cc3)OCCO)/CCCl,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,Orion Pharma,pharma,DUCHESNAY,pharma,41331,2013,Drugs@FDA,NO,NO,,,NA,NA,0.01,6.4,26,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,None,,,C,Less,C (probable rare cause of clinically apparent liver injury),Less,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,378.8912,1,2,1,2,1,8,29.46,0.166666667,4.14,5.24,5.559,All fragments measured,5.7,5.7,6,6.07,,,15,,Neutral,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.48083,0.53503,0.69956,0.23516,0.93048,0.98659,0.80963,0.39983,0.25672,224.3,2.94,11,33.6
21738-42-1,OXAMNIQUINE,VANSIL,PF-00344645,2009,CC(C)NCC1CCc2cc(c(cc2N1)N(=O)=O)CO,CAPSULE,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,PFIZER,major pharma,29425,1980,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,,,1,,,,12,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,,,,,2,Aniline; Nitroorganics,YES,NO,NO,,279.3348,3,4,3,6,0,5,90.11,0.571428571,0.00356,0.00356,2.255,All fragments measured,1.7,-0.37,1.97,-0.308,,9.83,15,9.4,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74117,0.7502,0.94584,0.93386,0.72615,0.37866,0.78528,0.84757,0.82734,266.7,3.75,8.01,22.5
53-39-4,OXANDROLONE,OXANDRIN,PF-00346500,2011,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,GEMINI LABS LLC,pharma,23579,1964,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.03,8.3,5,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,,,,None,0,,NO,NO,NO,,306.4397,1,2,1,3,0,0,46.53,0.947368421,2.87,2.599,2.963,All fragments measured,2.2,2.2,3.29,3.291,,,17,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72005,0.78173,0.99998,0.99545,0.9848,0.98659,0.98835,0.39503,0.47245,324.7,17,91.2,39.2
21256-18-8,OXAPROZIN,DAYPRO,PF-00345554,2013,c1ccc(cc1)c2c(oc(n2)CCC(=O)O)c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,1800,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,33906,1992,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.01,0.2,42,,,,549022,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,293.3166,1,3,1,4,0,5,63.33,0.111111111,1.1,1.1,2.948,All fragments measured,3.7,0.94,3.9,0.88,4.28,,4.6,0.73,Acidic,Class 1A,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76299,0.79084,0.98748,0.94805,0.9848,0.98659,0.97752,0.84757,0.25672,242.8,21.7,11.1,8.71
604-75-1,OXAZEPAM,SERAX,PF-00345393,2015,c1ccc(cc1)C2=NC(C(=O)Nc3c2cc(cc3)Cl)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,120,Prescription,,NO,NO,,,,,ALPHARMA US PHARMS,pharma,23897,1965,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.04,0.59,8.2,,,,2985358,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,286.713,2,2,2,4,0,1,61.69,0.066666667,2.13,2.65,2.305,All fragments measured,2.3,2.3,2.06,2.065,10.94,1.17,8.8,1.8,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.84877,0.89086,0.97129,0.99993,0.9848,0.79222,0.98375,0.63709,0.93773,293.2,33.6,10.8,8.19
28721-07-5,OXCARBAZEPINE,TRILEPTAL,PF-00346582,2017,c1ccc2c(c1)CC(=O)c3ccccc3N2C(=O)N,"SUSPENSION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,2400,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,36539,2000,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.6,0.7,2,,74,,405,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,252.268,2,2,1,4,0,1,63.4,0.066666667,0.875,0.875,1.206,Benzyl approx. based on a priori value,1.7,1.7,1.87,1.868,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76132,0.82379,0.79961,0.96894,0.93048,0.98659,0.97723,0.39503,0.93773,237.8,27.1,4.55,6.86
6452-71-7,OXPRENOLOL HYDROCHLORIDE,TRASICOR,PF-00345066,2027,CC(C)NCC(COc1ccccc1OCC=C)O,CAPSULE,YES,NO,NO,NO,ORAL,320,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,30678,1983,PharmaCircle,NO,NO,0.74,0.9,High,Reported bioavailability,0.22,1.2,2,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,265.348,2,4,2,4,0,9,50.72,0.466666667,0.0876,-0.2,2.092,All fragments measured,2,0.14,2.29,0.184,,9.44,15,9.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68305,0.75981,0.87898,0.97737,0.88651,0.79222,0.9986,0.29329,0.82734,231.3,22,34.9,18.9
5633-20-5,OXYBUTYNIN CHLORIDE,DITROPAN,PF-00345137,2028,CCN(CC)CC#CCOC(=O)C(c1ccccc1)(C2CCCCC2)O,"SYRUP, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,30,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,27591,1975,Drugs@FDA,NO,NO,0.06,,Low,Reported bioavailability,0.01,,2,,127,,413,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,1,Alkynes,NO,NO,NO,,357.4864,1,3,1,4,0,8,49.77,0.590909091,2.51,3.553,4.867,All fragments measured,4.3,3.9,4.62,3.724,11.95,8.24,15,7.2,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.61323,0.69649,0.82903,0.62738,0.88651,0.98659,0.99719,0.21184,0.82734,272.7,3.26,48.2,253
76-42-6,OXYCODONE HYDROCHLORIDE,ROXICODONE,PF-00345439,2029,CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)OC,"CAPSULE, SOLUTION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,90,Prescription,,NO,NO,,,,,ROXANE,pharma,36094,1998,Drugs@FDA,NO,NO,0.74,,High,Reported bioavailability,0.55,2.6,5.6,,51,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,315.3636,1,5,1,5,0,1,59,0.611111111,0.266,0.266,-0.039,All fragments measured,0.72,0.087,0.91,0.453,,7.57,17,8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83883,0.83944,0.99341,0.78929,0.72615,0.98659,0.99199,0.63709,0.82734,400.8,23.3,5.05,9.92
434-07-1,OXYMETHOLONE,ANADROL-50,PF-00346551,2033,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,TABLET,YES,NO,NO,NO,ORAL,1400,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,26316,1972,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,,,,None,0,,NO,NO,NO,,332.477,2,3,2,3,0,0,57.53,0.857142857,2.68,3.596,4.137,Valid estimate for difficult structure,3.5,1.3,3.63,0.825,4.5,,9.5,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68019,0.75242,0.94938,0.99228,0.9848,0.79222,0.99536,0.39503,0.47245,335.9,21.4,21.7,41.6
76-41-5,OXYMORPHONE HYDROCHLORIDE,OPANA ER,PF-02885642,2034,CN1CC[C@]23c4c5ccc(c4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,20,Prescription,,NO,NO,,,Endo International ,pharma,ENDO PHARMS,pharma,38890,2006,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,0.88,3.08,7.3,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,301.3371,2,5,2,5,0,0,70,0.588235294,0.248,0.248,-0.484,All fragments measured,0.52,-0.11,1.01,0.603,9.17,7.58,9.6,8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71352,0.74654,0.99828,0.72943,0.72615,0.79222,0.94399,0.39503,0.82734,387.7,6.03,19.5,8.41
129-20-4,OXYPHENBUTAZONE,TANDEARIL,PF-00345019,2036,CCCCC1C(=O)N(N(C1=O)c2ccc(cc2)O)c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,630,Discontinued,1984,YES,NO,Bone marrow suppression,WITHDRAWN,,,NOVARTIS,major pharma,22271,1960,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,324.3737,1,3,1,5,0,5,60.85,0.263157895,0.763,0.763,2.718,All fragments measured,2.9,2.9,2.48,0.243,5.08,,4.6,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.9351,0.94822,0.97503,0.92786,0.9848,0.98659,0.9866,0.84757,0.93773,288.8,16.2,2.35,8.33
125-53-1,OXYPHENCYCLIMINE HYDROCHLORIDE,DARICON,PF-00345531,2026,CN1CCCN=C1COC(=O)C(c2ccccc2)(C3CCCCC3)O,TABLET,YES,NO,NO,NO,ORAL,30,Discontinued,,NO,NO,,,,,PFIZER,major pharma,21550,1958,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,344.4479,1,3,1,5,0,6,62.13,0.6,1.34,1.272,4.445,All fragments measured,3.2,3.1,4.41,2.423,12.05,10.91,15,11,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86496,0.8639,0.89822,0.99756,0.72615,0.98659,0.98217,0.6885,0.82734,298.2,3.32,65.8,30.1
79-57-2,OXYTETRACYCLINE HYDROCHLORIDE,TERRAMYCIN,PF-00344906,2041,C[C@]1(c2cccc(c2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O,CAPSULE,YES,NO,NO,NO,ORAL,,Discontinued,,NO,NO,,,,,PFIZER,major pharma,23628,1964,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.7,1.7,9,,,,13244216,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,,1,Michael_acceptor,NO,YES,NO,,460.434,8,10,7,11,2,2,201.85,0.409090909,-0.956,-0.956,-1.266,Valid estimate for difficult structure,-1.9,-7,-1.32,-4.248,4.5,10.8,3.3,9.2,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.17972,0.13608,0.28295,0.09673,0.06191,0.01196,0.05922,0.87038,0.82734,565.4,3.84,1.82,7.01
571190-30-2,PALBOCICLIB,IBRANCE,PF-00080665,4941,Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5,CAPSULE,YES,NO,NO,NO,ORAL,125,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,42038,2015,Drugs@FDA,NO,NO,0.46,,High,Reported bioavailability,0.15,36.9,29,,,49,4676880469,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury and limited general availability),Less,1,Michael_acceptor,NO,YES,NO,2EUF,447.5328,2,6,2,9,0,5,105.04,0.458333333,1.25,1.323,2.345,All fragments measured,3.4,2.4,1.44,0.319,,8.66,,7.8,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68636,0.59384,0.33135,0.99998,0.19128,0.79222,0.65257,0.84757,0.93773,445.6,2.47,14.5,31.2
144598-75-4,PALIPERIDONE,INVEGA,PF-05279959,4137,Cc1c(c(=O)n2c(n1)C(CCC2)O)CCN3CCC(CC3)c4c5ccc(cc5on4)F,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,12,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,JANSSEN PHARMS,major pharma,39070,2006,Drugs@FDA,NO,NO,0.28,,Moderate,Reported bioavailability,0.26,7,23,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,426.4839,1,5,1,7,0,4,84.39,0.52173913,1.79,1.6,1.074,All fragments measured,1.5,0.59,1.68,0.874,,8.07,13,7.6,Basic,Class 2,0,1,0,0,0,0,0,3,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.80326,0.81366,0.42567,0.9945,0.72615,0.98659,0.85619,0.96969,0.93773,449.3,13.6,11.7,11.1
135729-61-2,PALONOSETRON HYDROCHLORIDE,ALOXI,PF-04087758,2046,c1cc2c3c(c1)C(=O)N(C[C@H]3CCC2)[C@@H]4CN5CCC4CC5,CAPSULE,YES,NO,NO,NO,ORAL,0.5,Discontinued,,NO,NO,,,Roche ,major pharma,HELSINN HLTHCARE,pharma,39682,2008,Drugs@FDA,NO,NO,0.97,,High,Reported bioavailability,0.38,8.3,40,,,,1668358,NO,Gastrointestinal,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,296.4067,0,2,0,3,0,1,23.55,0.631578947,1.87,1.883,2.177,All fragments measured,2.9,2.4,2.84,0.955,,9.71,,7.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78087,0.79431,0.99281,0.99967,0.93048,0.59178,0.69255,0.63709,0.82734,289.4,30,11.7,51.9
404950-80-7,PANOBINOSTAT LACTATE,FARYDAK,PF-06458595,4682,Cc1c(c2ccccc2[nH]1)CCNCc3ccc(cc3)/C=C/C(=O)NO,CAPSULE,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,42058,2015,Drugs@FDA,NO,NO,0.21,,Moderate,Reported bioavailability,0.1,,37,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,5EF8,349.4262,4,2,4,5,0,7,77.15,0.19047619,1.22,1.209,2.643,Benzyl approx. based on a priori value,2.6,-0.94,3.04,1.053,8.71,9.29,9.8,9.1,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.45582,0.5505,0.87316,0.98881,0.9848,0.14694,0.89595,0.53315,0.25672,286.5,2.62,34.4,16.3
102625-70-7,PANTOPRAZOLE SODIUM,PROTONIX,PF-05208751,2054,COc1ccnc(c1OC)CS(=O)c2[nH]c3cc(ccc3n2)OC(F)F,"FOR SUSPENSION, DELAYED RELEASE, TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,240,Prescription,,NO,NO,,,Torrent Pharmaceuticals,pharma,WYETH,major pharma,36558,2000,Drugs@FDA,NO,NO,0.77,,High,Reported bioavailability,0.02,0.3,1,Prodrug,12,187,140207131,NO,Gastrointestinal,NO,NO,,NO,NO,YES,NO,Less,Less,,,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,383.3698,1,6,1,7,0,7,86.33,0.25,1.86,1.907,2.111,Benzyl approx. based on a priori value,1.6,1.6,1.46,1.448,8.42,3.27,9.1,3.5,Neutral,Class 2,0,2,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.6257,0.60582,0.67169,0.99958,0.52457,0.98659,0.62973,0.53315,0.25672,453,24.9,8.85,8.63
115-67-3,PARAMETHADIONE,PARADIONE,PF-00345139,2059,CCC1(C(=O)N(C(=O)O1)C)C,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,2400,Discontinued,1995,YES,NO,"Safety and efficacy concerns, fetal trimethadione syndrome",Micromedex,,,ABBVIE,major pharma,18064,1949,Drugs@FDA,NO,NO,,,NA,NA,,,12,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,157.1671,0,2,0,4,0,1,46.61,0.714285714,0.716,0.716,0.412,A priori fragment value used,1.7,1.7,0.74,0.741,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5034,0.61168,0.23786,0.77665,0.9848,0.59178,0.98865,0.63709,0.47245,202.1,30.2,6.01,12.7
1597-82-6,PARAMETHASONE ACETATE,HALDRONE,PF-00345138,2060,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)C)F,TABLET,YES,NO,NO,NO,ORAL,2,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,22384,1961,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,,,,,,,,0,,NO,NO,NO,,434.4977,2,5,2,6,0,4,100.9,0.708333333,2.11,2.61,2.522,All fragments measured,2.4,2.4,2.36,2.358,12.29,,12,,Neutral,Class 2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.65953,0.64524,0.38748,0.93102,0.52457,0.79222,0.67796,0.96969,0.47245,495.4,16.6,42.4,52.8
555-57-7,PARGYLINE HYDROCHLORIDE,EUTONYL,PF-00344644,2065,CN(CC#C)Cc1ccccc1,TABLET,YES,NO,NO,NO,ORAL,25,Discontinued,,NO,NO,,,,,ABBOTT,major pharma,22282,1961,DrugCentral,NO,NO,,,NA,NA,,,,Suicide,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,Gerren Additions,0,,,,,1,Alkynes,NO,NO,NO,,159.2276,0,1,0,1,0,3,3.24,0.272727273,1.57,1.784,2.576,All fragments measured,2.1,2,2.36,2.307,,6.5,,6.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60393,0.49569,0.2455,0.99402,0.23327,0.59178,0.26577,0.99269,0.82734,103.3,41.3,12.1,22.8
131918-61-1,PARICALCITOL,ZEMPLAR,PF-06731076,2066,C[C@H](C=C[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,CAPSULE,YES,NO,NO,NO,ORAL,0.02,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,38498,2005,Drugs@FDA,NO,NO,0.72,,High,Reported bioavailability,0.002,0.44,4,,,,662454,YES,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,416.6365,3,3,3,3,1,5,60.69,0.777777778,4.28,6.17,5.688,All fragments measured,6.4,6.4,5.35,5.353,,,14,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.53771,0.62494,0.47632,0.53024,0.9848,0.37866,0.98712,0.84757,0.47245,347.3,13.2,33.1,54.9
1216941-48-8,PARITAPREVIR,VIEKIRA PAK (COPACKAGED),PF-07261624,4913,Cc1cnc(cn1)C(=O)N[C@H]2CCCCC/C=C/[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)Oc5c6ccccc6c7ccccc7n5)C(=O)NS(=O)(=O)C8CC8,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Enanta,pharma,ABBVIE,major pharma,41992,2014,Drugs@FDA,YES,NO,,,NA,NA,,,,,,77,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,C,Less,C (probable cause of liver injury arising in patients with pre-existing cirrhosis),Less,0,,NO,NO,NO,,765.8771,3,10,3,14,3,7,189.65,0.425,2.22,2.22,6.278,All fragments measured,5.3,2.6,2.32,0.649,5.47,4.44,4,3.5,Acidic,Class 3B,0,0,0,0,0,0,0,4,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,8,0,0,0,4,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,YES,0.1708,0.13508,0.02948,0.99361,0.06191,0.37866,0.0649,0.53315,0.03452,921.5,0.715,20.3,62.1
61869-08-7,PAROXETINE HYDROCHLORIDE,PAXIL,PF-02634376,2068,c1cc(ccc1[C@@H]2CCNC[C@H]2COc3ccc4c(c3)OCO4)F,"CAPSULE, SUSPENSION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,50,Prescription,,NO,NO,,,,,APOTEX TECHNOLOGIES,pharma,33967,1992,Drugs@FDA,NO,NO,,0.64,High,Fa estimated from reported excretion data,0.05,17.2,15,,105,,1198356,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,,,,Moderate,1,BenzoDioxolane,NO,NO,NO,5I6X,329.3654,1,2,1,4,0,4,39.72,0.368421053,1.29,1.678,4.238,All fragments measured,3.8,2,3.68,1.456,,9.68,,9.6,Basic,Class 4,0,1,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.9664,0.95277,0.96018,0.98654,0.88651,0.98659,0.94609,0.96969,0.93773,305.1,5.76,22.9,44.3
444731-52-6,PAZOPANIB HYDROCHLORIDE,VOTRIENT,PF-04967002,4118,Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,NOVARTIS,major pharma,40105,2009,Drugs@FDA,NO,NO,,,NA,NA,0.01,,30.9,,,180,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,1,Aniline,YES,NO,NO,,437.518,3,5,2,9,0,5,119.03,0.19047619,3.52,3.28,3.654,All fragments measured,4,4,2.68,2.654,10.19,6.13,10,5.4,Neutral,Class 4,0,0,0,0,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.40829,0.37726,0.37382,0.92245,0.33223,0.79222,0.40953,0.84757,0.03452,456.6,8.17,23,39.7
2152-34-3,PEMOLINE,CYLERT,PF-00346578,2075,c1ccc(cc1)C2C(=O)N=C(O2)N,"TABLET, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,112.5,Discontinued,2005,YES,YES,Liver failure,FederalRegister,,,ABBOTT,major pharma,27421,1975,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.5,,7,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Less,0,,NO,NO,NO,,176.172,2,3,1,4,0,1,64.68,0.111111111,0.429,0.429,0.457,A priori fragment value used,0.2,0.2,0.5,0.5,,,11,1.6,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65861,0.73759,0.31722,0.83572,0.88651,0.98659,0.97179,0.63709,0.82734,197.1,13.5,7.28,7.18
38363-40-5,PENBUTOLOL SULFATE,LEVATOL,PF-00344735,2078,CC(C)(C)NC[C@@H](COc1ccccc1C2CCCC2)O,TABLET,YES,NO,NO,NO,ORAL,20,Discontinued,,NO,NO,,,,,AUXILIUM PHARMS LLC,pharma,32141,1987,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.02,0.5,17,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,291.4284,2,3,2,3,0,6,41.49,0.666666667,1.74,1.792,3.639,All fragments measured,3.5,1.5,3.97,1.801,,9.51,16,9.3,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79557,0.84558,0.98351,0.95084,0.9848,0.79222,0.96041,0.53315,0.82734,217.7,5.07,37.4,81.2
52-67-5,PENICILLAMINE,CUPRIMINE,PF-00344737,2081,CC(C)([C@H](C(=O)O)N)S,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,VALEANT,pharma,25906,1970,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,,1.1,7.5,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,1,Thiol_Disulfide,NO,NO,NO,,149.2113,3,4,2,3,0,2,63.32,0.8,-1.49,-1.49,-1.729,All fragments measured,-0.16,-1.9,0.67,-1.843,2.13,8.75,1.9,8.7,Zwitter,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31909,0.38111,0.21047,0.06041,0.88651,0.37866,0.66535,0.87038,0.47245,117.2,6.15,2.72,10.9
1538-09-6,PENICILLIN G BENZATHINE,BICILLIN,PF-00345307,4347,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)Cc3ccccc3)C(=O)O)C,SUSPENSION,YES,NO,NO,NO,ORAL,,Discontinued,,NO,NO,,,,,WYETH,major pharma,18954,1951,Drugs@FDA,NO,NO,0.15,,Moderate,Reported bioavailability,0.4,0.6,,Parent CRG,,,148363373,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,,1,Beta_Lactams,NO,NO,NO,,334.3901,2,5,2,6,0,4,86.71,0.4375,-1.21,-1.21,1.747,Benzyl approx. based on a priori value,2,-1.3,2.02,-1.702,2.45,,2.8,,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86143,0.79268,0.94219,0.80446,0.72615,0.79222,0.56217,0.96969,0.82734,398.6,0.236,3.56,7.96
132-98-9,PENICILLIN V POTASSIUM,PEN-VEE K,PF-02451794,2083,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)COc3ccccc3)C(=O)O)C,TABLET,YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,WYETH,major pharma,21198,1958,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.3,0.5,,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,1,Beta_Lactams,NO,NO,NO,,350.3895,2,6,2,7,0,5,95.94,0.4375,-1.16,-1.16,1.944,Approximated fragment value used,1.9,-1.4,2.04,-1.683,2.44,,2.8,,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80565,0.70813,0.8681,0.75355,0.52457,0.79222,0.4684,0.84757,0.82734,426.9,1.8,3.16,7.34
359-83-1,PENTAZOCINE HYDROCHLORIDE,TALWIN 50,PF-00345098,3424,CC1[C@@H]2Cc3ccc(cc3[C@]1(CCN2CC=C(C)C)C)O,TABLET,YES,NO,NO,NO,ORAL,50,Discontinued,,NO,NO,Abuse potential,,,,SANOFI AVENTIS US,major pharma,25237,1969,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,,5.6,,,,,2934,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,285.4238,1,2,1,2,0,2,23.47,0.578947368,2.7,2.607,4.667,All fragments measured,4.4,2.8,3.8,2.416,10.1,8.94,10,9.1,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.88129,0.85246,0.96739,0.74051,0.93048,0.98659,0.69082,0.87038,0.82734,253.8,8.91,37.4,46.5
6493-05-6,PENTOXIFYLLINE,TRENTAL,PF-00345538,2099,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(c1=O)C,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,800,Prescription,,NO,NO,,,,,US PHARM HOLDINGS,pharma,30924,1984,Drugs@FDA,NO,NO,0.2,,Moderate,Reported bioavailability,,3.9,0.4,,,,,NO,Cardiovascular,YES,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,,,,Less,1,1_4_Diketones,NO,NO,NO,3TVX,278.307,0,4,0,7,0,5,78.89,0.538461538,0.458,0.4382,0.116,Valid estimate for difficult structure,0.65,0.65,0.54,0.541,,,,1.5,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.76874,0.79388,0.94172,0.63187,0.88651,0.59178,0.90793,0.84757,0.82734,305.8,26.8,4.38,6.65
380917-97-5,PERAMPANEL,FYCOMPA,PF-06684187,4684,c1ccc(cc1)n2cc(cc(c2=O)c3ccccc3C#N)c4ccccn4,"SUSPENSION, TABLET",YES,NO,NO,YES,ORAL,12,Prescription,,NO,NO,,,Eisai,pharma,EISAI INC,pharma,41204,2012,Drugs@FDA,NO,NO,,0.7,High,Fa estimated from reported excretion data,0.024,,105,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,1,Michael_acceptor,NO,YES,NO,5L1F,349.3847,0,3,0,4,0,3,58.68,0,3.12,3.56,4.169,Valid estimate for difficult structure,3.1,3.1,2.92,2.93,,4.74,,4.1,Neutral,Class 2,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69256,0.74118,0.87338,0.9507,0.9848,0.59178,0.99638,0.99269,0.25672,312.4,14.6,8.77,30.2
66104-22-1,PERGOLIDE MESYLATE,PERMAX,PF-00344817,2105,CCCN1C[C@@H](C[C@H]2[C@H]1Cc3c[nH]c4c3c2ccc4)CSC,TABLET,YES,NO,NO,NO,ORAL,1.5,Discontinued,2007,YES,YES,Valvular heart disease,FederalRegister,,,VALEANT,pharma,32507,1988,Drugs@FDA,NO,NO,,0.55,High,Fa estimated from reported excretion data,0.1,,27,,,,201916,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,1,3_Methyl_Indole,NO,NO,NO,,314.4881,1,2,1,2,0,4,19.03,0.578947368,3.13,2.9,4.398,All fragments measured,4.3,3.9,4.62,3.31,,7.98,10,7.7,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.94993,0.94547,0.99458,0.83136,0.93048,0.98659,0.97845,0.96969,0.93773,293,10.9,25,96.2
82834-16-0,PERINDOPRIL ERBUMINE,ACEON,PF-00579941,2108,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,TABLET,YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,,,SYMPLMED PHARMS LLC,pharma,34333,1993,Drugs@FDA,NO,YES,0.75,,High,Reported bioavailability,0.4,0.38,,,,,1,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproved but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,368.4678,2,5,2,7,0,10,95.94,0.842105263,-0.0284,-0.0284,1.21,Approximated fragment value used,2.3,-0.83,3.1,-0.676,3.15,5.67,3.2,6.2,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.51679,0.53485,0.76398,0.39071,0.52457,0.79222,0.72844,0.29329,0.47245,415.3,0.74,20.8,9.34
58-39-9,PERPHENAZINE,TRILAFON,PF-00345141,2113,c1ccc2c(c1)N(c3cc(ccc3S2)Cl)CCCN4CCN(CC4)CCO,TABLET,YES,NO,NO,NO,ORAL,24,Prescription,,NO,NO,,,,,SCHERING,major pharma,20878,1957,Drugs@FDA,NO,NO,0.2,,Moderate,Reported bioavailability,,10,9.5,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,403.9686,1,4,1,4,0,6,29.95,0.428571429,2.91,3.8,3.807,All fragments measured,4.3,3.7,4.24,3.897,,7.39,14,8.2,Basic,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.76668,0.79818,0.54703,0.81667,0.72615,0.98659,0.99884,0.6885,0.93773,352,2.36,35.1,41.7
2040295-03-0,PEXIDARTINIB HYDROCHLORIDE,TURALIO,PF-04982742,,FC(C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C43)C=C2)C=N1)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Plexxikon,pharma,DAIICHI SANKYO,pharma,43679,2019,Drugs@FDA,NO,NO,,0.48,High,Fa estimated from reported excretion data,0.01,2.7,26.6,,,,,YES,Oncology,NO,YES,II,NO,NO,NO,NO,,,,,,,,,1,3_Methyl_Indole,NO,NO,NO,4R7H,417.8147096,2,3,2,5,0,5,66.49,0.15,4.31,4.7,3.994,All fragments measured,4.4,4.4,4.41,4.38,12.81,5.69,9.7,4.9,Neutral,Class 4,0,3,0,0,1,0,0,4,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,2,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.39234,0.45735,0.47005,0.5537,0.88651,0.79222,0.96322,0.6885,0.03452,367.1,3.78,39.1,63.1
63-98-9,PHENACEMIDE,PHENURONE,PF-00345140,2114,c1ccc(cc1)CC(=O)NC(=O)N,TABLET,YES,NO,NO,NO,ORAL,5000,Discontinued,2003,YES,NO,Hepatotoxicity,JAMA.  1955(159)1437-1441. doi:10.1001/jama.1955.02960320013005,,,ABBVIE,major pharma,18807,1951,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,,1.5,22,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,178.1879,3,2,2,4,0,2,72.19,0.111111111,0.387,0.387,0.874,All fragments measured,0.68,0.68,1.2,1.137,12.38,,12,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65639,0.72851,0.32685,0.6746,0.93048,0.79222,0.93047,0.87038,0.82734,150.5,15.9,5.63,6.65
62-44-2,PHENACETIN,N/A,PF-00344578,2115,CCOc1ccc(cc1)NC(=O)C,N/A,N/A,N/A,N/A,NO,ORAL,300,Discontinued,1965,YES,YES,"Renal, urologic, and cardiovascular injury",FederalRegister,,,N/A,,7306,1920,DrugCentral,NO,NO,,,NA,NA,0.67,1.5,0.8,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,,Gerren Additions,1,,,,None,1,Aniline,YES,NO,NO,,179.2157,1,2,1,3,0,3,38.33,0.3,1.5,1.528,1.765,All fragments measured,1.7,1.7,1.7,1.701,,1.42,14,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73369,0.79242,0.33185,0.84051,0.93048,0.98659,0.93296,0.99269,0.82734,147.5,43.3,25.3,20.1
94-78-0,PHENAZOPYRIDINE HYDROCHLORIDE,AZO GANTRISIN,PF-00344902,2120,c1ccc(cc1)/N=N/c2ccc(nc2N)N,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,22822,1962,PharmaPendium,YES,NO,,0.66,High,Fa estimated from reported excretion data,,,,,,,17,NO,Genitourinary,NO,NO,,NO,NO,NO,NO,,Less,,,,,,Less,0,,NO,NO,NO,,213.2385,4,3,2,5,0,2,89.65,0,1.85,1.918,2.051,All fragments measured,2.8,2.4,2.77,2.703,,4.16,,7.4,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78662,0.79243,0.53046,0.99774,0.72615,0.79222,0.78961,0.87038,0.93773,190.8,31.2,16.5,25.3
634-03-7,PHENDIMETRAZINE TARTRATE,PHENDIMETRAZINE TARTRATE,PF-00346543,2122,C[C@H]1[C@@H](OCCN1C)c2ccccc2,"CAPSULE, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,210,Prescription,,NO,NO,,,,,VIRTUS PHARMS,pharma,28961,1979,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,,,3,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,191.2695,0,0,0,2,0,1,12.47,0.5,1.46,1.478,2.125,All fragments measured,2.2,1.7,1.91,1.553,,7.51,,7.7,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.62617,0.64901,0.39508,0.95565,0.93048,0.59178,0.44264,0.63709,0.82734,194.1,32.8,4.25,12.8
51-71-8,PHENELZINE SULFATE,NARDIL,PF-00345074,2123,c1ccc(cc1)CCNN,TABLET,YES,NO,NO,NO,ORAL,90,Prescription,,NO,NO,,,,,PARKE DAVIS,major pharma,22441,1961,Drugs@FDA,NO,NO,,0.79,High,Fa estimated from reported excretion data,,,,,,,2096353,NO,Neurological,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Hydrazines,NO,NO,NO,,136.1943,3,1,2,2,0,3,38.05,0.25,-0.227,-0.227,1.033,All fragments measured,0.78,0.33,1.33,0.512,,8.01,,7.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5959,0.68799,0.17226,0.7522,0.93048,0.79222,0.93002,0.99269,0.82734,73.87,27.2,15.6,23.1
834-28-6,PHENFORMIN HYDROCHLORIDE,DBI,PF-00344816,2126,c1ccc(cc1)CCNC(=N)NC(=N)N,N/A,N/A,N/A,N/A,NO,ORAL,300,Discontinued,1970,YES,YES,"high risk of lactic acidosis, which was fatal in 50% of cases",FederalRegister,,,CIBA,pharma,21551,1959,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,205.2596,6,5,5,5,1,6,97.78,0.2,-0.443,-0.443,-0.687,Valid estimate for difficult structure,-0.78,-4.2,-0.22,-2.203,,12.15,,12,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.39844,0.49817,0.4786,0.76233,0.93048,0.05547,0.7099,0.6885,0.82734,150.8,2.98,10.6,9.12
83-12-5,PHENINDIONE,HEDULIN,PF-00344741,2130,c1ccc(cc1)C2C(=O)c3ccccc3C2=O,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,Associated with hypersensitivity reactions,,,,SANOFI AVENTIS US,major pharma,19358,1952,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,1_3_Diketones,NO,NO,NO,,222.2387,0,2,0,2,0,1,34.14,0.066666667,1.17,1.17,2.81,Benzyl approx. based on a priori value,3.1,0.49,3.24,3.068,7.72,,4.4,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71382,0.77762,0.59175,0.99999,0.93048,0.59178,0.88329,0.63709,0.93773,162.5,26.3,43.8,39.9
134-49-6,PHENMETRAZINE HYDROCHLORIDE,PRELUDIN,PF-00345398,2133,CC1C(OCCN1)c2ccccc2,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,75,Discontinued,,NO,NO,Abuse potential,,,,BOEHRINGER INGELHEIM,major pharma,21618,1959,PharmaPendium,NO,NO,,0.89,High,Fa estimated from reported excretion data,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,177.2429,1,2,1,2,0,1,21.26,0.454545455,0.25,0.25,1.669,All fragments measured,1.6,0.28,1.67,0.464,,8.58,,8.4,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.66084,0.7064,0.3223,0.87667,0.93048,0.98659,0.64201,0.63709,0.82734,179.9,39.7,5.89,8.99
59-96-1,PHENOXYBENZAMINE HYDROCHLORIDE,DIBENZYLINE,PF-00345537,2136,CC(COc1ccccc1)N(CCCl)Cc2ccccc2,CAPSULE,YES,NO,NO,NO,ORAL,120,Prescription,,NO,NO,,,,,CONCORDIA PHARMS INC,pharma,19385,1953,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,,,24,Parent CRG,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,None,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,303.8264,0,2,0,2,0,8,12.47,0.333333333,3.52,3.64,4.917,All fragments measured,4.2,4.2,4.26,4.197,,6.58,,5.6,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.66924,0.66905,0.99961,0.65691,0.93048,0.59178,0.44264,0.39983,0.93773,224.9,10.5,36.5,99.8
435-97-2,PHENPROCOUMON,LIQUAMAR,PF-00344818,2138,CCC(c1ccccc1)c2c(c3ccccc3oc2=O)O,TABLET,YES,NO,NO,NO,ORAL,4.5,Discontinued,,NO,NO,,,,,ORGANON USA INC,pharma,21184,1957,Drugs@FDA,NO,NO,0.88,,High,Reported bioavailability,0.01,,96,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,1,Michael_acceptor,NO,YES,NO,,280.3178,1,1,1,3,0,3,50.44,0.166666667,1.76,1.76,4.711,All fragments measured,4,1.5,3.83,1.03,4.5,,4.6,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.95146,0.95635,0.94966,0.8619,0.9848,0.98659,0.98835,0.99269,0.93773,221.1,19.1,9.4,13.9
86-34-0,PHENSUXIMIDE,MILONTIN,PF-00344821,2139,CN1C(=O)CC(C1=O)c2ccccc2,CAPSULE,YES,NO,NO,NO,ORAL,3000,Discontinued,,NO,NO,,,,,PARKE DAVIS,major pharma,19610,1953,Drugs@FDA,NO,NO,,,NA,NA,,,5,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,189.2105,0,2,0,3,0,1,37.38,0.272727273,0.946,0.946,0.942,Valid estimate for difficult structure,1.2,1.2,0.61,0.606,,,,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60807,0.69333,0.38368,0.74924,0.93048,0.59178,0.92305,0.63709,0.82734,181.6,39.5,7.64,13.4
122-09-8,PHENTERMINE,IONAMIN,PF-00345401,2140,CC(C)(Cc1ccccc1)N,"CAPSULE, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,30,Prescription,,NO,NO,,,,,UCB INC,pharma,21674,1959,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,,,7,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,149.2328,2,1,1,1,0,2,26.02,0.4,-0.469,-0.469,2.141,All fragments measured,1.9,-0.55,2.27,-0.167,,9.94,,9.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.63723,0.58808,0.21053,0.93677,0.23327,0.98659,0.74426,0.87038,0.82734,78.91,31.1,6.5,11.6
133-11-9,PHENYL AMINOSALICYLATE,PHENY-PAS-TEBAMIN,PF-00346266,2143,c1ccc(cc1)OC(=O)c2ccc(cc2O)N,"POWDER, TABLET",YES,NO,NO,NO,ORAL,16000,Discontinued,,NO,NO,,,,,PHARM RES ASSOC,pharma,21587,1959,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,229.2313,3,1,2,4,0,3,72.55,0,2.29,2.464,2.77,All fragments measured,2.3,2.3,3.19,3.17,8.76,2.82,9.6,1.9,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.84757,0.87127,0.64066,0.9804,0.88651,0.79222,0.92814,0.99269,0.93773,185.1,18.4,56.8,31.3
50-33-9,PHENYLBUTAZONE,BUTAZOLIDIN,PF-00344905,2145,CCCCC1C(=O)N(N(C1=O)c2ccccc2)c3ccccc3,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,400,Discontinued,1985,YES,NO,Suppression of white blood cell production and aplastic anemia,Hist Philos Life Sci. 2018(40)27. doi: 10.1007/s40656-018-0191-4,,,NOVARTIS,major pharma,29230,1980,DrugCentral,NO,NO,1,,High,Reported bioavailability,0.05,0.13,48,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,Most,Gerren Additions,1,,,,None,0,,NO,NO,NO,,308.3743,0,2,0,4,0,5,40.62,0.263157895,1.41,0.9201,3.385,All fragments measured,3.4,3.4,2.9,0.595,4.64,,4.6,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83755,0.86594,0.99958,0.87506,0.93048,0.59178,0.95372,0.84757,0.93773,256.9,11.1,15.6,10.6
59-42-7,PHENYLEPHRINE HYDROCHLORIDE,PHENERGAN VC,PF-00345071,2146,CNC[C@@H](c1cccc(c1)O)O,SYRUP,YES,NO,NO,NO,ORAL,120,Over-the-counter,,NO,NO,,,,,ANI PHARMS,pharma,19981,1954,Drugs@FDA,YES,NO,0.38,,High,Reported bioavailability,,4.9,2,,,,416307,NO,"Cardiovascular, Respiratory",NO,NO,,NO,YES,NO,NO,,None,FEARS Addition ,1,,,,None,0,,NO,NO,NO,,167.205,3,3,3,3,0,3,52.49,0.333333333,-0.861,-0.861,-0.088,All fragments measured,0.12,-1.3,-0.14,-2.035,9.76,9.22,10,8.9,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.55977,0.66324,0.27724,0.66497,0.9848,0.37866,0.99991,0.99269,0.82734,147.3,1.33,26.2,12.6
14838-15-4,PHENYLPROPANOLAMINE POLISTIREX,CORSYM,CL-383071,2149,C[C@H]([C@H](c1ccccc1)O)N,"SUSPENSION, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,150,Discontinued,1987,YES,YES,Increased risk of hemorrhagic stroke,FederalRegister,,,UCB INC,pharma,30685,1984,Drugs@FDA,YES,NO,1,,High,Reported bioavailability,,2.5,3.3,,,,,NO,"Metabolic Disease, Respiratory",NO,NO,,NO,YES,YES,NO,,,,,,,,,0,,NO,NO,NO,,151.2056,3,2,2,2,0,2,46.25,0.333333333,-0.853,-0.853,0.584,All fragments measured,0.64,-0.98,0.73,-1.147,12.07,8.47,14,8.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60609,0.69942,0.21703,0.71985,0.93048,0.79222,0.98727,0.87038,0.82734,138.1,21.4,6.74,6.65
57-41-0,PHENYTOIN,DILANTIN-125,PF-00344577,2152,c1ccc(cc1)C2(C(=O)NC(=O)N2)c3ccccc3,SUSPENSION,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,PARKE DAVIS,major pharma,19365,1953,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.078,0.64,14,,,,99402493,NO,Neurological,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Hydantoin,NO,NO,NO,,252.268,2,2,2,4,0,2,58.2,0.066666667,1.64,2.334,2.085,All fragments measured,1.7,1.7,2.42,2.385,8.28,,7.9,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8651,0.8956,0.79961,0.96655,0.93048,0.79222,0.99393,0.87038,0.93773,217.4,21.4,3.82,8.23
84-80-0,PHYTONADIONE,MEPHYTON,PF-00344819,2843,CC1=C(C(=O)c2ccccc2C1=O)C/C=C(\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,,,VALEANT,pharma,20362,1955,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,450.6957,0,2,0,2,1,14,34.14,0.612903226,5.59,6.75,12.012,Very high LogP unrealistic in nature,9,9,9.53,9.54,,,,,Neutral,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.199,0.28825,0.31883,0.02424,0.93048,0.59178,0.88329,0.05315,0.82734,280.4,0.171,86,42.1
1353900-92-1,PIBRENTASVIR,MAVYRET,VC-001215228,5244,C[C@H]([C@@H](C(=O)N1CCC[C@H]1c2[nH]c3cc(c(cc3n2)F)[C@H]4CC[C@@H](N4c5cc(c(c(c5)F)N6CCC(CC6)c7ccc(cc7)F)F)c8cc9c(cc8F)nc([nH]9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)NC(=O)OC)OC,TABLET,YES,NO,NO,NO,ORAL,120,Prescription,,NO,NO,,,AbbVie,major pharma,ABBVIE,major pharma,42950,2017,Drugs@FDA,YES,NO,,,NA,NA,0.001,,13,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (suspected but unproven cause of clinically apparent liver injury due to reactivation of hepatitis B),None,1,Aniline,YES,NO,NO,,1113.1802,4,9,4,18,3,19,199.58,0.473684211,4.61,5.75,7.205,Approximated fragment value used,6.7,6.6,7.76,7.472,10.36,6.87,13,6.6,Basic,Class 4,0,5,0,0,0,0,0,6,2,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7,0,0,0,0,0,2,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,4,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,2,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,2,0,0,NO,0.03041,0.03214,0.02684,0.02589,0.02915,0.14694,0.06251,0.01822,0.01044,1280,0.141,4.94,22
92-13-7,PILOCARPINE HYDROCHLORIDE,SALAGEN,PF-00345028,2166,CC[C@H]1[C@H](COC1=O)Cc2cncn2C,TABLET,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,EISAI INC,pharma,34415,1994,Drugs@FDA,NO,NO,,,NA,NA,1,,1.1,,,,3237276,YES,Metabolic Disease,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Imidazole_Triazole,NO,NO,NO,,208.2569,0,2,0,4,0,3,44.12,0.636363636,0.42,0.42,-0.203,All fragments measured,-0.52,-0.63,0.39,0.242,,7.02,,7,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71366,0.78148,0.49776,0.76444,0.9848,0.59178,0.97733,0.99269,0.82734,210.3,24.2,17.3,18.8
706779-91-1,PIMAVANSERIN TARTRATE,NUPLAZID,PF-06780737,5142,CC(C)COc1ccc(cc1)CNC(=O)N(Cc2ccc(cc2)F)C3CCN(CC3)C,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,34,Prescription,,NO,NO,,,Acadia Pharmaceuticals,pharma,ACADIA PHARMS INC,pharma,42489,2016,Drugs@FDA,NO,NO,,,NA,NA,0.05,31,57,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,427.5548,1,3,1,5,0,9,44.81,0.48,2.44,3.166,4.111,Vinyl approx. based on a priori value,4.6,3.6,4.02,3.024,,8.65,12,8.7,Basic,Class 4,0,1,0,0,0,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.64192,0.73765,0.4204,0.79111,0.9848,0.98659,0.9809,0.39983,0.93773,322.4,10.2,24.6,100
2062-78-4,PIMOZIDE,ORAP,PF-00249451,2172,c1ccc2c(c1)[nH]c(=O)n2C3CCN(CC3)CCCC(c4ccc(cc4)F)c5ccc(cc5)F,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,TEVA,major pharma,30894,1984,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,,,55,,,,794,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,461.5462,1,2,1,4,1,7,41.03,0.321428571,4.65,5,6.401,All fragments measured,6,5,6.16,4.771,12.04,9.26,9.7,8.4,Basic,Class 4,0,2,0,0,0,0,0,4,1,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.42638,0.50521,0.2791,0.26555,0.93048,0.98659,0.9021,0.53315,0.25672,370.3,0.73,44.4,40
60560-33-0,PINACIDIL,PINDAC,PF-00345072,2173,CC(C(C)(C)C)N/C(=N\c1ccncc1)/NC#N,"CAPSULE, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,200,Discontinued,,NO,NO,,,,,LEO PHARM,pharma,32870,1989,Drugs@FDA,NO,NO,0.57,,High,Reported bioavailability,0.64,1.4,2.5,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,Gerren Additions,0,,,,,1,Pyridine,NO,NO,NO,,245.3235,2,3,2,5,0,4,73.1,0.461538462,1.8,1.852,1.348,Calculated fragment value,2.5,2.5,1.49,1.212,,7.36,,4.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8229,0.82623,0.75318,0.93572,0.72615,0.79222,0.92459,0.84757,0.82734,215.9,18.9,9.43,7.54
13523-86-9,PINDOLOL,VISKEN,PF-00344643,2176,CC(C)NCC(COc1cccc2c1cc[nH]2)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,30197,1982,Drugs@FDA,NO,NO,0.87,,High,Reported bioavailability,0.5,1.6,3,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,248.3208,3,3,3,4,0,6,57.28,0.428571429,0.495,-0.2909,1.671,All fragments measured,1.8,-0.069,1.86,-0.322,,9.54,11,9.2,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69956,0.78003,0.77348,0.94748,0.9848,0.37866,0.99585,0.6885,0.93773,234.5,10.5,4.92,10.3
111025-46-8,PIOGLITAZONE HYDROCHLORIDE,ACTOS,PF-00345560,2179,CCc1ccc(nc1)CCOc2ccc(cc2)CC3C(=O)NC(=O)S3,TABLET,YES,NO,NO,NO,ORAL,45,Prescription,,NO,NO,,,,,TAKEDA PHARMS USA,major pharma,36356,1999,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.01,0.63,3,,14,,1311903,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),None,1,Thiazolidinedione,NO,NO,NO,2XKW,356.4387,1,5,1,5,0,7,68.29,0.315789474,2.29,2.617,3.533,All fragments measured,3.5,0.58,2.58,1.54,6.35,5.46,6.2,6.9,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80199,0.79424,0.83498,0.88672,0.72615,0.98659,0.75184,0.53315,0.93773,348.3,12.1,45,26.1
84-04-8,PIPAMAZINE,MORNIDINE,PF-01690927,2180,c1ccc2c(c1)N(c3cc(ccc3S2)Cl)CCCN4CCC(CC4)C(=O)N,N/A,N/A,N/A,N/A,NO,ORAL,,Discontinued,1969,YES,YES,Hepatotoxicity,FederalRegister,,,GD SEARLE,major pharma,21551,1959,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Gastrointestinal,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,0,,NO,NO,NO,,401.9528,2,3,1,4,0,5,49.57,0.380952381,3.12,3.05,3.918,All fragments measured,4.5,3.1,4.62,3.708,,8.42,13,9.1,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.8045,0.83491,0.55878,0.79793,0.88651,0.98659,0.91245,0.84757,0.93773,350.2,5.54,12.6,44.5
3819-00-9,PIPERACETAZINE,QUIDE,PF-00344911,2186,CC(=O)c1ccc2c(c1)N(c3ccccc3S2)CCCN4CCC(CC4)CCO,TABLET,YES,NO,NO,NO,ORAL,,Discontinued,,NO,NO,,,,,DOW PHARM,pharma,25237,1969,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,410.5722,1,4,1,4,0,7,43.78,0.458333333,2.54,2.278,4.449,All fragments measured,4.8,3.2,4.41,2.627,,9.2,15,9.5,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,1,4,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71029,0.75374,0.50945,0.79793,0.72615,0.98659,0.94932,0.53315,0.93773,341.1,1.7,33.8,54.6
110-85-0,PIPERAZINE CITRATE,MULTIFUGE,PF-00345077,2188,C1CNCCN1,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,2000,Discontinued,,NO,NO,,,,,BLULINE,pharma,19917,1954,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.4,,,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,86.1356,2,2,2,2,0,0,24.06,1,-2.02,-2.02,-1.484,All fragments measured,-0.95,-3.4,-0.93,-3.046,,9.55,,10,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31861,0.41343,0.08346,0.25557,0.93048,0.79222,0.7035,0.39503,0.47245,61.29,2.21,2.13,6.65
54-91-1,PIPOBROMAN,VERCYTE,PF-00345559,2192,C1CN(CCN1C(=O)CCBr)C(=O)CCBr,TABLET,YES,NO,NO,NO,ORAL,210,Discontinued,,NO,NO,,,,,ABBOTT,major pharma,24289,1966,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,356.0542,0,2,0,4,0,6,40.62,0.8,1.97,1.815,0.232,Approximated fragment value used,0.77,0.77,1.04,1.043,,,,,Neutral,Class 2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.71298,0.7519,0.83715,0.6746,0.93048,0.59178,0.95372,0.96969,0.47245,212.8,16.7,9.11,9.69
53179-13-8,PIRFENIDONE,ESBRIET,PF-02059379,4224,Cc1ccc(=O)n(c1)c2ccccc2,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,2403,Prescription,,NO,NO,,,Marnac,pharma,GENENTECH,major pharma,41927,2014,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.42,0.9,3,,,171,,YES,Autoimmune Disease,NO,NO,,NO,NO,NO,NO,,Less,,,,,,Less,1,Michael_acceptor,NO,YES,NO,,185.2218,0,1,0,2,0,1,22,0.083333333,1.9,1.891,2.402,Valid estimate for difficult structure,1.8,1.8,1.69,1.692,,,,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60317,0.55121,0.3623,0.94509,0.23327,0.59178,0.62053,0.63709,0.82734,157.6,29.4,21.1,24.1
36322-90-4,PIROXICAM,FELDENE,PF-00345144,2210,CN1C(=C(c2ccccc2S1(=O)=O)O)C(=O)Nc3ccccn3,CAPSULE,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,PFIZER,major pharma,30047,1982,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.01,0.15,50,,,,54317396,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,1,Michael_acceptor,NO,YES,NO,,331.3464,2,3,2,7,0,2,99.6,0.066666667,0.0284,-0.01516,1.888,A priori fragment value used,2.4,-1.1,2.22,-1.16,3.03,4.35,3,4.9,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.83,0.77663,0.95343,0.63,0.72615,0.79222,0.60422,0.87038,0.93773,365.3,24.7,2.75,10.2
147511-69-1,PITAVASTATIN CALCIUM,LIVALO,PF-01620335,2214,c1ccc2c(c1)c(c(c(n2)C3CC3)/C=C/[C@H](C[C@H](CC(=O)O)O)O)c4ccc(cc4)F,TABLET,YES,NO,NO,NO,ORAL,4,Prescription,,NO,NO,,,Kowa,pharma,KOWA CO,pharma,40028,2009,Drugs@FDA,NO,NO,0.51,,High,Reported bioavailability,0.01,2.1,,,,,8099218,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible rare cause of clinically apparent liver injury),,0,,NO,NO,NO,,421.4608,3,5,3,5,0,8,90.65,0.28,1.62,1.206,3.589,All fragments measured,3.9,0.53,3.5,0.386,4.24,5.21,4.2,5.2,Acidic,Class 1B,0,1,0,0,0,0,0,3,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.43698,0.50766,0.451,0.87506,0.72615,0.37866,0.78016,0.39983,0.25672,364.8,8.14,14.5,12
362665-56-3,PITOLISANT HYDROCHLORIDE,WAKIX,PF-04473913,5048,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,TABLET,YES,NO,NO,NO,ORAL,35.6,Prescription,,NO,NO,,,BioProjet,pharma,HARMONY,pharma,43691,2019,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.06,10,20,,,,,YES,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,295.84718,0,2,0,2,0,8,12.47,0.647,1.94,2.18,4.82,All fragments measured,4.8,2.6,4.47,2.485,,9.41,,9.5,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.6756,0.67576,0.99195,0.80462,0.93048,0.59178,0.44264,0.39983,0.82734,181.3,33.3,25.7,97.4
346-18-9,POLYTHIAZIDE,RENESE,PF-00344823,2228,CN1C(Nc2cc(c(cc2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,4,Discontinued,,NO,NO,,,,,PFIZER,major pharma,22550,1961,Drugs@FDA,NO,NO,,,NA,NA,,4,25.7,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,439.8818,3,3,2,7,0,4,109.57,0.454545455,1.83,2.216,1.826,Benzyl approx. based on a priori value,2.1,2.1,1.59,1.582,9.3,,9.6,-2.4,Neutral,Class 4,0,3,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.67535,0.5796,0.3634,0.92656,0.52457,0.79222,0.22394,0.84757,0.82734,440,2.9,8.87,18.6
19171-19-8,POMALIDOMIDE,POMALYST,PF-06786723,4746,c1cc2c(c(c1)N)C(=O)N(C2=O)C3CCC(=O)NC3=O,CAPSULE,YES,NO,NO,NO,ORAL,4,Prescription,,NO,NO,,,Celgene,major pharma,CELGENE,major pharma,41313,2013,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,,1.4,7.5,,,94,,YES,Autoimmune Disease,NO,NO,,NO,NO,NO,NO,,Less,,,D,Less,D (possible cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,4TZU,273.2441,3,2,2,7,0,1,109.57,0.230769231,0.356,0.356,-0.189,Estimated fragment value used,0.049,-0.21,-0.09,-0.089,10.75,,7.8,1.8,Neutral,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66749,0.64675,0.91948,0.28892,0.72615,0.79222,0.5876,0.63709,0.82734,338.6,16.4,4.67,6.98
943319-70-8,PONATINIB HYDROCHLORIDE,ICLUSIG,PF-06700183,4716,Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C,TABLET,YES,NO,NO,NO,ORAL,45,Prescription,,NO,NO,,,Ariad,pharma,ARIAD,pharma,41257,2012,Drugs@FDA,NO,NO,,0.64,High,Fa estimated from reported excretion data,0.01,17.5,24,,,,,YES,Oncology,NO,YES,II,NO,NO,NO,NO,,,,,,,,,2,Alkynes; Aniline,YES,NO,NO,4C8B,532.5595,1,5,1,7,2,4,65.77,0.275862069,3.7,4.36,5.768,All fragments measured,5.2,4.4,3.8,3.396,12.99,7.54,12,8.4,Basic,Class 4,0,3,0,0,0,0,0,4,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.2819,0.36004,0.11812,0.52077,0.72615,0.98659,0.96669,0.53315,0.03452,475.3,1.7,17.7,108
171228-49-2,POSACONAZOLE,NOXAFIL,PF-06700533,3483,CC[C@@H]([C@H](C)O)n1c(=O)n(cn1)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OC[C@H]5C[C@](OC5)(Cn6cncn6)c7ccc(cc7F)F,"SUSPENSION, TABLET, DELAYED RELEASE",YES,YES,NO,YES,ORAL,800,Prescription,,NO,NO,,,Merck,major pharma,SCHERING,major pharma,38975,2006,Drugs@FDA,NO,NO,0.54,,High,Reported bioavailability,0.02,3.7,26,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproved but suspected cause of clinically apparent liver injury),Less,2,Aniline; Imidazole_Triazole,YES,NO,NO,5FSA,700.7774,1,6,1,12,2,12,115.7,0.405405405,4.27,5.48,4.113,A priori fragment value used,4.6,4.6,3.79,3.702,,6.49,12,5.6,Neutral,Class 4,0,2,0,0,0,0,0,5,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,2,0,0,2,0,1,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,NO,0.13978,0.16405,0.034,0.42707,0.10671,0.98659,0.56446,0.10729,0.03452,754.1,0.67,22.8,81.7
51-15-0,PRALIDOXIME CHLORIDE,PROTOPAM CHLORIDE,PF-03511221,2231,C[n+]1ccccc1/C=N/O,TABLET,YES,NO,NO,NO,ORAL,500,Discontinued,,NO,NO,,,,,WYETH,major pharma,23448,1964,Drugs@FDA,NO,NO,,,NA,NA,1,0.8,1.2,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,None,0,,NO,NO,NO,,137.1592,1,2,1,3,0,1,36.47,0.142857143,-0.378,-0.378,-3.666,Valid estimate for difficult structure,-3.2,-3.3,-3.04,-2.838,7.98,,7.9,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,NO,0.58265,0.68249,0.17483,0.89314,0.93048,0.98659,0.91282,0.63709,0.82734,132.7,41.6,20.7,12.2
104632-26-0,PRAMIPEXOLE DIHYDROCHLORIDE,MIRAPEX,PF-02314482,2233,CCCN[C@H]1CCc2c(sc(n2)N)C1,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,6,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,35612,1997,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.85,7.1,8,,145,,59376,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,211.3271,3,2,2,3,0,3,50.94,0.7,-0.0776,-0.7699,1.168,All fragments measured,1.6,-0.41,1.65,-0.369,,9.47,,9.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.77705,0.82112,0.5178,0.86153,0.9848,0.79222,0.88049,0.99269,0.82734,212.9,16.8,12.6,13.6
150322-43-3,PRASUGREL HYDROCHLORIDE,EFFIENT,PF-03442961,4113,CC(=O)Oc1cc2c(s1)CCN(C2)C(c3ccccc3F)C(=O)C4CC4,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Daiichi Sankyo  and Ube,pharma,ELI LILLY AND CO,major pharma,40004,2009,Drugs@FDA,NO,YES,0.79,,High,Reported bioavailability,0.02,,,Prodrug,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,,1,Thiophene,NO,NO,YES,,373.4411,0,2,0,4,0,6,46.61,0.4,3.23,4.18,3.431,Benzyl approx. based on a priori value,3.6,3.6,3.37,3.371,,3.65,,5.4,Neutral,Class 2,0,1,0,0,0,0,0,2,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.75042,0.79819,0.73341,0.91049,0.88651,0.59178,0.91266,0.6885,0.93773,358.1,14.6,32.1,240
81093-37-0,PRAVASTATIN SODIUM,PRAVACHOL,PF-00579899,2239,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,33542,1991,Drugs@FDA,NO,NO,0.17,,Moderate,Reported bioavailability,0.5,0.46,77,,65,,2926664,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,424.5277,4,6,4,7,0,11,124.29,0.739130435,0.0643,-0.4008,2.048,All fragments measured,2.3,-0.49,2.33,-0.754,4.31,,4.4,,Acidic,Class 3B,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31575,0.35033,0.43541,0.97115,0.33223,0.14694,0.43878,0.15134,0.47245,431,1.53,6.53,35.1
2955-38-6,PRAZEPAM,CENTRAX,PF-00345441,2240,c1ccc(cc1)C2=NCC(=O)N(c3c2cc(cc3)Cl)CC4CC4,CAPSULE,YES,NO,NO,NO,ORAL,60,Discontinued,,NO,NO,Abuse potential,,,,PARKE DAVIS,major pharma,29189,1979,Drugs@FDA,NO,NO,,,NA,NA,,,78,,,,11684896,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,FEARS Addition ,1,,,,,0,,NO,NO,NO,,324.8041,0,1,0,3,0,3,32.67,0.263157895,3.35,3.58,3.934,All fragments measured,3.6,3.6,3.53,3.529,,3.44,,2.9,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.85879,0.86841,0.97387,0.8654,0.93048,0.59178,0.86219,0.99269,0.93773,276.8,15.7,13.8,44.1
55268-74-1,PRAZIQUANTEL,BILTRICIDE,PF-00345078,2241,c1ccc2c(c1)CCN3C2CN(CC3=O)C(=O)C4CCCCC4,TABLET,YES,NO,NO,NO,ORAL,5250,Prescription,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,30314,1982,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.17,9.55,,,,,,NO,Anti-infective,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Moderate,0,,NO,NO,NO,,312.4061,0,2,0,4,0,2,40.62,0.578947368,1.98,2.4,3.36,Benzyl approx. based on a priori value,1.8,1.8,2.71,2.714,,,,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78576,0.83107,0.99691,0.99229,0.93048,0.59178,0.95372,0.63709,0.82734,305.1,34.9,29.9,20.6
19216-56-9,PRAZOSIN HYDROCHLORIDE,MINIPRESS,PF-00344579,4209,COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)c4ccco4,"CAPSULE, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,20,Prescription,,NO,NO,,,,,PFIZER,major pharma,27934,1976,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,0.03,0.73,2.5,,,,33348611,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,1,Furan,NO,NO,NO,,383.4011,2,5,1,9,0,5,106.95,0.315789474,1.7,1.451,2.028,All fragments measured,1.5,1.3,1.16,1.104,,6.52,,7.3,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70372,0.61313,0.6715,0.96674,0.33223,0.98659,0.61499,0.96969,0.25672,408.4,12.6,7.73,14
50-24-8,PREDNISOLONE,DELTA-CORTEF,PF-00332135,2245,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,20261,1955,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.25,1.5,3,,,,21806726,NO,"Autoimmune Disease, Cardiovascular, Metabolic Disease, Respiratory",NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,360.444,3,5,3,5,0,2,94.83,0.714285714,1.63,1.8,1.423,All fragments measured,1.6,1.6,1.66,1.66,12.46,,11,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64624,0.66372,0.81196,0.83572,0.72615,0.37866,0.73951,0.87038,0.47245,392.9,9.69,4.05,9.44
52-21-1,PREDNISOLONE ACETATE,FLO-PRED,PF-00346512,2247,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)O,SUSPENSION,YES,NO,NO,NO,ORAL,60,Discontinued,,NO,NO,,,Allergan ,major pharma,TARO,pharma,39464,2008,Drugs@FDA,NO,YES,,,NA,NA,,,3,,,,,NO,"Autoimmune Disease, Cardiovascular, Metabolic Disease, Respiratory",NO,NO,,NO,NO,NO,YES,,Less,,,,,,Less,0,,NO,NO,NO,,402.4807,2,5,2,6,0,4,100.9,0.695652174,1.95,2.15,1.96,All fragments measured,2.2,2.2,2.33,2.326,12.41,,12,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71174,0.67689,0.55569,0.90768,0.52457,0.79222,0.67796,0.96969,0.47245,435.2,16.3,30.1,63.2
125-02-0,PREDNISOLONE SODIUM PHOSPHATE,PEDIAPRED,PF-00579937,4451,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)(O)O)O)CCC4=CC(=O)C=C[C@]34C)O,"SOLUTION, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,SETON PHARM,pharma,31560,1986,Drugs@FDA,NO,YES (Presystemic),0.85,,High,Reported bioavailability,0.3,1.5,3,,,,,NO,"Autoimmune Disease, Cardiovascular, Metabolic Disease, Respiratory",NO,NO,,NO,NO,NO,YES,,Less,,,,,,Less,0,,NO,NO,NO,,440.4239,4,6,4,8,0,4,141.36,0.714285714,-1.14,-1.14,0.712,Calculated fragment value,1.3,-2.9,-0.01,-4.346,1.67,,1.7,,Acidic,Class 3B,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,NO,0.43308,0.36505,0.36104,0.81953,0.19128,0.14694,0.22676,0.96969,0.47245,454.6,0.473,3.25,9.86
53-03-2,PREDNISONE,METICORTEN,PF-00344739,2253,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,"TABLET, TABLET, DELAYED RELEASE",YES,YES,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,SCHERING,major pharma,20141,1955,Drugs@FDA,NO,NO,0.92,,High,Reported bioavailability,0.3,0.57,2.5,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,358.4281,2,5,2,5,0,2,91.67,0.666666667,1.66,1.832,1.661,All fragments measured,1.4,1.4,1.64,1.641,12.36,,12,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,6,0,0,0,6,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7537,0.74215,0.82364,0.82615,0.72615,0.79222,0.7704,0.87038,0.47245,375.9,13.2,7.36,102
148553-50-8,PREGABALIN,LYRICA,PF-01469713,2255,CC(C)C[C@@H](CC(=O)O)CN,"CAPSULE, SOLUTION, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,600,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,38351,2004,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,1,0.5,6.3,,52,11,6889687514,NO,"Musculoskeletal/Pain, Neurological",NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,159.2261,3,3,2,3,0,5,63.32,0.875,-0.0219,-0.0219,-0.915,All fragments measured,0.84,-1.4,0.75,-1.746,4.23,11.31,3.9,10,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.43209,0.51364,0.24549,0.1258,0.9848,0.79222,0.97756,0.84757,0.47245,97.66,2.4,3.51,7.97
187235-37-6,PRETOMANID,PRETOMANID,PF-06971607,,FC(OC1=CC=C(CO[C@H]2CN3C(OC2)=NC([N+]([O-])=O)=C3)C=C1)(F)F,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Chiron PathoGenesis,pharma,MYLAN IRELAND LTD,pharma,43691,2019,Drugs@FDA,NO,YES,,0.53,High,Fa estimated from reported excretion data,0.136,1.4,16,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,,,,,1,Nitroorganics,NO,NO,NO,,359.2575096,0,5,0,8,0,5,88.65,0.357,3.43,3.93,2.792,All fragments measured,2.9,2.9,2.31,2.314,,,,7.1,Neutral,Class 2,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,NO,0.73987,0.71702,0.81886,0.76741,0.52457,0.59178,0.77367,0.6885,0.93773,380.2,21.4,20.4,28.3
90-34-6,PRIMAQUINE PHOSPHATE,PRIMAQUINE,PF-00345143,2266,CC(CCCN)Nc1cc(cc2c1nccc2)OC,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,19016,1952,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,,3.8,5.5,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,259.3467,3,3,2,4,0,6,60.17,0.4,-0.157,-0.157,2.598,All fragments measured,2.7,-0.046,2.16,-0.564,,10.38,,10,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8296,0.8648,0.84418,0.95586,0.88651,0.79222,0.98873,0.6885,0.93773,247.9,9.26,6.28,17.8
125-33-7,PRIMIDONE,MYSOLINE,PF-00345079,2267,CCC1(C(=O)NCNC1=O)c2ccccc2,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,VALEANT,pharma,19791,1954,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.665,0.7,7,,,,9,NO,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,218.2518,2,2,2,4,0,2,58.2,0.333333333,0.643,0.643,0.882,All fragments measured,1.3,1.3,0.61,0.608,12.26,,13,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75519,0.80803,0.5643,0.75542,0.93048,0.79222,0.99393,0.87038,0.82734,179.2,10.6,2.93,8.05
57-66-9,PROBENECID,BENEMID,PF-00345145,2268,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,MERCK,major pharma,18744,1951,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.13,0.13,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Less,0,,NO,NO,NO,,285.3593,1,2,1,5,0,7,74.68,0.461538462,-0.375,0.1353,3.371,All fragments measured,3.3,-0.039,3.05,0.006,3.69,,3.5,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82998,0.84652,0.96719,0.98368,0.88651,0.98659,0.8487,0.53315,0.82734,228.8,14.9,12.8,12.1
23288-49-5,PROBUCOL,LORELCO,PF-00344825,2269,CC(C)(C)c1cc(cc(c1O)C(C)(C)C)SC(C)(C)Sc2cc(c(c(c2)C(C)(C)C)O)C(C)(C)C,TABLET,YES,NO,NO,NO,ORAL,1000,Discontinued,1989,YES,NO,QTc prolongation,Inxight,,,SANOFI AVENTIS US,major pharma,28157,1977,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,Gerren Additions,0,,,,,0,,NO,NO,NO,,516.8416,2,4,2,2,2,4,40.46,0.612903226,5.15,6.58,10.967,Very high LogP unrealistic in nature,9,9,10.03,10.033,10.27,,11,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.27932,0.35469,0.14186,0.02435,0.88651,0.79222,0.77625,0.39983,0.93773,255.7,0.0526,43.3,56.5
51-06-9,PROCAINAMIDE HYDROCHLORIDE,PRONESTYL,PF-00344576,2270,CCN(CC)CCNC(=O)c1ccc(cc1)N,"CAPSULE, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,6000,Discontinued,,NO,NO,,,,,APOTHECON,pharma,18416,1950,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.8,2,3.5,,,,3478597,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Aniline,YES,NO,NO,,235.3253,3,2,2,4,0,6,58.36,0.461538462,-0.567,-0.7894,1.423,All fragments measured,1.2,-0.49,1.25,-0.65,,9.09,12,8.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75682,0.81703,0.6836,0.80518,0.9848,0.79222,0.99356,0.6885,0.82734,181.4,6.82,3.12,10.4
671-16-9,PROCARBAZINE HYDROCHLORIDE,MATULANE,PF-00345147,2272,CC(C)NC(=O)c1ccc(cc1)CNNC,CAPSULE,YES,NO,NO,NO,ORAL,420,Prescription,,NO,NO,,,,,LEADIANT BIOSCI INC,pharma,25406,1969,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,,,0.2,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,None,1,Hydrazines,NO,NO,NO,,221.2988,3,1,3,4,0,5,53.16,0.416666667,-0.432,-0.432,-0.083,All fragments measured,-0.014,-0.19,0.95,0.258,,7.85,12,6.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64371,0.72701,0.58524,0.70147,0.9848,0.37866,0.99999,0.84757,0.82734,162.1,5.73,5.94,7.1
58-38-8,PROCHLORPERAZINE MALEATE,COMPAZINE,PF-00344646,2274,CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)Cl,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,40,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,20751,1956,Drugs@FDA,NO,NO,0.125,,Moderate,Reported bioavailability,,12.9,6.8,,,,,NO,"Gastrointestinal, Neurological",NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,None,0,,NO,NO,NO,,373.9427,0,3,0,3,0,4,9.72,0.4,3.3,3.985,4.382,All fragments measured,5,4,4.83,4.224,,7.66,,8.6,Basic,Class 4,0,0,0,0,1,0,0,2,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.75816,0.78796,0.7303,0.60484,0.88651,0.59178,0.895,0.96969,0.93773,326.8,1.86,42.6,83.6
77-37-2,PROCYCLIDINE HYDROCHLORIDE,KEMADRIN,PF-00344742,2276,c1ccc(cc1)C(CCN2CCCC2)(C3CCCCC3)O,TABLET,YES,NO,NO,NO,ORAL,20,Discontinued,,NO,NO,,,,,MONARCH PHARMS,pharma,20297,1955,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,,1.1,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,287.4397,1,2,1,2,0,5,23.47,0.684210526,1.33,1.304,4.592,All fragments measured,4.2,1.9,3.99,1.209,,10.49,16,9.5,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.90008,0.87025,0.97339,0.87327,0.93048,0.98659,0.69082,0.84757,0.82734,213.2,16,40,28.1
57-83-0,PROGESTERONE,PROMETRIUM,PF-00344648,2279,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CAPSULE,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,VIRTUS PHARMS,pharma,35929,1998,Drugs@FDA,NO,NO,0.12,,Moderate,Reported bioavailability,0.01,,,,,,90,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,A,Most,A (well established cause of clniically apparent liver injury),Less,0,,NO,NO,NO,2AA5,314.4617,0,2,0,2,0,1,34.14,0.80952381,3.36,4.06,3.965,Valid estimate for difficult structure,3.5,3.5,3.72,3.726,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70522,0.74775,0.99461,0.89768,0.93048,0.59178,0.88329,0.63709,0.47245,285.5,18.4,82.2,80
500-92-5,PROGUANIL HYDROCHLORIDE,MALARONE,PF-01388201,2282,CC(C)NC(=N)NC(=N)Nc1ccc(cc1)Cl,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,GLAXOSMITHKLINE,major pharma,36721,2000,Drugs@FDA,YES,NO,,0.6,High,Fa estimated from reported excretion data,0.25,42,12,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,LiverTox Additions,0,E*,Ambiguous,E* (unproven but sometimes suspected cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,253.7312,5,4,5,5,0,6,83.79,0.272727273,0.0832,0.0832,2.532,All fragments measured,0.95,-2.3,2.36,1.005,,11.15,,13,Basic,Class 4,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.4669,0.57012,0.80909,0.9769,0.93048,0.05547,0.84245,0.6885,0.82734,185.8,4.34,12.2,9.56
58-40-2,PROMAZINE HYDROCHLORIDE,SPARINE,PF-00344745,2284,CN(C)CCCN1c2ccccc2Sc3c1cccc3,"CONCENTRATE, SYRUP, TABLET",YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,WYETH,major pharma,20918,1957,Drugs@FDA,NO,NO,,,NA,NA,0.06,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,284.4191,0,2,0,2,0,4,6.48,0.294117647,2.16,2.7,4.399,All fragments measured,4.4,2.6,4.65,2.686,,9.43,,9,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8494,0.8659,0.96418,0.84184,0.9848,0.59178,0.84849,0.96969,0.93773,229.8,13,21.7,45.1
60-87-7,PROMETHAZINE HYDROCHLORIDE,PHENERGAN,PF-00344580,2286,CC(CN1c2ccccc2Sc3c1cccc3)N(C)C,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,,,DELCOR ASSET CORP,pharma,18716,1951,Drugs@FDA,NO,NO,0.287,,Moderate,Reported bioavailability,0.07,13.9,12,,,,430914,NO,"Gastrointestinal, Neurological, Respiratory",NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,284.4191,0,2,0,2,0,3,6.48,0.294117647,2.07,2.532,4.4,All fragments measured,4.2,2.5,4.58,3.099,,8.98,,9.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83583,0.85194,0.96418,0.73395,0.9848,0.59178,0.84849,0.99269,0.93773,256.8,8.38,35.7,44.9
54063-53-5,PROPAFENONE HYDROCHLORIDE,RYTHMOL,PF-00344649,2291,CCCNCC(COc1ccccc1C(=O)CCc2ccccc2)O,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,900,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,32839,1989,Drugs@FDA,NO,NO,0.23,,Moderate,Reported bioavailability,0.1,2.5,6.5,,,,,NO,Cardiovascular,NO,NO,,YES,YES,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,341.444,2,4,2,4,0,11,58.56,0.380952381,1.67,1.601,3.636,All fragments measured,3.3,1.5,3.43,1.451,,9.31,15,9.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60382,0.70248,0.91236,0.93476,0.88651,0.79222,0.99309,0.15134,0.93773,267.9,4.18,46.7,151
298-50-0,PROPANTHELINE BROMIDE,PRO-BANTHINE,PF-00345149,2293,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc3c1cccc3)C(C)C,TABLET,YES,NO,NO,NO,ORAL,75,Prescription,,NO,NO,,,,,SHIRE,major pharma,19451,1953,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,,,1,,,,436990,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,368.4892,0,2,0,4,0,7,35.53,0.434782609,2.15,2.898,1.493,Approximated fragment value used,2.7,2.7,-0.51,-0.513,,,,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.72642,0.79377,0.76385,0.9896,0.9848,0.59178,0.90148,0.53315,0.93773,279.8,1.37,13.9,64.4
469-62-5,PROPOXYPHENE HYDROCHLORIDE,DARVON,AXL012719,844,CCC(=O)O[C@](Cc1ccccc1)(c2ccccc2)[C@H](C)CN(C)C,CAPSULE,YES,NO,NO,NO,ORAL,390,Discontinued,2010,YES,YES,Cardiotoxicity,FederalRegister,,,XANODYNE PHARM,pharma,21048,1957,Drugs@FDA,NO,NO,,,Moderate,Based on textual comment,0.22,19,6,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,339.4712,0,2,0,3,1,9,29.54,0.409090909,2.44,2.85,5.21,All fragments measured,4.1,3.1,4.86,3.08,,9.19,,8.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.55109,0.63143,0.71796,0.42878,0.9848,0.59178,0.81105,0.29329,0.93773,0,7.71,20.7,43.7
525-66-6,PROPRANOLOL HYDROCHLORIDE,INDERAL,PF-00296693,2303,CC(C)NCC(COc1cccc2c1cccc2)O,"CAPSULE, EXTENDED RELEASE, SOLUTION, SUSPENSION, TABLET",YES,NO,YES,NO,ORAL,240,Prescription,,NO,NO,,,,,WYETH,major pharma,24789,1967,Drugs@FDA,NO,NO,0.38,,High,Reported bioavailability,0.07,6,,,158,,6322244,YES,"Cardiovascular, Musculoskeletal/Pain",NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,259.3434,2,3,2,3,0,6,41.49,0.375,1.11,1.182,2.753,All fragments measured,2.7,0.83,3.26,1.148,,9.5,15,9.2,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83574,0.87927,0.84416,0.99487,0.9848,0.79222,0.96048,0.6885,0.93773,216.3,13.5,27,69.6
51-52-5,PROPYLTHIOURACIL,PROPYLTHIOURACIL,PF-00345443,2308,CCCc1cc(=O)[nH]c(=S)[nH]1,TABLET,YES,NO,NO,NO,ORAL,900,Prescription,,NO,NO,,,,,DAVA PHARMS INC,pharma,17376,1947,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.2,0.34,,Parent CRG,,,23,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Thiourea,NO,NO,NO,4QYQ,170.2321,2,1,2,3,0,2,48.65,0.428571429,0.992,0.8476,0.971,A priori fragment value used,1.2,1.2,0.46,0.37,7.63,,8.6,,Acidic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.61021,0.68791,0.29022,0.89709,0.93048,0.79222,0.92373,0.87038,0.47245,158.1,20.8,4.66,17.7
438-60-8,PROTRIPTYLINE HYDROCHLORIDE,VIVACTIL,PF-00344827,2320,CNCCCC1c2ccccc2C=Cc3c1cccc3,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,TEVA,major pharma,24742,1967,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,,22,54,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,263.3767,1,1,1,1,0,4,12.03,0.263157895,1.41,1.467,4.865,All fragments measured,4.3,1.7,4.7,1.853,,10.61,,10,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.88899,0.67965,0.86789,0.85165,0.23327,0.98659,0.43308,0.96969,0.93773,168.2,8.07,8.26,18.3
179474-81-8,PRUCALOPRIDE SUCCINATE,MOTEGRITY,PF-01257838,3502,COCCCN1CCC(CC1)NC(=O)c2cc(c(c3c2OCC3)N)Cl,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,SHIRE,major pharma,43448,2018,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.7,8.1,24,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,,367.8703,3,4,2,6,0,6,76.82,0.611111111,0.965,0.6,1.414,All fragments measured,2.5,1,2.16,1.225,,8.23,11,8.6,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.76842,0.7815,0.76762,0.78779,0.72615,0.79222,0.89848,0.6885,0.82734,316.5,11,5.63,14.7
90-82-4,PSEUDOEPHEDRINE HYDROCHLORIDE,NOVAFED,PF-00344581,2326,C[C@@H]([C@H](c1ccccc1)O)NC,"CAPSULE, EXTENDED RELEASE, TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,240,Over-the-counter,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,27635,1975,Drugs@FDA,NO,NO,,0.96,High,Fa estimated from reported excretion data,,3,5,,,,,NO,Respiratory,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,165.2322,2,2,2,2,0,3,32.26,0.4,-1.17,-1.17,0.888,All fragments measured,0.93,-1,1.26,-0.752,,9.38,15,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66695,0.73486,0.26906,0.82997,0.93048,0.79222,0.85596,0.99269,0.82734,150.8,23.9,12.7,9.7
98-96-4,PYRAZINAMIDE,PYRAZINAMIDE,PF-00344743,2328,c1cnc(cn1)C(=O)N,"ORAL, TABLET",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,DAVA PHARMS INC,pharma,26087,1971,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,,1.2,6.7,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,123.1127,2,3,1,4,0,1,68.87,0,-0.401,-0.401,-0.676,All fragments measured,-1,-1,-0.27,-0.266,,,11,2.2,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44353,0.54438,0.14119,0.20613,0.9848,0.98659,0.95051,0.63709,0.82734,146.1,17.4,3.29,6.65
155-97-5,PYRIDOSTIGMINE BROMIDE,MESTINON,PF-00345080,2330,C[n+]1cccc(c1)OC(=O)N(C)C,"SYRUP, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,1500,Prescription,,NO,NO,,,,,VALEANT,pharma,20185,1955,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,1,1.1,,Parent CRG,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,181.2117,0,2,0,4,0,3,33.42,0.333333333,-0.958,-0.958,-4.264,Valid estimate for difficult structure,-3.7,-3.7,-3.34,-3.342,,,,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64813,0.72216,0.34173,0.8657,0.93048,0.59178,0.87319,0.87038,0.82734,178.1,32,4.7,15.1
65-23-6,PYRIDOXINE HYDROCHLORIDE,BENDECTIN,PF-00345081,2836,Cc1c(c(c(cn1)CO)CO)O,"TABLET, DELAYED RELEASE; TABLET, EXTENDED RELEASE",NO,YES,YES,NO,ORAL,50,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,20666,1956,Drugs@FDA,YES,NO,,0.63,High,Fa estimated from reported excretion data,,,360,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of liver injury),None,0,,NO,NO,NO,,169.1778,3,4,3,4,0,2,73.58,0.375,-0.122,-0.122,-0.345,All fragments measured,-0.56,-0.57,-0.62,-0.686,9.63,5.01,9.1,5.2,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.48935,0.57564,0.28564,0.32923,0.88651,0.37866,0.92132,0.87038,0.82734,143.5,2.7,13.5,8.16
58-14-0,PYRIMETHAMINE,DARAPRIM,PF-00344824,2332,CCc1c(c(nc(n1)N)N)c2ccc(cc2)Cl,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,,,VYERA PHARMS LLC,pharma,19382,1953,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.13,0.68,96,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,1J3J,248.7114,4,2,2,4,0,2,77.82,0.166666667,1.96,2.143,3.003,All fragments measured,2.9,2.7,2.57,2.344,,7.22,,7,Basic,Class 2,0,0,0,0,1,0,0,2,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.86127,0.87613,0.7761,0.99971,0.88651,0.79222,0.89098,0.87038,0.93773,190.8,17.2,14.6,9.93
36735-22-5,QUAZEPAM,DORAL,PF-00345447,2336,c1ccc(c(c1)C2=NCC(=S)N(c3c2cc(cc3)Cl)CC(F)(F)F)F,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,GALT PHARMS,pharma,31408,1985,Drugs@FDA,NO,NO,,0.31,High,Fa estimated from reported excretion data,0.05,8.6,25,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),None,1,Thioamide,NO,NO,NO,,386.7943,0,0,0,2,0,2,15.6,0.176470588,3.32,4.71,3.197,Benzyl approx. based on a priori value,4.2,4.2,4.35,4.346,,,,1.7,Neutral,Class 2,0,4,0,0,1,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,5,0,0,0,0,NO,0.6087,0.65965,0.65045,0.16428,0.93048,0.59178,0.99226,0.99269,0.93773,320.5,4.1,13.9,38.8
111974-69-7,QUETIAPINE FUMARATE,SEROQUEL,PF-00346606,2337,c1ccc2c(c1)C(=Nc3ccccc3S2)N4CCN(CC4)CCOCCO,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,800,Prescription,,NO,NO,,,,,ASTRAZENECA AB,major pharma,35699,1997,Drugs@FDA,NO,NO,,0.73,High,Fa estimated from reported excretion data,0.17,10,6.5,,11,174,1624764,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,383.5071,1,5,1,5,0,6,48.3,0.380952381,2.37,2.857,2.992,Approximated fragment value used,2.8,2.7,2.37,2.249,,6.74,14,7.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.82172,0.79803,0.67084,0.99827,0.52457,0.98659,0.92118,0.6885,0.93773,342.1,14.3,24.3,35.4
85441-61-8,QUINAPRIL HYDROCHLORIDE,ACCUPRIL,PF-00345406,2340,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3ccccc3C[C@H]2C(=O)O,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,PFIZER,major pharma,33561,1991,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.03,0.7,0.8,,,,20393259,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,438.5161,2,5,2,7,0,11,95.94,0.4,0.506,0.506,1.736,Approximated fragment value used,3.2,-0.2,3.45,-0.108,3.39,5.31,2.9,5.3,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.49817,0.54907,0.36939,0.67729,0.52457,0.79222,0.72844,0.21184,0.93773,429.8,1.24,37.2,14.1
152-43-2,QUINESTROL,ESTROVIS,PF-00344912,2342,C[C@]12CC[C@@H]3c4ccc(cc4CC[C@H]3[C@@H]1CC[C@]2(C#C)O)OC5CCCC5,TABLET,YES,NO,NO,NO,ORAL,0.2,Discontinued,,NO,NO,,,,,PARKE DAVIS,major pharma,35181,1996,Drugs@FDA,NO,NO,,,NA,NA,,,120,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,1,Alkynes,NO,NO,NO,,364.5204,1,2,1,2,1,2,29.46,0.68,4.05,5.61,5.922,All fragments measured,5.5,5.5,5.32,5.328,,,14,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59534,0.61326,0.78784,0.07737,0.93048,0.98659,0.80963,0.87038,0.82734,337.5,4.37,88.4,61.2
73-49-4,QUINETHAZONE,HYDROMOX,PF-00344829,2343,CCC1Nc2cc(c(cc2C(=O)N1)S(=O)(=O)N)Cl,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,,NO,NO,,,,,LEDERLE,major pharma,23111,1963,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,,,,,,,1,Aniline,YES,NO,NO,,289.7386,4,3,3,6,0,2,101.29,0.3,1.13,1.161,0.578,All fragments measured,1.3,1.3,0.83,0.824,9.98,,9.1,2.6,Neutral,Class 4,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.72178,0.72149,0.97951,0.73277,0.88651,0.37866,0.58655,0.87038,0.82734,305.7,1.73,2.24,7.31
56-54-2,QUINIDINE SULFATE,QUINIDEX,PF-00344583,2346,COc1ccc2c(c1)c(ccn2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,4000,Prescription,,NO,NO,,,,,WYETH,major pharma,22698,1962,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.12,2.5,7,,,,54116,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,324.4168,1,4,1,4,0,4,45.59,0.45,1.85,1.74,2.785,All fragments measured,2.9,2,3.02,1.727,12.8,8.57,13,8.3,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.97243,0.96209,0.97491,0.99954,0.88651,0.98659,0.98453,0.96969,0.93773,352.8,14.2,12.7,20.7
130-95-0,QUININE SULFATE,QUALAQUIN,PF-00930241,4523,COc1ccc2c(c1)c(ccn2)[C@H]([C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O,CAPSULE,YES,NO,NO,NO,ORAL,1944,Prescription,,NO,NO,,,Takeda,major pharma,SUN PHARM INDUSTRIES,pharma,38576,2005,Drugs@FDA,NO,NO,0.76,,High,Reported bioavailability,0.2,1.8,,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,324.4168,1,4,1,4,0,4,45.59,0.45,1.85,1.4,2.785,All fragments measured,2.9,2,3.02,1.727,12.8,8.57,13,8.3,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.97243,0.96209,0.97491,0.99954,0.88651,0.98659,0.98453,0.96969,0.93773,352.8,14.2,13.6,21
117976-89-3,RABEPRAZOLE SODIUM,ACIPHEX,PF-00346587,2350,Cc1c(ccnc1CS(=O)c2[nH]c3ccccc3n2)OCCCOC,"CAPSULE, DELAYED RELEASE, TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,EISAI INC,pharma,36391,1999,Drugs@FDA,NO,NO,0.52,,High,Reported bioavailability,0.037,0.22,1.5,Prodrug,34,,13511110,NO,Gastrointestinal,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Reactive_HeteroCycle,NO,NO,NO,,359.4426,1,5,1,6,0,8,77.1,0.333333333,1.93,2.181,2.078,Benzyl approx. based on a priori value,2.1,2.1,1.81,1.802,9.05,5.18,9.1,4,Neutral,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.61763,0.63793,0.81779,0.98649,0.72615,0.98659,0.72473,0.39983,0.25672,405.1,22.6,3.47,11.7
84449-90-1,RALOXIFENE HYDROCHLORIDE,EVISTA,PF-00579911,2351,c1cc(ccc1c2c(c3ccc(cc3s2)O)C(=O)c4ccc(cc4)OCCN5CCCCC5)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,ELI LILLY AND CO,major pharma,35773,1997,Drugs@FDA,NO,NO,0.02,0.06,Low,Reported bioavailability,,36.7,32,,77,,,YES,Genitourinary,NO,NO,,NO,NO,NO,YES,None,None,DILIRank,0,C,Less,C (probable rare cause of clinically apparent liver injury),Less,1,BenzoThiophene,NO,NO,NO,2QXS,473.5833,2,5,2,5,1,7,70,0.25,3.59,3.735,6.861,All fragments measured,6.4,5.3,5.57,4.311,8.83,8.52,8.8,8.2,Basic,Class 4,0,0,0,0,0,0,0,4,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,3,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.23562,0.28363,0.24052,0.08221,0.72615,0.79222,0.70522,0.53315,0.03452,371.7,0.744,51.5,24.1
518048-05-0,RALTEGRAVIR POTASSIUM,ISENTRESS,PF-04545030,2352,Cc1nnc(o1)C(=O)NC(C)(C)c2nc(c(c(=O)n2C)O)C(=O)NCc3ccc(cc3)F,"POWDER, TABLET, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,39367,2007,Drugs@FDA,NO,NO,0.32,,High,Reported bioavailability,0.17,,9,,,91,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,,444.4163,3,7,3,11,1,6,152.24,0.3,0.738,0.738,1.16,Approximated fragment value used,-0.42,-0.97,-0.52,-3.365,4.5,,6.8,2.3,Acidic,Class 3B,0,1,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.48446,0.42513,0.3441,0.38407,0.33223,0.37866,0.23381,0.6885,0.93773,494.2,1.84,3.55,9.21
196597-26-9,RAMELTEON,ROZEREM,PF-00724076,2355,CCC(=O)NCC[C@@H]1CCc2c1c3c(cc2)OCC3,TABLET,YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,Takeda,major pharma,TAKEDA PHARMS USA,major pharma,38555,2005,Drugs@FDA,NO,NO,0.018,0.84,Low,Reported bioavailability,0.18,1,1,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),None,0,,NO,NO,NO,,259.3434,1,2,1,3,0,4,38.33,0.5625,2.8,2.926,2.485,All fragments measured,2.7,2.7,3.07,2.804,,,13,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92274,0.92514,0.84416,0.99998,0.93048,0.98659,0.93296,0.96969,0.82734,222.6,30.6,46.8,43.4
87333-19-5,RAMIPRIL,ALTACE,PF-00345628,2356,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,KING PHARMS,pharma,33266,1991,Drugs@FDA,NO,YES,0.44,0.6,High,Reported bioavailability,0.27,1.2,,,50,,16357728,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,416.5106,2,5,2,7,0,11,95.94,0.608695652,0.0364,0.5843,1.54,Approximated fragment value used,2.8,-0.56,3.44,-0.132,3.15,5.44,3.2,5.5,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.503,0.54567,0.477,0.5692,0.52457,0.79222,0.72844,0.21184,0.82734,447.6,1.09,28.8,10.5
66357-35-5,RANITIDINE HYDROCHLORIDE,ZANTAC 150,PF-01462553,2358,CN/C(=C\N(=O)=O)/NCCSCc1ccc(o1)CN(C)C,"CAPSULE, GRANULE, EFFERVESCENT, SYRUP, TABLET, TABLET, EFFERVESCENT",YES,NO,NO,NO,ORAL,700,Over-the-counter,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,30476,1983,Drugs@FDA,NO,NO,0.5,,High,Reported bioavailability,0.85,1.4,,,,,294070,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,B,Most,B (very likely but rare cause of clinically apparent liver injury),Less,1,Furan,NO,NO,NO,,314.4038,2,6,2,7,0,10,86.26,0.538461538,0.525,0.525,0.67,Estimated fragment value used,0.33,-0.66,0.37,-0.629,,8.36,,8.3,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,NO,0.61914,0.61206,0.99469,0.78352,0.52457,0.79222,0.56685,0.21184,0.82734,282.8,0.922,3.26,13.4
95635-55-5,RANOLAZINE,RANEXA,PF-00930000,2359,Cc1cccc(c1NC(=O)CN2CCN(CC2)CC(COc3ccccc3OC)O)C,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,2000,Prescription,,NO,NO,,,Roche ,major pharma,GILEAD SCIENCES INC,major pharma,38744,2006,Drugs@FDA,NO,NO,0.55,,High,Reported bioavailability,0.38,1.9,7,,,199,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,427.5365,2,6,2,7,0,9,74.27,0.458333333,2.48,2.547,1.012,All fragments measured,2.3,2.2,2.47,2.472,,6.54,13,6.8,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.58733,0.63994,0.42049,0.99767,0.52457,0.79222,0.91662,0.29329,0.93773,391.2,8.25,19.6,41.2
136236-51-6,RASAGILINE MESYLATE,AZILECT,PF-05012604,3521,C#CCN[C@@H]1CCc2c1cccc2,TABLET,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,Teva,major pharma,TEVA,major pharma,38853,2006,Drugs@FDA,NO,NO,0.36,,High,Reported bioavailability,0.08,1.2,0.75,Suicide,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Alkynes,NO,NO,NO,,171.2383,1,1,1,1,0,2,12.03,0.333333333,1.17,1.207,2.524,All fragments measured,2.5,2.1,2.47,2.337,,6.95,,7.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68533,0.57585,0.29465,0.99291,0.23327,0.98659,0.43308,0.87038,0.82734,144.6,26.5,17.5,27
755037-03-7,REGORAFENIB,STIVARGA,PF-06700176,4654,CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl,TABLET,YES,NO,NO,YES,ORAL,160,Prescription,,NO,NO,,,Bayer,major pharma,BAYER HEALTHCARE,major pharma,41179,2012,Drugs@FDA,NO,NO,0.69,,High,Reported bioavailability,0.05,,28,,,,,YES,Oncology,NO,YES,II,NO,NO,NO,NO,,Most,,,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,482.8154,3,3,3,7,1,5,92.35,0.095238095,4.74,5.16,5.185,All fragments measured,4.8,4.8,4.41,4.396,12.04,3.26,11,2.7,Neutral,Class 4,0,4,0,0,1,0,0,3,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,5,0,0,0,0,NO,0.40756,0.49392,0.21456,0.73743,0.88651,0.37866,0.76383,0.6885,0.25672,455.9,3.3,10.7,18.7
135062-02-1,REPAGLINIDE,PRANDIN,PF-00835131,2366,CCOc1cc(ccc1C(=O)O)CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3,TABLET,YES,NO,NO,NO,ORAL,12,Prescription,,NO,NO,,,,,GEMINI LABS LLC,pharma,35786,1997,Drugs@FDA,NO,NO,0.56,,High,Reported bioavailability,0.02,0.44,1,,,,,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury)  ,Moderate,1,Aniline,YES,NO,NO,,452.5857,2,5,2,6,1,10,78.87,0.481481481,2.09,2.218,5.303,Benzyl approx. based on a priori value,5.8,2.5,4.88,1.998,4.19,5.78,4.4,3.8,Acidic,Class 1B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.43539,0.52313,0.31156,0.34111,0.72615,0.79222,0.88283,0.21184,0.93773,376.1,3.9,24.2,19.9
24815-24-5,RESCINNAMINE,MODERIL,PF-00579918,2369,COc1ccc2c(c1)[nH]c3c2CCN4[C@@H]3C[C@H]5[C@@H](C4)C[C@H]([C@@H]([C@H]5C(=O)OC)OC)OC(=O)/C=C/c6cc(c(c(c6)OC)OC)OC,TABLET,YES,NO,NO,NO,ORAL,1,Discontinued,,NO,NO,,,,,PFIZER,major pharma,20759,1956,Drugs@FDA,NO,NO,,0.4,High,Fa estimated from reported excretion data,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,,,,,,,,1,Michael_acceptor,NO,YES,NO,,634.716,1,8,1,11,2,11,117.78,0.485714286,3.74,4.35,4.12,All fragments measured,4.4,4.2,4.24,4.009,,7.25,10,6.7,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,8,0,0,0,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.23276,0.22922,0.04646,0.5995,0.06191,0.98659,0.50294,0.15134,0.25672,677.2,3.3,75.3,22.7
50-55-5,RESERPINE,RESERPINE,PF-00344585,2370,COc1ccc2c(c1)[nH]c3c2CCN4[C@@H]3C[C@H]5[C@@H](C4)C[C@H]([C@@H]([C@H]5C(=O)OC)OC)OC(=O)c6cc(c(c(c6)OC)OC)OC,"ELIXIR, TABLET",YES,NO,NO,NO,ORAL,1,Discontinued,,NO,NO,,,,,SANDOZ,pharma,20172,1955,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,0.04,,200,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,608.6787,1,8,1,11,2,10,117.78,0.515151515,3.92,4.4,3.859,All fragments measured,4,3.7,4.16,3.931,,7.25,10,6.9,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,0,8,0,0,0,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.27244,0.25684,0.05598,0.78835,0.06191,0.98659,0.50294,0.21184,0.25672,662.9,2.22,64.7,20.1
36791-04-5,RIBAVIRIN,REBETOL,PF-00344584,2373,c1nc(nn1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,MERCK,major pharma,35949,1998,Drugs@FDA,NO,YES,0.64,,High,Reported bioavailability,1,40.8,298,,,,17167,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven although suspected rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,244.2047,5,6,4,9,0,3,143.72,0.625,-1.56,-1.56,-2.849,All fragments measured,-2.8,-2.8,-2.07,-2.069,12.95,1.31,12,1.5,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.36924,0.3295,0.74551,0.05119,0.33223,0.14694,0.27562,0.99269,0.82734,376.3,0.72,2.41,6.94
1211441-98-3,RIBOCICLIB SUCCINATE,KISQALI,PF-06732777,5218,CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5,TABLET,YES,NO,NO,YES,ORAL,600,Prescription,,NO,NO,,,Astex Pharmaceuticals ,pharma,NOVARTIS,major pharma,42807,2017,Drugs@FDA,NO,NO,,0.75,High,Fa estimated from reported excretion data,0.3,15.6,32,,,,,NO,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,C,Less,C (probable cause of clinically apparent liver injury),,0,,NO,NO,NO,5L2T,434.5373,2,5,2,9,0,6,91.21,0.47826087,1.19,0.9072,1.954,All fragments measured,3,2,1.04,-0.043,,8.67,,7.8,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5837,0.55956,0.3873,0.99945,0.33223,0.79222,0.77481,0.84757,0.25672,441.2,2.41,12.4,38.7
72559-06-9,RIFABUTIN,MYCOBUTIN,PF-00345095,2376,Cc1c(c2c3c4c1O[C@@](C4=O)(O/C=C\[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C\C=C(/C(=O)NC(=C5C3=NC6(N5)CCN(CC6)CC(C)C)C2=O)\C)C)O)C)O)C)OC(=O)C)C)OC)C)O,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,33961,1992,Drugs@FDA,NO,NO,0.2,0.58,Moderate,Reported bioavailability,0.15,9.3,36,,,,19023446,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,2A68,847.0047,5,12,5,15,2,5,205.55,0.586956522,3.42,3.602,4.732,Benzyl approx. based on a priori value,6.3,3.8,4.2,,,,6.1,7.8,Zwitter,Class 3B,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,8,0,0,0,7,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,2,YES,0.20161,0.14126,0.0276,0.88085,0.02183,0.05547,0.05436,0.84757,0.82734,915.7,2.39,26.3,71.3
13292-46-1,RIFAMPIN,RIFADIN,PF-00344660,2377,Cc1c(c2c3c4c1O[C@@](C4=O)(O/C=C\[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C\C=C(/C(=O)Nc(c2O)c(c3O)/C=N/N5CCN(CC5)C)\C)C)O)C)O)C)OC(=O)C)C)OC)C)O,CAPSULE,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,26074,1971,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.2,0.9,1.5,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well established cause of clinically apparent liver injury),Moderate,2,Michael_acceptor; Quinones,NO,YES,NO,,822.9402,6,12,6,16,3,5,220.15,0.534883721,1.5,1.095,3.71,All fragments measured,4.6,2.1,2.24,-0.189,4.96,7.3,2.9,7.4,Zwitter,Class 3B,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,0,6,0,0,0,4,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,YES,0.17403,0.12271,0.02794,0.98419,0.02075,0.02306,0.04004,0.84757,0.93773,892.4,0.585,5,14.8
61379-65-5,RIFAPENTINE,PRIFTIN,PF-00579924,2378,Cc1c(c2c3c4c1O[C@@](C4=O)(O/C=C\[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C\C=C(/C(=O)Nc(c2O)c(c3O)/C=N/N5CCN(CC5)C6CCCC6)\C)C)O)C)O)C)OC(=O)C)C)OC)C)O,TABLET,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35968,1998,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.023,1,13.1,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,2,Michael_acceptor; Quinones,NO,YES,NO,2A69,877.0307,6,12,6,16,4,6,220.15,0.574468085,2.25,2.492,5.092,All fragments measured,6,3.7,3.37,0.949,4.97,7.67,3,7.4,Zwitter,Class 3B,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,3,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,2,0,6,0,0,0,4,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,YES,0.15401,0.11114,0.02731,0.61946,0.02075,0.02306,0.04004,0.6885,0.93773,926.7,1.46,4.2,20.4
500287-72-9,RILPIVIRINE HYDROCHLORIDE,EDURANT,PF-04746628,4174,Cc1cc(cc(c1Nc2ccnc(n2)Nc3ccc(cc3)C#N)C)/C=C/C#N,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Johnson & Johnson,major pharma,JANSSEN PHARMS,major pharma,40683,2011,Drugs@FDA,NO,NO,,0.66,High,Fa estimated from reported excretion data,0.003,,50,,,87,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,LiverTox Additions,1,D,Less,D (possible rare cause of clinically apparent liver injury),,2,Aniline; Michael_acceptor,YES,YES,NO,4G1Q,366.4185,2,3,2,6,1,5,97.42,0.090909091,4.07,5.19,5.752,All fragments measured,5.1,5.1,3.63,3.628,,5.24,,5.4,Neutral,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,NO,0.56984,0.5499,0.77642,0.30347,0.52457,0.79222,0.71365,0.84757,0.25672,308.3,1.21,34.5,99.7
1744-22-5,RILUZOLE,RILUTEK,PF-00344586,2382,c1cc2c(cc1OC(F)(F)F)sc(n2)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,COVIS PHARMA BV,pharma,35045,1995,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.04,3.4,12,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),None,0,,NO,NO,NO,,234.1983,2,2,1,3,0,1,48.14,0.125,2.81,3.6,3.235,All fragments measured,3.1,3.1,2.44,2.438,,2.96,,4.3,Neutral,Class 2,0,3,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.86198,0.88849,0.67566,0.90476,0.9848,0.98659,0.90164,0.87038,0.93773,219.3,24.2,21.6,34.7
13392-28-4,RIMANTADINE HYDROCHLORIDE,FLUMADINE,PF-00579919,2383,CC(C12CC3CC(C1)CC(C3)C2)N,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,SUN PHARM INDUSTRIES,pharma,34229,1993,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.6,17,25.4,,,,,NO,Anti-infective,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,179.3018,2,1,1,1,0,1,26.02,1,0.473,0.473,3.963,All fragments measured,2.3,-0.86,2.98,0.071,,10.76,,10,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60542,0.55734,0.33227,0.97516,0.23327,0.98659,0.74426,0.63709,0.47245,106.2,30,6.22,8.89
625115-55-1,RIOCIGUAT,ADEMPAS,PF-06785690,4807,CN(c1c(nc(nc1N)c2c3cccnc3n(n2)Cc4ccccc4F)N)C(=O)OC,TABLET,YES,NO,NO,NO,ORAL,7.5,Prescription,,NO,NO,,,Bayer,major pharma,BAYER HEALTHCARE,major pharma,41555,2013,Drugs@FDA,NO,NO,0.94,,High,Reported bioavailability,0.05,0.4,7,,,,,YES,Cardiovascular,YES,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,422.4157,4,6,2,10,0,6,138.07,0.15,2.96,2.245,1.844,A priori fragment value used,2.3,2.3,2.22,2.216,,1.41,,4.6,Neutral,Class 2,0,1,0,0,0,0,0,4,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.42285,0.34812,0.44611,0.98496,0.19128,0.79222,0.31794,0.84757,0.03452,435.2,16.1,35.4,35.5
105462-24-6,RISEDRONATE SODIUM,ACTONEL,PF-00579921,2387,c1cc(cnc1)CC(O)(P(=O)(O)O)P(=O)(O)O,"TABLET, TABLET, DELAYED RELEASE",YES,YES,NO,NO,ORAL,5,Prescription,,NO,NO,,,,,APIL,pharma,35881,1998,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,0.76,13.8,561,,48,,12327231,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury) ,Moderate,1,Pyridine,NO,NO,NO,5CG5,283.1123,5,4,5,8,0,4,148.18,0.285714286,-1.63,-1.63,-2.622,A priori fragment value used,-2.2,-7,-3.47,-8.834,1.41,5.07,2.2,4.2,Acidic,Class 3A,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,NO,0.42639,0.33382,0.95981,0.39216,0.19128,0.05547,0.14418,0.96969,0.82734,236.4,0.702,1.98,9.05
106266-06-2,RISPERIDONE,RISPERDAL,PF-00327962,2389,Cc1c(c(=O)n2c(n1)CCCC2)CCN3CCC(CC3)c4c5ccc(cc5on4)F,"SOLUTION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,16,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,34332,1993,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.1,1.5,20,,18,142,2565592,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,410.4845,0,4,0,6,0,4,64.16,0.52173913,2.91,1.7,2.711,All fragments measured,3.1,2.2,2.6,1.812,,8.07,,7.6,Basic,Class 2,0,1,0,0,0,0,0,3,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.75573,0.81275,0.50994,0.97979,0.88651,0.59178,0.98286,0.96969,0.93773,407.1,25.3,5.4,16.3
26652-09-5,RITODRINE HYDROCHLORIDE,YUTOPAR,PF-05312204,2390,C[C@H]([C@H](c1ccc(cc1)O)O)NCCc2ccc(cc2)O,TABLET,YES,NO,NO,NO,ORAL,120,Discontinued,1998,YES,NO,"Ineffective and risk of side effects, including bleeding",N Engl J Med 1992(327)308-312. DOI: 10.1056/NEJM199207303270503,,,ASTRAZENECA AB,major pharma,29567,1980,Drugs@FDA,NO,NO,0.3,,Moderate,Reported bioavailability,0.68,3.5,1,,,,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,,,Suzuki Additions,1,,,,,0,,NO,NO,NO,,287.3535,4,4,4,4,0,6,72.72,0.294117647,0.0486,0.0486,1.651,All fragments measured,1.9,0.39,1.84,-0.063,9.97,9.31,10,8.7,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60906,0.69167,0.97314,0.99825,0.88651,0.14694,0.92703,0.6885,0.93773,240.2,2.6,12.3,20.7
155213-67-5,RITONAVIR,NORVIR,PF-00346560,2391,CC(C)c1nc(cs1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc2ccccc2)C[C@@H]([C@H](Cc3ccccc3)NC(=O)OCc4cncs4)O,"CAPSULE, POWDER, SOLUTION, TABLET",YES,NO,NO,YES,ORAL,1200,Prescription,,NO,NO,,,,,ABBVIE,major pharma,35125,1996,Drugs@FDA,NO,NO,,0.7,High,Fa estimated from reported excretion data,0.02,0.41,4,,125,77,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Moderate,1,Thiazole,NO,NO,NO,1HXW,720.9442,4,6,4,11,2,19,145.78,0.432432432,3.98,4.95,4.937,Benzyl approx. based on a priori value,5.5,5.5,5.09,5.092,11.47,2.51,12,3.8,Neutral,Class 4,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.05802,0.07909,0.0321,0.47866,0.33223,0.14694,0.05866,0.01273,0.03452,727.4,1.54,37.4,219
366789-02-8,RIVAROXABAN,XARELTO,PF-03965244,4182,c1cc(ccc1N2CCOCC2=O)N3C[C@@H](OC3=O)CNC(=O)c4ccc(s4)Cl,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Bayer,major pharma,JANSSEN PHARMS,major pharma,40725,2011,Drugs@FDA,NO,NO,0.66,,High,Reported bioavailability,0.05,0.69,5,,,27,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,Most,FEARS Addition ,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,2,Aniline; Thiophene,YES,NO,YES,2W26,435.8813,1,3,1,8,0,5,88.18,0.315789474,1.81,1.612,2.394,Estimated fragment value used,2.6,2.6,1.83,1.828,,1.01,10,,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,NO,0.74567,0.72416,0.38117,0.93115,0.72615,0.98659,0.51675,0.84757,0.93773,476.4,16.4,8.31,29.4
123441-03-2,RIVASTIGMINE TARTRATE,EXELON,PF-04439734,2392,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,12,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,36637,2000,Drugs@FDA,NO,NO,0.36,,High,Reported bioavailability,0.6,2.25,1.5,Parent CRG,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,"D (possible, rare cause of clinically apparent drug-induced liver injury)",Moderate,0,,NO,NO,NO,,250.3367,0,3,0,4,0,6,32.78,0.5,0.79,0.8625,2.099,All fragments measured,2.8,1.4,2.29,1.086,,8.62,,8.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79331,0.83241,0.78692,0.99682,0.9848,0.59178,0.86383,0.84757,0.82734,232.3,37.1,9.17,15.6
144034-80-0,RIZATRIPTAN BENZOATE,MAXALT,PF-01157088,2393,CN(C)CCc1c[nH]c2c1cc(cc2)Cn3cncn3,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,MERCK,major pharma,35975,1998,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,0.86,1.6,2,,190,,4712377,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (suspected but unproven cause of liver injury),Moderate,2,3_Methyl_Indole; Imidazole_Triazole,NO,NO,NO,,269.3449,1,2,1,5,0,5,49.74,0.333333333,0.53,-0.5977,1.178,All fragments measured,1.6,-0.036,1.97,0.04,,9.49,10,8.7,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74958,0.78442,0.9003,0.96289,0.9848,0.98659,0.99714,0.84757,0.25672,246.1,16.3,3.09,9.49
162011-90-7,ROFECOXIB,VIOXX,PF-00346485,2397,CS(=O)(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,50,Discontinued,2004,YES,YES,"Increased risk of serious cardiovascular events, including heart attack and stroke",FederalRegister,,,MERCK,major pharma,36300,1999,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.13,1.3,17,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,Less,Suzuki Additions,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,1,Michael_acceptor,NO,YES,NO,5KIR,314.3557,0,3,0,4,0,3,60.44,0.117647059,0.997,0.997,1.798,All fragments measured,-0.29,-0.29,2.07,2.069,,,,,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.88338,0.8955,0.99475,0.99976,0.88651,0.59178,0.95085,0.99269,0.93773,239.3,29.6,26.3,8.05
162401-32-3,ROFLUMILAST,DALIRESP,PF-01666626,3531,c1cc(c(cc1C(=O)Nc2c(cncc2Cl)Cl)OCC3CC3)OC(F)F,TABLET,YES,NO,NO,NO,ORAL,0.5,Prescription,,NO,NO,,,Takeda,major pharma,ASTRAZENECA AB,major pharma,40602,2011,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.01,2.9,17,,,,,NO,Respiratory,YES,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Pyridine,NO,NO,NO,,403.2075,1,4,1,5,0,7,60.45,0.294117647,3.58,4,3.003,All fragments measured,3.5,3.5,4.06,4.116,9.89,,11,2.1,Neutral,Class 2,0,2,0,0,2,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,NO,0.71588,0.77877,0.55145,0.72928,0.88651,0.98659,0.98787,0.53315,0.93773,342.3,13.4,27.2,24.5
552292-08-7,ROLAPITANT HYDROCHLORIDE,VARUBI,VC-001215227,5027,C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)c4ccccc4,TABLET,YES,NO,NO,NO,ORAL,16,Prescription,,NO,NO,,,Merck,major pharma,TERSERA THERAPS LLC,pharma,42248,2015,Drugs@FDA,NO,NO,0.91,,High,Reported bioavailability,0.002,5.5,169,,,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,500.4766,2,3,2,4,1,5,50.36,0.48,2.86,3.846,4.707,All fragments measured,5.1,4.7,5,4.17,,8.85,12,9.7,Basic,Class 4,0,6,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,1,0,0,NO,0.5108,0.62853,0.17273,0.57622,0.9848,0.79222,0.99813,0.53315,0.93773,461,3.86,10.5,59.8
91374-21-9,ROPINIROLE HYDROCHLORIDE,REQUIP,PF-00419626,2402,CCCN(CCC)CCc1cccc2c1CC(=O)N2,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,24,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,35692,1997,Drugs@FDA,NO,NO,0.45,,High,Reported bioavailability,0.9,7.5,6,,122,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,"D (possible, rare cause of clinically apparent liver injury)",Less,0,,NO,NO,NO,,260.3746,1,2,1,3,0,7,32.34,0.5625,1.16,0.8566,2.796,All fragments measured,2.9,0.31,3.21,1.212,,9.45,11,9.1,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80925,0.83984,0.85035,0.99844,0.93048,0.98659,0.85719,0.53315,0.82734,205.6,18.9,16.1,15.1
122320-73-4,ROSIGLITAZONE MALEATE,AVANDIA,PF-00346591,2405,CN(CCOc1ccc(cc1)CC2C(=O)NC(=O)S2)c3ccccn3,TABLET,YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,,,SB PHARMCO,pharma,36305,1999,Drugs@FDA,NO,NO,0.99,,High,Reported bioavailability,0.002,0.2,3,,17,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),,1,Thiazolidinedione,NO,NO,NO,3DZY,357.4268,1,5,1,6,0,7,71.53,0.277777778,2.56,2.483,3.02,All fragments measured,3.2,2,2.75,1.689,6.34,6.5,6.3,5.6,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.80861,0.76397,0.82937,0.98374,0.52457,0.98659,0.7195,0.53315,0.93773,368.9,19.6,23.2,36.3
287714-41-4,ROSUVASTATIN CALCIUM,CRESTOR,PF-00579949,2406,CC(C)c1c(c(nc(n1)N(C)S(=O)(=O)C)c2ccc(cc2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,Shionogi,pharma,ASTRAZENECA AB,major pharma,37845,2003,Drugs@FDA,NO,NO,0.2,,Moderate,Reported bioavailability,0.12,1.7,19,,37,20,1693371,YES,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,481.5376,3,6,3,9,0,10,140.92,0.409090909,0.00645,0.1204,1.898,All fragments measured,2,-1.1,1.36,-1.773,4.25,,4.2,2.9,Acidic,Class 3B,0,1,0,0,0,0,0,2,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.38813,0.35704,0.21798,0.98987,0.19128,0.37866,0.23825,0.21184,0.93773,463.3,1.47,7.75,11.7
283173-50-2,RUCAPARIB CAMSYLATE,RUBRACA,PF-01367338,5203,CNCc1ccc(cc1)c2c3c4c(cc(cc4[nH]2)F)C(=O)NCC3,TABLET,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,Pfizer,major pharma,CLOVIS ONCOLOGY INC,pharma,42723,2016,Drugs@FDA,NO,NO,0.36,,High,Reported bioavailability,0.3,2.7,18,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,4RV6,323.3641,3,2,3,4,0,3,56.92,0.210526316,1.07,0.9498,3.006,All fragments measured,2,-0.0021,2.68,0.382,,9.59,8.5,9.4,Basic,Class 4,0,1,0,0,0,0,0,3,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,4,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.65222,0.7059,0.97764,0.99844,0.93048,0.37866,0.99651,0.99269,0.25672,289.7,3.55,5.41,29.6
106308-44-5,RUFINAMIDE,BANZEL,PF-04527461,3534,c1cc(c(c(c1)F)Cn2cc(nn2)C(=O)N)F,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,3200,Prescription,,NO,NO,,,Novartis,major pharma,EISAI INC,pharma,39766,2008,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.72,0.7,6,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,238.1935,2,3,1,5,0,3,73.8,0.1,0.81,0.81,0.514,Benzyl approx. based on a priori value,0.4,0.4,0.42,0.417,,,12,-1.5,Neutral,Class 2,0,2,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.89049,0.90844,0.70375,0.87212,0.9848,0.98659,0.91983,0.99269,0.93773,230.2,23.6,4.58,8.53
941678-49-5,RUXOLITINIB PHOSPHATE,JAKAFI,PF-05079996,4190,c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,Incyte,pharma,INCYTE CORP,pharma,40863,2011,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.03,1,3,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,C,Less,C (probable cause of reactivation of hepatitis B in susceptible patients),,0,,NO,NO,NO,4U5J,306.365,1,3,1,6,0,4,83.18,0.411764706,2.7,2.114,2.177,All fragments measured,1.8,1.8,2.14,2.314,11.63,3.67,8.7,4.5,Neutral,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79082,0.78549,0.99999,0.99967,0.88651,0.98659,0.84768,0.96969,0.25672,324.1,27.7,13.7,26.1
149709-62-6,SACUBITRIL,ENTRESTO,VC-001215230,5012,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)c2ccccc2)NC(=O)CCC(=O)O,TABLET,YES,NO,NO,NO,ORAL,194,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,42192,2015,Drugs@FDA,YES,YES,0.6,,High,Reported bioavailability,0.03,1.5,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,411.4908,2,4,2,6,0,12,92.7,0.375,1.08,1.08,4.469,All fragments measured,3.7,0.69,3.99,1.115,4.72,,4,,Acidic,Class 1B,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.48537,0.5735,0.50434,0.91917,0.72615,0.79222,0.76044,0.10729,0.93773,327.8,3.29,31.5,13
133865-89-1,SAFINAMIDE MESYLATE,XADAGO,PF-02449415,4921,C[C@@H](C(=O)N)NCc1ccc(cc1)OCc2cccc(c2)F,TABLET,YES,NO,NO,YES,ORAL,100,Prescription,,NO,NO,,,Pharmacia,major pharma,US WORLDMEDS LLC,nonprofit,42815,2017,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.11,2.4,23,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,302.3434,3,3,2,4,0,7,64.35,0.235294118,2.28,2.024,2.49,Benzyl approx. based on a priori value,1.7,1.3,2.16,2.092,,7.07,13,6.9,Basic,Class 2,0,1,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.82028,0.86969,0.99893,0.99233,0.9848,0.79222,0.97325,0.53315,0.93773,267.4,17.8,5.69,9.09
62989-33-7,SAPROPTERIN DIHYDROCHLORIDE,KUVAN,VC-000055307,2612,C[C@@H]([C@@H]([C@H]1CNc2c(c(=O)nc([nH]2)N)N1)O)O,"POWDER, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Daiichi Sankyo,pharma,BIOMARIN PHARM,pharma,39429,2007,Drugs@FDA,NO,NO,,,NA,NA,,,6.7,,,,,YES,Cardiovascular,YES,NO,,NO,NO,NO,NO,,None,,,,,,Less,0,,NO,NO,NO,1J8U,241.2471,7,4,6,8,1,2,136.29,0.555555556,-0.77,-0.77,-3.694,Valid estimate for difficult structure,-2.9,-2.9,-2.83,-3.567,,9.2,11,5.6,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,2,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,NO,0.23397,0.24764,0.72507,0.06787,0.33223,0.02306,0.36827,0.87038,0.47245,328.7,0.758,2.09,6.65
127779-20-8,SAQUINAVIR MESYLATE,INVIRASE,PF-00345563,2422,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)N)NC(=O)c4ccc5ccccc5n4)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,35039,1995,Drugs@FDA,NO,NO,0.07,,Low,Reported bioavailability,0.02,10,13,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (Possible rare cause of clinically apparent liver injury),,0,,NO,NO,NO,1HXB,670.8408,6,7,5,11,3,12,166.75,0.5,2.92,5.85,4.727,All fragments measured,3.6,3.6,4.14,4.111,11.05,6.3,11,7.7,Basic,Class 4,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.11397,0.15226,0.03816,0.93578,0.33223,0.05547,0.14839,0.07566,0.25672,707.8,1.14,33.3,252
1035979-44-2,SARECYCLINE HYDROCHLORIDE,SEYSARA,VC-001215229,,CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(c4C(=O)C3=C([C@@]2(C(=O)C(=C1O)C(=O)N)O)O)O)CN(C)OC,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Paratek Pharmaceuticals,pharma,ALMIRALL,pharma,43374,2018,Drugs@FDA,NO,NO,,0.72,High,Fa estimated from reported excretion data,0.25,1.3,21,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,1,Michael_acceptor,NO,YES,NO,,487.5024,6,8,5,11,2,5,173.86,0.458333333,-0.216,-0.216,0.032,Calculated fragment value,-0.43,-5.5,-0.25,-3.002,4.5,11.06,3.1,9.5,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.27688,0.21117,0.2025,0.31446,0.06191,0.05547,0.12211,0.84757,0.82734,539.5,1.51,2.43,11.8
361442-04-8,SAXAGLIPTIN HYDROCHLORIDE,ONGLYZA,PF-06780604,4114,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,ASTRAZENECA AB,major pharma,40025,2009,Drugs@FDA,NO,NO,0.67,,High,Reported bioavailability,1,2.2,2.5,Parent CRG,,183,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,None,None,LiverTox Additions,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),,0,,NO,NO,NO,3BJM,315.41,3,3,2,5,0,3,90.35,0.888888889,0.721,0.721,-0.023,Approximated fragment value used,0.086,0.052,0.71,-0.198,,8.3,16,5.2,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74228,0.74342,0.99334,0.5587,0.88651,0.79222,0.78301,0.87038,0.47245,374.8,5.04,6.47,10.8
3366-95-8,SECNIDAZOLE,SOLOSEC,PF-00346572,2427,Cc1ncc(n1CC(C)O)N(=O)=O,GRANULE,YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,Sanofi,major pharma,LUPIN,pharma,42993,2017,Drugs@FDA,NO,YES,,,NA,NA,0.95,0.6,17,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),None,1,Nitroorganics,NO,NO,NO,,185.1805,1,4,1,6,0,3,83.87,0.571428571,0.657,0.657,-0.148,All fragments measured,0.11,0.11,0.24,0.235,,2.62,11,2.8,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68481,0.7257,0.36209,0.48415,0.88651,0.98659,0.84177,0.99269,0.82734,216.8,27.8,6.99,6.65
309-43-3,SECOBARBITAL SODIUM,SECONAL SODIUM,PF-00344651,2428,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,CAPSULE,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,BARR,pharma,27491,1975,Drugs@FDA,NO,NO,,,High,Based on textual comment,0.45,1.5,19,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),,0,,NO,NO,NO,,238.2829,2,3,2,5,0,5,75.27,0.583333333,1.31,1.476,2.157,All fragments measured,2.1,2,1.92,1.779,7.81,,7.6,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74625,0.78926,0.70438,0.95312,0.9848,0.79222,0.90963,0.84757,0.47245,209.8,11.4,2.95,7.4
14611-51-9,SELEGILINE HYDROCHLORIDE,SELEGILINE HYDROCHLORIDE,PF-00344653,2429,C[C@H](Cc1ccccc1)N(C)CC#C,"CAPSULE, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,SOMERSET,pharma,32664,1989,Drugs@FDA,NO,NO,0.04,,Low,Reported bioavailability,0.15,1.9,10,Suicide,,,,YES,Neurological,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Alkynes,NO,NO,NO,,187.2808,0,1,0,1,0,4,3.24,0.384615385,1.96,2.8,3.024,All fragments measured,2.8,2.4,2.88,2.51,,7.53,,7.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65071,0.51808,0.37323,0.91194,0.23327,0.59178,0.26577,0.96969,0.82734,142.3,43.1,14.4,32
475086-01-2,SELEXIPAG,UPTRAVI,PF-06780710,5077,CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)c1cnc(c(n1)c2ccccc2)c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,3.2,Prescription,,NO,NO,,,Nippon Shinyaku,pharma,ACTELION PHARMS LTD,pharma,42359,2015,Drugs@FDA,NO,YES,0.49,,High,Reported bioavailability,0.01,0.2,0.8,,,,,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,496.6217,1,6,1,8,0,12,101.49,0.346153846,1.83,1.83,4.176,All fragments measured,4.7,2.4,4.02,2.079,4.52,2.39,3.9,2.8,Acidic,Class 3B,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.3189,0.36269,0.18105,0.86406,0.33223,0.98659,0.58446,0.10729,0.25672,445.7,3.57,29.6,119
1393477-72-9,SELINEXOR,XPOVIO,PF-06831112,,O=C(NNC1=NC=CN=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Karyopharm Therapeutics,pharma,KARYOPHARM THERAPS,pharma,43649,2019,Drugs@FDA,NO,NO,,,NA,NA,0.05,1.8,7,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,,,,,,,,,2,Hydrazines; Michael_acceptor,NO,YES,NO,,443.3062392,2,4,2,8,0,5,97.62,0.118,3.52,3.84,2.68,Benzyl approx. based on a priori value,2.8,1.8,2.9,2.923,9.74,1.9,8.8,2.6,Neutral,Class 2,0,6,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,5,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.51717,0.54292,0.34874,0.98521,0.52457,0.79222,0.71152,0.53315,0.25672,398.2,11.9,7.22,8.25
79617-96-2,SERTRALINE HYDROCHLORIDE,ZOLOFT,PF-00579897,2436,CN[C@H]1CC[C@H](c2c1cccc2)c3ccc(c(c3)Cl)Cl,"CONCENTRATE, TABLET",YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,PFIZER,major pharma,33602,1991,Drugs@FDA,NO,NO,,0.76,High,Fa estimated from reported excretion data,0.02,20,24,,15,,320472722,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,6AWO,306.2296,1,1,1,1,1,2,12.03,0.294117647,1.81,2.97,5.347,All fragments measured,4.7,2.6,5.18,3.103,,9.47,,10,Basic,Class 4,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.81736,0.62745,0.99999,0.47068,0.23327,0.98659,0.43308,0.87038,0.93773,239.2,2.91,16.3,29.7
106650-56-0,SIBUTRAMINE HYDROCHLORIDE,MERIDIA,PF-00346585,2440,CC(C)CC(C1(CCC1)c2ccc(cc2)Cl)N(C)C,CAPSULE,YES,NO,NO,NO,ORAL,15,Discontinued,2002,YES,YES,Increased risk of heart attack and stroke,FederalRegister,,,ABBOTT,major pharma,35756,1997,Drugs@FDA,NO,NO,0.77,,High,Reported bioavailability,0.03,,1.1,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (unproven but suspected rare cause of clinicallyapparent liver injury),Less,0,,NO,NO,NO,,279.848,0,1,0,1,1,5,3.24,0.647058824,2.57,3.167,5.587,All fragments measured,4.8,3.2,5.13,2.901,,9.69,,9.2,Basic,Class 2,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.68231,0.51487,0.94785,0.39335,0.23327,0.59178,0.26577,0.84757,0.82734,169.1,7.5,17.6,75
139755-83-2,SILDENAFIL CITRATE,VIAGRA,PF-01000000,2441,CCCc1c2c(c(=O)[nH]c(n2)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)C)n(n1)C,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,,,PFIZER,major pharma,35881,1998,Drugs@FDA,NO,NO,0.41,,High,Reported bioavailability,0.04,1.4,4,,46,,1046303894,NO,"Cardiovascular, Genitourinary",YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,C,Less,C (probable rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,1UDT,474.5764,1,5,1,10,0,7,113.42,0.5,2.19,2.715,1.981,All fragments measured,1.6,1.5,1.81,1.659,9.14,6.03,6.6,7.4,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60297,0.56881,0.23758,0.9785,0.33223,0.98659,0.50567,0.53315,0.93773,502.5,12,18.6,60.4
160970-54-7,SILODOSIN,RAPAFLO,PF-06780708,4151,C[C@H](Cc1cc2c(c(c1)C(=O)N)N(CC2)CCCO)NCCOc3ccccc3OCC(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,8,Prescription,,NO,NO,,,Kissei,pharma,ALLERGAN,major pharma,39729,2008,Drugs@FDA,NO,NO,0.32,,High,Reported bioavailability,0.03,0.7,13.3,,,,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinicallyapparent liver injury),Less,1,Aniline,YES,NO,NO,,495.5345,4,5,3,7,0,13,97.05,0.48,1.43,1.535,2.968,Benzyl approx. based on a priori value,3,2.1,2.62,1.16,,8.78,13,8.6,Basic,Class 4,0,3,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.286,0.38524,0.18347,0.96638,0.52457,0.37866,0.71728,0.05315,0.93773,437.3,3.33,10.1,36
923604-59-5,SIMEPREVIR SODIUM,OLYSIO,PF-06959637,4812,Cc1c(ccc2c1nc(cc2O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(CCCC/C=C/[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)c7nc(cs7)C(C)C)OC,CAPSULE,YES,NO,NO,YES,ORAL,150,Discontinued,,NO,NO,,,Medivir,pharma,JANSSEN PHARMS,major pharma,41600,2013,Drugs@FDA,NO,NO,0.62,,High,Reported bioavailability,0.001,,10,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,D,Less,D (possible rare cause of clinically apparent liver injury in susceptible individuals),,0,,NO,NO,NO,3KEE,749.9391,2,9,2,12,3,8,156.89,0.552631579,2.56,2.56,5.297,All fragments measured,5.8,2.4,4.49,3.076,5.55,4.15,4.1,6.9,Acidic,Class 3B,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,2,6,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,YES,0.24023,0.19487,0.03022,0.56047,0.10671,0.79222,0.07262,0.39983,0.25672,834.1,1.84,24.2,21.1
79902-63-9,SIMVASTATIN,ZOCOR,PF-00344654,2445,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,"SUSPENSION, TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,MERCK,major pharma,33595,1991,Drugs@FDA,NO,YES,0.05,,Low,Reported bioavailability,0.05,1.65,3,,8,110,1058871,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,418.5662,1,3,1,5,0,7,72.83,0.76,3.67,5.5,4.481,All fragments measured,5,5,4.6,4.603,,,15,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60104,0.6505,0.46608,0.63264,0.72615,0.98659,0.92631,0.53315,0.47245,402.8,8.2,34.3,269
1230487-00-9,SIPONIMOD FUMARIC ACID,MAYZENT,VC-001107422,,O=C(C1CN(CC2=CC=C(/C(C)=N/OCC3=CC=C(C4CCCCC4)C(C(F)(F)F)=C3)C=C2CC)C1)O,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,43550,2019,Drugs@FDA,NO,NO,0.84,,High,Reported bioavailability,0.001,1.8,30,,,,,NO,Autoimmune Disease,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,516.5950896,1,3,1,5,2,9,62.13,0.517,4.5,4.5,6.401,Benzyl approx. based on a priori value,6.6,4.3,6.66,4.15,2.69,9.15,3.4,8.3,Zwitter,Class 3B,0,3,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.44592,0.56317,0.14228,0.90346,0.72615,0.98659,0.98217,0.21184,0.93773,368.1,0.996,22,18.6
53123-88-9,SIROLIMUS,RAPAMUNE,PF-00835135,2446,C[C@@H]1CC[C@H]2C[C@@H](/C(=C\C=C\C=C[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,PFIZER,major pharma,36418,1999,Drugs@FDA,NO,NO,0.14,,Moderate,Reported bioavailability,0.08,12,61.3,,,,215729805,YES,Autoimmune Disease,YES,YES,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,1FKB,914.1719,3,12,3,14,3,6,195.43,0.745098039,3.88,6.43,7.039,A priori fragment value used,5.9,5.2,4.21,4.208,10.4,,9,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,1,0,4,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,YES,0.18692,0.12788,0.0271,0.10017,0.02416,0.37866,0.06921,0.6885,0.47245,992.7,0.113,18.3,102
486460-32-6,SITAGLIPTIN PHOSPHATE,JANUVIA,PF-03078939,2448,c1c(c(cc(c1F)F)F)C[C@H](CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,39006,2006,Drugs@FDA,NO,NO,0.87,,High,Reported bioavailability,0.62,2.8,12,,,17,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),None,0,,NO,NO,NO,1X70,407.3136,2,4,1,6,0,5,77.04,0.4375,1.04,0.2116,0.691,Approximated fragment value used,0.46,-0.29,1.17,1.085,,7.2,,8.4,Basic,Class 4,0,6,0,0,0,0,0,2,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,0,NO,0.81558,0.8467,0.52781,0.94807,0.88651,0.98659,0.89684,0.84757,0.93773,413,10.5,6.45,6.65
502-85-2,SODIUM OXYBATE,XYREM,PF-01018594,4566,C(CC(=O)O)CO,SOLUTION,YES,NO,NO,NO,ORAL,9,Prescription,,NO,NO,,,Jazz Pharmaceuticals ,pharma,JAZZ,pharma,37454,2002,Drugs@FDA,NO,NO,0.88,,High,Reported bioavailability,0.99,0.33,0.5,,,,,YES,Neurological,NO,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,104.1045,2,3,2,3,0,3,57.53,0.75,-1.73,-1.73,-0.581,All fragments measured,-0.47,-3.2,-0.64,-3.354,4.67,,4.6,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44121,0.54752,0.1068,0.3792,0.9848,0.79222,0.99536,0.99269,0.47245,65.51,2.57,6.17,6.65
1821-12-1,SODIUM PHENYLBUTYRATE,BUPHENYL,PF-01364636,24,c1ccc(cc1)CCCC(=O)O,"POWDER, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,HORIZON PHARMA INC,pharma,35185,1996,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,,0.2,0.76,,,,,YES,Genitourinary,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E,None,"E (unlikely cause of clinically apparent liver injury, but experience with its use is limited)",Less,0,,NO,NO,NO,,164.2011,1,2,1,2,0,4,37.3,0.3,-0.306,-0.306,2.282,All fragments measured,2.1,-0.44,2.29,-0.32,4.76,,4.6,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7118,0.78139,0.26487,0.98881,0.93048,0.98659,0.92207,0.96969,0.82734,94.6,27,16.6,8.12
1190307-88-0,SOFOSBUVIR,SOVALDI,VC-001215233,4811,C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)n2ccc(=O)[nH]c2=O)(C)F)O)Oc3ccccc3,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,41614,2013,Drugs@FDA,NO,YES,,0.8,High,Fa estimated from reported excretion data,0.35,,0.4,,,2,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury in susceptible individuals),Less,0,,NO,NO,NO,,529.4525,3,6,3,12,2,11,158.18,0.5,1.72,2.134,0.844,All fragments measured,0.61,0.6,0.72,0.717,9.37,,9.2,0.55,Neutral,Class 4,0,1,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,NO,0.29289,0.25875,0.12241,0.75274,0.10671,0.37866,0.16657,0.15134,0.82734,737,1.69,12.5,30.1
242478-37-1,SOLIFENACIN SUCCINATE,VESICARE,PF-02669968,2457,c1ccc(cc1)[C@H]2c3ccccc3CCN2C(=O)O[C@H]4CN5CCC4CC5,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,Astellas Pharma,major pharma,ASTELLAS,major pharma,38310,2004,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.02,8.2,45,,,117,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,362.4647,0,3,0,4,0,4,32.78,0.434782609,1.85,2.335,4.68,Benzyl approx. based on a priori value,4.4,3.3,3.79,2.122,,9.02,,8.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82137,0.85,0.80008,0.85502,0.9848,0.59178,0.86383,0.99269,0.93773,348.7,13.3,47.2,104
178429-62-4,SOLRIAMFETOL,SUNOSI,VC-001274382,,NC(OC[C@H](N)CC1=CC=CC=C1)=O,TABLET,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,SK Biopharmaceuticals,pharma,JAZZ,pharma,43544,2019,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.84,2.8,7.1,,,,,YES,Neurological,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,194.23044,4,3,2,4,0,5,78.34,0.3,-0.302,-0.302,0.626,All fragments measured,0.53,-0.23,0.84,0.676,,7.17,14,7.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.69852,0.76269,0.41188,0.75113,0.9848,0.79222,0.88693,0.84757,0.82734,168.1,8.68,4.1,6.65
956697-53-3,SONIDEGIB PHOSPHATE,ODOMZO,PF-05588470,5008,Cc1c(cccc1C(=O)Nc2ccc(nc2)N3C[C@H](O[C@H](C3)C)C)c4ccc(cc4)OC(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Novartis,major pharma,SUN PHARM INDUSTRIES,pharma,42209,2015,Drugs@FDA,NO,NO,0.1,,Low,Reported bioavailability,0.03,131,672,,,,,NO,Oncology,NO,NO,,NO,YES,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,0,,NO,NO,NO,,485.4981,1,3,1,6,1,5,63.69,0.307692308,4.43,5.6,5.84,All fragments measured,6.8,6.8,5.18,5.175,8.48,4.25,10,3.4,Neutral,Class 4,0,3,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,NO,0.33549,0.39758,0.20757,0.0612,0.72615,0.98659,0.97603,0.6885,0.25672,468,1.52,14.4,38.1
284461-73-0,SORAFENIB TOSYLATE,NEXAVAR,PF-01673287,2459,CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl,TABLET,YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,Bayer,major pharma,BAYER HEALTHCARE,major pharma,38687,2005,Drugs@FDA,NO,NO,0.38,,High,Reported bioavailability,0.005,,25,,,139,,YES,Oncology,NO,YES,II,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),,0,,NO,NO,NO,4ASD,464.8249,3,3,3,7,1,5,92.35,0.095238095,4.42,5.003,5.455,All fragments measured,4.8,4.8,4.26,4.264,12.89,3.7,11,2.7,Neutral,Class 4,0,3,0,0,1,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.43456,0.51683,0.26804,0.81086,0.88651,0.37866,0.76383,0.6885,0.25672,417.5,4.22,11.9,15.2
3930-20-9,SOTALOL HYDROCHLORIDE,BETAPACE,PF-00345466,2464,CC(C)NCC(c1ccc(cc1)NS(=O)(=O)C)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,320,Prescription,,NO,NO,,,,,COVIS PHARMA BV,pharma,33907,1992,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,1,1.3,12,,,,5792,YES,Cardiovascular,NO,NO,,YES,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,272.3638,3,4,3,5,0,6,78.43,0.5,-1.02,-1.752,0.226,All fragments measured,0.43,-1.6,0.29,-1.538,8.46,9.31,10,9.3,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66386,0.70853,0.9153,0.62783,0.88651,0.37866,0.8158,0.6885,0.82734,244.8,2.26,3.24,6.89
110871-86-8,SPARFLOXACIN,ZAGAM,PF-00345565,2466,C[C@@H]1CN(C[C@@H](N1)C)c2c(c(c3c(c2F)n(cc(c3=O)C(=O)O)C4CC4)N)F,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,2001,YES,NO,QTc prolongation and phototoxicity,WITHDRAWN,,,MYLAN PHARMS INC,pharma,35418,1996,Drugs@FDA,NO,NO,0.92,,High,Reported bioavailability,0.55,3.9,20,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Less,FEARS Addition ,1,,,,Moderate,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,,392.3998,4,4,3,7,0,3,100.59,0.473684211,1.06,-0.2036,-0.605,All fragments measured,2.7,-0.37,0.04,-2.199,5.9,8.59,6,8.5,Zwitter,Class 3A,0,2,0,0,0,0,0,1,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,2,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.54236,0.51056,0.616,0.20341,0.33223,0.37866,0.6985,0.99269,0.82734,442.3,2.47,3.32,10.1
83647-97-6,SPIRAPRIL HYDROCHLORIDE,RENORMAX,PF-00345564,2474,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3,TABLET,YES,NO,NO,NO,ORAL,6,Discontinued,,NO,NO,,,,,SCHERING,major pharma,34697,1994,Drugs@FDA,NO,YES,0.5,,High,Reported bioavailability,0.14,3.9,0.8,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,466.614,2,7,2,7,0,11,95.94,0.590909091,0.132,0.132,1.046,Approximated fragment value used,2.7,-0.79,2.94,-0.697,2.99,5.28,3.1,5.1,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.4235,0.37326,0.26218,0.5657,0.19128,0.79222,0.25625,0.21184,0.82734,453.8,0.986,29,12.7
52-01-7,SPIRONOLACTONE,ALDACTONE,PF-00344589,2475,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,GD SEARLE,major pharma,21936,1960,Drugs@FDA,NO,NO,0.73,,High,Reported bioavailability,0.1,10,1.4,,,,67750266,NO,Cardiovascular,NO,NO,,YES,NO,NO,YES,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,Thiol_Disulfide,NO,NO,NO,2AB2,416.5735,0,4,0,4,0,2,60.44,0.791666667,2.29,2.632,2.839,Valid estimate for difficult structure,2.9,2.9,2.78,2.78,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64055,0.67563,0.47666,0.92434,0.72615,0.59178,0.82539,0.87038,0.47245,448.9,16.7,22.9,25.5
10418-03-8,STANOZOLOL,WINSTROL,PF-00346459,2477,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(Cc5cn[nH]c5C4)C,TABLET,YES,NO,NO,NO,ORAL,2,Discontinued,,NO,NO,,,,,LUNDBECK PHARMS LLC,pharma,22655,1962,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,NO,YES,,,Suzuki Additions,1,,,,,0,,NO,NO,NO,,328.4916,2,2,2,3,0,0,48.91,0.857142857,4.18,4.23,4.56,All fragments measured,4.2,4.2,4.79,4.796,,3.85,15,6.6,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,8,0,0,0,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73083,0.7947,0.963,0.86673,0.93048,0.79222,0.99547,0.39503,0.82734,352.5,23.6,71.6,58.6
3056-17-5,STAVUDINE,ZERIT,PF-00345567,2478,Cc1cn(c(=O)[nH]c1=O)[C@H]2C=C[C@H](O2)CO,"CAPSULE; CAPSULE, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,80,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,34509,1994,Drugs@FDA,NO,NO,0.864,,High,Reported bioavailability,1,0.5,1.6,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Less,0,,NO,NO,NO,,224.2133,2,4,2,6,0,2,84.32,0.4,-0.375,-0.375,-0.488,All fragments measured,-0.71,-0.72,-0.67,-0.674,9.55,,9.4,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.61224,0.65149,0.60548,0.3227,0.88651,0.79222,0.88283,0.87038,0.47245,304.8,3.19,2.61,10.2
49763-96-4,STIRIPENTOL,DIACOMIT,PF-04087763,2480,CC(C)(C)C(/C=C/c1ccc2c(c1)OCO2)O,"CAPSULE, FOR SUSPENSION",YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,Biocodex,pharma,BIOCODEX SA,pharma,43332,2018,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.01,1.03,4.5,,,,,YES,Neurological,NO,NO,,YES,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,1,BenzoDioxolane,NO,NO,NO,,234.2909,1,1,1,3,0,2,38.69,0.428571429,2.05,2.643,3.209,All fragments measured,3.1,3.1,2.8,2.804,,,16,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.88361,0.90693,0.67631,0.99853,0.9848,0.98659,0.93652,0.99269,0.82734,198.7,22,23.6,23.4
304-55-2,SUCCIMER,CHEMET,VC-001215430,2486,[C@@H]([C@@H](C(=O)O)S)(C(=O)O)S,CAPSULE,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,RECORDATI RARE,pharma,33268,1991,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,,,,,,,,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Thiol_Disulfide,NO,NO,NO,,182.218,2,6,2,4,0,3,74.6,0.5,-1.17,-1.17,-1.476,All fragments measured,-0.44,-5.7,1.33,-3.411,2.74,,2.3,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.41346,0.3968,0.34681,0.55997,0.52457,0.14694,0.22061,0.99269,0.47245,169.1,1.54,5.59,6.65
17784-12-2,SULFACYTINE,RENOQUID,PF-05610119,2499,CCn1ccc(nc1=O)NS(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,2000,Discontinued,,NO,NO,,,,,GLENWOOD,pharma,27649,1975,Drugs@FDA,NO,NO,,,NA,NA,,,4,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,294.3296,3,4,2,7,0,4,107.08,0.166666667,0.272,0.272,-0.327,All fragments measured,0.15,-0.46,-0.47,-2.464,2.78,3.36,7.1,3.4,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8177,0.75108,0.98939,0.53736,0.72615,0.79222,0.54952,0.96969,0.82734,303.4,4.96,3.7,7.51
68-35-9,SULFADIAZINE,SULFADIAZINE,PF-00344914,2500,c1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,4000,Prescription,,NO,NO,,,,,LEDERLE,major pharma,15199,1941,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.62,0.29,7,,,,4505243,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,1,Aniline,YES,NO,NO,,250.277,3,4,2,6,0,3,97.97,0,-0.237,-1.192,0.1,All fragments measured,0.11,-0.86,-0.07,-0.791,6.81,1.57,6.6,2,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8065,0.76214,0.78653,0.57079,0.72615,0.79222,0.62127,0.99269,0.93773,241.2,18.1,4.36,6.65
122-11-2,SULFADIMETHOXINE,MABRIDON,PF-00345151,2501,COc1cc(nc(n1)OC)NS(=O)(=O)c2ccc(cc2)N,N/A,N/A,N/A,N/A,NO,ORAL,1000,Discontinued,1966,YES,YES,Stevens-Johnson syndrome and fatalities,FederalRegister,,,HOFFMANN-LA ROCHE,major pharma,21186,1958,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,Less,,,,,,Less,1,Aniline,YES,NO,NO,,310.329,3,6,2,8,0,5,116.43,0.166666667,0.355,0.355,1.981,All fragments measured,1.6,0.23,1.46,-0.477,6.21,3,6.1,1.9,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85714,0.6941,0.99859,0.85648,0.33223,0.79222,0.43382,0.84757,0.93773,332.7,12.3,6.99,10.6
2447-57-6,SULFADOXINE,FANSIDAR,PF-00345150,2503,COc1c(ncnc1OC)NS(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,1500,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,29887,1981,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,C,Less,C (probable cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,,310.329,3,6,2,8,0,5,116.43,0.166666667,-0.645,-0.645,1.231,All fragments measured,0.52,-1,0.79,-1.08,6.16,1.77,6.2,2.4,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83614,0.6784,0.99859,0.72971,0.33223,0.79222,0.43382,0.84757,0.93773,327.9,7,3.75,10.8
127-79-7,SULFAMERAZINE,TRIPLE SULFAS,PF-00344831,2510,Cc1ccnc(n1)NS(=O)(=O)c2ccc(cc2)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,LEDERLE,major pharma,18126,1949,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,None,1,Aniline,YES,NO,NO,,264.3036,3,4,2,6,0,3,97.97,0.090909091,-0.515,-0.515,0.599,All fragments measured,0.51,-0.35,0.4,0.039,7.35,1.58,6.8,2.5,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.84401,0.78963,0.87315,0.6589,0.72615,0.79222,0.62127,0.99269,0.93773,264.4,8.66,3.23,8.41
651-06-9,SULFAMETER,SULLA,PF-00345544,2511,COc1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,500,Discontinued,,NO,NO,,,,,BAYER HEALTHCARE,major pharma,24289,1966,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,280.303,3,5,2,7,0,4,107.2,0.090909091,-0.199,-0.199,0.648,All fragments measured,0.31,-0.54,0.36,-0.543,6.58,1.48,7,2.1,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82815,0.72633,0.9496,0.5657,0.52457,0.79222,0.52533,0.96969,0.93773,271.9,7.69,3.61,7.34
57-68-1,SULFAMETHAZINE,TRIPLE SULFAS,PF-00344656,2502,Cc1cc(nc(n1)NS(=O)(=O)c2ccc(cc2)N)C,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,1336,Discontinued,,NO,NO,,,,,LEDERLE,major pharma,18126,1949,Drugs@FDA,YES,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Less,,,,,,None,1,Aniline,YES,NO,NO,,278.3302,3,4,2,6,0,3,97.97,0.166666667,0.162,0.162,1.097,All fragments measured,0.93,0.17,0.44,0.302,7.89,1.08,7,2.9,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87409,0.81172,0.94181,0.74106,0.72615,0.79222,0.62127,0.99269,0.93773,264.5,13.9,4.23,12.4
144-82-1,SULFAMETHIZOLE,THIOSULFIL,PF-00345085,2512,Cc1nnc(s1)NS(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,4000,Discontinued,,NO,NO,,,,,WYETH,major pharma,19660,1953,Drugs@FDA,NO,NO,,0.98,High,Fa estimated from reported excretion data,0.1,,1.5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Aniline,YES,NO,NO,,270.3313,3,5,2,6,0,3,97.97,0.111111111,-0.691,-0.691,0.418,All fragments measured,0.41,-1.7,0.54,-1.176,5.51,1.19,5.3,2.9,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.82177,0.71483,0.90531,0.56825,0.72615,0.79222,0.3462,0.99269,0.93773,281.2,3.09,3.02,9.02
723-46-6,SULFAMETHOXAZOLE,GANTANOL,PF-00344588,2514,Cc1cc(no1)NS(=O)(=O)c2ccc(cc2)N,"SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,3,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,26875,1973,Drugs@FDA,NO,NO,,1,High,Fa estimated from reported excretion data,0.3,0.3,10,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,FEARS Addition ,1,,,,Moderate,1,Aniline,YES,NO,NO,3TZF,253.2776,3,3,2,6,0,3,98.22,0.1,-0.197,0.3185,0.563,All fragments measured,1.1,0.11,0.65,-0.556,5.81,1.39,5.8,2.1,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83841,0.80857,0.80616,0.693,0.88651,0.79222,0.61865,0.99269,0.93773,263.8,2.22,4.11,7.7
526-08-9,SULFAPHENAZOLE,SULFABID,PF-00345514,2523,c1ccc(cc1)n2c(ccn2)NS(=O)(=O)c3ccc(cc3)N,TABLET,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,PURDUE PHARMA LP,pharma,27121,1974,DrugCentral,NO,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,314.3623,3,3,2,6,0,4,90.01,0,0.581,0.581,2.067,All fragments measured,1.5,0.32,1.68,1.142,6.47,1.79,5.6,1.8,Acidic,Class 1A,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.74599,0.73503,0.99474,0.94713,0.88651,0.79222,0.7037,0.96969,0.25672,294.5,12.7,12.9,14
144-83-2,SULFAPYRIDINE,SULFAPYRIDINE,PF-00344748,2524,c1ccnc(c1)NS(=O)(=O)c2ccc(cc2)N,TABLET,YES,NO,NO,NO,ORAL,6000,Discontinued,,NO,NO,,,,,ELI LILLY AND CO,major pharma,14313,1939,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.9,0.8,6.5,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,249.2889,3,3,2,5,0,3,85.08,0,0.673,0.673,0.836,All fragments measured,1,0.88,0.47,0.402,8.54,2.13,8.1,2.5,Neutral,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.84811,0.83911,0.77996,0.76286,0.88651,0.79222,0.75302,0.99269,0.93773,237.1,11.8,3.34,6.65
599-79-1,SULFASALAZINE,AZULFIDINE,PF-00344658,2525,c1ccnc(c1)NS(=O)(=O)c2ccc(cc2)/N=N/c3ccc(c(c3)C(=O)O)O,"SUSPENSION, TABLET, TABLET, DELAYED RELEASE",YES,YES,NO,NO,ORAL,4000,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,18434,1950,Drugs@FDA,NO,YES (Presystemic),0.15,,Moderate,Reported bioavailability,0.007,0.11,12.6,,,,88909147,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,398.3926,3,8,3,9,0,6,141.31,0,0.2,0.2,3.88,All fragments measured,3.6,0.15,3.37,0.217,2.88,,2.3,0.94,Acidic,Class 3A,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50431,0.40176,0.57984,0.96498,0.19128,0.37866,0.23586,0.6885,0.25672,386.7,1.96,16.7,13
72-14-0,SULFATHIAZOLE,N/A,PF-00345452,2527,c1cc(ccc1N)S(=O)(=O)Nc2nccs2,N/A,N/A,N/A,N/A,NO,ORAL,3000,Discontinued,1970,YES,YES,"Renal complications, rash, fever, blood dyscrasias, and liver damage",FederalRegister,,,ORTHO MCNEIL,major pharma,15342,1942,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,None,1,Aniline,YES,NO,NO,3TYE,255.3167,3,3,2,5,0,3,85.08,0,0.381,0.381,0.726,All fragments measured,0.71,-0.45,0.42,0.033,7.24,2.19,7.3,2.4,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8284,0.77082,0.81921,0.65067,0.88651,0.79222,0.46398,0.99269,0.93773,256.3,4.35,3.7,6.65
57-96-5,SULFINPYRAZONE,ANTURANE,PF-00345087,2528,c1ccc(cc1)N2C(=O)C(C(=O)N2c3ccccc3)CCS(=O)c4ccccc4,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,800,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,21683,1959,Drugs@FDA,NO,NO,0.93,,High,Reported bioavailability,0.02,0.12,4,,,,,NO,Metabolic Disease,NO,NO,,NO,NO,YES,NO,,,,,,,,,0,,NO,NO,NO,,404.4815,0,3,0,5,0,6,57.69,0.130434783,0.932,0.5405,1.655,All fragments measured,2.7,2.7,2.28,-0.22,2.75,,2.9,,Acidic,Class 3B,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.57586,0.64943,0.54406,0.9683,0.9848,0.59178,0.89781,0.6885,0.25672,392.9,7.1,11.1,28.1
127-69-5,SULFISOXAZOLE,GANTRISIN,PF-00345088,2529,Cc1c(noc1NS(=O)(=O)c2ccc(cc2)N)C,TABLET,YES,NO,NO,NO,ORAL,8000,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,17743,1948,PharmaPendium,NO,NO,1,,High,Reported bioavailability,0.15,0.17,7,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,Moderate,1,Aniline,YES,NO,NO,,267.3042,3,3,2,6,0,3,98.22,0.181818182,-0.187,-1.164,0.222,All fragments measured,0.79,-1.9,0.85,-0.77,4.83,1.52,4.8,2.1,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86787,0.82964,0.88961,0.75193,0.88651,0.79222,0.61865,0.99269,0.93773,282.6,2.65,1.66,6.65
80-74-0,SULFISOXAZOLE ACETYL,GANTRISIN,PF-01462546,4458,Cc1c(noc1N(C(=O)C)S(=O)(=O)c2ccc(cc2)N)C,"EMULSION, SUSPENSION, SYRUP",YES,NO,NO,NO,ORAL,12000,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,19697,1953,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.15,0.14,7,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,Moderate,1,Aniline,YES,NO,NO,,309.3409,2,2,1,7,0,4,106.5,0.230769231,0.68,0.68,1.026,Benzyl approx. based on a priori value,1.1,1.1,0.4,0.396,,,,1.4,Neutral,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92516,0.82757,0.99916,0.74924,0.72615,0.98659,0.53251,0.99269,0.93773,343,8.4,6.05,12.4
144-75-2,SULFOXONE SODIUM,DIASONE SODIUM,RS-051398,2533,c1cc(ccc1NCS(=O)O)S(=O)(=O)c2ccc(cc2)NCS(=O)O,"TABLET, DELAYED RELEASE",NO,YES,NO,NO,ORAL,990,Discontinued,,NO,NO,,,,,ABBVIE,major pharma,17096,1946,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,,,,,1,Aniline,YES,NO,NO,,404.4816,4,4,4,8,0,8,132.8,0.142857143,-1.91,-1.91,-1.212,Calculated fragment value,-5,-5,-1.26,-5.761,2.58,,2.4,4.2,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.44106,0.34488,0.54406,0.96867,0.19128,0.14694,0.10449,0.39983,0.93773,419,0.472,20.9,6.65
38194-50-2,SULINDAC,CLINORIL,PF-00344830,2534,CC\1=C(c2cc(ccc2/C1=C/c3ccc(cc3)S(=O)C)F)CC(=O)O,TABLET,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,MERCK,major pharma,28760,1978,Drugs@FDA,NO,YES,0.9,,High,Reported bioavailability,0.06,,7.8,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,356.4106,1,3,1,3,0,4,54.37,0.15,0.192,0.192,3.157,All fragments measured,3.1,0.24,3.37,0.295,4.26,,4.3,,Acidic,Class 3A,0,1,0,0,0,0,0,3,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.93113,0.93808,0.83514,0.94043,0.9848,0.98659,0.92132,0.96969,0.93773,309,6.68,3.9,37.4
103628-46-2,SUMATRIPTAN SUCCINATE,IMITREX,PF-00257403,2543,CNS(=O)(=O)Cc1ccc2c(c1)c(c[nH]2)CCN(C)C,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,34851,1995,Drugs@FDA,NO,NO,0.15,0.6,Moderate,Reported bioavailability,0.83,2.4,2.4,,43,,650687,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,3_Methyl_Indole,NO,NO,NO,,295.4004,2,3,2,5,0,6,65.2,0.428571429,0.112,-1.082,0.743,Benzyl approx. based on a priori value,1.5,-0.15,1.32,-0.563,11.31,9.49,10,8.7,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.84788,0.87765,0.99123,0.87192,0.9848,0.79222,0.92132,0.6885,0.93773,263.1,6.86,5.11,11.1
557795-19-4,SUNITINIB MALATE,SUTENT,PF-00262192,2544,CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C,CAPSULE,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,38743,2006,Drugs@FDA,NO,NO,,,NA,NA,0.05,31.9,40,,,115,925829878,NO,Oncology,NO,YES,I,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,"B (highly likely cause of clinically apparent liver injury, including hyperammonemic syndrome)",,2,Michael_acceptor; Pyrrole,NO,YES,NO,2Y7J,398.4738,3,3,3,6,0,7,77.23,0.363636364,2.24,2.231,2.998,All fragments measured,2.3,0.66,2.92,1.09,11.7,9.09,9.4,8.8,Basic,Class 4,0,1,0,0,0,0,0,3,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.62396,0.716,0.57935,0.99751,0.9848,0.37866,0.89535,0.53315,0.93773,376.1,4.71,16.1,31.2
40828-46-4,SUPROFEN,N/A,PF-00344750,2546,CC(c1ccc(cc1)C(=O)c2cccs2)C(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,800,Discontinued,1986,YES,YES,"Flank pain syndrome, nephrotoxicity",FederalRegister,,,ALCON,pharma,31404,1985,DrugCentral,NO,NO,0.92,,High,Reported bioavailability,0.01,0.2,3,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,None,,,,,,None,1,Thiophene,NO,NO,YES,,260.3083,1,3,1,3,0,4,54.37,0.142857143,-0.254,-0.254,2.538,All fragments measured,2.7,-0.33,3,-0.193,4.07,,4.2,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.93929,0.93557,0.84996,0.98004,0.9848,0.98659,0.8525,0.96969,0.93773,202.7,19.8,7.13,25.7
1030377-33-3,SUVOREXANT,BELSOMRA,VC-000722511,4881,Cc1ccc(c(c1)C(=O)N2CCN(CC[C@H]2C)c3nc4cc(ccc4o3)Cl)n5nccn5,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,41864,2014,Drugs@FDA,NO,NO,0.82,,High,Reported bioavailability,0.01,0.7,12,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,4S0V,450.9207,0,4,0,8,0,4,80.29,0.304347826,4.61,4.84,4.791,A priori fragment value used,5.9,5.9,3.34,3.39,,1.47,,1.2,Neutral,Class 2,0,0,0,0,1,0,0,4,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.38882,0.4439,0.31796,0.83197,0.72615,0.59178,0.8716,0.99269,0.03452,489.2,4.85,26.1,115
321-64-2,TACRINE HYDROCHLORIDE,COGNEX,PF-00345617,2551,c1ccc2c(c1)c(c3c(n2)CCCC3)N,CAPSULE,YES,NO,NO,NO,ORAL,160,Discontinued,2013,YES,NO,Hepatotoxicity,Martindale,,,SHIONOGI INC,pharma,34221,1993,Drugs@FDA,NO,NO,0.17,,Moderate,Reported bioavailability,0.45,5,3,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,,,Suzuki Additions,1,,,,,0,,NO,NO,NO,4BDS,198.2637,2,1,1,2,0,0,38.91,0.307692308,2.98,0.6727,3.274,All fragments measured,3.3,0.76,2.87,0.707,,9.82,,11,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66789,0.75435,0.43555,0.99996,0.93048,0.98659,0.93854,0.39503,0.93773,169,17.8,26,90.4
104987-11-3,TACROLIMUS,PROGRAF,PF-00579923,2552,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,"CAPSULE; CAPSULE, EXTENDED RELEASE, FOR SUSPENSION, TABLET, EXTENDED RELEASE",YES,NO,YES,YES,ORAL,10.5,Prescription,,NO,NO,,,,,ASTELLAS,major pharma,34432,1994,Drugs@FDA,NO,NO,0.25,,Moderate,Reported bioavailability,0.01,0.9,8.7,,86,66,49804039,YES,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,1FKF,804.0182,3,11,3,13,3,7,178.36,0.772727273,3.92,5.39,5.776,A priori fragment value used,4,3.9,4.1,4.075,9.97,,9.9,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,4,0,0,YES,0.23479,0.17296,0.02831,0.54423,0.02915,0.37866,0.10807,0.53315,0.47245,911.5,4.45,11.4,99.4
171596-29-5,TADALAFIL,CIALIS,PF-00346018,2553,CN1CC(=O)N2[C@@H](C1=O)Cc3c4ccccc4[nH]c3[C@H]2c5ccc6c(c5)OCO6,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Eli Lilly,major pharma,ELI LILLY AND CO,major pharma,37946,2003,Drugs@FDA,NO,NO,,0.97,High,Fa estimated from reported excretion data,0.06,1,15,,93,37,,YES,"Cardiovascular, Genitourinary",YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,1,BenzoDioxolane,NO,NO,NO,1UDU,389.404,1,2,1,7,0,1,74.87,0.272727273,2.4,2.508,2.584,Benzyl approx. based on a priori value,2,2,1.88,1.889,,,9.6,,Neutral,Class 1A,0,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,8,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65025,0.69785,0.63435,0.97345,0.88651,0.98659,0.91245,0.63709,0.25672,477.4,12.2,8.33,14
594839-88-0,TAFAMIDIS MEGLUMINE,VYNDAQEL,PF-06291826,4192,O=C(C1=CC=C2N=C(C3=CC(Cl)=CC(Cl)=C3)OC2=C1)O,CAPSULE,YES,NO,NO,YES,ORAL,80,Prescription,,NO,NO,,,Scripps Research Institute,pharma,PFIZER,major pharma,43588,2019,Drugs@FDA,NO,NO,,0.22,Moderate,Fa estimated from reported excretion data,0.001,0.3,49,,,,,YES,Neurological,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,308.11572,1,3,1,4,0,2,63.33,0,1.74,2.124,4.998,All fragments measured,5.2,1.9,4.66,1.649,3.49,,4.2,1.4,Acidic,Class 1A,0,0,0,0,2,0,0,3,1,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.74801,0.7747,0.99967,0.78939,0.9848,0.98659,0.97752,0.87038,0.25672,269,29.5,3.24,10.1
106635-80-7,TAFENOQUINE SUCCINATE,KRINTAFEL,GI-525781,3578,Cc1cc(nc2c1c(c(cc2NC(C)CCCN)OC)Oc3cccc(c3)C(F)(F)F)OC,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,GLAXOSMITHKLINE,major pharma,43301,2018,Drugs@FDA,NO,NO,,,NA,NA,0.005,22.9,360,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,463.4926,3,4,2,6,1,9,78.63,0.375,2.49,2.483,6.522,All fragments measured,6,3.2,4.55,1.817,,10.36,,10,Basic,Class 4,0,3,0,0,0,0,0,3,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.32863,0.3937,0.27248,0.26911,0.52457,0.79222,0.8847,0.21184,0.25672,423.5,0.683,13.7,12.1
1373431-65-2,TALAZOPARIB TOSYLATE,TALZENNA,PF-06944076,,Cn1c(ncn1)[C@H]2c3c4c(cc(cc4N[C@@H]2c5ccc(cc5)F)F)c(=O)[nH]n3,CAPSULE,YES,NO,NO,NO,ORAL,1,Prescription,,NO,NO,,,BioMarin,pharma,PFIZER,major pharma,43389,2018,Drugs@FDA,NO,NO,,0.69,High,Fa estimated from reported excretion data,0.26,6,,,,,4673134,NO,Oncology,YES,NO,,NO,NO,NO,NO,,None,,,E*,Ambiguous,E* (unproved but suspected cause of clinically apparent liver injury),None,1,Aniline,YES,NO,NO,,380.3509,2,3,2,7,0,2,88.49,0.157894737,2.56,1.791,0.351,All fragments measured,1.7,1.7,2.1,2.154,10.14,2.61,12,5,Neutral,Class 2,0,2,0,0,0,0,0,4,1,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,4,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,NO,0.67672,0.68919,0.69047,0.99183,0.72615,0.79222,0.839,0.87038,0.25672,421.2,9.25,7.06,19.1
115-44-6,TALBUTAL,LOTUSATE,PF-05239798,2556,CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,TABLET,YES,NO,NO,NO,ORAL,120,Discontinued,,NO,NO,Abuse potential,,,,SANOFI AVENTIS US,major pharma,19920,1954,PharmaPendium,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,224.2563,2,3,2,5,0,4,75.27,0.545454545,1.08,1.107,1.628,All fragments measured,1.6,1.5,1.66,1.513,7.81,,7.7,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.73502,0.77941,0.60578,0.88714,0.9848,0.79222,0.90963,0.96969,0.47245,203.8,9.58,2.24,7.21
10540-29-1,TAMOXIFEN CITRATE,NOLVADEX,PF-00344590,2561,CC/C(=C(/c1ccccc1)\c2ccc(cc2)OCCN(C)C)/c3ccccc3,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,ASTRAZENECA AB,major pharma,28489,1977,Drugs@FDA,NO,NO,,0.7,High,Fa estimated from reported excretion data,,,120,,,,691531,NO,Oncology,NO,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,371.5146,0,2,0,2,1,8,12.47,0.230769231,4.27,4.66,6.818,All fragments measured,6.2,5.1,6.82,5.65,,8.69,,8.3,Basic,Class 2,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.37832,0.40586,0.7453,0.09729,0.93048,0.59178,0.44264,0.39983,0.25672,227.2,54.5,6.53,8.63
106133-20-4,TAMSULOSIN HYDROCHLORIDE,FLOMAX,PF-00833929,2562,CCOc1ccccc1OCCN[C@H](C)Cc2ccc(c(c2)S(=O)(=O)N)OC,CAPSULE,YES,NO,NO,NO,ORAL,0.8,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35535,1997,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.01,0.21,9,,47,,3175148,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,408.5117,3,6,2,7,0,11,99.88,0.4,1.34,1.5,2.167,All fragments measured,2.5,1.5,2.14,0.772,10.08,8.78,9.9,8.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.52856,0.56537,0.52101,0.99937,0.52457,0.79222,0.60129,0.15134,0.93773,388.5,10.6,22.4,49.6
175591-09-0,TAPENTADOL HYDROCHLORIDE,NUCYNTA,VC-001213078,4283,CC[C@@H](c1cccc(c1)O)[C@@H](C)CN(C)C,"SOLUTION, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,600,Prescription,,NO,NO,,,Grunenthal ,pharma,DEPO NF,pharma,39772,2008,Drugs@FDA,NO,NO,0.32,,High,Reported bioavailability,0.8,7.71,4.5,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,YES,NO,None,None,DILIRank,0,,,,,0,,NO,NO,NO,,221.3385,1,2,1,2,0,5,23.47,0.571428571,1.35,1.308,3.154,All fragments measured,3.6,1.4,2.64,0.63,9.97,9.45,9.9,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.81643,0.82088,0.58552,0.96462,0.93048,0.98659,0.69082,0.84757,0.82734,158.5,19.3,49.5,22.2
609799-22-6,TASIMELTEON,HETLIOZ,VC-001215232,4820,CCC(=O)NC[C@@H]1C[C@H]1c2cccc3c2CCO3,CAPSULE,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Bristol-Meyers Squibb,major pharma,VANDA PHARMS INC,pharma,41670,2014,Drugs@FDA,NO,NO,0.38,,High,Reported bioavailability,0.1,1.3,1.3,,,,,YES,Neurological,NO,NO,,NO,YES,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,245.3169,1,2,1,3,0,4,38.33,0.533333333,2.3,2.534,1.886,All fragments measured,2.1,2.1,2.19,2.184,,,12,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.89613,0.90691,0.75313,0.97508,0.93048,0.98659,0.93296,0.96969,0.82734,227.3,17.4,21.6,22.1
869572-92-9,TECOVIRIMAT,TPOXX,VC-000478066,,c1cc(ccc1C(=O)NN2C(=O)[C@@H]3[C@@H]4C=C[C@H]([C@@H]3C2=O)[C@@H]5[C@H]4C5)C(F)(F)F,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,SIGA Technologies,pharma,SIGA TECHNOLOGIES,pharma,43294,2018,Drugs@FDA,NO,NO,,0.73,High,Fa estimated from reported excretion data,0.28,14.7,20,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,None,,,,,,Less,0,,NO,NO,NO,,376.3292,1,3,1,5,0,2,66.48,0.421052632,2.99,3.696,2.94,Calculated fragment value,1.4,-1.3,2.12,0.284,5.06,,10,,Neutral,Class 2,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.88951,0.9125,0.7155,0.95789,0.9848,0.98659,0.96322,0.99269,0.82734,393.2,23.2,14.2,12.4
856867-55-5,TEDIZOLID PHOSPHATE,SIVEXTRO,VC-001215431,4873,Cn1nc(nn1)c2ccc(cn2)c3ccc(cc3F)N4C[C@@H](OC4=O)COP(=O)(O)O,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Cubist,pharma,CUBIST PHARMS,pharma,41810,2014,Drugs@FDA,NO,YES (Presystemic),0.91,,High,Reported bioavailability,0.1,1,12,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of liver injury),,1,Aniline,YES,NO,NO,,450.3177,2,7,2,12,1,6,152.79,0.235294118,-1.92,-1.92,0.355,Calculated fragment value,1.9,-2.9,0.39,-3.882,1.81,1.04,0.86,4.1,Acidic,Class 3B,0,1,0,1,0,0,0,3,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,NO,0.49736,0.3298,0.32031,0.91899,0.06191,0.79222,0.1663,0.6885,0.25672,472.8,0.498,5.14,6.7
145158-71-0,TEGASEROD MALEATE,ZELNORM,PF-00579950,2579,CCCCCNC(=N)N/N=C/c1c[nH]c2c1cc(cc2)OC,TABLET,YES,NO,NO,NO,ORAL,6,Discontinued,2007,YES,YES,"Higher chance of heart attack, stroke, and unstable angina (heart/chest pain)",www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/zelnorm-tegaserod-maleate-information,Novartis,major pharma,US WORLDMEDS LLC,nonprofit,37461,2002,Drugs@FDA,NO,NO,0.11,0.33,Moderate,Reported bioavailability,0.02,5.3,,,89,,,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely causes of clinically apparent liver injury),None,0,,NO,NO,NO,,301.3867,4,3,4,6,0,9,85.29,0.375,0.523,0.523,2.807,Calculated fragment value,2.6,1.1,3.07,2.702,,9.65,11,12,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50747,0.61347,0.99832,0.99233,0.9848,0.14694,0.82938,0.29329,0.93773,258.7,2.24,41.1,52.4
402957-28-2,TELAPREVIR,INCIVEK,PF-03436659,4173,CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)c5cnccn5,TABLET,YES,NO,NO,YES,ORAL,2250,Discontinued,2014,YES,NO,"Serious skin reactions.  Official reason was ""available alternative treatments and the diminishing market demand""",WITHDRAWN,Vertex Pharmaceuticals,pharma,VERTEX PHARMS,pharma,40686,2011,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.24,3.6,10,Parent CRG,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,Ambiguous,FEARS Addition ,1,E*,Ambiguous,E* (unproven but suspected cause of liver injury),Most,0,,NO,NO,NO,,679.8493,4,8,4,13,3,14,179.56,0.722222222,3.29,4.66,5.351,Vinyl approx. based on a priori value,3.2,3.2,3.2,2.97,11.84,,10,2.5,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.15339,0.17355,0.0367,0.99884,0.19128,0.14694,0.10463,0.05315,0.82734,755.5,0.77,21.7,254
3424-98-4,TELBIVUDINE,TYZEKA,PF-02560709,4220,Cc1cn(c(=O)[nH]c1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,600,Discontinued,,NO,NO,,,Idenix (Merck & Co.),pharma,NOVARTIS,major pharma,39015,2006,Drugs@FDA,NO,NO,,0.42,High,Fa estimated from reported excretion data,0.967,,0.8,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Less,0,,NO,NO,NO,,242.2286,3,5,3,7,0,2,104.55,0.6,-1.05,-1.05,-1.385,All fragments measured,-1.3,-1.3,-1,-1.002,9.64,,9.5,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.49415,0.51768,0.73188,0.17288,0.72615,0.37866,0.69645,0.87038,0.47245,344.7,0.294,1.66,6.93
191114-48-4,TELITHROMYCIN,KETEK,PF-04087752,2581,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCn4cc(nc4)c5cccnc5)C,TABLET,YES,NO,NO,NO,ORAL,800,Discontinued,2016,YES,NO,Hepatotoxicity,N Engl J Med 2007(356)1601-1604. DOI: 10.1056/NEJMp078032,Sanofi,major pharma,SANOFI AVENTIS US,major pharma,38078,2004,Drugs@FDA,NO,NO,0.57,,High,Reported bioavailability,0.35,2.9,9.8,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),Less,1,Pyridine,NO,NO,NO,,812.0037,1,11,1,15,2,11,171.85,0.720930233,1.74,2.85,3.746,All fragments measured,3.1,1.8,4.35,3.682,10.85,8.13,12,8.8,Basic,Class 4,0,0,0,0,0,0,0,2,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,2,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,3,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,2,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,YES,0.25766,0.19301,0.02814,0.81216,0.02416,0.98659,0.12905,0.15134,0.93773,1012,2.79,35.9,102
144701-48-4,TELMISARTAN,MICARDIS,PF-00346561,2583,CCCc1nc2c(cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C)C,TABLET,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,,,BOEHRINGER INGELHEIM,major pharma,36109,1998,Drugs@FDA,NO,NO,0.42,,High,Reported bioavailability,0.005,5.3,24,,,125,1650150,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (Unproved but suspected rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,3VN2,514.6169,1,4,1,6,2,7,72.94,0.181818182,3.64,2.44,7.293,Very high LogP unrealistic in nature,7.7,4.4,7,4.372,3.86,5.01,3.6,6.5,Zwitter,Class 1B,0,0,0,0,0,0,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.15698,0.21286,0.14566,0.03015,0.88651,0.98659,0.92558,0.53315,0.01044,454.9,0.293,9.64,16
1033805-22-9,TELOTRISTAT ETIPRATE,XERMELO,VC-001215434,5214,CCOC(=O)[C@H](Cc1ccc(cc1)c2cc(nc(n2)N)O[C@H](c3ccc(cc3n4ccc(n4)C)Cl)C(F)(F)F)N,TABLET,YES,NO,NO,YES,ORAL,750,Prescription,,NO,NO,,,Symphony Icon (Lexicon Pharmaceuticals),pharma,LEXICON PHARMS INC,pharma,42794,2017,Drugs@FDA,NO,YES,,,NA,NA,0.01,,,,,,,YES,Metabolic Disease,YES,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,574.9819,4,6,2,9,2,10,131.17,0.259259259,3.76,4.8,5.357,Benzyl approx. based on a priori value,4.4,4.2,4.81,4.658,,6.72,,7,Basic,Class 4,0,3,0,0,1,0,0,4,0,2,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,6,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,4,0,0,0,0,NO,0.15439,0.17348,0.07531,0.21115,0.19128,0.79222,0.37562,0.15134,0.03452,548.8,0.665,28.3,47.6
105784-61-0,TEMAFLOXACIN HYDROCHLORIDE,OMNIFLOX,VC-001229291,2584,CC1CN(CCN1)c2cc3c(cc2F)c(=O)c(cn3c4ccc(cc4F)F)C(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,1200,Discontinued,1992,YES,YES,"Hypoglycemia in elderly patients, as well as a constellation of multisystem organ involvement characterized by hemolytic anemia, frequently associated with renal failure",FederalRegister,,,ABBOTT,major pharma,33604,1992,NIH NCATS,NO,NO,0.9,,High,Reported bioavailability,,,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,Gerren Additions,1,,,,,2,Aniline; Quinolones_Naphthyridinones,YES,NO,NO,,417.3811,2,4,2,6,0,3,74.57,0.238095238,0.998,0.998,1.374,All fragments measured,3.5,0.68,0.32,-2.048,5.69,8.74,5.8,8.7,Zwitter,Class 3B,0,3,0,0,0,0,0,2,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.73967,0.73229,0.47235,0.66739,0.52457,0.79222,0.92598,0.99269,0.93773,443.7,3.59,3.25,7.35
846-50-4,TEMAZEPAM,RESTORIL,PF-00344752,2585,CN1c2ccc(cc2C(=NC(C1=O)O)c3ccccc3)Cl,CAPSULE,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,,,SPECGX LLC,pharma,29644,1981,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,0.04,1.4,12.3,,,,457226,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (Unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,300.7396,1,2,1,4,0,1,52.9,0.125,2.04,2.186,2.34,All fragments measured,2.2,2.2,2.11,2.113,11.66,1.58,8.9,1.5,Neutral,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.89295,0.92439,0.99782,0.99582,0.9848,0.98659,0.99999,0.63709,0.93773,307.3,32.9,7.29,7.57
85622-93-1,TEMOZOLOMIDE,TEMODAR,PF-00579922,2589,Cn1c(=O)n2cnc(c2nn1)C(=O)N,CAPSULE,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,MERCK,major pharma,36383,1999,Drugs@FDA,NO,NO,0.98,,High,Reported bioavailability,0.85,0.4,1.9,Parent CRG,157,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,194.1508,2,5,1,8,0,1,108.17,0.166666667,-0.0479,-0.0479,-0.811,Valid estimate for difficult structure,-1.1,-1.1,-0.99,-0.989,,,13,2.2,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.63417,0.64692,0.41143,0.48792,0.72615,0.98659,0.62555,0.63709,0.82734,243.3,22,2.16,8.67
379270-37-8,TENOFOVIR ALAFENAMIDE FUMARATE,VEMLIDY,VC-001215235,4944,C[C@H](Cn1cnc2c1ncnc2N)OCP(=O)(N[C@@H](C)C(=O)OC(C)C)Oc3ccccc3,TABLET,YES,NO,NO,NO,ORAL,25,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,42684,2016,Drugs@FDA,NO,YES,,0.68,High,Fa estimated from reported excretion data,0.2,,0.5,,,81,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E,None,E (Unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,1T03,476.4659,3,6,2,11,1,12,143.48,0.428571429,2.52,2.801,2.18,Calculated fragment value,2,2,2.24,2.081,,4.21,,4.5,Neutral,Class 4,0,0,0,1,0,0,0,3,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,NO,0.31105,0.26935,0.23209,0.88856,0.10671,0.79222,0.2142,0.10729,0.25672,619.4,2.8,15.7,74
201341-05-1,TENOFOVIR DISOPROXIL FUMARATE,VIREAD,PF-06785702,2593,C[C@H](Cn1cnc2c1ncnc2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,"POWDER, TABLET",YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,37190,2001,Drugs@FDA,NO,YES,0.25,,Moderate,Reported bioavailability,,1.2,17,,66,19,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,,,E,None,E (Unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,519.4428,2,7,1,15,2,17,185.44,0.631578947,1.04,1.043,0.801,All fragments measured,-0.95,-0.95,1.52,1.517,,4.2,,4.5,Neutral,Class 2,0,0,0,1,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,2,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,NO,0.23168,0.16424,0.13756,0.91566,0.02183,0.98659,0.06951,0.01822,0.93773,537.4,4.35,68.2,14.9
63590-64-7,TERAZOSIN HYDROCHLORIDE,HYTRIN,PF-00344832,3584,COc1cc2c(cc1OC)nc(nc2N)N3CCN(CC3)C(=O)C4CCCO4,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,ABBOTT,major pharma,31996,1987,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.08,0.4,12,,,,,NO,"Cardiovascular, Genitourinary",NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,387.4329,2,6,1,9,0,5,103.04,0.526315789,1.57,1.045,2.182,Approximated fragment value used,2,1.8,0.55,0.493,,6.52,,7.3,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.83829,0.67316,0.6465,0.86093,0.19128,0.98659,0.6558,0.96969,0.93773,422.7,15.5,2.41,9.22
91161-71-6,TERBINAFINE HYDROCHLORIDE,LAMISIL,PF-00579927,2597,CC(C)(C)C#C/C=C/CN(C)Cc1cccc2c1cccc2,"GRANULE, TABLET",YES,NO,NO,NO,ORAL,250,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,35195,1996,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,0.01,13.5,22,,,,790031,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (highly likely cause of clinically apparent liver injury),Moderate,1,Alkynes,NO,NO,NO,,291.4299,0,1,0,1,1,3,3.24,0.333333333,3.65,6.2,5.96,All fragments measured,5.1,4.9,6.01,5.885,,6.92,,7,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65294,0.49896,0.98351,0.33049,0.23327,0.59178,0.26577,0.6885,0.93773,182,4.61,47.3,65
23031-25-6,TERBUTALINE SULFATE,BRICANYL,PF-00344659,2598,CC(C)(C)NCC(c1cc(cc(c1)O)O)O,TABLET,YES,NO,NO,NO,ORAL,15,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,27506,1975,Drugs@FDA,NO,NO,0.14,0.62,Moderate,Reported bioavailability,,1.5,11,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,225.2842,4,4,4,4,0,3,72.72,0.5,-0.779,-1.297,0.482,All fragments measured,0.93,-0.39,0.52,-1.609,9.11,9.65,9.5,8.8,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56574,0.65219,0.61296,0.84523,0.88651,0.14694,0.92703,0.96969,0.82734,179.7,0.435,3.09,8.79
50679-08-8,TERFENADINE,SELDANE,PF-00344593,2600,CC(C)(C)c1ccc(cc1)C(CCCN2CCC(CC2)C(c3ccccc3)(c4ccccc4)O)O,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,1997,YES,YES,risk of cardiac arrhythmia caused by QT interval prolongation,FederalRegister,,,MERRELL,pharma,31175,1985,PharmaPendium,NO,NO,,0.7,High,Fa estimated from reported excretion data,0.03,3.4,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,Gerren Additions,0,,,,,0,,NO,NO,NO,,471.6734,2,3,2,3,1,8,43.7,0.4375,3.59,4.42,6.073,All fragments measured,6.5,5.4,5.67,3.664,,9.42,15,9,Basic,Class 4,0,0,0,0,0,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.28887,0.37842,0.24627,0.07879,0.9848,0.79222,0.97499,0.29329,0.25672,299.4,0.995,13.1,83.4
163451-81-8,TERIFLUNOMIDE,AUBAGIO,PF-01484535,4634,C/C(=C(\C#N)/C(=O)Nc1ccc(cc1)C(F)(F)F)/O,TABLET,YES,NO,NO,NO,ORAL,14,Prescription,,NO,NO,,,Genzyme,major pharma,SANOFI AVENTIS US,major pharma,41164,2012,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,0.01,0.16,432,,,92,98608,NO,Autoimmune Disease,YES,NO,,NO,NO,NO,NO,,Less,,,D,Less,D (possible cause of clinically apparent liver injury but experience with its use is limited),Moderate,2,Aniline; Michael_acceptor,YES,YES,NO,,270.2073,2,2,2,4,0,2,73.12,0.166666667,1.25,1.25,2.132,All fragments measured,3.9,2.4,2.06,-0.372,5.2,,8.5,,Acidic,Class 1A,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.89613,0.91011,0.90469,0.96523,0.9848,0.79222,0.92439,0.99269,0.82734,209,18.7,3.16,23.9
968-93-4,TESTOLACTONE,TESLAC,PF-00346546,2606,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC(=O)O2)CCC4=CC(=O)C=C[C@]34C,TABLET,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,25715,1970,Drugs@FDA,NO,NO,,0.94,High,Fa estimated from reported excretion data,,,,,,,,NO,Oncology,YES,NO,,NO,NO,NO,NO,,None,,,,,,None,0,,NO,NO,NO,,300.3921,0,2,0,3,0,0,43.37,0.684210526,2.43,2.323,2.633,All fragments measured,2.5,2.5,3.07,3.068,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64659,0.72363,0.99752,0.98412,0.9848,0.59178,0.97306,0.39503,0.47245,310.7,18.9,73.9,19
5949-44-0,TESTOSTERONE UNDECANOATE,JATENZO,PF-06241316,2608,CCCCCCCCCCC(O[C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O,CAPSULE,YES,NO,NO,YES,ORAL,792,Prescription,,NO,NO,,,Clarus Therapeutics,pharma,CLARUS,pharma,43551,2019,Drugs@FDA,NO,YES,,,NA,NA,,,,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,,,,,1,1_4_Diketones,NO,NO,NO,,456.70032,0,2,0,3,1,11,43.37,0.867,4.66,6.34,9.116,Very high LogP unrealistic in nature,8.4,8.4,9.07,9.072,,,,,Neutral,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,6,0,0,0,6,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.22972,0.31792,0.29624,0.02732,0.9848,0.59178,0.97306,0.15134,0.47245,375.4,0.558,138,23.9
58-46-8,TETRABENAZINE,XENAZINE,VC-001215435,2609,CC(C)C[C@H]1CN2CCc3cc(c(cc3[C@@H]2CC1=O)OC)OC,TABLET,YES,NO,NO,NO,ORAL,50,Prescription,,NO,NO,,,Life Health,pharma,VALEANT,pharma,39675,2008,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.18,,17.5,,,,,YES,Neurological,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,317.4226,0,4,0,4,0,4,38.77,0.631578947,2.04,1.952,3.465,All fragments measured,2.9,1.8,3.17,3.122,,6.46,,7.9,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85685,0.87124,0.99021,0.97543,0.88651,0.59178,0.9373,0.96969,0.82734,295.3,30.4,34.8,40.1
60-54-8,TETRACYCLINE HYDROCHLORIDE,ACHROMYCIN V,PF-00344662,2611,C[C@]1(c2cccc(c2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O,"CAPSULE, SUSPENSION",YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,LEDERLE,major pharma,20116,1955,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.95,,9,,,,1179269,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A[HD],Most,A[HD] (well known cause of clinically apparent liver injury but usually when given in high doses intravenously),Less,1,Michael_acceptor,NO,YES,NO,5J5B,444.4346,7,9,6,10,1,2,181.62,0.409090909,-0.909,-0.3032,-0.896,Valid estimate for difficult structure,-0.87,-5.9,-0.76,-3.553,4.5,11.02,3.3,9.5,Zwitter,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.25122,0.20287,0.34402,0.23439,0.10671,0.02306,0.09897,0.87038,0.82734,523.2,2.07,2.72,7.11
1152311-62-0,TEZACAFTOR,TRIKAFTA,PF-06469672,5276,O=C(C1(CC1)C2=CC=C(OC(F)(F)O3)C3=C2)NC4=CC5=C(N(C[C@@H](O)CO)C(C(C)(C)CO)=C5)C=C4F,TABLET,YES,NO,NO,YES,ORAL,100,Prescription,,NO,NO,,,Vertex Pharmaceuticals,pharma,VERTEX PHARMS,pharma,43759,2019,Drugs@FDA,YES,NO,,,NA,NA,0.01,1.2,17.4,,,,,YES,Respiratory,NO,NO,,NO,NO,YES,NO,,,,,,,,,1,Aniline,YES,NO,NO,,520.4976696,4,4,4,8,1,8,113.18,0.423,3.25,4.8,3.679,All fragments measured,3.9,3.9,2.59,2.587,,,13,,Neutral,Class 4,0,3,0,0,0,0,0,3,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,4,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.2389,0.30086,0.13586,0.37738,0.52457,0.14694,0.55004,0.39983,0.25672,507,4.67,18.1,25.6
50-35-1,THALIDOMIDE,THALOMID,PF-00344592,2616,c1ccc2c(c1)C(=O)N(C2=O)C3CCC(=O)NC3=O,CAPSULE,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,,,CELGENE,major pharma,35992,1998,Drugs@FDA,NO,NO,,0.92,High,Fa estimated from reported excretion data,0.45,1.7,6,,118,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (well known but rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,4TZC,258.2295,1,2,1,6,0,1,83.55,0.230769231,0.893,0.893,0.528,Estimated fragment value used,0.87,0.6,0.48,0.481,10.7,,7.8,,Neutral,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.75302,0.77218,0.83737,0.50211,0.88651,0.98659,0.84452,0.63709,0.82734,309.3,30.5,7.85,6.65
86-12-4,THENALIDINE,SANDOSTENE,VC-001215234,2617,CN1CCC(CC1)N(Cc2cccs2)c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,100,Discontinued,1958,YES,NO,Neutropenia,WITHDRAWN,,,SANDOZ,pharma,20455,1956,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,2,Aniline; Thiophene,YES,NO,YES,,286.435,0,1,0,2,0,4,6.48,0.411764706,1.61,1.787,3.779,Benzyl approx. based on a priori value,4.2,3,4.06,2.692,,8.78,,9.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86942,0.88334,0.97047,0.96918,0.93048,0.59178,0.89109,0.96969,0.93773,220.7,13.5,16.4,20
148-79-8,THIABENDAZOLE,MINTEZOL,PF-00344755,2621,c1ccc2c(c1)[nH]c(n2)c3cscn3,"SUSPENSION, TABLET, CHEWABLE",YES,NO,NO,NO,ORAL,3000,Discontinued,,NO,NO,,,,,MERCK,major pharma,24569,1967,Drugs@FDA,NO,NO,,0.9,High,Fa estimated from reported excretion data,,,,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,0,,NO,NO,NO,3SFE,201.2477,1,2,1,3,0,1,41.57,0,2.5,2.219,2.358,All fragments measured,2.4,2.4,2.39,2.386,9.87,3.23,11,4.6,Neutral,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.60424,0.67295,0.45361,0.97098,0.93048,0.98659,0.94511,0.63709,0.25672,219.4,29.6,39.9,59.2
1420-55-9,THIETHYLPERAZINE MALEATE,TORECAN,PF-00345325,2630,CCSc1ccc2c(c1)N(c3ccccc3S2)CCCN4CCN(CC4)C,TABLET,YES,NO,NO,NO,ORAL,30,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,22480,1961,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,399.6158,0,4,0,3,0,6,9.72,0.454545455,3.36,3.82,4.552,All fragments measured,5.3,4.2,5.27,4.666,,7.66,,8.6,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,2,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.64679,0.69586,0.57256,0.50323,0.72615,0.59178,0.98827,0.6885,0.93773,349.6,0.952,33.9,89.9
154-42-7,THIOGUANINE,THIOGUANINE,PF-00344661,2632,c1[nH]c2c(n1)c(=S)[nH]c(n2)N,TABLET,YES,NO,NO,NO,ORAL,210,Prescription,,NO,NO,,,,,ASPEN GLOBAL,pharma,24125,1966,Drugs@FDA,NO,NO,0.3,,Moderate,Reported bioavailability,,,1.2,,,,,NO,Oncology,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,A,Most,A (well known cause of clinically apparent liver injury),None,1,Thioamide,NO,NO,NO,,167.1917,4,2,3,5,0,0,83.38,0,-0.203,-0.203,-1.703,All fragments measured,-1.9,-1.9,-0.19,-1.196,6.79,2.45,8.2,4.2,Acidic,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.45165,0.50516,0.27719,0.60938,0.72615,0.37866,0.48796,0.39503,0.93773,192.3,3.27,2.48,8.8
50-52-2,THIORIDAZINE HYDROCHLORIDE,MELLARIL,PF-00344594,2637,CN1CCCCC1CCN2c3ccccc3Sc4c2cc(cc4)SC,"CONCENTRATE, TABLET",YES,NO,NO,NO,ORAL,800,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,22720,1962,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.05,17.8,22.5,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,,,,None,0,,NO,NO,NO,,370.5745,0,3,0,2,1,4,6.48,0.428571429,3.53,3.5,6.003,All fragments measured,6,4.4,6.1,3.69,,9.84,,9.2,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,2,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66772,0.709,0.75108,0.2523,0.88651,0.59178,0.99622,0.96969,0.93773,344.8,1.14,28.1,75.6
3313-26-6,THIOTHIXENE,NAVANE,PF-00344665,2639,CN1CCN(CC1)CC/C=C/2\c3ccccc3Sc4c2cc(cc4)S(=O)(=O)N(C)C,CAPSULE,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,PFIZER,major pharma,24677,1967,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,443.6253,0,3,0,5,0,5,43.86,0.391304348,2.89,3.552,3.228,All fragments measured,4,2.9,3.86,3.341,,7.62,,8.6,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,2,2,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66771,0.72103,0.3474,0.95614,0.72615,0.59178,0.8931,0.84757,0.93773,388.8,2.56,18,308
115103-54-3,TIAGABINE HYDROCHLORIDE,GABITRIL,PF-00579967,2648,Cc1ccsc1C(=CCCN2CCC[C@H](C2)C(=O)O)c3c(ccs3)C,TABLET,YES,NO,NO,NO,ORAL,56,Prescription,,NO,NO,,,,,CEPHALON,pharma,35703,1997,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.022,1.1,8,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Thiophene,NO,NO,YES,,375.548,1,3,1,3,0,6,40.54,0.45,2.2,2.2,2.775,All fragments measured,5.3,2.4,4.95,2.158,3.86,9.62,3.4,9.8,Zwitter,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83693,0.84879,0.72035,0.97888,0.9848,0.98659,0.71759,0.6885,0.93773,298.2,3.59,12.3,12.5
274693-27-5,TICAGRELOR,BRILINTA,PF-00757796,4184,CCCSc1nc(c2c(n1)n(nn2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4c5ccc(c(c5)F)F,TABLET,YES,NO,NO,NO,ORAL,180,Prescription,,NO,NO,,,AstraZeneca,major pharma,ASTRAZENECA AB,major pharma,40744,2011,Drugs@FDA,NO,NO,0.36,,High,Reported bioavailability,0.01,1.3,7,,,148,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,Ambiguous,,,,,,Less,1,Reactive_HeteroCycle,NO,NO,NO,,522.568,4,9,4,10,1,10,138.44,0.565217391,3.45,3.76,2.546,All fragments measured,2.4,2.4,2.03,2.027,,3.4,13,3.4,Neutral,Class 4,0,2,0,0,0,0,0,3,1,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,2,0,1,0,0,NO,0.22628,0.19462,0.1326,0.99993,0.06191,0.14694,0.16123,0.21184,0.25672,629,6.65,15.7,21.5
55142-85-3,TICLOPIDINE HYDROCHLORIDE,TICLID,PF-00346127,2657,c1ccc(c(c1)CN2CCc3c(ccs3)C2)Cl,TABLET,YES,NO,NO,NO,ORAL,500,Prescription,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,33542,1991,Drugs@FDA,NO,NO,0.85,,High,Reported bioavailability,0.02,,12,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,,,,Moderate,1,Thiophene,NO,NO,YES,,263.7857,0,1,0,1,0,2,3.24,0.285714286,2.85,4.4,4.388,Benzyl approx. based on a priori value,3.3,3.2,4.11,3.929,,7.1,,7.1,Basic,Class 2,0,0,0,0,1,0,0,2,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.7982,0.68887,0.87022,0.89005,0.23327,0.59178,0.84356,0.87038,0.93773,207.6,16.6,49.5,104
40180-04-9,TICRYNAFEN,SELACRYN,PF-00314315,2658,c1cc(sc1)C(=O)c2ccc(c(c2Cl)Cl)OCC(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,,Discontinued,1980,YES,YES,Risk of liver injury,FederalRegister,,,SMITHKLINE BEECHAM,major pharma,28856,1979,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,1,Thiophene,NO,NO,YES,,331.1712,1,4,1,4,0,5,63.6,0.076923077,-0.0684,-0.0684,3.233,All fragments measured,3.4,0.087,3.24,-0.45,2.79,,3.2,,Acidic,Class 1A,0,0,0,0,2,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.91478,0.89007,0.95405,0.86805,0.88651,0.98659,0.76876,0.84757,0.93773,270.4,12.6,7.54,11.7
89987-06-4,TILUDRONATE DISODIUM,SKELID,PF-00596733,2666,c1cc(ccc1SC(P(=O)(O)O)P(=O)(O)O)Cl,TABLET,YES,NO,NO,NO,ORAL,400,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,35496,1997,Drugs@FDA,NO,NO,0.06,,Low,Reported bioavailability,0.1,,43,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,0,,NO,NO,NO,,318.6083,4,3,4,6,0,4,115.06,0.142857143,-1.2,-1.2,0.258,A priori fragment value used,0.35,-4.5,-1.44,-6.949,,,1.9,,Acidic,Class 3A,0,0,0,2,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,1,0,0,0,0,NO,0.61249,0.49002,0.9881,0.98097,0.33223,0.14694,0.17871,0.96969,0.82734,220.8,0.462,4.61,13
26839-75-8,TIMOLOL MALEATE,BLOCADREN,PF-00344664,4061,CC(C)(C)NC[C@@H](COc1c(nsn1)N2CCOCC2)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,MERCK,major pharma,29915,1981,Drugs@FDA,NO,NO,0.61,,High,Reported bioavailability,0.9,1.5,3,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,3D4S,316.4197,2,5,2,7,0,6,79.74,0.846153846,0.392,0.392,1.214,All fragments measured,1.4,-0.34,1.53,-0.343,,9.35,16,8.8,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.75561,0.66251,0.99184,0.80518,0.33223,0.79222,0.60422,0.53315,0.82734,313.8,14.8,11.7,14.3
19387-91-8,TINIDAZOLE,TINDAMAX,PF-00346535,2671,CCS(=O)(=O)CCn1c(ncc1N(=O)=O)C,TABLET,YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,Presutti Laboratories,pharma,MISSION PHARMA,pharma,38124,2004,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.88,0.59,13.2,,,,3677462,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,1,Nitroorganics,NO,NO,NO,,247.2715,0,5,0,7,0,5,97.78,0.625,0.731,0.731,-0.319,All fragments measured,-0.48,-0.48,-0.38,-0.38,,2.3,,2,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70445,0.69024,0.76641,0.51859,0.72615,0.59178,0.62325,0.84757,0.82734,253.5,18,4.02,9.96
1953-02-2,TIOPRONIN,THIOLA,VC-001229331,2676,CC(C(=O)NCC(=O)O)S,TABLET,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,MISSION PHARMA,pharma,32366,1988,Drugs@FDA,NO,NO,0.63,,High,Reported bioavailability,,,53,,,,1113061,YES,Genitourinary,NO,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Less,1,Thiol_Disulfide,NO,NO,NO,,163.1949,2,4,2,4,0,3,66.4,0.6,-1.52,-1.52,-0.235,All fragments measured,-0.23,-3.6,-0.24,-3.922,3.36,,3.6,,Acidic,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.45445,0.51391,0.26085,0.36395,0.88651,0.37866,0.63339,0.99269,0.47245,155,0.479,1.66,12
183204-74-2,TIPIRACIL HYDROCHLORIDE,LONSURF,PF-07239882,4893,C1CC(=N)N(C1)Cc2c(c(=O)[nH]c(=O)[nH]2)Cl,TABLET,YES,NO,NO,NO,ORAL,160,Prescription,,NO,NO,,,Taiho,pharma,TAIHO ONCOLOGY,pharma,42269,2015,Drugs@FDA,YES,NO,,0.6,High,Fa estimated from reported excretion data,0.92,,2.4,,,,,NO,Oncology,YES,NO,,NO,NO,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,242.6622,3,4,3,6,0,2,92.81,0.444444444,-0.525,-0.525,-0.305,Calculated fragment value,0.051,-2.8,-0.65,-3.124,6.19,11.48,7.8,-0.06,Zwitter,Class 3A,0,0,0,0,1,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.69258,0.67989,0.73488,0.87173,0.52457,0.37866,0.73284,0.87038,0.82734,256.5,0.43,2.3,6.72
174484-41-4,TIPRANAVIR,APTIVUS,PF-00558824,3609,CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)c2cccc(c2)NS(=O)(=O)c3ccc(cn3)C(F)(F)F)O)CCc4ccccc4,"CAPSULE, SOLUTION",YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,Pfizer,major pharma,BOEHRINGER INGELHEIM,major pharma,38525,2005,Drugs@FDA,NO,NO,,0.2,Moderate,Fa estimated from reported excretion data,0.001,9,,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),Less,2,Michael_acceptor; Reactive_HeteroCycle,NO,YES,NO,2O4P,602.6643,2,5,2,7,2,11,105.59,0.35483871,4.19,4.19,7.764,Very high LogP unrealistic in nature,7.1,4.8,6.75,2.594,4.5,,5,-5.6,Acidic,Class 3B,0,3,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.15359,0.2103,0.05875,0.04991,0.52457,0.79222,0.54198,0.10729,0.25672,538.6,1.12,9.9,152
51322-75-9,TIZANIDINE HYDROCHLORIDE,ZANAFLEX,PF-00346240,2683,c1cc(c(c2c1nsn2)NC3=NCCN3)Cl,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,36,Prescription,,NO,NO,,,,,COVIS PHARMA BV,pharma,35396,1996,Drugs@FDA,NO,NO,0.4,0.95,High,Reported bioavailability,0.7,2.4,2,,,,,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,C,Less,C (Probable rare cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,,253.7113,2,3,2,5,0,2,62.2,0.222222222,0.632,0.6842,2.093,Estimated fragment value used,1.4,1.3,1.29,0.985,,7.48,,9.1,Basic,Class 2,0,0,0,0,1,0,0,2,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.85498,0.83263,0.80896,0.93386,0.72615,0.79222,0.78215,0.87038,0.93773,267.4,15.3,7.06,11.1
41708-72-9,TOCAINIDE HYDROCHLORIDE,TONOCARD,PF-00345156,2686,Cc1cccc(c1NC(=O)C(C)N)C,TABLET,YES,NO,NO,NO,ORAL,1800,Discontinued,,NO,NO,,,,,ASTRAZENECA AB,major pharma,30995,1984,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.9,2.3,16,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,,,FEARS Addition ,1,,,,,1,Aniline,YES,NO,NO,,192.2575,3,2,2,3,0,2,55.12,0.363636364,0.0525,0.0525,0.257,All fragments measured,0.65,0.25,0.61,0.175,,8.1,13,7.6,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71585,0.78616,0.40063,0.87365,0.93048,0.79222,0.99897,0.87038,0.82734,168,34.8,8.09,9.19
477600-75-2,TOFACITINIB CITRATE,XELJANZ,PF-04524477,4713,C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,10,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,41219,2012,Drugs@FDA,NO,NO,0.74,,High,Reported bioavailability,0.6,1.2,3,,,136,2377187362,NO,Autoimmune Disease,NO,YES,I,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (suspected but unproven rare cause of clinically apparent liver injury),,0,,NO,NO,NO,3LXN,312.3696,1,3,1,7,0,4,88.91,0.5,1.26,1.133,1.517,Approximated fragment value used,1.5,1.5,1.14,-0.46,,5.97,9.2,5.4,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.95679,0.89754,0.99695,0.88606,0.72615,0.98659,0.79653,0.99269,0.93773,360.8,5.12,4.77,14.9
1156-19-0,TOLAZAMIDE,TOLINASE,PF-00344833,2694,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2,TABLET,YES,NO,NO,NO,ORAL,1000,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,24306,1966,Drugs@FDA,NO,NO,,0.85,High,Fa estimated from reported excretion data,,,7,,,,,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,311.3998,2,3,2,6,0,3,78.51,0.5,0.594,0.594,1.338,All fragments measured,1.9,0.16,1.41,-0.41,6.17,3.26,6,3.6,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91196,0.89303,0.99781,0.96551,0.88651,0.79222,0.81517,0.99269,0.82734,271.1,16.8,3.97,14.1
64-77-7,TOLBUTAMIDE,ORINASE,PF-00344663,2696,CCCCNC(=O)NS(=O)(=O)c1ccc(cc1)C,TABLET,YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,20971,1957,Drugs@FDA,NO,NO,,0.75,High,Fa estimated from reported excretion data,0.05,0.12,5.5,,,,,NO,Metabolic Disease,NO,NO,,YES,NO,YES,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Less,0,,NO,NO,NO,,270.3479,2,3,2,5,0,5,75.27,0.416666667,0.312,0.3963,2.497,All fragments measured,2.3,0.29,2.17,0.295,5.37,,5.3,,Acidic,Class 1A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86689,0.88086,0.90539,0.98465,0.9848,0.79222,0.84366,0.84757,0.82734,233.4,18.2,14,9.92
134308-13-7,TOLCAPONE,TASMAR,PF-00482974,2697,Cc1ccc(cc1)C(=O)c2cc(c(c(c2)O)O)N(=O)=O,TABLET,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,VALEANT,pharma,35824,1998,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.001,0.12,2.5,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinically apparent liver injury),Less,2,Nitroorganics; Quinones,NO,NO,NO,3S68,273.2408,2,5,2,6,0,3,103.35,0.071428571,1.27,1.27,3.245,All fragments measured,3,0.73,3.48,1.218,4.78,,5,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91056,0.84935,0.91946,0.99238,0.72615,0.79222,0.65257,0.99269,0.93773,237.8,13.6,27,23.9
26171-23-3,TOLMETIN SODIUM,TOLECTIN,PF-00344835,2699,Cc1ccc(cc1)C(=O)c2ccc(n2C)CC(=O)O,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,1800,Prescription,,NO,NO,,,,,ORTHO MCNEIL JANSSEN,major pharma,27843,1976,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,0.098,5,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,1,Pyrrole,NO,NO,NO,,257.2845,1,3,1,4,0,4,59.3,0.2,-0.307,-0.2862,2.206,All fragments measured,2.5,-0.71,2.4,-0.676,4.22,,3.6,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.93814,0.95347,0.83155,0.98381,0.9848,0.98659,0.9912,0.96969,0.93773,210,13,10,11.7
124937-51-5,TOLTERODINE TARTRATE,DETROL,PF-00346634,2705,Cc1ccc(c(c1)[C@H](CCN(C(C)C)C(C)C)c2ccccc2)O,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,4,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,35879,1998,Drugs@FDA,NO,NO,0.35,0.77,High,Reported bioavailability,0.04,1.5,2.2,,60,,81697737,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,,325.4876,1,2,1,2,1,7,23.47,0.454545455,1.41,1.456,5.24,All fragments measured,5.4,2.8,5.42,2.127,10.13,10.68,9.9,9.2,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.67172,0.68233,0.97199,0.22344,0.93048,0.98659,0.69082,0.53315,0.93773,208.8,2.26,63,178
150683-30-0,TOLVAPTAN,SAMSCA,WYE-250415,4110,Cc1ccccc1C(=O)Nc2ccc(c(c2)C)C(=O)N3CCCC(c4c3ccc(c4)Cl)O,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,Otsuka Pharmaceutical ,pharma,OTSUKA AMERICA PHARM,pharma,39952,2009,Drugs@FDA,NO,NO,0.56,,High,Reported bioavailability,0.02,3,,,,,,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,,,,Less,1,Aniline,YES,NO,NO,,448.9413,2,3,2,5,0,4,69.64,0.230769231,4.38,5.21,4.31,All fragments measured,5.2,5.2,4.21,4.212,,,13,,Neutral,Class 2,0,0,0,0,1,0,0,3,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.51867,0.59158,0.32572,0.41386,0.9848,0.79222,0.9461,0.99269,0.25672,408.6,9.99,38,25
97240-79-4,TOPIRAMATE,TOPAMAX,PF-00346605,2706,CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C,"CAPSULE; CAPSULE, EXTENDED RELEASE; TABLET",YES,NO,YES,NO,ORAL,400,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,35423,1996,Drugs@FDA,NO,NO,0.8,,High,Reported bioavailability,0.8,0.7,21,,20,,5075,YES,"Musculoskeletal/Pain, Neurological",YES,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,3HKU,339.362,2,7,1,9,0,3,115.54,1,0.469,0.469,0.042,A priori fragment value used,0.47,0.44,2.15,2.145,9.22,,8.6,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,4,0,0,0,4,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,5,0,0,NO,0.57429,0.44365,0.92167,0.09375,0.19128,0.98659,0.44233,0.99269,0.47245,431.8,1.08,2.15,8.56
123948-87-8,TOPOTECAN HYDROCHLORIDE,HYCAMTIN,PF-00346579,2707,CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccc(c(c5c4)CN(C)C)O)O,CAPSULE,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,NOVARTIS,major pharma,39366,2007,Drugs@FDA,NO,NO,0.4,,High,Reported bioavailability,0.65,,3,,,,1894345,NO,Oncology,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,Less,1,Michael_acceptor,NO,YES,NO,1K4T,421.4458,2,6,2,8,0,3,104.89,0.347826087,1.36,1.36,0.73,Benzyl approx. based on a priori value,1.3,-1.1,1.32,0.777,8.92,7.65,5.6,11,Zwitter,Class 3B,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,8,0,0,0,8,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7553,0.67655,0.45108,0.89743,0.33223,0.79222,0.65413,0.99269,0.93773,454.4,3.79,4.81,6.65
89778-26-7,TOREMIFENE CITRATE,FARESTON,PF-00346580,2709,CN(C)CCOc1ccc(cc1)/C(=C(\CCCl)/c2ccccc2)/c3ccccc3,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,KYOWA KIRIN,pharma,35579,1997,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.003,8.3,120,,,,,NO,Oncology,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,D,Less,D (possible cause of clinically apparent liver injury),None,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,405.9596,0,2,0,2,1,9,12.47,0.230769231,4.22,4.72,6.531,All fragments measured,6.4,5.2,6.86,5.696,,8.69,,8.3,Basic,Class 2,0,0,0,0,1,0,0,3,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.32978,0.37174,0.53554,0.09981,0.93048,0.59178,0.44264,0.29329,0.25672,242.8,6.97,1.98,17.8
56211-40-6,TORSEMIDE,DEMADEX,PF-00346626,2708,Cc1cccc(c1)Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,MYLAN PHARMS INC,pharma,34204,1993,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.01,0.21,3,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,None,,,,,,Moderate,2,Aniline; Pyridine,YES,NO,NO,,348.42,3,4,3,7,0,5,100.19,0.25,1.28,0.5911,3.358,All fragments measured,2.9,0.33,3.43,1.598,3.29,,6.1,6.7,Acidic,Class 3A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,NO,0.74417,0.73074,0.87838,0.96912,0.72615,0.37866,0.59805,0.84757,0.93773,350.6,2.59,4.51,19.3
27203-92-5,TRAMADOL HYDROCHLORIDE,ULTRAM,PF-00346470,2711,CN(C)C[C@H]1CCCC[C@@]1(c2cccc(c2)OC)O,"CAPSULE, EXTENDED RELEASE, TABLET, TABLET, EXTENDED RELEASE, TABLET, ORALLY DISINTEGRATING",YES,NO,YES,NO,ORAL,400,Prescription,,NO,NO,,,,,JANSSEN PHARMS,major pharma,34761,1995,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,0.8,2.8,6,,,,57952007,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,YES,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely to cause clinically apparent liver injury),Moderate,0,,NO,NO,NO,,263.3752,1,3,1,3,0,4,32.7,0.625,0.548,0.548,3.1,All fragments measured,2.6,0.59,2.54,0.519,,9.61,15,9.1,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92773,0.92582,0.86788,0.9991,0.9848,0.98659,0.86264,0.96969,0.82734,233.3,21,4.86,18.3
871700-17-3,TRAMETINIB DIMETHYL SULFOXIDE,MEKINIST,PF-06700582,4802,Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,Japan Tobacco,major pharma,NOVARTIS,major pharma,41423,2013,Drugs@FDA,NO,NO,0.72,,High,Reported bioavailability,0.026,3.1,96,,,,,YES,Oncology,NO,YES,III,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury),,2,Aniline; Organic_Iodide,YES,NO,NO,,615.3948,2,4,2,9,1,5,107.13,0.230769231,3.7,4.4,4.985,A priori fragment value used,4.6,4.6,2.34,2.345,,,15,0.23,Neutral,Class 2,0,1,0,0,0,0,1,4,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,NO,0.46687,0.55403,0.05316,0.98989,0.72615,0.79222,0.66597,0.84757,0.93773,557.3,8.45,10.2,37.1
87679-37-6,TRANDOLAPRIL,MAVIK,PF-04087773,2712,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@H]3CCCC[C@@H]3C[C@H]2C(=O)O,TABLET,YES,NO,NO,NO,ORAL,4,Prescription,,NO,NO,,,,,ABBVIE,major pharma,35181,1996,Drugs@FDA,NO,YES,0.4,,High,Reported bioavailability,0.08,0.25,0.6,,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,430.5372,2,5,2,7,0,11,95.94,0.625,0.697,0.697,2.099,Approximated fragment value used,3.2,-0.14,3.75,0.177,3.15,5.44,3.2,5.5,Acidic,Class 3B,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.5021,0.55025,0.40601,0.70899,0.52457,0.79222,0.72844,0.21184,0.82734,453.6,1.47,47.6,11.9
1197-18-8,TRANEXAMIC ACID,CYKLOKAPRON,PF-00345620,2713,C1[C@@H](CC[C@H](C1)C(=O)O)CN,TABLET,YES,NO,NO,NO,ORAL,2600,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,31776,1986,Drugs@FDA,NO,NO,0.45,,High,Reported bioavailability,0.97,0.39,11,,,,22593359,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,,,,None,0,,NO,NO,NO,1CEB,157.2102,3,3,2,3,0,2,63.32,0.875,-0.739,-0.739,-1.801,All fragments measured,0.34,-1.9,0.3,-2.206,4.65,10.27,4.3,11,Zwitter,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.42234,0.50311,0.23802,0.1093,0.9848,0.79222,0.9776,0.87038,0.47245,105.7,7.35,3.8,6.9
155-09-9,TRANYLCYPROMINE SULFATE,PARNATE,PF-01247242,2715,c1ccc(cc1)[C@@H]2C[C@H]2N,TABLET,YES,NO,NO,NO,ORAL,60,Prescription,,NO,NO,,,,,CONCORDIA PHARMS INC,pharma,22333,1961,Drugs@FDA,NO,NO,,,NA,NA,,3.09,1.5,,,,,NO,Neurological,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,133.1903,2,1,1,1,0,1,26.02,0.333333333,-0.0318,-0.0318,1.478,All fragments measured,1.6,0.74,1.36,0.464,,8.24,,8.2,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.552,0.53281,0.16452,0.82068,0.23327,0.98659,0.74426,0.63709,0.82734,115.4,51.8,6.12,21.8
19794-93-5,TRAZODONE HYDROCHLORIDE,DESYREL,PF-00344595,2717,c1ccn2c(c1)nn(c2=O)CCCN3CCN(CC3)c4cccc(c4)Cl,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,600,Prescription,,NO,NO,,,,,PRAGMA,pharma,29944,1981,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.05,0.65,7,,,,5474754,NO,Neurological,NO,NO,,NO,YES,YES,NO,Less,Less,DILIRank,1,,,,Less,1,Aniline,YES,NO,NO,,371.8639,0,3,0,6,0,5,45.78,0.368421053,3.06,3.46,3.85,A priori fragment value used,4.5,4.4,2.77,2.589,,7.52,,7.2,Basic,Class 2,0,0,0,0,1,0,0,3,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.78278,0.82563,0.74315,0.9894,0.88651,0.59178,0.96684,0.84757,0.82734,357.1,14.9,9.14,58.3
81846-19-7,TREPROSTINIL DIOLAMINE,ORENITRAM,PF-06889204,2720,CCCCC[C@@H](CC[C@@H]1[C@H]2Cc3cccc(c3C[C@H]2C[C@H]1O)OCC(=O)O)O,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,1,Prescription,,NO,NO,,,Supernus Pharmaceuticals,pharma,UNITED THERAP,pharma,41628,2013,Drugs@FDA,NO,NO,0.17,,Moderate,Reported bioavailability,0.04,3.65,,,,,,YES,Cardiovascular,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely to cause clinically apparent liver injury),,1,1_4_Diketones,NO,NO,NO,,390.5131,3,5,3,5,0,10,86.99,0.695652174,1.17,0.7658,3.723,All fragments measured,4.6,1.3,4.9,1.275,3.19,,3.4,,Acidic,Class 3A,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.47974,0.56167,0.62754,0.71624,0.72615,0.37866,0.81417,0.21184,0.82734,349.1,5.7,15.7,12.2
302-79-4,TRETINOIN,VESANOID,PF-01064143,2722,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,CAPSULE,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,,,CHEPLAPHARM,pharma,35025,1995,Drugs@FDA,NO,NO,,0.6,High,Fa estimated from reported excretion data,0.05,,1.25,,,,,YES,Oncology,NO,NO,,NO,NO,NO,YES,Ambiguous,Ambiguous,,,,,,Less,1,Michael_acceptor,NO,YES,NO,2LBD,300.4351,1,2,1,2,1,5,37.3,0.45,3.35,3.35,6.744,All fragments measured,6.6,3.7,5.9,3.259,4.73,,4.2,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.68759,0.70501,0.99756,0.25603,0.93048,0.98659,0.92207,0.84757,0.47245,167.4,5.73,46.7,38.5
396-01-0,TRIAMTERENE,DYRENIUM,PF-00344667,2728,c1ccc(cc1)c2c(nc3c(n2)c(nc(n3)N)N)N,CAPSULE,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,,,CONCORDIA PHARMS INC,pharma,23599,1964,Drugs@FDA,NO,NO,0.51,,High,Reported bioavailability,0.39,13.4,2,,,,,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,253.2626,6,4,3,7,1,1,129.62,0,1.73,1.176,1.608,All fragments measured,1.1,1.1,1.2,1.157,,6.19,,6.8,Neutral,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.52608,0.46942,0.80607,0.77793,0.33223,0.37866,0.38931,0.63709,0.25672,260.7,17.5,4.91,8.36
28911-01-5,TRIAZOLAM,HALCION,PF-00345457,2729,Cc1nnc2n1-c3ccc(cc3C(=NC2)c4ccccc4Cl)Cl,TABLET,YES,NO,NO,NO,ORAL,0.5,Prescription,,NO,NO,,,,,PHARMACIA AND UPJOHN,major pharma,30270,1982,Drugs@FDA,NO,NO,0.44,,High,Reported bioavailability,0.06,0.58,3.5,,,,68363515,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (Unproven but suspected rare cause of clinically apparent liver injury),None,0,,NO,NO,NO,,343.21,0,2,0,4,0,1,43.07,0.117647059,2.42,2.654,2.618,Benzyl approx. based on a priori value,2.6,2.6,3.01,3.007,,2.2,,13,Neutral,Class 2,0,0,0,0,2,0,0,3,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.61754,0.68084,0.90414,0.81021,0.9848,0.59178,0.97123,0.63709,0.25672,313.7,24.8,6.74,27.5
133-67-5,TRICHLORMETHIAZIDE,NAQUA,PF-00344836,2733,c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,TABLET,YES,NO,NO,NO,ORAL,4,Discontinued,,NO,NO,,,,,SCHERING,major pharma,21984,1960,Drugs@FDA,NO,NO,,,NA,NA,,,2.3,,,,,NO,Cardiovascular,NO,NO,,NO,NO,YES,NO,,None,FEARS Addition ,1,,,,None,2,Alkyl_halide_Sulfate_ester; Aniline,YES,NO,NO,,380.6558,4,4,3,7,0,2,118.36,0.25,1.12,1.12,0.88,All fragments measured,0.85,0.3,0.76,0.648,8,,7,0.86,Acidic,Class 3A,0,0,0,0,3,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,1,0,0,0,3,0,0,0,0,NO,0.66505,0.62341,0.68858,0.78528,0.72615,0.37866,0.34179,0.87038,0.82734,375.2,0.769,4.12,7.01
68786-66-3,TRICLABENDAZOLE,EGATEN,PF-01039536,2734,CSc1[nH]c2cc(c(cc2n1)Oc3cccc(c3Cl)Cl)Cl,TABLET,YES,NO,NO,NO,ORAL,1400,Prescription,,NO,NO,,,Novartis,major pharma,NOVARTIS,major pharma,43509,2019,Drugs@FDA,NO,NO,,,NA,NA,0.033,,8,,,,,YES,Anti-infective,NO,NO,,NO,NO,NO,NO,,None,,,,,,Less,1,Reactive_HeteroCycle,NO,NO,NO,,359.6581,1,2,1,3,1,3,37.91,0.071428571,4.75,5.56,6.44,All fragments measured,5.7,5.7,5.75,5.744,9.3,3.49,8.5,2.7,Neutral,Class 4,0,0,0,0,3,0,0,3,1,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,3,0,0,0,0,NO,0.56819,0.6041,0.81654,0.14847,0.9848,0.98659,0.97804,0.99269,0.25672,318.3,0.758,30.5,38.5
306-52-5,TRICLOFOS SODIUM,TRICLOS,PF-01418866,2735,C(C(Cl)(Cl)Cl)OP(=O)(O)O,"SOLUTION, TABLET",YES,NO,NO,NO,ORAL,2000,Discontinued,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,26299,1972,NIH NCATS,NO,YES,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,229.3835,2,2,2,4,0,2,66.76,1,0.255,0.255,1.01,Calculated fragment value,1.4,-3.1,0.41,-3.936,1.65,,1.2,,Acidic,Class 3A,0,0,0,1,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,NO,0.73708,0.76624,0.64173,0.81489,0.88651,0.79222,0.90032,0.99269,0.47245,111.7,1.29,1.99,6.65
112-24-3,TRIENTINE HYDROCHLORIDE,SYPRINE,PF-00344757,2738,C(CNCCNCCN)N,CAPSULE,YES,NO,NO,NO,ORAL,2000,Prescription,,NO,NO,,,,,ATON,pharma,31359,1985,Drugs@FDA,NO,NO,0.08,,Low,Reported bioavailability,,,,,,,,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,146.2339,6,4,4,4,1,7,76.1,1,-2.48,-2.48,-2.369,All fragments measured,-2.9,-5.8,-1.91,-5.976,,10.05,,11,Basic,Class 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.24113,0.32984,0.20103,0.07125,0.88651,0.14694,0.90375,0.53315,0.47245,107.9,0.394,1.81,6.65
117-89-5,TRIFLUOPERAZINE HYDROCHLORIDE,STELAZINE,PF-00344597,2740,CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)C(F)(F)F,"CONCENTRATE, TABLET",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,21656,1959,Drugs@FDA,NO,NO,,,NA,NA,0.1,,24,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,,,,Less,0,,NO,NO,NO,,407.4956,0,3,0,3,0,4,9.72,0.428571429,3.44,4.3,4.692,All fragments measured,5.2,4.2,4.94,4.406,,7.66,,8.6,Basic,Class 4,0,3,0,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.66052,0.71374,0.52677,0.48,0.88651,0.59178,0.895,0.84757,0.93773,342.1,0.764,25.9,52
146-54-3,TRIFLUPROMAZINE HYDROCHLORIDE,VESPRIN,PF-00344669,2742,CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,50,Discontinued,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,21079,1957,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,352.4171,0,2,0,2,1,4,6.48,0.333333333,3.33,3.865,5.61,All fragments measured,5.4,3.6,5.57,3.633,,9.4,,9,Basic,Class 4,0,3,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.73203,0.7665,0.85725,0.46141,0.9848,0.59178,0.84849,0.84757,0.93773,282.4,3.25,19.2,64.8
70-00-8,TRIFLURIDINE,LONSURF,PF-00345157,2743,c1c(c(=O)[nH]c(=O)n1[C@H]2C[C@@H]([C@H](O2)CO)O)C(F)(F)F,TABLET,YES,NO,NO,NO,ORAL,,Prescription,,NO,NO,,,GlaxoSmithKline,major pharma,TAIHO ONCOLOGY,pharma,42269,2015,Drugs@FDA,YES,NO,0.57,,High,Reported bioavailability,0.04,,0.025,,,,7842,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,296.1999,3,5,3,7,0,2,104.55,0.6,-0.3,-0.3,-0.413,All fragments measured,-0.84,-0.93,-0.45,-0.744,7.45,,8,,Acidic,Class 3A,0,3,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,NO,0.57915,0.58352,0.9925,0.25843,0.72615,0.37866,0.69645,0.99269,0.47245,375.5,0.658,1.66,7.37
144-11-6,TRIHEXYPHENIDYL HYDROCHLORIDE,ARTANE,PF-00345090,2745,c1ccc(cc1)C(CCN2CCCCC2)(C3CCCCC3)O,"CAPSULE, EXTENDED RELEASE, ELIXIR, TABLET",YES,NO,YES,NO,ORAL,15,Prescription,,NO,NO,,,,,LEDERLE,major pharma,18031,1949,Drugs@FDA,NO,NO,,0.76,High,Fa estimated from reported excretion data,,,3.7,,,,7110017,NO,Neurological,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E*,Ambiguous,E* (Unproven but suspected rare cause of clinically apparent liver injury),None,0,,NO,NO,NO,,301.4662,1,2,1,2,1,5,23.47,0.7,1.77,1.716,5.151,All fragments measured,4.6,2.6,4.36,2.47,,9.31,16,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.87915,0.85022,0.99837,0.72338,0.93048,0.98659,0.69082,0.84757,0.82734,216.2,10.3,51.4,68.2
13647-35-3,TRILOSTANE,MODRASTANE,PF-04073583,2746,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C,CAPSULE,YES,NO,NO,NO,ORAL,960,Discontinued,,NO,NO,,,,,BIOENVISION,pharma,31047,1984,PharmaCircle,NO,NO,,,NA,NA,,,,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,YES,,None,,,,,,Less,2,Epoxide; Michael_acceptor,NO,YES,NO,,329.4333,2,3,2,4,0,0,76.78,0.85,1.69,1.69,2.335,All fragments measured,2.8,1.3,2.87,2.834,8.57,,3.1,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,5,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.67904,0.73141,0.95995,0.99023,0.88651,0.79222,0.8987,0.39503,0.47245,409.1,21.5,14.6,24.5
84-96-8,TRIMEPRAZINE TARTRATE,TEMARIL,PF-00344840,2749,CC(CN1c2ccccc2Sc3c1cccc3)CN(C)C,"CAPSULE, EXTENDED RELEASE, SYRUP, TABLET",YES,NO,YES,NO,ORAL,100,Discontinued,,NO,NO,,,,,ALLERGAN,major pharma,21205,1958,PharmaPendium,NO,NO,0.7,,High,Reported bioavailability,,,4.78,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,None,,,,,,None,0,,NO,NO,NO,,298.4457,0,2,0,2,0,4,6.48,0.333333333,2.69,2.9,4.798,All fragments measured,4.8,3,4.79,2.888,,9.34,,8.9,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.8276,0.8437,0.99553,0.6798,0.9848,0.59178,0.84849,0.96969,0.93773,247.3,5.94,27.9,78.7
127-48-0,TRIMETHADIONE,TRIDIONE,PF-00344920,2751,CC1(C(=O)N(C(=O)O1)C)C,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,2400,Prescription,,NO,NO,,,,,ABBVIE,major pharma,16827,1946,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,143.1406,0,2,0,4,0,0,46.61,0.666666667,0.0957,0.0957,-0.117,A priori fragment value used,1.2,1.2,0.32,0.318,,,,,Neutral,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.41797,0.53715,0.19167,0.62596,0.9848,0.59178,0.98865,0.39503,0.47245,156.1,30.5,4.34,11.7
138-56-7,TRIMETHOBENZAMIDE HYDROCHLORIDE,TIGAN,PF-00345159,2754,CN(C)CCOc1ccc(cc1)CNC(=O)c2cc(c(c(c2)OC)OC)OC,CAPSULE,YES,NO,NO,NO,ORAL,1200,Prescription,,NO,NO,,,,,KING PHARMS,pharma,27222,1974,Drugs@FDA,NO,NO,,0.5,High,Fa estimated from reported excretion data,,,8,,,,107480,NO,Gastrointestinal,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,388.4574,1,6,1,7,0,10,69.26,0.380952381,0.832,0.832,2.332,Approximated fragment value used,2.1,0.93,2.31,0.926,,8.67,15,8.3,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62875,0.67272,0.64018,0.999,0.52457,0.98659,0.94829,0.21184,0.93773,324.5,13.4,13.3,28.6
738-70-5,TRIMETHOPRIM,PROLOPRIM,PF-00344596,2755,COc1cc(cc(c1OC)OC)Cc2cnc(nc2N)N,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,,,MONARCH PHARMS,pharma,29371,1980,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.56,1.1,9,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,290.3177,4,5,2,7,0,5,105.51,0.285714286,0.7,0.6759,0.981,All fragments measured,1.1,0.91,1.12,0.994,,6.9,,7.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.86557,0.73444,0.98093,0.89157,0.33223,0.79222,0.63005,0.84757,0.93773,262.2,19.1,7.02,8.03
739-71-9,TRIMIPRAMINE MALEATE,SURMONTIL,PF-00345526,2758,CC(CN1c2ccccc2CCc3c1cccc3)CN(C)C,CAPSULE,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,,,ODYSSEY PHARMS,pharma,29018,1979,Drugs@FDA,NO,NO,,,NA,NA,0.05,30.9,23,,,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,Ambiguous,Ambiguous,,,,,,Less,0,,NO,NO,NO,,294.4338,0,1,0,2,1,4,6.48,0.4,2.44,3.015,5.436,All fragments measured,4.6,2.9,4.98,3.039,,9.38,,8.9,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.78185,0.70482,0.98957,0.54242,0.93048,0.59178,0.32149,0.96969,0.93773,228.1,7.31,18,36.3
3902-71-4,TRIOXSALEN,TRISORALEN,PF-00345091,2759,Cc1cc(=O)oc2c1cc3cc(oc3c2C)C,TABLET,YES,NO,NO,NO,ORAL,10,Discontinued,,NO,NO,,,,,VALEANT,pharma,23582,1964,Drugs@FDA,NO,NO,,,NA,NA,,,2,,,,,NO,Autoimmune Disease,NO,NO,,NO,NO,NO,NO,,,,,,,,,2,Furocoumarins; Michael_acceptor,NO,YES,NO,,228.2433,0,0,0,3,0,0,43.35,0.214285714,2.79,3.318,3.469,All fragments measured,3.6,3.6,3.23,3.232,,,,,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.6519,0.73855,0.63371,0.98274,0.93048,0.59178,0.94357,0.39503,0.93773,207.4,11.6,10.2,194
78-41-1,TRIPARANOL,N/A,PF-04087772,2761,CCN(CC)CCOc1ccc(cc1)C(Cc2ccc(cc2)Cl)(c3ccc(cc3)C)O,N/A,N/A,N/A,N/A,NO,ORAL,250,Discontinued,1962,YES,NO,"Severe adverse effects such as nausea and vomiting, vision loss due to irreversible cataracts, alopecia, skin disorders (e.g., dryness, itching, peeling, and ""fish-scale"" texture), and accelerated atherosclerosis and is now considered to be obsolete",WITHDRAWN,,,N/A,,21916,1960,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Cardiovascular,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,438.0015,1,3,1,3,1,10,32.7,0.333333333,3.45,4.08,6.707,All fragments measured,6.4,4.7,6.02,3.954,,9.62,14,8.6,Basic,Class 4,0,0,0,0,1,0,0,3,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.30383,0.38406,0.37167,0.07275,0.9848,0.98659,0.86264,0.21184,0.25672,314.8,0.98,22.1,80.3
91-81-6,TRIPELENNAMINE HYDROCHLORIDE,PBZ,PF-00344758,2762,CN(C)CCN(Cc1ccccc1)c2ccccn2,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,600,Discontinued,,NO,NO,,,,,NOVARTIS,major pharma,17582,1948,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,419842,NO,Respiratory,NO,NO,,NO,YES,NO,NO,,,Gerren Additions,1,,,,,0,,NO,NO,NO,,255.358,0,2,0,3,0,6,19.37,0.3125,1.42,1.222,3.306,Benzyl approx. based on a priori value,3,1.8,2.83,0.862,,9.04,,7.7,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.77441,0.78492,0.81947,0.9937,0.9848,0.59178,0.59909,0.6885,0.93773,198.8,20,7.76,40
486-12-4,TRIPROLIDINE HYDROCHLORIDE,ACTIDIL,PF-00344672,2763,Cc1ccc(cc1)/C(=C/CN2CCCC2)/c3ccccn3,"SYRUP, TABLET",YES,NO,NO,NO,ORAL,10,Discontinued,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,21312,1958,PharmaPendium,NO,NO,,,NA,NA,,,2.1,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,0,,NO,NO,NO,,278.3914,0,2,0,2,0,4,16.13,0.315789474,2.18,1.968,3.634,All fragments measured,3.6,2,3.78,2.253,,8.99,,9,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83607,0.79926,0.94206,0.84184,0.93048,0.59178,0.52472,0.96969,0.93773,205,11.6,28.1,20.3
97322-87-7,TROGLITAZONE,PRELAY,PF-00579898,2767,Cc1c(c2c(c(c1O)C)CCC(O2)(C)COc3ccc(cc3)CC4C(=O)NC(=O)S4)C,TABLET,YES,NO,NO,NO,ORAL,600,Discontinued,1997,YES,YES,Hepatotoxicity,FederalRegister,,,SANKYO,pharma,35459,1997,Drugs@FDA,NO,NO,0.45,,High,Reported bioavailability,,,,,,,,NO,Metabolic Disease,YES,NO,,NO,NO,NO,YES,Most,Most,DILIRank,1,A,Most,A (well recognized cause of clinically apparent liver injury),None,1,Thiazolidinedione,NO,NO,NO,,441.5399,2,6,2,6,1,5,84.86,0.416666667,3.63,3.608,5.585,All fragments measured,5.8,4.6,4.3,3.258,6.34,,6.3,,Acidic,Class 3B,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.55889,0.54825,0.35624,0.21763,0.52457,0.79222,0.58144,0.84757,0.93773,453.5,1.6,33.9,49.6
2751-09-9,TROLEANDOMYCIN,TAO,PF-06786685,2769,C[C@@H]1C[C@@H]([C@H]([C@@H](O1)O[C@H]2[C@H](C[C@@]3(CO3)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]2C)O[C@H]4C[C@@H]([C@H]([C@@H](O4)C)OC(=O)C)OC)C)C)C)OC(=O)C)C)C)OC(=O)C)N(C)C,CAPSULE,YES,NO,NO,NO,ORAL,1000,Discontinued,,NO,NO,,,,,PFIZER,major pharma,25350,1969,Drugs@FDA,NO,NO,,,NA,NA,,,1,,,,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,Gerren Additions,1,,,,,1,Epoxide,NO,NO,NO,1OND,813.9684,0,12,0,16,2,12,184.19,0.87804878,1.64,2.286,4.197,All fragments measured,4.1,3.5,3.79,3.212,,7.84,,7.9,Basic,Class 2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,YES,0.19681,0.14823,0.0281,0.9962,0.02025,0.59178,0.09244,0.10729,0.47245,1067,2.45,39.2,94.8
10405-02-4,TROSPIUM CHLORIDE,SANCTURA,PF-04087761,2776,c1ccc(cc1)C(c2ccccc2)(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)[N+]45CCCC5)O,"CAPSULE, EXTENDED RELEASE, TABLET",YES,NO,YES,NO,ORAL,60,Prescription,,NO,NO,,,Rottapharm Madaus (Mylan),pharma,ALLERGAN,major pharma,38135,2004,Drugs@FDA,NO,NO,0.096,,Low,Reported bioavailability,0.5,5.6,20,,,,,NO,Genitourinary,NO,NO,,NO,YES,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,392.5106,1,3,1,4,0,5,46.53,0.48,1.53,-0.5667,-1.155,Approximated fragment value used,0.83,0.83,0.07,0.069,11.23,,14,,Neutral,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.85211,0.89577,0.61532,0.98546,0.9848,0.98659,0.98835,0.84757,0.93773,370.2,3.85,28.8,12.7
147059-72-1,TROVAFLOXACIN MESYLATE,TROVAN,PF-00345571,2777,c1cc(c(cc1F)F)n2cc(c(=O)c3c2nc(c(c3)F)N4C[C@@H]5[C@H](C4)[C@H]5N)C(=O)O,TABLET,YES,NO,NO,NO,ORAL,200,Discontinued,1999,YES,YES,Hepatotoxicity,FederalRegister,,,PFIZER,major pharma,35782,1997,Drugs@FDA,NO,NO,0.88,,High,Reported bioavailability,0.24,1.3,10,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,,1,Quinolones_Naphthyridinones,NO,NO,NO,4Z2E,416.3533,3,6,2,7,0,3,101.45,0.25,0.667,0.2326,-0.178,All fragments measured,2.6,0.22,0.51,-1.555,5.8,7.92,6,8,Zwitter,Class 1B,0,3,0,0,0,0,0,2,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.67346,0.61046,0.47784,0.39129,0.33223,0.79222,0.68969,0.99269,0.93773,472.6,13.7,4.09,7.86
1374248-77-7,UBROGEPANT,UBRELVY,VC-001275219,,O=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O,TABLET,YES,NO,NO,NO,ORAL,200,Prescription,,NO,NO,,,Merck,major pharma,ALLERGAN,major pharma,43822,2019,Drugs@FDA,NO,NO,,0.58,High,Fa estimated from reported excretion data,0.13,5,6,,,,,NO,Neurological,NO,NO,,NO,YES,NO,NO,,,,,,,,,0,,NO,NO,NO,,549.5438496,2,5,2,8,1,4,104.29,0.345,3.39,3.4,2.925,Benzyl approx. based on a priori value,2.6,2.6,2.94,2.9,8.36,3.38,8.4,3.9,Acidic,Class 1B,0,3,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.43394,0.50046,0.09778,0.99949,0.72615,0.79222,0.64278,0.84757,0.25672,589.6,6.33,12,25.6
126784-99-4,ULIPRISTAL ACETATE,ELLA,VC-000703980,4166,CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)c5ccc(cc5)N(C)C)C)OC(=O)C,TABLET,YES,NO,NO,NO,ORAL,30,Prescription,,NO,NO,,,HRA Pharma,pharma,LAB HRA PHARMA,pharma,40403,2010,Drugs@FDA,NO,NO,,,NA,NA,0.06,,32,,,,,NO,Genitourinary,NO,NO,,NO,NO,NO,YES,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,,475.6191,0,3,0,5,0,5,63.68,0.566666667,3.41,4.19,4.507,Valid estimate for difficult structure,4.6,4.6,4.69,4.681,,5.49,,3.7,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,6,0,0,0,6,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.56015,0.6358,0.23454,0.60884,0.72615,0.59178,0.97608,0.84757,0.82734,435.9,11.7,43.7,158
1310726-60-3,UPADACITINIB,RINVOQ,PF-07223216,,O=C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F,"TABLET, EXTENDED RELEASE",NO,NO,YES,NO,ORAL,15,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,43693,2019,Drugs@FDA,NO,NO,,0.58,High,Fa estimated from reported excretion data,0.48,,12,,,,,NO,Autoimmune Disease,NO,YES,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,380.3678096,2,3,2,7,0,4,78.32,0.471,2.36,2.36,2.262,Benzyl approx. based on a priori value,1.3,1.3,2.55,,11.89,,10,4.6,Neutral,Class 2,0,3,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,4,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.69287,0.73261,0.69037,0.95233,0.9848,0.79222,0.88709,0.96969,0.25672,413.9,8.19,3.1,11.5
66-75-1,URACIL MUSTARD,URACIL MUSTARD,PF-00345160,2795,c1c(c(=O)[nH]c(=O)[nH]1)N(CCCl)CCCl,CAPSULE,YES,NO,NO,NO,ORAL,10.5,Discontinued,,NO,NO,,,,,SHIRE,major pharma,22902,1962,Drugs@FDA,NO,NO,,,NA,NA,,,,,,,,NO,Oncology,NO,NO,,NO,NO,NO,NO,,None,Gerren Additions,1,,,,None,1,Alkyl_halide_Sulfate_ester,NO,NO,NO,,252.0978,2,2,2,5,0,5,68.96,0.5,0.423,0.423,0.598,All fragments measured,0.27,0.26,0.75,0.741,9.42,,9.4,3.4,Neutral,Class 2,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,0,0,NO,0.69539,0.74104,0.7985,0.49958,0.9848,0.79222,0.98463,0.84757,0.47245,226.1,9.96,5.74,11.4
4105-38-8,URIDINE TRIACETATE,XURIDEN,PF-00346089,5029,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n2ccc(=O)[nH]c2=O)OC(=O)C)OC(=O)C,GRANULE,YES,NO,NO,YES,ORAL,40,Prescription,,NO,NO,,,Wellstat Therapeutics,pharma,WELLSTAT THERAP,pharma,42251,2015,Drugs@FDA,NO,YES,,,NA,NA,,,2,,,,257043,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,,,,,,,,,0,,NO,NO,NO,,370.3114,1,6,1,11,1,8,142.99,0.533333333,-0.136,-0.136,-0.267,All fragments measured,-0.62,-0.69,-0.22,-0.226,9.37,,9,,Neutral,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.48158,0.35967,0.7527,0.16147,0.10671,0.98659,0.32213,0.39983,0.47245,507,3.08,7.97,8
128-13-2,URSODIOL,ACTIGALL,PF-00344842,2797,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C,"CAPSULE, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,ALLERGAN,major pharma,32142,1987,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.3,,,,,,,YES,Gastrointestinal,NO,NO,,NO,NO,NO,YES,,Less,,,D,Less,D (possible rare cause of acute decompensation of preexisting liver disease),Less,0,,NO,NO,NO,,392.572,3,4,3,4,0,4,77.76,0.958333333,1.61,1.61,4.514,All fragments measured,4.4,1.9,3.76,1.166,4.76,,5,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62922,0.68727,0.61495,0.85917,0.88651,0.37866,0.89136,0.96969,0.47245,391.8,4.56,21.4,7.18
124832-27-5,VALACYCLOVIR HYDROCHLORIDE,VALTREX,PF-00346583,2798,CC(C)[C@@H](C(=O)OCCOCn1cnc2c1[nH]c(nc2=O)N)N,TABLET,YES,NO,NO,NO,ORAL,3000,Prescription,,NO,NO,,,,,GLAXOSMITHKLINE,major pharma,34873,1995,Drugs@FDA,NO,YES,0.55,,High,Reported bioavailability,0.9,,2.5,,,,2403658,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,0,,NO,NO,NO,,324.3357,5,6,3,10,0,8,151.14,0.538461538,-1.34,-1.34,-1.402,Valid estimate for difficult structure,-1.5,-1.9,-0.51,-1.025,,7.75,8.8,7.7,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.5027,0.4013,0.97513,0.28224,0.19128,0.37866,0.25418,0.39983,0.82734,362.8,1,10.9,6.65
1025504-45-3,VALBENAZINE TOSYLATE,INGREZZA,VC-001215350,5227,CC(C)C[C@@H]1CN2CCc3cc(c(cc3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC,CAPSULE,YES,NO,NO,NO,ORAL,80,Prescription,,NO,NO,,,Neurocrine Biosciences,pharma,NEUROCRINE,pharma,42836,2017,Drugs@FDA,NO,YES,0.49,,High,Reported bioavailability,0.01,1.3,15,,,,,NO,Neurological,NO,NO,,NO,NO,YES,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,,418.5695,2,5,1,6,0,8,74.02,0.708333333,2.83,2.729,3.974,All fragments measured,3.4,2.1,4.18,3.591,,7.76,,8.1,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.65082,0.68005,0.46606,0.91799,0.52457,0.98659,0.91833,0.39983,0.82734,411.5,4.37,25.7,72.7
181695-72-7,VALDECOXIB,BEXTRA,PF-00579925,2799,Cc1c(c(no1)c2ccccc2)c3ccc(cc3)S(=O)(=O)N,TABLET,YES,NO,NO,NO,ORAL,40,Discontinued,2005,YES,YES,"Increased risk of serious cardiovascular events and an increased risk of serious skin reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme) compared to other NSAIDs",FederalRegister,Pfizer,major pharma,GD SEARLE,major pharma,37211,2001,Drugs@FDA,NO,NO,0.83,,High,Reported bioavailability,0.02,1.2,8,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Most,0,,NO,NO,NO,,314.359,2,3,1,5,0,3,86.19,0.0625,2.47,2.801,1.832,All fragments measured,2.5,2.5,2.54,2.539,9.83,,9.7,-2.3,Neutral,Class 2,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.79288,0.78409,0.99474,0.99685,0.9848,0.98659,0.74208,0.99269,0.25672,280.9,20.3,12.4,12.8
175865-59-5,VALGANCICLOVIR HYDROCHLORIDE,VALCYTE,PF-06780707,2801,CC(C)[C@@H](C(=O)OCC(CO)OCn1cnc2c1[nH]c(nc2=O)N)N,"FOR SOLUTION, TABLET",YES,NO,NO,NO,ORAL,900,Prescription,,NO,NO,,,Roche,major pharma,HOFFMANN LA ROCHE,major pharma,36979,2001,Drugs@FDA,NO,YES,0.6,,High,Reported bioavailability,0.98,0.7,4,,31,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,E,None,E (unlikely cause of clinically apparent liver injury) ,None,0,,NO,NO,NO,,354.3617,6,7,4,11,2,9,171.37,0.571428571,-1.65,-1.65,-2.18,Valid estimate for difficult structure,-2.3,-2.7,-0.95,-1.455,,7.73,8.8,7.8,Basic,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.38281,0.26685,0.8466,0.35041,0.06191,0.14694,0.12979,0.29329,0.93773,411.4,0.153,7.47,10.2
99-66-1,VALPROIC ACID,DEPAKENE,PF-00345161,2803,CCCC(CCC)C(=O)O,"CAPSULE; CAPSULE, DELAYED RELEASE; SYRUP",YES,YES,YES,NO,ORAL,4200,Prescription,,NO,NO,,,,,ABBVIE,major pharma,28549,1978,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.08,0.14,,,,,159706,NO,"Musculoskeletal/Pain, Neurological",YES,NO,,YES,NO,NO,NO,Most,Most,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,144.2114,1,2,1,2,0,5,37.3,0.875,0.143,0.7562,2.76,All fragments measured,2.6,0.24,2.65,0.098,4.82,,4.9,,Acidic,Class 1A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.59068,0.67825,0.19486,0.9997,0.93048,0.98659,0.92207,0.84757,0.47245,71.51,62.4,12.4,7.12
137862-53-4,VALSARTAN,DIOVAN,PF-00579895,2806,CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3[nH]nnn3)[C@@H](C(C)C)C(=O)O,"CAPSULE, SOLUTION, TABLET",YES,NO,NO,NO,ORAL,320,Prescription,,NO,NO,,,,,NOVARTIS,major pharma,35422,1996,Drugs@FDA,NO,NO,0.39,,High,Reported bioavailability,0.04,0.22,6,,39,118,222742,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,D,Less,D (Possible rare cause of clinically apparent liverinjury),Moderate,0,,NO,NO,NO,,435.5188,2,6,2,8,0,11,112.07,0.375,0.695,-0.8433,4.859,Benzyl approx. based on a priori value,5.3,0.086,3.84,-0.839,3.56,,3.8,,Acidic,Class 3B,0,0,0,0,0,0,0,3,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.41848,0.45529,0.38282,0.83469,0.52457,0.79222,0.56155,0.21184,0.25672,355,0.939,13.4,31.6
443913-73-3,VANDETANIB,CAPRELSA,PF-00335487,4178,CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br,TABLET,YES,NO,NO,YES,ORAL,300,Prescription,,NO,NO,,,AstraZeneca,major pharma,GENZYME CORP,pharma,40639,2011,Drugs@FDA,NO,NO,,0.55,High,Fa estimated from reported excretion data,0.1,106,456,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,,,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Moderate,1,Aniline,YES,NO,NO,2IVU,475.354,1,6,1,6,1,6,59.51,0.363636364,2.97,3.098,5.836,All fragments measured,5.3,3.3,4.75,3.264,,8.92,,9.4,Basic,Class 4,0,1,0,0,0,1,0,3,1,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,2,0,0,0,0,NO,0.46432,0.51173,0.23531,0.43093,0.52457,0.98659,0.99063,0.6885,0.25672,393.4,4.66,24.1,53.3
224785-90-4,VARDENAFIL HYDROCHLORIDE,LEVITRA,PF-02400225,2809,CCCc1nc(c2n1nc([nH]c2=O)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC4)CC)C,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Bayer,major pharma,BAYER HEALTHCARE,major pharma,37852,2003,Drugs@FDA,NO,NO,0.15,0.9,Moderate,Reported bioavailability,0.05,3,4,,156,,,NO,Genitourinary,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E*,Ambiguous,E* (unproven but suspected rare cause of clinically apparent liver injury),Less,0,,NO,NO,NO,3B2R,488.603,1,5,1,10,0,8,112.9,0.52173913,2.38,2.38,2.232,All fragments measured,1.2,1,2.03,1.642,9.86,7.15,,7.6,Basic,Class 2,0,0,0,0,0,0,0,3,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.54032,0.49265,0.19978,0.9854,0.19128,0.98659,0.50567,0.39983,0.93773,510.5,12.1,46.5,96.8
249296-44-4,VARENICLINE TARTRATE,CHANTIX,PF-03430574,2808,c1cnc2cc3c(cc2n1)C4CC3CNC4,TABLET,YES,NO,NO,NO,ORAL,2,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,38847,2006,Drugs@FDA,NO,NO,0.9,,High,Reported bioavailability,0.8,,24,,,147,1364403637,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,,0,,NO,NO,NO,4AFG,211.2624,1,3,1,3,0,0,37.81,0.384615385,0.228,0.228,0.899,All fragments measured,0.99,-0.75,1.23,-0.744,,9.6,,8.9,Basic,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,6,0,0,0,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.66865,0.75144,0.51737,0.78327,0.9848,0.98659,0.92763,0.39503,0.93773,232.6,30.8,3.47,9.64
1377049-84-7,VELPATASVIR,EPCLUSA,VC-001215239,5154,C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)c2[nH]c3c(n2)ccc4c3cc5c(c4)-c6ccc(cc6CO5)c7cnc([nH]7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](c9ccccc9)NC(=O)OC)COC,TABLET,YES,NO,NO,NO,ORAL,100,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,42549,2016,Drugs@FDA,YES,NO,0.25,,Moderate,Reported bioavailability,0.005,,15,,,61,,NO,Anti-infective,NO,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury in susceptible individuals),Less,0,,NO,NO,NO,,883.0019,4,8,4,16,3,15,193.1,0.387755102,4.25,4.95,5.705,Benzyl approx. based on a priori value,5.5,5.5,6.21,6.228,10.75,6.11,11,7.5,Neutral,Class 4,0,0,0,0,0,0,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,4,0,8,0,0,0,8,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.05765,0.0598,0.02727,0.19006,0.06191,0.14694,0.07336,0.07566,0.01044,997.9,0.62,9.67,19.1
918504-65-1,VEMURAFENIB,ZELBORAF,PF-06376026,4185,CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F,TABLET,YES,NO,NO,YES,ORAL,1920,Prescription,,NO,NO,,,Plexxikon ,pharma,HOFFMANN LA ROCHE,major pharma,40772,2011,Drugs@FDA,NO,NO,,,NA,NA,0.01,1.5,57,,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,Ambiguous,FEARS Addition ,1,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury.,Moderate,0,,NO,NO,NO,3OG7,489.9221,2,4,2,6,0,7,91.92,0.130434783,4.61,4.793,4.169,All fragments measured,5.4,5.3,4.27,3.406,6.55,3.03,8.1,4.2,Acidic,Class 3B,0,2,0,0,1,0,0,4,1,1,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,2,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,3,0,0,0,0,NO,0.29783,0.36431,0.19656,0.4898,0.88651,0.79222,0.68425,0.53315,0.03452,440.1,3.31,24.2,42.3
1257044-40-8,VENETOCLAX,VENCLEXTA,PF-06730011,5133,CC1(CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc6cc[nH]c6nc5)C(=O)NS(=O)(=O)c7ccc(c(c7)N(=O)=O)NCC8CCOCC8)C,TABLET,YES,NO,NO,YES,ORAL,400,Prescription,,NO,NO,,,Abbott,major pharma,ABBVIE,major pharma,42471,2016,Drugs@FDA,NO,NO,,0.8,High,Fa estimated from reported excretion data,0.01,4.1,26,,,,,YES,Oncology,NO,NO,,NO,NO,NO,NO,,None,,,E,None,E (unlikely cause of clinically apparent liver injury),Less,2,Aniline; Nitroorganics,YES,NO,NO,,868.4392,3,8,3,14,3,13,174.71,0.377777778,4.17,4.17,10.312,Very high LogP unrealistic in nature,8.9,6.5,8.48,6.502,4.04,6.69,1.8,7.9,Zwitter,Class 3B,0,0,0,0,1,0,0,5,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,3,1,2,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,NO,0.05358,0.05214,0.02738,0.02886,0.03975,0.37866,0.09519,0.07566,0.01222,795.2,0.121,15.3,45.2
93413-69-5,VENLAFAXINE HYDROCHLORIDE,EFFEXOR,PF-00345408,2813,CN(C)CC(c1ccc(cc1)OC)C2(CCCCC2)O,"CAPSULE, EXTENDED RELEASE, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,375,Prescription,,NO,NO,,,,,WYETH,major pharma,34331,1993,Drugs@FDA,NO,NO,0.45,0.92,High,Reported bioavailability,0.73,7.5,5,,6,,365644565,NO,Neurological,NO,NO,,NO,NO,YES,NO,Less,Less,DILIRank,1,B,Most,B (highly likely rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,277.4018,1,3,1,3,0,5,32.7,0.647058824,0.705,0.7658,3.269,All fragments measured,3.4,1.7,3.15,1.431,,9.26,18,9.3,Basic,Class 2,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.91615,0.91802,0.93797,0.99677,0.9848,0.98659,0.86264,0.84757,0.82734,184.3,20.3,4.38,9.32
52-53-9,VERAPAMIL HYDROCHLORIDE,ISOPTIN,PF-00249188,2815,CC(C)C(CCCN(C)CCc1ccc(c(c1)OC)OC)(C#N)c2ccc(c(c2)OC)OC,"CAPSULE, EXTENDED RELEASE, TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,480,Prescription,,NO,NO,,,,,MT ADAMS,pharma,30018,1982,Drugs@FDA,NO,NO,0.21,0.7,Moderate,Reported bioavailability,0.09,3.7,4,,,,22556694,NO,Cardiovascular,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,B,Most,B (Likely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,454.6016,0,5,0,6,0,13,63.95,0.518518519,2.13,2.566,4.466,All fragments measured,4.5,3.1,3.95,2.441,,8.97,,9.1,Basic,Class 2,0,0,0,0,0,0,0,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.31132,0.40232,0.30397,0.26139,0.52457,0.59178,0.97494,0.07566,0.93773,372.8,4.18,49.1,232
68506-86-5,VIGABATRIN,SABRIL,PF-00345623,2819,C=CC(CCC(=O)O)N,"FOR SOLUTION, TABLET",YES,NO,NO,NO,ORAL,6000,Prescription,,NO,NO,,,Sanofi,major pharma,LUNDBECK PHARMS LLC,pharma,40046,2009,Drugs@FDA,NO,NO,0.65,,High,Reported bioavailability,0.83,1.1,10.5,Suicide,,,,YES,Neurological,YES,NO,,NO,NO,NO,NO,Ambiguous,Ambiguous,,,D,Less,D (possible rare cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,129.157,3,3,2,3,0,4,63.32,0.5,-1.06,-1.06,-2.217,All fragments measured,-0.45,-2.2,-0.23,-2.728,4.36,10.61,4,10,Zwitter,Class 3A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.36111,0.44441,0.15471,0.06333,0.9848,0.79222,0.9776,0.96969,0.47245,106.2,1.08,2.97,7.05
163521-12-8,VILAZODONE HYDROCHLORIDE,VIIBRYD,PF-05906886,4223,c1cc2c(cc1C#N)c(c[nH]2)CCCCN3CCN(CC3)c4ccc5c(c4)cc(o5)C(=O)N,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,Merck kGaA,pharma,ALLERGAN,major pharma,40564,2011,Drugs@FDA,NO,NO,0.72,,High,Reported bioavailability,0.04,,25,,,,,NO,Neurological,NO,NO,,NO,YES,YES,NO,,,,,,,,,3,3_Methyl_Indole; Aniline; Benzofuran,YES,NO,NO,,441.5249,3,3,2,7,0,7,102.29,0.307692308,3.47,3.28,4.077,All fragments measured,4,3.1,3.81,3.001,,7.95,11,8.4,Basic,Class 4,0,0,0,0,0,0,0,4,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,2,0,2,0,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.35699,0.41339,0.3563,0.67476,0.88651,0.79222,0.66369,0.53315,0.03452,417,1.77,8.45,41.9
879085-55-9,VISMODEGIB,ERIVEDGE,PF-04983154,4227,CS(=O)(=O)c1ccc(c(c1)Cl)C(=O)Nc2ccc(c(c2)c3ccccn3)Cl,CAPSULE,YES,NO,NO,NO,ORAL,150,Prescription,,NO,NO,,,Curis,pharma,GENENTECH,major pharma,40938,2012,Drugs@FDA,NO,NO,0.32,,High,Reported bioavailability,0.01,0.3,96,,,,,NO,Oncology,NO,NO,,NO,YES,NO,NO,,Less,LiverTox Additions,1,C,Less,C (probable cause of clinically apparent liver injury),None,1,Aniline,YES,NO,NO,5L7I,421.2971,1,4,1,5,0,4,76.13,0.052631579,3.41,3.39,2.744,All fragments measured,3.9,3.9,3.13,3.13,10.72,3,11,3.2,Neutral,Class 2,0,0,0,0,2,0,0,3,0,1,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,2,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,NO,0.63771,0.67553,0.45185,0.78031,0.88651,0.98659,0.83622,0.96969,0.25672,371.1,11.9,4.19,19.9
618385-01-6,VORAPAXAR SULFATE,ZONTIVITY,VC-000510344,4870,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/c4ccc(cn4)c5cccc(c5)F)[C@H](OC3=O)C,TABLET,YES,NO,NO,NO,ORAL,2.08,Prescription,,NO,NO,,,Merck,major pharma,ARALEZ PHARMS,pharma,41767,2014,Drugs@FDA,NO,NO,1,,High,Reported bioavailability,0.01,6,192,,,,,NO,Cardiovascular,NO,NO,,NO,YES,NO,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,0,,NO,NO,NO,3VW7,492.5817,1,3,1,6,0,6,77.52,0.482758621,3.97,5.02,4.341,All fragments measured,5.1,5.1,4.76,4.748,12.49,3.91,15,3.7,Neutral,Class 4,0,1,0,0,0,0,0,2,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,4,0,0,0,4,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,NO,0.53261,0.60067,0.19024,0.35898,0.72615,0.98659,0.89317,0.6885,0.93773,514.8,0.826,25.8,131
137234-62-9,VORICONAZOLE,VFEND,PF-00579955,2846,C[C@@H](c1c(cncn1)F)[C@](Cn2cncn2)(c3ccc(cc3F)F)O,"FOR SUSPENSION, TABLET",YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,37400,2002,Drugs@FDA,NO,NO,0.96,,High,Reported bioavailability,0.42,4.6,6,,,,377595153,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,B,Most,B (likely cause of clinically apparent liver injury),Moderate,1,Imidazole_Triazole,NO,NO,NO,5HS1,349.3105,1,4,1,6,0,5,76.72,0.25,1.6,1.744,0.523,All fragments measured,1.5,1.5,1.39,1.386,11.54,3.12,15,3.4,Neutral,Class 2,0,3,0,0,0,0,0,3,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,5,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,NO,0.73931,0.73688,0.87377,0.96329,0.72615,0.98659,0.89914,0.84757,0.25672,394.3,38.5,7.43,36.5
149647-78-9,VORINOSTAT,ZOLINZA,PF-00998508,4124,c1ccc(cc1)NC(=O)CCCCCCC(=O)NO,CAPSULE,YES,NO,NO,NO,ORAL,400,Prescription,,NO,NO,,,Merck,major pharma,MERCK,major pharma,38996,2006,Drugs@FDA,NO,NO,0.43,,High,Reported bioavailability,0.29,0.76,2,,,,,YES,Oncology,YES,NO,,NO,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),None,1,Aniline,YES,NO,NO,4LXZ,264.3202,3,2,3,5,0,8,78.43,0.428571429,1.19,0.9729,0.989,All fragments measured,1.6,1.5,1.2,1.195,9.48,,9.3,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.62474,0.7104,0.87324,0.95651,0.9848,0.37866,0.88624,0.39983,0.82734,209,2.94,18.1,9.65
508233-74-7,VORTIOXETINE HYDROBROMIDE,TRINTELLIX,VC-001215238,4806,Cc1ccc(c(c1)C)Sc2ccccc2N3CCNCC3,TABLET,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,Lundbeck,pharma,TAKEDA PHARMS USA,major pharma,41547,2013,Drugs@FDA,NO,NO,0.75,,High,Reported bioavailability,,,,,,,,NO,Neurological,NO,NO,,YES,YES,YES,NO,,,,,E,None,E (unlikely cause of clinically apparent liver injury),,1,Aniline,YES,NO,NO,,298.4457,1,2,1,2,0,3,15.27,0.333333333,2.32,2.907,4.92,All fragments measured,4.8,3.2,4.55,3.372,,8.85,,8.9,Basic,Class 4,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.92786,0.92754,0.99553,0.68814,0.9848,0.98659,0.95332,0.99269,0.93773,234.8,1.04,16.6,35.5
1446321-46-5,VOXELOTOR,OXBRYTA,PF-06759497,,O=CC1=C(OCC2=CC=CN=C2C3=CC=NN3C(C)C)C=CC=C1O,TABLET,YES,NO,NO,NO,ORAL,1500,Prescription,,NO,NO,,,Global Blood Therapeutics,pharma,GLOBAL BLOOD THERAPS,pharma,43794,2019,Drugs@FDA,NO,NO,,0.65,High,Fa estimated from reported excretion data,0.002,4.8,35.5,Parent CRG,,,,YES,Metabolic Disease,NO,NO,,NO,NO,NO,NO,,,,,,,,,1,Aldehyde,NO,NO,NO,5U3I,337.37258,1,5,1,6,0,6,77.24,0.211,2.4,2.945,3.236,Benzyl approx. based on a priori value,2.9,2.8,3.239,3.199,7.67,3.75,8.4,4.7,Acidic,Class 1A,0,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7175,0.72246,0.93019,0.97417,0.72615,0.98659,0.89528,0.6885,0.25672,317.8,17.3,33.4,54.6
1535212-07-7,VOXILAPREVIR,VOSEVI,VC-001215353,5242,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C,TABLET,YES,NO,NO,NO,ORAL,300,Prescription,,NO,NO,,,Gilead Sciences,major pharma,GILEAD SCIENCES INC,major pharma,42934,2017,Drugs@FDA,YES,NO,,,NA,NA,0.01,,33,,,,,NO,Anti-infective,YES,NO,,NO,NO,NO,NO,,,,,E*,Ambiguous,E* (unproven but suspected cause of clinically apparent liver injury in susceptible individuals),Less,0,,NO,NO,NO,,868.9343,3,10,3,15,3,8,195.22,0.7,3.56,3.56,6.69,Benzyl approx. based on a priori value,6.9,4.2,4.14,2.568,5.59,1.31,4.8,1.6,Acidic,Class 3B,0,4,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,8,0,0,0,4,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,6,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,0,0,0,0,YES,0.22114,0.16249,0.02738,0.46405,0.03975,0.37866,0.05685,0.29329,0.93773,1020,1.8,30.3,45.6
81-81-2,WARFARIN SODIUM,COUMADIN,PF-00344599,2847,CC(=O)CC(c1ccccc1)c2c(c3ccccc3oc2=O)O,TABLET,YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,BRISTOL MYERS SQUIBB,major pharma,19883,1954,Drugs@FDA,NO,NO,0.95,,High,Reported bioavailability,0.02,0.14,168,Suicide,,,,NO,Cardiovascular,YES,NO,,NO,NO,NO,NO,Less,Less,DILIRank,1,,,,Less,1,Michael_acceptor,NO,YES,NO,,308.3279,1,2,1,4,0,4,67.51,0.157894737,1.43,0.9537,2.901,All fragments measured,2.6,0.2,3.1,0.303,4.5,,4.8,,Acidic,Class 1A,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.97775,0.96446,0.9996,0.99998,0.88651,0.98659,0.97641,0.96969,0.93773,252.3,18.8,2.34,7.21
107753-78-6,ZAFIRLUKAST,ACCOLATE,PF-00346624,2855,Cc1ccccc1S(=O)(=O)NC(=O)c2ccc(c(c2)OC)Cc3cn(c4c3cc(cc4)NC(=O)OC5CCCC5)C,TABLET,YES,NO,NO,NO,ORAL,40,Prescription,,NO,NO,,,,,PAR PHARM,pharma,35334,1996,Drugs@FDA,NO,NO,,,NA,NA,0.01,,10,,,,,NO,Respiratory,NO,NO,,NO,YES,NO,NO,Most,Most,DILIRank,1,C,Less,C (probable cause of clinical apparent liver injury),Less,1,Aniline,YES,NO,NO,,575.6752,2,5,2,9,2,9,115.73,0.290322581,3.02,2.805,7.092,Very high LogP unrealistic in nature,5.8,2.8,5.66,3.786,4.94,,3.7,,Acidic,Class 3B,0,0,0,0,0,0,0,4,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,3,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.16186,0.20221,0.0748,0.09968,0.52457,0.79222,0.44051,0.29329,0.03452,544.4,0.303,29.2,182
7481-89-2,ZALCITABINE,HIVID,PF-00345430,2856,c1cn(c(=O)nc1N)[C@H]2CC[C@H](O2)CO,TABLET,YES,NO,NO,NO,ORAL,2.25,Discontinued,,NO,NO,,,,,HOFFMANN LA ROCHE,major pharma,33774,1992,Drugs@FDA,NO,YES,0.8,,High,Reported bioavailability,,0.6,2,,,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,,None,LiverTox Additions,0,,,,Less,0,,NO,NO,NO,,211.2178,3,4,2,6,0,2,90.37,0.555555556,-0.555,-0.25,-1.247,All fragments measured,-0.96,-0.96,-1.12,-1.118,,4.26,13,4.3,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.55238,0.57655,0.51708,0.21546,0.72615,0.79222,0.80357,0.87038,0.47245,283.5,0.357,2.44,7.01
151319-34-5,ZALEPLON,SONATA,PF-00346564,2857,CCN(c1cccc(c1)c2ccnc3n2ncc3C#N)C(=O)C,CAPSULE,YES,NO,NO,NO,ORAL,20,Prescription,,NO,NO,,,,,PFIZER,major pharma,36385,1999,Drugs@FDA,NO,NO,0.31,1,High,Reported bioavailability,0.4,1.4,1,,,,1060614,NO,Neurological,NO,NO,,YES,NO,NO,NO,None,None,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,1,Aniline,YES,NO,NO,,305.3339,0,4,0,6,0,4,74.29,0.176470588,1.49,1.593,1.435,All fragments measured,1.8,1.8,1.45,1.451,,,,0.73,Neutral,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.70547,0.73004,0.99996,0.90197,0.88651,0.59178,0.91655,0.99269,0.25672,321.7,25.2,13.7,9.51
1691249-45-2,ZANUBRUTINIB,BRUKINSA,PF-07105421,,O=C(C1=C2NCC[C@@H](C3CCN(C(C=C)=O)CC3)N2N=C1C4=CC=C(OC5=CC=CC=C5)C=C4)N,CAPSULE,YES,NO,NO,NO,ORAL,320,Prescription,,NO,NO,,,Beigene,pharma,BEIGENE,pharma,43783,2019,Drugs@FDA,NO,NO,,0.57,High,Fa estimated from reported excretion data,0.06,12.6,3,Parent CRG,,,,YES,Oncology,NO,YES,I,NO,NO,NO,NO,,,,,,,,,1,Michael_acceptor,NO,YES,NO,6J6M,471.55106,3,3,2,8,0,7,102.48,0.296,3.24,3.4,2.847,Approximated fragment value used,3.1,3.1,3.37,3.366,,1.76,12,1.5,Neutral,Class 2,0,0,0,0,0,0,0,3,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.50667,0.55383,0.24665,0.96319,0.72615,0.79222,0.66161,0.6885,0.25672,448.6,22.3,33.3,45
30516-87-1,ZIDOVUDINE,RETROVIR,PF-00344677,2861,Cc1cn(c(=O)[nH]c1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],"CAPSULE, SYRUP, TABLET",YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,,,VIIV HLTHCARE,pharma,31855,1987,Drugs@FDA,NO,NO,0.64,,High,Reported bioavailability,0.62,1.6,1.4,,99,,,YES,Anti-infective,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Most,0,,NO,NO,NO,,267.2413,2,4,2,9,0,3,133.08,0.6,-0.0455,0.174,0.044,Valid estimate for difficult structure,-0.32,-0.32,-0.09,-0.129,9.64,,9.3,,Neutral,Class 4,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,NO,0.71455,0.61678,0.88928,0.4917,0.52457,0.79222,0.39844,0.99269,0.47245,367.1,,2.9,7.15
111406-87-2,ZILEUTON,ZYFLO,PF-00346588,2862,CC(c1cc2ccccc2s1)N(C(=O)N)O,"TABLET, TABLET, EXTENDED RELEASE",YES,NO,YES,NO,ORAL,2400,Prescription,,NO,NO,,,,,CHIESI USA INC,pharma,35408,1996,Drugs@FDA,NO,NO,,0.95,High,Fa estimated from reported excretion data,0.07,1.2,2.5,,,,,NO,Respiratory,YES,NO,,NO,NO,NO,NO,Most,Most,DILIRank,1,,,,Less,1,BenzoThiophene,NO,NO,NO,,236.2902,3,1,2,4,0,3,66.56,0.181818182,1.9,2.13,2.483,Benzyl approx. based on a priori value,1.2,1.2,2.49,2.497,9.97,,8,,Neutral,Class 1A,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.83327,0.84164,0.69039,0.97353,0.93048,0.79222,0.7398,0.87038,0.93773,243.4,27.1,14.7,18.5
146939-27-7,ZIPRASIDONE HYDROCHLORIDE,GEODON,PF-00346491,2865,c1ccc2c(c1)c(ns2)N3CCN(CC3)CCc4cc5c(cc4Cl)NC(=O)C5,"CAPSULE, SUSPENSION",YES,NO,NO,NO,ORAL,160,Prescription,,NO,NO,,,Pfizer,major pharma,PFIZER,major pharma,36927,2001,Drugs@FDA,NO,NO,0.6,,High,Reported bioavailability,0.01,1.5,7,,,,68800183,NO,Neurological,NO,NO,,NO,YES,NO,NO,Less,Less,DILIRank,1,E,None,E (unlikely cause of clinically apparent liver injury),Moderate,0,,NO,NO,NO,,412.9356,1,3,1,5,0,4,48.47,0.333333333,3.87,4.276,4.21,All fragments measured,3.8,3.5,4.08,4.055,,6.77,11,6.8,Basic,Class 4,0,0,0,0,1,0,0,3,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,2,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.6524,0.69206,0.49637,0.78243,0.88651,0.98659,0.89921,0.96969,0.25672,385.3,5.41,20.8,70.7
139264-17-8,ZOLMITRIPTAN,ZOMIG,PF-00346558,2869,CN(C)CCc1c[nH]c2c1cc(cc2)C[C@H]3COC(=O)N3,"TABLET, TABLET, ORALLY DISINTEGRATING",YES,NO,NO,NO,ORAL,10,Prescription,,NO,NO,,,,,IPR,pharma,35759,1997,Drugs@FDA,NO,NO,0.39,,High,Reported bioavailability,0.75,7,2.5,,194,,1310411,NO,Musculoskeletal/Pain,NO,NO,,NO,YES,NO,NO,Ambiguous,Ambiguous,DILIRank,0,D,Less,D (probable rare cause of clinically apparent liver injury),Less,1,3_Methyl_Indole,NO,NO,NO,,287.3568,2,2,2,5,0,5,57.36,0.4375,0.495,0.495,1.288,All fragments measured,1.5,-0.2,2.37,0.433,12.57,9.52,11,8.7,Basic,Class 4,0,0,0,0,0,0,0,2,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.90288,0.92866,0.97315,0.99136,0.9848,0.79222,0.9957,0.84757,0.93773,282.6,12.6,7.24,15.2
82626-48-0,ZOLPIDEM TARTRATE,AMBIEN,PF-00345480,2870,Cc1ccc(cc1)c2c(n3cc(ccc3n2)C)CC(=O)N(C)C,"SPRAY, METERED, TABLET, TABLET, EXTENDED RELEASE, TABLET, ORALLY DISINTEGRATING",YES,NO,YES,NO,ORAL,10,Prescription,,NO,NO,,,,,SANOFI AVENTIS US,major pharma,33954,1992,Drugs@FDA,NO,NO,0.7,,High,Reported bioavailability,0.08,0.54,,,13,,3438266,NO,Neurological,NO,NO,,YES,NO,NO,NO,Ambiguous,Ambiguous,DILIRank,0,E,None,E (unlikely cause of clinically apparent liver injury),Less,0,,NO,NO,NO,,307.3895,0,2,0,4,0,4,37.61,0.263157895,2.56,2.872,3.026,Benzyl approx. based on a priori value,3,3,3.12,2.966,,6.72,,5.5,Basic,Class 2,0,0,0,0,0,0,0,3,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.71476,0.74438,0.99986,0.97524,0.93048,0.59178,0.92552,0.99269,0.25672,273.2,23.7,18.3,35.5
64092-48-4,ZOMEPIRAC SODIUM,ZOMAX,PF-00344679,2871,Cc1cc(n(c1C(=O)c2ccc(cc2)Cl)C)CC(=O)O,N/A,N/A,N/A,N/A,NO,ORAL,600,Discontinued,1983,YES,YES,Fatal and near-fatal anaphylactoid reactions,FederalRegister,,,ORTHO MCNEIL,major pharma,29221,1980,NIH NCATS,NO,NO,,,NA,NA,,,,,,,,NO,Musculoskeletal/Pain,YES,NO,,NO,NO,NO,NO,,,Gerren Additions,0,,,,,1,Pyrrole,NO,NO,NO,,291.7296,1,3,1,4,0,4,59.3,0.2,0.0529,0.0529,2.945,All fragments measured,3.1,-0.12,2.94,-0.154,4.2,,3.6,,Acidic,Class 1A,0,0,0,0,1,0,0,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,NO,0.9574,0.9614,0.98418,0.88085,0.9848,0.98659,0.9912,0.96969,0.93773,228.4,16.9,9.88,8.33
68291-97-4,ZONISAMIDE,ZONEGRAN,PF-01049030,2872,c1ccc2c(c1)c(no2)CS(=O)(=O)N,CAPSULE,YES,NO,NO,NO,ORAL,600,Prescription,,NO,NO,,,Sumitomo Dainippon Pharma,pharma,SUNOVION PHARMS INC,pharma,36612,2000,Drugs@FDA,NO,NO,,0.62,High,Fa estimated from reported excretion data,0.56,1.45,63,,,,,NO,Neurological,NO,NO,,YES,NO,NO,NO,Less,Less,DILIRank,1,,,,Moderate,0,,NO,NO,NO,,212.2257,2,3,1,5,0,2,86.19,0.125,0.509,0.5768,-0.363,Benzyl approx. based on a priori value,-0.079,-0.082,0.45,0.45,9.56,,10,-4.3,Neutral,Class 2,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NO,0.7617,0.78609,0.52373,0.60183,0.9848,0.98659,0.74208,0.87038,0.93773,226.7,23.2,2.06,10.8
